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Abstract 
 
At present, 805 mitochondrial DNA (mtDNA) deletions have been described. Short direct 
repeat regions of DNA flank many of these deletions, suggesting that specific regions of 
the mtDNA molecule have a susceptibility to deletion formation. Despite this, the exact 
underlying cellular mechanisms facilitating mtDNA deletions are unclear.  
PR domain 9 (PRDM9) is a meiotic-specific protein responsible for determining the site 
of recombination in the nuclear genome. Through its zinc finger repeat region, PRDM9 
binds a specific DNA consensus sequence, and acts as a methyl transferase, opening 
chromatin for DNA crossover events to occur. This is of interest as mitochondrial DNA 
also contains PRDM9 binding motif sites. 
This thesis outlines the experimental steps taken to determine if PRDM9 has any 
involvement in mtDNA maintenance and viability.  
Firstly, an in silico approach was used to screen mtDNA sequences from 31,551 
individuals for the presence of the PRDM9 binding motif, identifying multiple putative 
binding sites in and around known deletion forming flanking regions. In addition, 
population and phylogenetic stratification showed differential mtDNA binding motif 
patterns, potentially explaining the variable deletion frequencies between mtDNA 
haplogroups and populations. 
Secondly, to test the potential interaction between PRDM9 and mtDNA, complete 
genotyping of the PRDM9 zinc finger repeat region in a cohort of 48 mitochondrial single 
deletion patients and 50 healthy controls was performed. However, there was no 
association between PRDM9 haplotype and the formation of mtDNA deletions. 
Heterozygous individuals were significantly increased in the patient cohort compared to 
controls although no particular allele was associated with mtDNA deletion. 
Finally, PRDM9 protein levels were interrogated in cell lines and tissue samples. 
However, due to timing of expression it was not possible to reliably detect nascent 
protein using commercially available antibodies. To overcome this, stable cell lines 
overexpressing Flag-tagged PRDM9 were created. Low levels of PRDM9 expression were 
detected by immunoblotting indicating overexpression had worked but also indicating 
that PRDM9 turnover in cells is likely rapid.  
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Given the data presented, and despite the presence of multiple putative PRDM9 binding 
sites in almost all mitochondrial genomes studied, we conclude that it is unlikely that 
PRDM9 has a significant effect on the maintenance of mtDNA. However, to the best of my 
knowledge this is the first stable PRDM9 overexpression model created and it has 
provided a unique insight into some of the functions of this protein. 
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1.1 Mitochondrial biology 
1.1.1 Evolutionary origins of the mitochondria 
Mitochondria are double membrane bound subcellular organelles present in all 
eukaryotic cells. They act as a host for many critical cellular processes such as the 
tricarboxylase acid cycle (TCA), fatty-acid β-oxidation, branched chain amino acid 
degradation, oxidative phosphorylation (OXPHOS), glycolysis, iron-sulphur cluster 
formation and apoptosis. The evolutionary origins of the eukaryotic cell are thought to 
be the result of an internalisation event around 1.7 billion years ago, when an 
α-proteobacteria entered an archaeon, thus establishing a symbiotic relationship 
(Parfrey et al., 2011; Williams et al., 2013; Raymann et al., 2015; Spang et al., 2015). 
Whilst the presence of an endosymbiont could be detrimental to the host cell, this 
particular event introduced an attractive trade off; production of cellular energy in the 
form of adenosine triphosphate (ATP).  
Three main advantages are thought to have been vital for the success of the eukaryotic 
ancestor. Firstly, the switch from asexual (clonal) to sexual reproduction allowed 
greater genetic diversity and limited the accumulation of deleterious mutations from 
generation to generation (Muller, 1964; Felsenstein, 1974). This key difference allowed 
eukaryotes to switch from unidirectional lateral gene transfer (LGT) to genome 
recombination and segregation via meiosis and mitosis (Ku et al., 2015; Speijer et al., 
2015). Secondly, eukaryotic cells became compartmentalised by the establishment of a 
nuclear membrane which allowed gene regulation to be segregated from a dedicated 
translation compartment, the cytosol (French et al., 2007). Importantly, this physical 
separation allows production of pre-mRNA species before maturation and transfer to 
the cytosol where protein synthesis can occur. Finally, by allowing the cell to produce 
large amounts of ATP, the eukaryotic cell was able to provide an environment where 
high rates of protein translation could occur, providing the cell with a diverse selection 
of protein species (das Neves et al., 2010). In addition, both the archaeal host and the 
α-proteobacteria brought to the table two independent genomes. Studies have shown 
that in the 1.7 billion years since this endosymbiotic event, large portions of the 
mitochondrial DNA molecule have been transferred into the host nuclear genome and 
that this process is ongoing (Huang et al., 2005; Ju et al., 2015).  
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1.1.2 Mitochondrial OXPHOS 
The success of the eukaryotic cell is also due to the ability to perform aerobic respiration 
using molecular oxygen. Located on the inner mitochondrial membrane are the five 
protein complexes required to perform OXPHOS, utilising oxygen to generate cellular 
energy in the form of ATP. These protein complexes are comprised of both nuclear and 
mitochondrially encoded core subunits as well as a host of assembly factors. The 
electron transport chain (ETC) comprises Complexes I-IV and is responsible for 
pumping protons across the inner membrane by the transport of electrons (for review 
see Papa et al. (2012)). 
Electrons are donated to Complex I by nicotinamide adenine dinucleotide (NADH) and 
Complex II by flavin adenine dinucleotide (FADH2) (Ziegler et al., 1959; Sumegi and 
Srere, 1984). Next, electrons from both complexes I and II are transferred to Complex III 
via reduction of the lipid molecule ubiquinone (UQ) (Crane et al., 1959), which in turn 
donates electrons to Complex III (de Vries et al., 1981). Electrons flow from Complex III 
to Complex IV via reduction of the hemeprotein cytochrome c (CytC) (Lester et al., 
1959). The energy released as electrons are transferred along the ETC is used to 
establish a proton gradient between the inner membrane space and the mitochondrial 
matrix through Complexes I, III and IV (Baum and Rieske, 1966). To complete OXPHOS, 
Complex V utilises this transmembrane proton motive force to drive ATP production 
(Zoratti et al., 1982). Phosphate (Pi) and adenosine diphosphate (ADP) available in the 
mitochondrial matrix are converted to ATP by the rotary mechanism of Complex V 
(Cooper and Lehninger, 1957; Stock et al., 1999). Figure 1.1 shows the classical view of 
the five respiratory chain complexes, however recent data has demonstrated that the 
localisation and interaction of these protein complexes are highly plastic (Lapuente-
Brun et al., 2013). High molecular weight complexes termed ‘supercomplexes’ are 
formed by different combinations of Complex I, III and IV, creating a more dynamic ETC 
than previously described (for review see Chaban et al. (2014)).  
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Figure 1.1 Schematic of the five protein complexes required for OXPHOS, located on the inner mitochondrial membrane. Complexes I-IV comprise the electron transport 
chain (ETC) required for respiration through production of oxygen. The ETC also relies on prosthetic groups; flavin mononucleotide (FMN), ubiquinone (UQ) and 
cytochrome c (CytC). Complex V (ATP Synthase) is required for oxidative phosphorylation as it utilises available protons generated by the ETC to catalyse the conversion 
of ADP+Pi to ATP. 
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1.2 Mitochondrial DNA 
1.2.1 Structure of mtDNA 
In humans, mitochondrial DNA (mtDNA) is a ~16.5 Kb plasmid molecule contained 
within the organelle, physically separated from the nuclear genome (Corneo et al., 
1966). mtDNA encodes 13 protein subunits of the OXPHOS complexes as well as 22 
tRNA’s and 2 rRNA’s required for mtDNA synthesis and mitochondrial protein synthesis 
respectively (Andrews et al., 1999). Human mtDNA is double stranded with the majority 
of the coding regions located on the heavy strand and only one protein encoding gene on 
the light strand, MT-ND6 (Figure 1.2). 
 
 
Figure 1.2 Map of the human mitochondrial DNA. Both strands are shown; the heavy strand is the outer 
circle and the light strand is the inner. All 13 protein coding genes, 22 tRNAs, 2 rRNAs and replication start 
sites are shown. The ‘major arc’ of the molecule comprises m.5721 (OL) to m.15887 (MT-TT). Adapted 
from (Stewart and Chinnery, 2015). 
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Within the inner mitochondrial matrix, mtDNA molecules are encased in proteinaceous 
structures called nucleoids, allowing some protection from reactive oxygen species 
generated by the ETC (Bogenhagen, 2012; Logan et al., 2014; Kukat et al., 2015; Rajala et 
al., 2015). Despite this protective barrier, mtDNA has a significantly higher mutation 
rate than the nuclear genome (Hunter et al., 2012). 
Replication of mtDNA is independent of that of the nuclear genome and the cell cycle, 
therefore mtDNA content can be increased at any time in response to extra- or 
intracellular demand. Several proteins required for mtDNA replication and maintenance 
have been uncovered, all encoded by nuclear genes. The exact mechanism of mtDNA 
replication is still debated with two main theories supported by experimental data; the 
strand displacement model and the strand coupled model. During strand displacement, 
replication occurs unidirectionally from the origin of heavy strand replication site (OH) 
and occurs continuously until the light strand replication site is exposed (OL) 
(Bogenhagen et al., 1979; Kang et al., 1997; Brown et al., 2005) mitochondrial RNA 
polymerase (POLRMT) then synthesises RNA primers which are utilised by 
mitochondrial DNA polymerase gamma (POLG) to begin light strand synthesis (Fuste et 
al., 2010). In the strand coupled model, unidirectional replication occurs at OH but in this 
model RNA/DNA hybrid molecules are created (Pohjoismaki et al., 2010). The lagging 
strand is comprised of RNA primers which are then replaced by DNA as replication 
proceeds, eventually creating the new mtDNA molecule (Reyes et al., 2013). 
The plasmid nature of the mtDNA molecule means that it is transcribed firstly as a 
polycistronic transcript which is then cleaved to allow translation of the mtDNA 
encoded proteins (Ojala et al., 1981). Although replication and translation of mtDNA are 
two independent processes, many of the proteins involved are required for both, 
suggesting that they are intrinsically linked. In addition, the OH site within the D-loop 
region of mtDNA is used for both replication and translation initiation (Chang et al., 
1985) and recently POLRMT has been shown to be required for both processes (Kuhl et 
al., 2016). This is not surprising, as mtDNA replication would primarily occur to increase 
transcript levels and therefore protein expression, requiring these two processes to 
occur within a close time frame.   
 
 30 
 
1.2.2 Inheritance of mtDNA 
The inheritance of mtDNA is uniparental, only transmitted from the maternal gamete, as 
paternal mitochondria are removed from the zygote shortly after fertilisation (Al Rawi 
et al., 2011; Sato and Sato, 2011). Interestingly, evidence of paternal mtDNA 
transmission has been described in a patient with mitochondrial myopathy (Schwartz 
and Vissing, 2002) as well as after strain crossings of mice, opening the possibility of 
paternal ‘leakage’ in rare cases (Luo et al., 2013). It was suggested that levels of paternal 
mtDNA are present within the population but are low-level and have not been detected 
due to inadequate sensitivity of sequencing analysis (Nunes et al., 2013). However, the 
recent use of next-generation sequencing technologies on parent-offspring trios has 
shown no evidence of paternal transmission (Pyle et al., 2015). New research suggests 
that mitochondrial endonuclease G mediates paternal mtDNA degradation (Zhou et al., 
2016) most likely through activation of autophagic degradation pathways (Song et al., 
2016b). It is therefore widely accepted that the mtDNA population within a cell is solely 
maternally inherited.  
Each mitochondrion contains several mtDNA molecules and in turn, each cell contains 
many mitochondria. Therefore, depending on the energy demand of the cell and tissue, 
there can be up to ~100,000 copies of mtDNA per cell (Yu-Wai-Man and Chinnery, 2012; 
Smeets, 2013). This polyploidy genome, coupled with a high mutation rate, can lead to 
the phenomenon of heteroplasmy; where a single mitochondria, cell, tissue or organ can 
have several distinct ‘populations’ of mtDNA molecules. In contrast, homoplasmy occurs 
when all of the mtDNA molecules are identical. This high mutation rate leads to the 
occurrence of both pathogenic mutations and neutral variants. Importantly, the 
heteroplasmy level of pathogenic mutations can be quantified and correlated with 
mitochondrial function and disease severity (Payne et al., 2013). 
 
1.2.3 Mitochondrial population haplogroups 
Due to the polymorphic nature of mtDNA, human populations contain several distinct 
and heritable mtDNA sequences known as mtDNA haplogroups (Wallace et al., 1985). 
The high mutation rate of mtDNA has resulted in rapid divergence of mtDNA sequences 
amongst human populations. These population specific single nucleotide 
polymorphisms (SNPs) are non-pathogenic and therefore persist within the population 
 31 
 
allowing ancestry to be traced back through the maternal lineage. Haplogroup status has 
also been used to determine where populations originated and to trace the migration 
patterns of early humans across continents (Cann et al., 1987; Torroni et al., 1992; 
Torroni et al., 1993). A phylogenetic tree of mtDNA variants can be found on the 
PhyloTree website (PhyloTree); combining extensive sequencing analysis of mtDNA 
from several populations, from the most ancestral African haplogroup L0 to the most 
recent variants, as this divergence is still occurring. African populations harbour the 
most ancient of mtDNA sequences, consistent with evidence that the last common 
ancestor of Homo Sapiens originated in this region (Cann et al., 1987; Chen et al., 1995). 
Asian haplogroups have been well defined due to the migration of founder populations 
into northern America and Australasia (Brown et al., 1998; Starikovskaya et al., 1998; 
Derenko et al., 2000; Kong et al., 2003). European haplogroups are diverse due to 
several different migration patterns of founder groups into this region, as shown in 
Figure 1.3 (Torroni et al., 1996; Richards et al., 2000; Torroni et al., 2000).   
 
 
Figure 1.3 mtDNA population haplogroups shown on a map of the continents of the earth. This map 
indicates that Homo sapiens migration patterns correlate with the divergence of mtDNA sequence from the 
most ancestral African haplogroups L1, L2 and L3. Adapted from (Shriver and Kittles, 2004). 
 
The influence of mtDNA sequence variants in human disease is complex, with several 
studies showing that mtDNA haplogroup status can perpetuate or protect against 
certain disease states. Mitochondrial haplogroups have been associated with complex 
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disorders such as obesity (Ebner et al., 2015), pulmonary arterial hypertension (Farha et 
al., 2016) and multiple sclerosis (Tranah et al., 2015) amongst others. A recent large 
scale analysis of mtDNA sequences from patients with complex diseases confirmed 
previous observations that there were correlations between haplogroup status and 
increased or decreased risk of developing diseases including schizophrenia, multiple 
sclerosis and Parkinson’s (Hudson et al., 2014) although the mechanisms underlying 
mtDNA involvement in vivo remain unknown. Diseases caused by mtDNA mutations are 
also influenced by the mitochondrial haplogroup. For example, Lebers hereditary optic 
neuropathy (LHON) is caused by three known pathogenic mtDNA mutations (Johns et 
al., 1992; Mackey and Howell, 1992; P et al., 2003) however, the disease penetrance in 
carriers of these mutations varies widely. Haplogroups J and UK were found to be 
associated with increased risk of developing LHON (Brown et al., 1997; Howell et al., 
2003; Carelli et al., 2006; Hudson et al., 2007; Gomez-Duran et al., 2012). This is 
assumed to be influenced by two main factors; the metabolic profile of the mtDNA 
haplogroup itself and nuclear mitochondrial complementation and crosstalk (Gomez-
Duran et al., 2012; Giordano et al., 2014). Recently, data has shown the emerging 
importance of compatibility between the nuclear and mitochondrial genomes for the 
success of reproduction in mouse and pig embryos (Park et al., 2015; Ma et al., 2016). 
Similarly, comparisons of transmitochondrial cybrid cell lines with identical nuclear 
backgrounds have highlighted the important differences in OXPHOS between 
haplogroups (Gomez-Duran et al., 2010; Kenney et al., 2014). 
 
1.3 Mitochondria and disease 
Mitochondria, and mtDNA, are of particular research interest for their involvement in 
human disease. Mitochondrial dysfunction and dysregulation underlies several human 
disorders affecting tissues with high energy demand such as brain, liver, heart and 
skeletal muscle. These conditions often present as complex multisystem phenotypes 
however, mitochondrial disorders are a heterogeneous category with some patients 
severely affected whilst others have very mild clinical presentations (for review see 
Lightowlers et al. (2015); Magner et al. (2015)). Given the intricate relationship of the 
nuclear and mitochondrial genomes within the cell, it is not surprising that 
mitochondrial pathologies can be the result of mutations in either the mtDNA or nuclear 
encoded mitochondrial genes. In recent years, mitochondrial dysfunction has 
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increasingly been implicated in several categories of human disease including 
immunological, metabolic and neurodegenerative (for review see Koopman et al. 
(2013)). Whether mitochondrial dysfunction and dysregulation are contributing to or 
result as a consequence of these disease states is still to be elucidated.  
 
1.3.1 mtDNA mutations 
Mutations in the mtDNA molecule itself can occur through two main events; point 
mutations or large-scale rearrangements such as deletions or insertions. Interestingly, 
very little is known about insertions within the mtDNA, most likely due to lack of clinical 
presentation (Poulton et al., 1993; Krishnan and Birch-Machin, 2006). Point mutations 
in the mtDNA can present as several clinical phenotypes depending on the position and 
type of mutation. For example, there are three well characterised point mutations which 
cause LHON in 95% of cases at positions m.11778G>A, m.3460G>A and m.14484T>C (P 
et al., 2003). Other examples include multiple mutations causing microencephalopathy 
lactic acidosis and stroke like episodes (MELAS), at positions m.3243A>G and 
m.3271T>C, and myoclonic epilepsy with ragged red fibres (MERRF) at position 
m.8344A>G (Pavlakis et al., 1984; Goto et al., 1990; Shoffner et al., 1990). Several other 
mtDNA mutations are also associated with these clinical phenotypes, in genes encoding 
members of the OXPHOS subunits, rRNAs or tRNAs, giving rise to a spectrum of different 
phenotypes. Interestingly, due to the phenomenon of heteroplasmy, mtDNA mutation 
level must be sufficiently high to result in a biochemical defect (Schon et al., 2012).  
The transmission of mtDNA mutations is still not clearly understood. Remarkably, de 
novo point mutations are a frequent cause of mitochondrial disorders (~25%) but 
appear to have a low recurrence risk (Sallevelt et al., 2016). One hypothesis as to how 
deleterious mtDNA mutations are removed from the germline is that mtDNA molecules 
undergo a phenomenon termed ‘clonal expansion’ after a genetic bottleneck effect 
during development of female primordial germ cells (PGCs) (Cao et al., 2007; Cree et al., 
2008). This is hypothesised to occur after depletion of mtDNA during the early 
specification of PGCs resulting in a reduced population of molecules which then proceed 
to expand and repopulate the cell. Murine PGCs sampled during early development were 
found to have variable levels of mtDNA heteroplasmy whereas PGCs sampled later in 
development showed less variation in heteroplasmy levels, suggesting a highly 
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regulated selection mechanism during embryogenesis (Freyer et al., 2012). In 
concordance with this, mtDNA copy number measurements in zebrafish oocytes 
revealed high variation in oocytes isolated from the same female (Otten et al., 2016). 
Interestingly, comparisons between PGCs and somatic cells in developing zebrafish 
embryos showed that mtDNA copy number decreased in both cell types but that there 
were differences in the timing of mtDNA depletion. Nevertheless, mtDNA mutations do 
persist within the human population as evidenced by paediatric cases of mitochondrial 
disease (Ardissone et al., 2014). Moreover, different mtDNA mutations have different 
rates of bottleneck segregation, as shown by in silico prediction models (Wilson et al., 
2016). Together, this suggests that both the timing of the mtDNA bottleneck during 
development as well as the type of mutation drives the differences observed in mature 
oocytes. This goes some way towards explaining the differences in mutation load and 
disease severity observed between offspring from the same mother. 
 
1.3.2 mtDNA deletions 
Deletions within the mtDNA can be of any size and occur at any position on the 
molecule, although these events mainly occur within the major arc. Patients can present 
with multiple mtDNA deletions in the cell or tissue, often due to mutations in genes 
essential for mtDNA replication and maintenance (Campbell et al., 2014). Many patients 
harbour a single 4977bp deletion, known as the ‘common’ deletion, thought to occur 
from clonal expansion of one mutant molecule (Brierley et al., 1998). This deletion is the 
underlying mtDNA rearrangement in sporadic mitochondrial disorders such as 
Kearns-Sayre syndrome (KSS), Pearson’s syndrome and chronic progressive external 
ophthalmoplegia (CPEO), with heteroplasmy levels and deletion location differing 
between the conditions (Lopez-Gallardo et al., 2009). The ‘common’ deletion 
heteroplasmy level is also known to increase with age and is used as a biomarker of 
mitochondrial dysfunction in several age-related conditions (for review see Krishnan et 
al. (2008)). More recently, interrogation of a large patient cohort has shown that 
heteroplasmy as well as deletion size and location within the mtDNA can be used as 
predictors of disease progression and severity (Grady et al., 2014).  
The ‘common’ deletion occurs between positions m.8455 and m.13446 on the mtDNA 
molecule, and is flanked by 13bp direct repeat sequences (Mita et al., 1990; Samuels et 
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al., 2004). It is hypothesised that during mtDNA maintenance, these regions, which are 
complimentary to one another, align and allow the 4977bp region in-between to be 
excised resulting in two smaller mtDNA molecules (Figure 1.4) (Krishnan et al., 2008). 
Although this hypothesis is probable, there is a lack of experimental evidence and 
isolating mtDNA to study such mechanisms has proved extremely difficult (Yamashita et 
al., 2008; Sadikovic et al., 2010; Tang et al., 2013).  
 
 
Figure 1.4 Schematic of mtDNA deletion formation. Direct repeats are depicted by orange boxes on the 
circular mtDNA molecule. Aberrant replication leads to formation of two smaller molecules shown on the 
right hand side. 
 
Deletion formation is thought to be caused by a decline in the efficiency of mtDNA 
replication (Copeland and Longley, 2014). The underlying biochemical mechanisms 
thought to be responsible for this decline fall into three main categories; the error rate 
and activity of POLG, nucleotide metabolism and mitochondrial network dynamics. 
During mtDNA replication, spontaneous errors made by POLG can lead to both point 
mutations and deletions (Longley et al., 1998; Zheng et al., 2006). Additionally, POLG 
possesses exonuclease activity which has been shown to be disrupted when mutated, 
thus leading to an increased risk of mtDNA deletion formation (Zhang et al., 2000). 
Discrimination between ribonucleic and deoxyribonucleic acids also relies upon the 
proofreading ability of POLG. In the strand coupled model of mtDNA replication, 
RNA/DNA hybrid molecules are utilised by POLG to create the daughter DNA molecule 
and therefore is reliant upon the ability for the replication machinery to distinguish 
between the two nucleic acid species (Yang et al., 2002). Loss of this essential function 
may lead to mutation or deletion of the molecule. Lastly, mitochondrial dynamics plays 
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an important role in ensuring that deleterious mtDNA is removed from the organelle 
and cell, presumed to be through mitophagy (Nunnari and Suomalainen, 2012). This 
cellular process requires several key proteins and the aberrant activity of many of these 
has been associated with impaired mitophagy and therefore an accumulation of mutated 
mtDNA species (Chen et al., 2010). Several other pathways have been implicated in the 
formation of deletions including inefficient DNA repair mechanisms and mutations in 
exonucleases, helicases and nucleases within the mitochondria (Copeland and Longley, 
2014). 
Deletions also occur in childhood suggesting that these molecules can persist through 
the germline genetic bottleneck described in Section 1.2.2 (Poulton et al., 1991). 
Although this mechanism has not yet been proven, clinical data shows that the risk 
associated with transmitting mtDNA deletions from an affected mother to child is 1 in 24 
births, suggesting that deletions can be transmitted but that deletion levels in oocytes 
are most likely variable (Chinnery et al., 2004).  
The mechanisms as to how clonal expansion of mtDNA deletions occur within tissues 
are still debated. One hypothesis is that smaller molecules have a replicative advantage 
due to their reduced size (Wallace, 1992). This theory is controversial and new evidence 
suggests that in human muscle fibres there is no clear bias for large or small scale 
deletion molecules with regards to clonal expansion rates (Campbell et al., 2014). 
Recently, the involvement of the mitochondrial uncoupled protein response (UPRmt) in 
deletion propagation has been demonstrated in C.elegans harbouring a large scale 
mtDNA deletion (Gitschlag et al., 2016; Lin et al., 2016). Persistence and stabilisation of 
this mtDNA deletion under cellular stress conditions suggests that the normal 
mitochondrial degradation response, mitophagy, is dampened to allow propagation of 
the deleterious genome (Gitschlag et al., 2016) possibly through the signalling pathway 
mediated by the activating transcription factor associated with stress (ATFS-1) (Lin et 
al., 2016). Although germline transmission has not been fully explored in this model, it is 
an interesting observation that hijacking of cellular homeostatic responses can allow for 
expansion of such molecules.  
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1.3.3 Nuclear-mitochondrial genes 
Over the last ~1.5 billion years there has been transfer of mtDNA into the nuclear 
genome of the cell most likely driven by the need to limit mutation accumulation caused 
in part by free radicals from the ETC. It is estimated that ~98% of the mitochondrial 
genome has now been transferred, as evidenced by the vast number of proteins which 
are nuclear encoded and imported into the mitochondria within mammalian cells 
(Wessels et al., 2013). Nuclear DNA sequences with homology to the mtDNA molecule, 
known as NuMts, present a problem in extraction of mtDNA sequences from whole 
genome sequencing datasets as it is unclear whether such sequences map to the mtDNA 
or to the NuMt region (Gould et al., 2015; Malik et al., 2016). However, it is clear that 
NuMt sequences are a common phenomenon as they are present in almost every 
genome sequenced from animal and plant species (Soto-Calderon et al., 2012; Dayama et 
al., 2014). Increased genomic incorporation of mtDNA has been described in several 
cancer types as well as during the normal ageing process suggesting that DNA transfer 
events are either a trigger for or a consequence of cellular dysregulation (Ju et al., 2014; 
Ju et al., 2015).  
It is widely acknowledged that mtDNA is utilised by the cell to repair double strand 
breaks (DSBs) within the nuclear genome (Ricchetti et al., 1999). The precise molecular 
mechanism of such events has been debated with some studies suggesting that 
non-homologous end joining during cell division is the mechanism by which mtDNA 
fragments are incorporated into transcriptionally silent regions of the genome (Hazkani-
Covo and Covo, 2008) whilst others suggest NuMt incorporation is preferentially in 
regions with open chromatin conformation, as shown in germline cells (Tsuji et al., 
2012). A recent study has demonstrated further evidence that NuMt integration is 
non-random and occurs mostly within repetitive DNA elements, such as centromeric 
regions (Doynova et al., 2016). Regardless of the method of transfer, it is clear that 
mtDNA integration into the nuclear genome is prevalent and ongoing.  
 
1.4 Mitochondria and methylation 
1.4.1 mtDNA methylation 
Modifications to the transcriptional control of DNA not by changes in the DNA sequence 
itself, termed epigenomics, has been well characterised as an additional layer of 
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regulation within the nuclear genome (Berger et al., 2009). Primarily, epigenetic control 
is mediated by methylation and acetylation of histone protein complexes but can also 
occur through the presence of CpG islands. These C-G rich regions are common near the 
promoter region of genes and can be activated or silenced depending on methylation 
status and recruitment of protein complexes. Although the epigenetic landscape is 
widely accepted as a regulatory mechanism within the nucleus, the importance of DNA 
methylation and acetylation within the mtDNA remains controversial. Of course, mtDNA 
is not organised in the same way as nDNA around histones, the primary mechanism of 
global epigenetic regulation within the nucleus, or wrapped up into higher order 
chromatin. However, mtDNA is packaged by proteinaceous nucleoids which could offer a 
similar regulatory mechanism as the nuclear histone proteins (Bogenhagen, 2012). In 
addition to histone modification, direct methylation of DNA plays a key role in epigenetic 
regulation and could be influencing expression patterns of mtDNA.  
Methylation of mtDNA was characterised as far back as the 1970’s and 80’s (Nass, 1973; 
Pollack et al., 1984) but was not extensively investigated due to contradictory reports 
that there was no methylation of mtDNA (Dawid, 1974). Technical limitations also 
contribute to a lack of mtDNA methylation data as the mtDNA copy number varies 
depending on the cell type used and can be contaminated with NuMt sequences as 
described in Section 1.2.6. Levels of methylated cytosines (5mC) within the mtDNA have 
been investigated as these marks have been proposed to modify transcription of the 
molecule from the D-loop regulatory region (Bellizzi et al., 2013). The presence of CpG 
tracts within the mtDNA have been mapped and show a similar rate of suppression to 
nDNA (Cardon et al., 1994; Ghosh et al., 2014). A comprehensive study using bisulphite 
pyrosequencing has shown that mtDNA CpG sites occur at ~2% of the mtDNA and can 
be mapped to regulatory regions in the D-loop, mitochondrially encoded 12S RNA 
(RNR1) and mitochondrial encoded 16S RNA (RNR2) as well as within genes encoding 
several OXPHOS proteins (Liu et al., 2016). Recently, the DNA cytosine-5 
methyltransferase1 (DNMT1) protein was shown to have mitochondrial localisation 
(Shock et al., 2011) and has been proposed as the major regulator of mtDNA 
methylation. The presence of DNMT1 as well as characterisation of methylated cytosines 
by bisuphite sequencing suggests that mtDNA methylation may play an important 
regulatory role within the organelle. 
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1.4.2 Mitochondrial regulation of nuclear DNA methylation 
Recently, studies have shown that metabolic pathways contained within the 
mitochondria directly influence nDNA methylation status. This coupling of metabolism 
to genome methylation allows for transcriptional regulation based on nutrient 
availability and sensing. One recent study showed that brain samples from patients with 
multiple sclerosis had lower altered histone H3 methylation marks compared to 
controls. This altered methylation pattern was linked to mitochondrial dysfunction via 
the methionine metabolism pathway (Singhal et al., 2015).  
Methylation of DNA is reliant upon cellular availability of the methyl group donor 
S-adenosylmethionine (SAM), synthesised from methionine (Figure 1.5). 
Methyltransferase enzymes utilise available SAM to carry out methylation of DNA, RNA 
and protein. Delivery of SAM to the mitochondrial matrix has also now been shown to 
occur through the carrier protein SLC25A26 (Kishita et al., 2015). SAM availability is 
directly affected by 1-carbon folate metabolism, which was recently demonstrated to 
increase hypermethylation of 5mC in the mtDNA of oocytes isolated from patients with 
polycystic ovaries (Jia et al., 2016). Defective mtDNA replication has also been shown to 
alter the 1-carbon folate dependent pathways of the cell including dNTP synthesis, SAM 
production and methylation (Nikkanen et al., 2016). 
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Figure 1.5 Metabolic pathways involved in DNA methylation. S-adenosylmethionine (SAM) is synthesised in the cytosol from adenosine and can be transported to the 
nucleus or mitochondria where it is used as a methyl group donor. Transulphuration and 1-carbon folate pathways are directly linked to SAM synthesis. Mitochondria 
metabolise choline within the inner matrix to produce betaine, which is utilised to convert homocysteine (Hcy) to methionine (MET).  
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In addition, mitochondrial content has been linked to nDNA methylation patterns in 
single cells further suggesting that cellular ATP production can drive alterations in 
transcription levels (Guantes et al., 2015). Uncovering such regulation demonstrates the 
importance of tightly regulating the balance between substrate availability and 
transcriptional control within the cell. Additional proteins involved in these mechanisms 
remain to be elucidated, such as transcription factors and methyltransferases that 
mediate mitochondrial-nuclear methylation status.  
 
1.5 PR-domain containing 9 
1.5.1 The PRDM family and gametogenesis 
For vertebrates to reproduce, primordial germ cells (PGCs) must undergo both 
specification and meiosis to produce haploid gametes. This process is controlled by 
several transcriptional activators and repressors which alter the global gene expression 
profile via epigenetic reprogramming. In mammals, PGCs are derived from the 
mesoderm lineage and are specified by repression of the somatic program and 
re-activation of pluripotency potential (Fuhrmann et al., 2001). One group of proteins 
required during germ cell development is the PR-domain containing (PRDM) family. In 
primates, there are 17 PRDM family members, all containing the characteristic 
N-terminal PR domain, which is highly similar to the SET domain (Huang et al., 1998). 
This domain is associated with methyltransferase activity, although only four PRDMs 
have so far been shown to possess intrinsic methyltransferase activity (Kim et al., 2003; 
Hayashi et al., 2005; Ancelin et al., 2006; Eom et al., 2009; Blazer et al., 2016). All PRDM 
family members (excluding PRDM11) have a variable number of zinc finger repeats, 
known to be responsible for protein-DNA binding. PRDM11, -4, -6, -7, -9, -10 and -15 
also have zinc knuckle domains, most likely to allow protein-protein interactions. These 
proteins have diverse cellular functions from the differentiation of cardiac smooth 
muscle cells to tumour suppressor functions (for review see Fog et al. (2012)).  
Pluripotent cells differentiate to PGCs by the activation of pathways controlled by 
expression of PRDM1 (BLIMP1) and PRDM14. In PRDM1 knockout mice, PGCs do not 
repress mesodermal homeobox genes and fail to migrate to the genital ridge, remaining 
clustered as PGC-like cells (Ohinata et al., 2005; Vincent et al., 2005). Recently, PRDM1 
protein expression has been harnessed to experimentally derive germ cells from human 
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embryonic stem cells (hESCs) (Lin et al., 2014; Sasaki et al., 2015). The PGCs of PRDM14 
knockout mice do not reactivate pluripotency and also fail to repress histone 3 lysine 9 
di-methylation (H3K9me2) (Yamaji et al., 2008). The functions of both of these proteins 
are critical, independent of each other, for the correct specification of PGCs. Remarkably, 
overexpression of PRDM1 and -14 in the presence of transcription factor AP-2 gamma 
(AP2γ) allowed pre-cursor germ cells to specify as PGCs in the absence of cytokines 
(Magnusdottir et al., 2013) suggesting that activation of these proteins is enough to 
prompt differentiation, overriding the cell cycle. More recently, the core pluripotency 
marker Nanog homeobox (NANOG) has been shown to induce differentiation of ESCs in 
culture to epiblast-like cells with PGC-like fate through binding and activation of PRDM1 
and PRDM14 (Murakami et al., 2016).  
The timing of expression of PRDM1 and -14 are known to occur in early PGCs to prompt 
specification of these cells (Ohinata et al., 2005). After specification, PGCs must undergo 
meiotic recombination regulated by the PRDM9 (MEISETZ) gene. PRDM9 was first 
described as a gene required for hybrid sterility in mouse (Forejt et al., 1991). Scientific 
interest in this protein increased as the PRDM9 protein was found to have 
methyltransferase activity, driving global epigenetic changes in the cell and prompting 
progression of meiotic prophase I (Hayashi et al., 2005). It is important to note that the 
development of gonadal tissue and PGCs differs between males and females. Female 
PGCs arrest during prophase I and remain in this state until female puberty is reached. 
Male PGCs arrest after mitosis and meiosis is only resumed in spermatocytes following 
puberty. Whilst specification of PGCs and migration of these cells to the genital ridge is 
the same for both sexes, PRDM9 expression is assumed to differ between the sexes 
based on timing of meiosis (Figure 1.6). 
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Figure 1.6 Specification of primordial germ cells (PGCs) during human development from pluripotent 
stem cell to germ cell. Male germ cells are shown in blue and female in pink. A developmental timeline is 
given along the bottom of the figure in days post conception (dpc).  
 
1.5.2 PRDM9 and meiosis 
Meiotic recombination occurs via chromatin remodelling, subsequent DSB formation 
and resolution by homologous recombination of sister chromatids (McClintock, 1939). 
Human recombination takes place in regions close to genes but not within transcribed 
regions, termed ‘hotspots’, which have been characterised as more likely to contain 
specific genomic factors such as the retroviral-like retrotransposons THE1A and THE1B, 
as well as CT-rich and GA-rich repeats when compared to recombination ‘coldspots’. 
Hotspots are present across the genome at a density of around one hotspot per 50 kb 
(Myers et al., 2005).  
Crossover events during meiosis are critical for sexually reproducing organisms to 
exchange genetic information; in fact, without recombination during meiosis the 
resulting offspring are in most cases sterile (Dobzhansky, 1936). PRDM9 knockout mice 
are only able to reproduce as heterozygotes because homozygous null mutants of both 
sexes are completely sterile (Mihola et al., 2009), attributed to a loss of histone 3 lysine 4 
trimethylation (H3K4me3) that leads to meiotic arrest of gametocytes (Hayashi et al., 
2005). Interestingly, inter-species hybrid mice show male sterility, and semi-sterility, 
that can be rescued by adding copies of PRDM9 to the appropriate genetic background 
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(Flachs et al., 2012). Genetic variation in PRDM9 between mouse strains crossed was 
undetectable by sequencing analysis and is therefore not solely responsible for hybrid 
sterility (Flachs et al., 2014). This dosage dependent effect on fertility suggests that 
PRDM9 not only plays an important role in gametogenesis but must also be interacting 
with other hybrid sterility genes. Hybrid sterility gene interactions are still not fully 
understood, however, a recent study using mouse interspecies crossings has identified 
one such modifier locus, hybrid sterility X chromosome 2 (Hstx2/Meir1) (Balcova et al., 
2016) and it is likely there are several genomic loci harbouring important modifiers 
which have subtle effects not yet identifiable by mapping and linkage analysis.  
 
1.5.3 PRDM9 protein function 
The PRDM9 protein is responsible for determining where a large proportion of 
chromosome crossover events occur within the mouse (Baudat et al., 2010), human 
(Sarbajna et al., 2012) and chimpanzee (Auton et al., 2012) genomes. PRDM9 functions 
as a methyltransferase by binding to DNA through its tandem-repeat zinc finger (ZnF) 
domain (Brick et al., 2012). The protein consists of several domains; an N-terminal 
Kruppel-associated box (KRAB), an SSX repression domain (SSXRD), a zinc-knuckle and 
zinc-finger surround the PR/SET domain with a zinc-finger DNA binding array in the 
C-terminus (Figure 1.7).  
 
 
Figure 1.7 PRDM9 protein structure. Important regulatory and binding regions are shown; KRAB, SSXRD, 
PR/SET, zinc finger and knuckle and the C2H2 ZnF array domains.  
 
Proteins containing KRAB and C2H2 zinc finger domains make up a subset of 
transcription factors with the ability to repress genomic targets through binding of 
specific DNA motifs. PRDM9 recognises the so called ‘Myers motif’ (CCNCCNTNNCCNC), a 
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13bp degenerate motif estimated to be present at ~40% of human recombination 
hotspots (Myers et al., 2008). Initial bioinformatic prediction analysis identified PRDM9 
as a candidate binding protein for the motif (Myers et al., 2010). Therefore, PRDM9 
functions as a trans-acting factor; in other words it influences the stability of DNA 
molecules other than the one that encodes it. Purification of a partial ZnF region of 
human PRDM9 showed that the ZnF binds within the major groove of the DNA helix and 
forms hydrogen bonds (Patel et al., 2016). In addition, analysis of mouse PRDM9 showed 
that ZnF binding affinity for DNA sequence is dependent on the position of the ZnF 
within the array; ZnF’s at the beginning and end of the array have variable binding 
intensities whereas internal ZnF’s have selective binding affinity, depicted in Figure 1.8 
(Billings et al., 2013). This characteristic allows PRDM9 to bind a number of DNA motifs 
which differ subtly. 
 
 
Figure 1.8 Schematic of PRDM9 KRAB (orange box) mediated ZnF binding to DNA motifs. Each coloured 
curve represents an individual ZnF in the PRDM9 array. Grey circles represent zinc ions held in pockets to 
create the ‘finger’ structure. Each finger contacts a codon of DNA bases. 
 
X-ray crystallography has revealed the native protein conformation of both human and 
mouse PRDM9 (Wu et al., 2013). PRDM9 binds the H3K4me2 peptide substrate in a cleft 
similar to other SET proteins and in the absence of a substrate, PRDM9 exists in an 
autoinhibited state, whereby the binding sites are closed off by the conformation of the 
protein. Binding of substrate peptides along with a cofactor induces a conformational 
change in the proteins pre- and post-SET domains. This is carried out by a hinge 
mechanism allowing for complete rearrangement of the binding sites. Electron density 
revealed that PRDM9 binds H3K4me2 through interactions with the backbone of the 
β-sheet and α-helix in the cleft as well as side chain interactions, possibly explaining 
substrate specificity. This suggests that PRDM9 inhibition is tightly controlled by other 
factors or post-translational modifications (Wu et al., 2013). During meiosis, PRDM9 
protein functions by firstly binding the 13bp DNA motif through its ZnF array, followed 
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by methylation of lysine residues on histone H3 protein tails and finally allowing double 
strand break complexes to bind and prompt chromosome crossover events (Figure 1.9) 
(Grey et al., 2011; Brick et al., 2012). New analysis of meiotic hotspot data suggests that 
this binding occurs in ‘valleys’ between the histone methylation signals created by 
PRDM9, although precise binding sites are difficult to ascertain due to variation between 
generations in any given pedigree (Lange et al., 2016).  
 
 
Figure 1.9 Schematic of the role of PRDM9 during meiosis. PRDM9 protein binds DNA motifs through the 
zinc finger array. It also methylates histone H3 residues to allow for chromatin remodelling. Double strand 
break machinery can then recognise and bind to the DNA sites directed by PRDM9 and allow for meiotic 
recombination to occur. 
 
The extent of PRDM9 methyltransferase activity has now been extended to histone H3 
lysine residues other than H3K4. Crystal structure analysis suggested that PRDM9 might 
also methylate H3K36 and H3K9 (Wu et al., 2013). Analysis of enzyme kinetics has 
revealed that human PRDM9 is active in the presence of un-, mono- and di-methylated 
H3K4 and H3K36 peptide substrates, and is in fact, one of the most active histone 
methyltransferases (Eram et al., 2014). In contrast, PRDM9 does not react with 
trimethylated K4 or K36 confirming that it specifically methylates these residues on H3 
peptides.  This opens up a new category of PRDM9 methylation targets previously 
 47 
 
unknown, as levels of both H3K4 and H3K36 trimethylation were increased upon 
overexpression of partial PRDM9 in HEK293 cells (Eram et al., 2014). This was also later 
confirmed in vivo using mouse spermatocytes (Powers et al., 2016). The ability for 
PRDM9 to bind to several genomic targets through ZnF variability and target H3K4, 
H3K9 and H3K36 residues for trimethylation suggests that PRDM9 may be regulating a 
much higher number of recombination hotspots than previously thought. The full extent 
of the role of PRDM9 in meiosis is therefore still largely unknown, however, mutations 
within the SET domains or ZnF domains affecting protein function could lead to 
activation or inactivation of PRDM9 at a very critical point in germ cell development. 
 
1.5.4 PRDM9 gene function 
The human PRDM9 gene (NC_000005.10) is located on chromosome 5 and encodes 
three differentially spliced transcripts; 001, 003 and 004. Only one of the transcripts is 
known to encode a protein product, transcript 001, which forms the 894aa full length 
PRDM9 protein (Figure 1.10). It is not yet known if the other two transcripts play a 
functional role within the cell. 
 
 
Figure 1.10 Schematic of the three transcripts produced by the PRDM9 gene. Transcript 001 is the only 
known protein coding transcript, containing all of the functional elements present in the 894aa full length 
PRDM9 protein.  
 
The region responsible for DNA binding activity, the zinc finger array, is encoded by a 
minisatellite located in the final exon of the PRDM9 gene (Hayashi et al., 2005). In 
humans, PRDM9 alleles have between 8 and 18 ZnF repeats within the array (Berg et al., 
2010). Each repeat is 83bp in length and due to the highly polymorphic nature of this 
 48 
 
region, repeats can differ at the nucleotide level creating 29 distinct PRDM9 alleles 
within the population (Figure 1.11). Each allele is comprised of distinct repeat 
combinations (e.g. ABCDD…) based on the number of repeats within the ZnF array 
region. Allele ‘A’ (ABCDDECFGHFIJ) is the most common allele, present at a high 
frequency in European (86%) and African (50%) populations (Berg et al., 2010). 
 
 
Figure 1.11 PRDM9 alleles found identified in European and African populations. Allele structure is shown 
along with repeat length and frequency within the population. Binding motif for each allele is also shown 
(Berg et al., 2010). 
 
The effect of different PRDM9 alleles on global human recombination hotspot patterns is 
complex. Variation in PRDM9 is rapid and contributes to the differences seen in global 
genome recombination patterns over the course of human evolution (Lesecque et al., 
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2014) as well as between human and chimpanzee (Myers et al., 2008; Groeneveld et al., 
2012). Analysis of sperm DNA has shown that men carrying the common 13 repeat 
length allele ‘A’ have more crossovers at hotspots containing the Myers motif; whereas 
men with non-’A’ variant PRDM9 alleles have changes in hotspot usage (Berg et al., 
2010). This suggests two things; firstly, that allele A has higher binding affinity for the 
motif and secondly, some PRDM9 alleles are able to recognise and bind to variant 
hotspot motifs. For example, the PRDM9 allele ‘C’ has 14 ZnF repeats and recognises a 
longer motif, resulting in a shift in recombination pattern for individuals carrying this 
allele (Berg et al., 2011; Hinch et al., 2011). In mice, inter-species crosses have 
demonstrated that different PRDM9 alleles influence the erosion of recombination 
hotspots over evolutionary time due to the different binding properties of each allele 
(Baker et al., 2015; Smagulova et al., 2016). Interestingly, the PRDM9 allele was 
successfully ‘humanised’ in C57BL/6 mice, revealing that altering one allele affects 
crossovers controlled by the other allele (Davies et al., 2016). Such modifications were 
also linked to the fertility of the mice suggesting that PRDM9 allele interactions 
themselves are directly influencing hybrid sterility, further supporting the role of this 
protein in mammalian speciation events. This study also demonstrated that PRDM9 
protein species encoded by different PRDM9 alleles differed in their binding affinity for 
the Myers motif supporting the idea that there might be dominance over hotspot 
location based on the PRDM9 alleles present in the genome, previously suggested to also 
be the case in the human genome (Thomas et al., 2009; Jeffreys et al., 2013). The 
proposed mechanism for this hotspot erosion is shown in Figure 1.12. 
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Figure 1.12 Schematic of the proposed mechanism by which PRDM9 influences hotspot erosion in mouse 
and human genomes. As two populations become isolated, a new PRDM9 allele is created in one (PRDM9C) 
whilst the other still maintains the ancestral allele (PRDM9A). The two alleles have different binding 
motifs within the genome. Over time, the allele begins to erode the hotspot on the ‘self’ chromosomes, 
leaving other binding sites in-tact. Thus, when the two populations interbreed (F1) the PRDM9 alleles will 
still bind to their corresponding motif that has not been eroded. Asymmetric hotspots result in hybrid 
sterility, therefore driving the creation of new PRDM9 alleles and new motifs within the population to 
regain symmetry of recombination (Zelazowski and Cole, 2016). 
 
Moreover, sperm genotyping indicates that many recombined and lengthened PRDM9 
alleles exist within sperm cells that are not represented in somatic cells within the 
human population (Jeffreys et al., 2013). Lack of these alleles within the population 
suggests a unique mechanism whereby PRDM9 influences its own stability at the meiotic 
level leading to a phenomenon where diversity is driven by the most stable alleles. 
Perhaps this is a mechanism to limit the shifting of recombination patterns and combat 
deleterious effects (Boulton et al., 1997). The evolutionary pressures upon PRDM9 
remain to be fully understood and could be due to several reasons; a high mutation rate 
due to minisatellite instability, purifying or positive selection controlling DNA binding 
specificity, the erosion of binding sites as described in Figure 1.12, or epistatic 
interactions which cause incompatibility after population divergence (Buard et al., 
2014).  
Additionally, there is an argument that other proteins act in a functionally redundant 
manner with respect to PRDM9 driven recombination. The entire canid lineage lacks 
active PRDM9 (Munoz-Fuentes et al., 2011; Axelsson et al., 2012; Campbell et al., 2016), 
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whilst in equids no association between PRDM9 genetic variation and hybrid sterility 
was found (Steiner and Ryder, 2013). Recently, there has been a reported case in 
humans of an individual who lacks PRDM9 expression due to a homozygous mutation 
rendering both alleles non-functional (Narasimhan et al., 2016). This individual has no 
clinical phenotype and has two daughters, suggesting that in this case PRDM9 activity 
was not required for successful meiosis. Tissue biopsies or cultured cells from this 
individual would help aid functional investigations. These observations suggest that 
although PRDM9 might be the master regulator of meiotic recombination in some 
species, it is not required in others. In addition, other as yet unidentified proteins must 
be facilitating crossover events in the absence of PRDM9. Nevertheless, PRDM9 clearly 
plays an important functional role during human meiosis. 
 
1.6 PRDM9 and disease 
1.6.1 PRDM9 and genomic rearrangement disorders 
In recent years, the role of PRDM9 in human disease has become an area of great 
interest. Firstly, mutations in the PRDM9 gene have been associated with infertility 
characterised by nonobstructive azoospermia, which is perhaps not surprising as 
PRDM9 knockout mice are sterile (Miyamoto et al., 2008; Irie et al., 2009; He et al., 
2013). A mutagenesis screen in mice also showed that PRDM9 gene mutations caused a 
severe depletion of germ cells, suggesting that human mutations might have a similar 
effect (Weiss et al., 2012). However, due to the polymorphic nature of the PRDM9 gene it 
is challenging to prove the true pathogenic nature of these SNPs. It is more likely that 
PRDM9 influences fertility by the hybrid paradox outlined in Section 1.5.4 due to 
incompatibility of different PRDM9 alleles during recombination (Flachs et al., 2014). 
Further studies into the effects of PRDM9 on human fertility are required, especially in 
female oocytes. However, such samples are difficult to obtain and would therefore most 
appropriately be tested in an animal model such as mouse or zebrafish. 
Genomic rearrangement disorders are characterised as diseases resulting from 
deletions, insertions and copy number changes within the genome. Sequencing of the 
ZnF region of the PRDM9 gene in patients with genomic rearrangement disorders and 
their parents showed an association of ZnF variants with Williams-Beuren disease, 
caused by microdeletions in a region of chromosome 7 (Borel et al., 2012). PRDM9 has 
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also been implicated in complex duplication-triplication rearrangements of the 
Duchenne muscular dystrophy (DMD) gene (Ishmukhametova et al., 2013). This event 
was studied in a male patient with DMD, where it was shown that inverted repeats allow 
rearrangement of regions spanning several exons of the DMD gene; leading to large scale 
exon shuffling and resulting in a disease phenotype. The regions flanking the 
rearrangement break point were visualised and the PRDM9 binding motif was found 
~300 bp upstream. This was not in a region known to be a meiotic recombination 
hotspot, however, Ishmukhametova et al hypothesised that LD-based hotspots are only 
representative of hotspot activity in female meiosis, leading them to believe that this 
might be a male meiosis specific event. PRDM9 recruitment of initiator of meiotic double 
strand breaks (SPO11) could initiate the strand break needed to facilitate incorrect 
strand invasion and therefore a duplication-triplication event in DMD. However, the 
authors did not sequence PRDM9 in the patient or parents to determine if rare PRDM9 
alleles were present in the family and further analysis needs to be carried out to confirm 
that this putative binding site is actually bound by PRDM9 and if this is indeed the 
causative molecular mechanism. 
Disorders influenced by epigenomic changes such as schizophrenia have also been 
associated with PRDM9 function (Wockner et al., 2015). Whilst this is an intriguing 
hypothesis, the effects of PRDM9 on epigenetic methylation patterns is not clear. As 
discussed, in order for PRDM9 to bind to DNA motifs it methylates histone H3 lysine 
residues, inducing chromatin unwinding and DNA exposure. Whilst this process is 
important for meiotic recombination during development of germ cells, there is not yet 
any evidence to support a functional link between PRDM9 methyltransferase activity 
and global epigenetic regulation. 
 
1.6.2 PRDM9 as a cancer testes antigen 
The SSX region in the PRDM9 N-terminus along with the KRAB domain indicates that 
PRDM9 has homology to the SSX class of proteins, which are suggested to have testis 
specific functions, although this remains to be explored along with the full functional 
role of PRDM9. In recent years, the role of a class of biomarkers known as cancer testes 
(CT) antigens has emerged and is of particular interest in the field of cancer 
immunotherapy. These CT antigens are defined as proteins expressed specifically in the 
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testes of adult males but not in other somatic tissues. Interestingly, these proteins have 
been found to be expressed in tumours from various tissues and are therefore 
biomarkers of tumourigenesis with the potential to be targeted through antibody based 
immunotherapy strategies (for review see Suzuki et al. (2013)). PRDM9 has been 
identified as a CT antigen as its expression was detected in several cancer cell lines and 
tissues by RT-PCR (Feichtinger et al., 2012). Under normal circumstances, PRDM9 is 
only expressed in testes and at very low levels in ovaries. This suggests that PRDM9 
might be upregulated in cells to induce chromatin remodelling and genomic 
rearrangements, promoting a cancer phenotype. 
Cancer genomics has largely focussed on identifying genomic mutations through linkage 
association analysis. Paediatric cancers are an interesting group as mutations causing 
these disorders would be assumed to be lost from the population quickly. However, 
emerging evidence suggests that parental alleles could be risk factors for childhood 
cancers even if the affected individual themselves does not inherit the mutated allele. 
For example, in around 25-30% of B-cell lymphoblastic leukaemias there is a 
non-random gain of chromosomes leading to hyperploid cells (for review see Paulsson 
et al. (2009)). Rare PRDM9 alleles were found to be enriched in a group of parents with 
children diagnosed with B-cell precursor acute lymphoblastic leukaemia (B-ALL) 
compared to ethnically matched controls (Hussin et al., 2013). Mothers of B-ALL 
children were significantly more likely to carry the rare PRDM9 allele than fathers. 
Transmission disequilibrium may be a factor in B-ALL cases, with only half of all affected 
children carrying the rare PRDM9 allele. More recently, PRDM9 alleles were investigated 
in a parental cohort of patients with high hyperploidy acute lymphoblastic leukaemia 
(HeH ALL) (Woodward et al., 2014). Again, rare PRDM9 alleles were overrepresented in 
both the parental and patient cohort when compared to controls, suggesting that 
PRDM9 activity may cause genomic rearrangements at the chromosomal level in these 
patients. However, it is unclear when and in which cell types this happens. Perhaps rare 
PRDM9 alleles are modifying the activity of PRDM9 protein in the somatic cells to cause 
rearrangements. The transmission of the ‘risk’ allele to only ~60% of offspring suggests 
that the effect of PRDM9 is actually happening at the gamete stage, when the cells are 
somehow predisposed to developing ALL.  
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1.6.3 PRDM9 and mtDNA deletions: the missing link? 
PRDM9 recognises and binds a 13 bp motif enriched in human hotspots. Surprisingly, in 
the bioinformatics screen used to identify this PRDM9 recognition motif, it was 
identified within the human mtDNA sequence (Myers et al., 2008). The motif was 
suggested by the authors to flank the large scale pathogenic 4977bp ‘common deletion’. 
Although the authors do not suggest any possible functional role of this motif site, there 
remains the possibility that PRDM9 is localising to mitochondria and binding mtDNA. As 
PRDM9 is expressed solely during meiosis, it could be involved in regulating deletion 
heteroplasmy levels in oocytes and potentially predispose individuals to mtDNA 
deletion disorders.  
Deletions in mtDNA are often flanked by direct repeat regions (Larsson and Holme, 
1992; Samuels et al., 2004) leading to the hypothesis that these repeats align during 
replication and allow deletions to occur within the molecule. The use of inverted repeats 
during recombination repair is not new and has been described within the nuclear 
genome, in disorders with duplication-triplication gene events (Shimojima et al., 2012; 
Beri et al., 2013; Dittwald et al., 2013). Recent evidence that PRDM9 alleles are 
associated with rearrangement disorders raises the possibility that such mechanisms 
could also be creating mtDNA rearrangements. Mutations in genes known to be involved 
in mtDNA maintenance and replication cause mtDNA deletion via aberrant repair 
however, these known mutations only partially explain the prevalence of mtDNA 
deletions within the population. It is therefore important to try and elucidate factors 
which predispose the repeat regions of the mtDNA to undergo such deletions, as the 
mechanism cannot solely hinge on defects in the already characterised mitochondrial 
replication machinery. 
Any possible involvement of PRDM9 in mtDNA maintenance must be proven by directly 
assessing the mitochondrial localisation of this protein and it’s ability to bind mtDNA. 
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Chapter 2 Aims and Objectives 
 
2.1 Hypothesis 
Due to a previous report that PRDM9 binding motifs are present within the human 
mtDNA sequence, this thesis aims to identify whether this is the case at a population 
level and whether such motifs could be of functional significance within the 
mitochondria. More specifically the following aims will be tested; 
1. PRDM9 motifs will be present in the majority of mtDNA sequences, at known 
sites of mtDNA deletions. 
2. The PRDM9 protein will localise to the mitochondria, as this must be where any 
binding events occur. 
 
2.2 Aims and Objectives  
Two main approaches will be used to study this hypothesis. Firstly, in Chapters 4 and 5 
the genetic aspects of PRDM9 will be explored in relation to mtDNA. More specifically, 
the aims of these chapters will be;  
1. To determine whether PRDM9 binding sites exist within the mtDNA sequence of 
a large cohort of individuals from several populations. 
2. Sequence the ZnF region of the PRDM9 alleles in a cohort of single deletion 
patients compared to controls.   
 
Secondly, in Chapters 6, 7 and 8 the localisation and function of PRDM9 protein will be 
explored. The aims of these three chapters are; 
1. To identify an appropriate model to experimentally determine the function of the 
PRDM9 protein. 
2. Modify the expression of PRDM9 in a cell culture system to understand how this 
protein is potentially interacting with mitochondria. 
3. Create a cell culture model, using overexpression, to determine whether PRDM9 
expression affects mitochondrial protein levels or mtDNA copy number.
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Chapter 3 Materials and Methods 
 
3.1 Sample cohort 
Total DNA was extract from 48 patients, known to harbour a single mtDNA deletion, 
using a DNAeasy extraction Kit (Qiagen, Manchester, UK), according to manufacturers 
recommended protocol. DNA aliquots were kindly provided by Professor R.W. Taylor 
(Newcastle Mitochondrial NSCT Diagnostic Service). Further patient details are provided 
in Chapter 5 Table 5.1. In addition, control cohort (WTCCC 1958 Birth Cohort) total DNA 
was extracted from whole blood (using same method as above). 
 
3.2 Polymerase chain reaction 
Polymerase chain reaction (PCR) for amplification of the gene of interest was carried out 
using TaKaRa LA Taq, TaKaRa GXL Taq (TaKaRa Bio Europe/Clontech, France) or MyTaq 
(Bioline, London, UK) polymerases. Primer pairs (Integrated DNA Technologies, IA, USA) 
were designed using PrimerBLAST or from previous publications. Optimisation of 
annealing temperatures (by temperature gradient PCR) and DNA concentrations (by 
concentration titration) was carried out to determine optimal conditions for product 
amplification.  
 
3.3 Sanger sequencing 
Cycle sequencing reactions was carried out using the following reaction mix; 2 μL 
Big-Dye Terminator v3.1, 1.5 μL Big-Dye reaction buffer (both Applied Biosystems, 
Thermo Fisher Scientific, Loughborough, UK), 3.2 pmol product specific primer, 10 % 
betaine and 25 ng of PCR product. Reactions were made to volume (20 μL) using 
nanopure water. Thermocycling conditions were; 96 °C for 1 min, followed by 25 cycles 
of 96 °C for 10 sec, 50 °C for 5 sec, 60 °C for 4 min.  
To remove excess dye labelled nucleotides, PCR products were cleaned by ethanol 
precipitation. Briefly, 3 M sodium acetate125 mM EDTA and 70 μL 100% ethanol were 
added to each reaction in a 96-well plate. The plate was spun at 2000 x rcf for 30 
minutes and then inverted on tissue paper. The plate was centrifuged to 100 x rcf, 70 μL 
 58 
 
of 70% ethanol was added and the plate spun at 1650 x rcf for 15 min. The supernatant 
was removed by inversion and the plate allowed to air dry in the dark. The pellets were 
resuspended in Hi-Di formamide (Applied Biosystems, Thermo Fisher Scientific, 
Loughborough, UK).  
The Big-Dye suspension was then transferred to an Applied Biosystems 3130xl genetic 
analyser for analysis. Analysis of electropherogram data was performed using SeqScape 
software V2.6 (Thermo Fisher Scientific, Loughborough, UK) via alignment with the gene 
of interest reference sequence. 
 
3.4 Cell Culture 
3.4.1 Maintenance of HEK293 cell line 
Human Embryonic Kidney cells (HEK293), kindly provided by Professor R.N. 
Lightowlers (Institute of Cell and Molecular Biosciences Newcastle University) were 
cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% foetal 
bovine serum (FBS) and non-essential amino acids (all GIBCO, Thermo Fisher Scientific, 
Loughborough, UK). Cells were grown under normal culture conditions (37 °C in 
5% CO2) in T75 flasks. Media was changed every 48-72 hours.  
HEK293 cells were harvested every 3-5 days and split in a 1 to 3 basis. Briefly, media 
was aspirated; cells were washed using 1X phosphate buffered solution (PBS, Oxiod, 
Thermo Fisher Scientific, Loughborough, UK) and trypsinised by incubation with 
PBS-EDTA (0.05%) at room temperature for 5 minutes. Fresh media was added and the 
sides of the flasks were sluiced to ensure all cells were suspended in the media. Cells 
were centrifuged at 1300 x rcf for 5 minutes and the pellet resuspended in fresh media. 
To split 1:3, the resuspended pellet in media was split evenly between three flasks. The 
cells were then incubated and inspected daily. 
3.4.2 Freezing/thawing cells 
Once obtained (as described in Section 3.4.1) cell pellets were resuspended in freezing 
media (DMEM supplemented with 20% FBS (GIBCO) and 10% DMSO) at 3-5x106 cells 
per cryovial and frozen using the freezing container Nalgene® Mr. Frosty (Sigma Aldrich, 
Dorset, UK) at -80 °C. In this system, the cooling rate is 1 °C/min promoting a successful 
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cryopreservation.  After 24 hours the cells were transferred to liquid nitrogen for long-
term storage.  
To defrost cells from liquid nitrogen, cells were quickly resuspended in appropriate 
media, transferred into a falcon tube and centrifuged at 1300 x rcf for 5 minutes. The 
supernatant was discarded and the pellet resuspended in 5 mL of culture media and 
seeded.  
3.4.3 Limited dilutions of cultured cells 
To obtain single cell colonies, cells were harvested as described (Section 3.4.2), counted 
using a haemocytometer and resuspended in DMEM to a concentration of 
2x104 cells/mL. In a 96 well plate, 4000 cells were added to well A1 and were 
sequentially diluted across the plate, giving rise to 1 cell per well in the most diluted 
regions of the plate (as shown in Figure 3.1). After 14 days of culture the cells were 
scored by the presence of a single colony by microscopy. On day 18 of culture the 
colonies were trypsinised and moved to a 24 well tissue culture dish for expansion of 
the colony.  
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Figure 3.1 Dilution series of cells set up in a 96 well plate format. The top plate shows the direction of 
pipetting from the initial 4000 cell well (block grey). The bottom plate shows the corresponding cell 
number in each well. Block grey depicts wells where the cell number is >0.4 cell/well. 
 
3.5 DNA and RNA extraction from cultured cells 
Total DNA was extracted from cell culture pellets using a DNeasy Extraction Kit (Qiagen, 
Manchester, UK), according to manufacturers recommended protocol. Total RNA was 
extracted from cell culture pellets using the RNeasy extraction kit (Qiagen, Manchester, 
UK) according to the manufacturers recommended protocol.  Cells were pelleted by 
centrifuging at 1300 rcf for 5 minutes and washed 3 times with PBS before DNA or RNA 
was extracted. DNA concentration was measured using the Nanodrop2000 UV-vis 
Spectrophotometer (Thermo Fisher Scientific, Loughborough, UK). 
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3.6 Protein Extraction  
Different protein extractions were carried out during this project (see Sections 3.7.1 – 
3.7.5). 
3.6.1 Whole cell protein lysis 
Cells were harvested as previously described (Section 3.4.1) and washed twice with cold 
PBS. On ice, the pellet was resuspended in an appropriate volume of Laemmli buffer 
(50 mM Tris pH7.5 (Sigma), 130 mM NaCl (BDH AnalaR), 2 mM MgCl2 (BDH AnalaR), 
0.1% Triton X-100 (Sigma), 1 tablet protease inhibitor (Roche, West Sussex, UK), dH2O) 
or PathScan ELISA sandwich lysis buffer (Cell Sinaling, Boston, MA, USA) with protease 
inhibitor and vortexed for 30 seconds every 5 minutes for 15 minutes. The lysate was 
sonicated for 7 seconds on ice using a microtip, centrifuged at 2500 x rcf for 5 minutes at 
4 °C. Supernatant was kept and the pellet discarded (Laemmli, 1970). 
3.6.2 Tissue lysis 
Tissue was cut and weighed on dry ice. The tissue sample was ground using a pestle and 
mortar on dry ice. To the ground tissue, 1 mL of lysis buffer with protease inhibitor per 
100 mg of tissue was added and the mix transferred to a 2 mL Dounce homogeniser 
(Wheaton) on ice. Cells were disrupted with 10-20 strokes on the homogeniser drill at 
4 °C. A small volume of lysate (~5 μL) was checked under a light microscope to ensure 
the cell membranes were disrupted. The lysate was sonicated for 7 seconds on ice using 
a microtip, centrifuged at 2500 x rcf for 5 minutes at 4 °C. Supernatant was kept and the 
pellet discarded (Laemmli, 1970). 
3.6.3 Intact mitochondrial isolation 
The cell pellet or tissue sample was suspended in 1 mL of Medium B; 250 mM Sucrose, 
2 mM HEPES, 0.1 mM EGTA (Kirby et al., 2007) and transferred into a 2 mL Dounce 
homogeniser (Wheaton) where the cells were disrupted with 20-60 strokes on the 
homogeniser drill at 4 °C. The sample was then transferred into a 1.5 mL 
micro-centrifuge tube and centrifuged for 10 minutes at 400 x rcf at 4 °C. The 
supernatant was removed and kept as the cytosolic fraction containing mitochondria. 
The pellet was resuspended in 800 μL Medium B and homogenised again to increase the 
amount of mitochondria harvested. The sample was centrifuged as before. The two 
supernatants were then combined and centrifuged for 10 minutes at 10,000 x rcf at 4 °C. 
The supernatant was removed and stored and comprises the cytosolic fraction. The final 
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pellet comprises the mitochondrial fraction (Fernandez-Vizarra et al., 2010). All samples 
were stored at -80 °C.  
To isolate mitochondria from the mitochondrial associated membrane (MAM) a percoll 
gradient method was used (Wieckowski et al., 2009). The cell pellet was suspended in 
30 mL PBS and centrifuged for 5 minutes at 600 x rcf at 4 °C. Pellet was resuspended in 
5 mL PBS and centrifuged as before. Pellet was then suspended in 20 mL buffer IBcells1 
(225-mM mannitol, 75-mM sucrose, 0.1-mM EGTA and 30-mM Tris–HCl pH 7.4) and 
transferred to a 30 mL Dounce homogeniser using a 1 mL Pasteur pipette where cells 
were disrupted with 100 strokes using a drill at 4 °C. Cells were transferred back into a 
plastic tube and centrifuged as before. The pellet was stored as the nuclear fraction and 
the supernatant was centrifuged for 10 minutes at 7000 x rcf at 4 °C. The supernatant 
was stored as the cytosolic fraction and the pellet resuspended in 20 mL buffer IBcells2 
(225 mM mannitol, 75 mM sucrose and 30 mM Tris–HCl pH 7.4) before centrifugation as 
before. The supernatant was discarded and the mitochondrial pellet resuspended in 
20 mL IBcells2 before centrifugation for 10 minutes at 10,000 x rcf at 4 °C. The 
supernatant was discarded and the mitochondria suspended in 2 mL mitochondrial 
resuspension buffer (MRB; 250 mM mannitol, 5 mM HEPES (pH 7.4) and 0.5 mM EGTA). 
A small amount of this was stored as the ‘crude’ mitochondrial fraction. Next, 8 mL of 
percoll medium (225 mM mannitol, 25 mM HEPES (pH 7.4), 1 mM EGTA and 30% 
Percoll (vol/vol)) was placed in a 15 mL thin wall polyethylene ultracentrifuge tube. The 
mitochondrial suspension was layered on top of the percoll medium followed by 3.5 mL 
MRB gently layered on the top.  This suspension was centrifuged for 30 minutes at 
95,000 x rcf at 4 °C in a Sorvall ultracentrifuge (Thermo Fisher Scientific, Loughborough, 
UK). The mitochondria appear as a small pellet at the bottom of the tube whilst the MAM 
is a white band suspended in the layer above the pellet, this is collected by gentle 
pipetting using a 1 mL Pasteur pipette and diluted with 10 X the volume of MRB. The 
mitochondrial pellet is diluted in 10X the volume of MRB. Both suspensions were 
centrifuged for 10 minutes at 6,300 x rcf at 4 °C, the mitochondrial pellet suspended in 
20 mL MRB and centrifuged again. This pellet was finally resuspended in 200 µL MRB 
and stored as the ‘pure’ mitochondrial fraction. MAM fraction was centrifuged for 1 hour 
at 100,000 x rcf at 4 °C and then suspended in a final volume of 200 µL MRB.  
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3.6.4 Mitochondrial enrichment 
Native protein preparations are used to isolate multiprotein complexes from cells using 
a gentler cell lysis procedure than traditional SDS containing lysis buffers. After 
treatment with non-ionic detergents and centrifugation a final pellet is created which is 
enriched for mitochondria and can therefore provide a crude mitochondrial enrichment 
from a small number of cells. 
5 x 106 HEK293 cells were harvested and the pellet washed three times with PBS. The 
pellet was resuspended in 100 μL PBS + protease inhibitor (Roche Diagnostics Limited, 
West Sussex, UK), 10 μL was diluted in 90 μL dH2O and sonicated for 4 seconds. Protein 
concentration was determined as described in Section 3.7.5 by maxi Bradford. Digitonin 
is a mild non-ionic detergent which solubilises receptors and permeabilises the cell and 
nuclear membranes and was added to the non-sonicated cell suspension in a 1:6 ratio 
based on the formula below: 
 
𝑌 = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑥 1.6 (𝑟𝑎𝑡𝑖𝑜) 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑑𝑖𝑔𝑖𝑡𝑜𝑛𝑖𝑛 =
Y x Volume of PBS
Concentration of digitonin
 
 
Stock concentration of 6 mg/mL digitonin diluted in PBS was used. The digitonin treated 
lysate was made up to a final volume of 200μL with PBS and centrifuged at 10,000 x rcf 
for 10 minutes at 4 °C. The mitochondrial enriched pellet was resuspended in 30μL of 
MB2 buffer (500μL 3XGB (0.5 M aminocaproic acid, 50 mM Tris-HCL pH7), 1M 
aminocaproic acid, 20mM EDTA), 1% laurel malthoside added and incubated on ice for 
15 minutes. The sample was centrifuged at 20,000 x rcf for 20 minutes at 4 °C and the 
supernatant was placed in a new 1.5 mL tube. Protein concentration was determined 
using the supernatant to perform a Bradford assay (Section 3.7.5).  
3.6.5 Determining protein concentration 
The Bradford Assay was used to determine the protein concentration (Bradford, 1976). 
Two methods were used depending on the absorbance being measured. 
Maxi Bradford was performed as follows, a calibration curve was created using bovine 
serum albumin (BSA) at known concentrations of 0.05 μg, 0.1 μg, 0.2 μg, 0.3 μg, 0.4 μg 
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and 0.5 μg/μL solution. An example of this curve is shown in Figure 3.2. A blank was also 
set up to correct for any background absorbance in the buffer itself. Samples were run at 
different dilutions depending on the type of lysate e.g. cellular or tissue. In a 96 well 
plate, 10 μL of each calibration standard plus samples were measured in triplicate. To 
this, 200 μL of 1:5 dilution of Bradford solution (BioRad Laboratories, Hemel Hempsted, 
UK) was added. Detection was carried out on a plate reader. Analysis was carried out 
using Microsoft Office Excel package to determine standard curve and final protein 
concentration. 
 
 
Figure 3.2 Example of calibration curve used to determine protein concentration of lysate samples in this 
study. 
 
Mini Bradford was performed for protein lysis where a commercial lysis buffer was 
used. This allows for accurate protein detection in the presence of glycerol and NP-40. 
BSA protein standards were set up as shown in Table 3.1. Standards were set up in 
semi-micro polystyrene cuvettes (VWR International, Leicestershire, UK). To this, 
200 µL of Bradford solution was added and values were measured on the Eppendorf 
BioPhotometer. Final protein concentrations were analysed as outlined previously. 
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Concentration of 
BSA (mg/mL) 
Volume (µL) 
BSA (1mg/mL) 
Volume (µL) dH2O 
0.01 1 799 
0.03 3 797 
0.05 5 795 
0.1 10 790 
0.15 15 785 
0.2 20 780 
Blank 0 800 
Table 3.1 Dilutions for setting up a standard curve for a mini-Bradford used in this study.  
 
3.7 Protein Investigations  
Western blot method was used to quantify proteins. Briefly, a 10 μL sample volume was 
made by adding 1 μL 10X Sample Reducing Agent, 2.5 μL 4X LDS Sample Buffer (both 
Novex®, Thermo Fisher Scientific, Loughborough, UK) and the appropriate volume of 
sample lysate based on the protein concentration determined as described in Section 
3.7.5. Samples were heated at 70 °C for 10 minutes.  
3.7.1 Polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein electrophoresis was performed using SDS-PAGE denaturing acrylamide gels 
(4-20% NuPAGE® Bis-Tris Precast Gels or 4-20% MiniPROTEAN TGX Precast Gels, 
BioRad Laboratories, Hemel Hempsted, UK). The electrophoresis was carried out in MES 
buffer with 500 μL antioxidant added (both NuPAGE®, ThermoFisher Scientific, 
Loughborough, UK) at 120 V for 30 minutes and 160 V thereafter using the X-Cell system 
(Novex®, Thermo Fisher Scientific, Loughborough, UK). Two molecular markers were 
run in parallel with the samples, one coloured marker (See Blue Plus 2, Thermo Fisher 
Scientific, Loughborough, UK) to ensure the correct molecular weight was present in gel 
and one biotinylated marker (Biotinylated Protein Marker, Cell Signaling, Boston, MA, 
USA) to determine molecular weight during western blot detection. 
3.7.2 Western Blotting 
Transfer of protein to a membrane was carried out in the iBlot™ 2 Semi Dry Transfer 
System (Thermo Fisher Scientific, Loughborough, UK). Briefly, the gel was removed from 
its case and soaked in 10% ethanol for 10 minutes. Pre-prepared stacks were soaked in 
dH2O. The components were assembled as follows; stack-membrane-gel-stack, a 
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protocol for mixed molecular weight was used for 7 minutes at 1.3 A constant. Once 
transferred, the membrane was removed and blocked in 5% buffer (2.5 g non-fat milk in 
50 mL 1X TTBS) for 1 hour. After this, the primary antibody at an appropriate 
concentration (Table 3.2) was incubated overnight at 4 °C. Three washes with TTBS 
buffer (20 mM Tris-HCL pH7.5 (Sigma Aldrich, Dorset, UK), 0.5 M NaCl (BDH AnalR, 
VWR, Leicestershire, UK), 0.1% Tween 20 (Sigma Aldrich, Dorset, UK) for 10 minutes 
each were followed by incubation with a secondary antibody and anti-biotin antibody 
(Cell Signaling, Boston, MA, USA) diluted in blocking buffer for 1 hour at room 
temperature. Membrane was then washed 4 times for 5 minutes each in TTBS before 
developing with 1 mL (1:40 dilution) Pierce ECL Blotting Substrate (Fisher Scientific, 
Loughborough, UK Scientific) for 5 minutes in the dark. Membrane was exposed and 
imaged using the Amersham Imager 600 (GE Healthcare, Amersham, London, UK). 
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Antibody Manufacturer Catalog # Dilution  
Anti-PRDM9 Abcam, Cambridge, UK ab85654 1:500 
Anti-PRDM9 Novex, Thermo Fisher Scientific 730062 1:500 
Anti-PRDM9  Human Protein Atlas HPA063372 1:100 
Anti-PRDM9  Human Protein Atlas HPA059555 1:100 
Anti-GAPDH Santa Cruz, Dallas, Texas, USA sc-25778 1:1000 
Anti-MTCO1 Abcam, Cambridge, UK ab14705 1:1000 
Anti-β actin Sigma Aldrich, Dorset, UK A1978  1:2000 
Anti-HSPA5 (Bip1) Abnova, Cambridge, UK PAB2462 1:1000 
Anti-SDHA Abcam, Cambridge, UK ab14715 1:5000 
Anti-MTCO2 Abcam, Cambridge, UK ab3298 1:1000 
Anti-TFAM Source Bioscience, Manchester, UK LS-C143233 1:1000 
Anti-α tubulin Abcam, Cambridge, UK ab59680 1:1000 
Anti-VDAC1 Abcam, Cambridge, UK ab14734 1:250 
Anti-HSP60 GeneTex, California, USA GTX110089 1:5000 
Anti-histone H3 Abcam, Cambridge, UK ab1791 1:1000 
Anti-H3K4me1 Cell Signaling, Boston, MA, USA #5326 1:1000 
Anti-H3K4me2 Cell Signaling, Boston, MA, USA #9725 1:1000 
Anti-H3K4me3 Cell Signaling, Boston, MA, USA #9751 1:1000 
Anti-OXPHOS cocktail MitoSciences, Oregon, USA MS604 1:250 
Anti-biotin Cell Signaling, Boston, MA, USA #7727 1:1000 
Rabbit anti-mouse DAKO, Cambridge, UK P0260 1:1000 
Swine anti-rabbit DAKO, Cambridge, UK P0399 1:1000 
Biotinylated protein ladder Cell Signaling, Boston, MA, USA #7727 1:2000 
See Blue Plus2 ladder Fisher Scientific, Loughborough, UK LC5925 5 µL 
PRDM9 synthetic protein Abcam, Cambridge, UK ab87806 1 µg/mL 
Table 3.2 List of antibodies and protein ladders used in this study. Manufacturer is provided 
along with the working dilutions used in all experiments. 
 
3.7.4 Immunoprecipitation 
Immunoprecipitation (IP) was performed using an IP kit (Pierce Classic Magnetic 
#88804) following the manufacturers guidelines. Cell pellets were washed with PBS and 
collected on ice. For each pellet, 500 µL lysis buffer (Pierce) with 2% proteinase 
inhibitor cocktail (Roche Diagnostics Limited, West Sussex, UK) was added and after an 
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incubation of 5 minutes, the samples were centrifuged at 13,000 x rcf for 10 minutes at 
4 °C. Lysate was analysed for protein concentration via mini Bradford outlined above. 
Antibody (Table 3.3) was added to the lysate and incubated overnight at 4 °C with 
constant rotation to form protein-antibody complexes. The protein-lysate complexes 
were incubated with A/G magnetic agarose beads for 2 hours at room temperature with 
constant rotation. Beads were then collected on a magnetic stand and washed several 
times in lysis buffer and dH2O to remove any unbound protein. Final elution of bound 
protein was performed with 25 µL of elution buffer with 10% neutralisation buffer. 
Protein concentration was determined for each wash step plus final elution lysate via 
mini Bradford. SDS-PAGE was performed using the X-Cell electrophoresis unit (Novex) 
with 4-20% precast gels (Novex). After electrophoresis, gels were removed and 
incubated for 1 hour in InstantBlue solution (Expedeon). Gels were washed in warm 
dH2O until background staining was eliminated and only protein bands were stained.   
  
Antibody Manufacturer Quantity used 
Anti-PRDM9 Abcam, Cambridge, UK 10 mg 
Anti-PRDM9 Novex 10 mg 
Anti-PRDM9  
HPA059555 
Human Protein Atlas 1.7 mg 
Anti-PRDM9 
HPA063372 
Human Protein Atlas 3.5 mg 
Table 3.3 Antibodies used for PRDM9 immunodetection. 
 
3.7.5 Mass spectrometry analysis 
Mass spectrometry analysis was performed at the Newcastle University Protein and 
Proteome Analysis Unit. Briefly, bands were cut out and reduction of the proteins 
performed in gel. Alkylation with iodoacetamide was carried out before in gel digestion 
with modified trypsin. Resulting peptides were extracted from the gel and purified on 
custom reversed phase columns. Analysis was performed by LCMSMS on a nano-HPLC 
system (column: 25 cm x 75 µm ID, flow rate 300 nL/min). Data was processed using the 
open source search engine X!Tandem and the Global Proteome Machine interface 
(http://www.thegpm.org/).  
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3.7.6 siRNA experiments 
HEK293 cells were transfected with pre-designed PRDM9 siRNA (Silencer Select, 
Thermo Fisher Scientific, Loughborough, UK) following manufacturer’s specifications 
with small modifications to the protocol. Briefly, cells were seeded at 10 x 104 cells/flask 
and incubated overnight in appropriate media. siRNA was diluted to 20 nM 
concentration in Opti-MEM media (GIBCO, Thermo Fisher Scientific, Loughborough, UK). 
Lipofectamine (RNAiMAX, Thermo Fisher Scientific, Loughborough, UK) was diluted to 
0.5% in Opti-MEM. Reactions were set up as shown in Table 3.4. 
  
siRNA target 10µM siRNA Opti-MEM Lipofectamine Opti-MEM 
PRDM9 (20nM)  100 µL 400 µL 2.5 µL 497.5 µL 
Blank control - - - 1000 µl 
Lipofectamine control - 500 μL 2.5 µL 497.5 µL 
Non-targeting control (20nM) 100 µL 400 µL 2.5 µL 497.5 µL 
Table 3.4 siRNA and lipofectamine dilutions. Controls were also used including a blank (Opti-MEM only), 
lipofectamine control (no siRNA) and a non-targeting siRNA control (Negative control #2, Thermo Fisher 
Scientific, Loughborough, UK). 
 
The lipofectamine and siRNA dilutions were then combined and incubated at room 
temperature for 20 minutes. The dilutions were then added to the appropriate flasks 
and cells were left to transfect for 2-3 days depending on confluency.  Forward 
transfection was performed every 2-3 days for the duration of the experiment. 
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3.8 Immunostaining and Imaging 
3.8.1 CryoSectioning  
Human tissue samples were collected by the relevant tissue bank, snap frozen in liquid 
nitrogen and stored at -80 °C. CryoSectioning was performed by mounting the tissue 
block in optimum cutting temperature formulation (OCT) and allowing the sample to 
adjust to -20 °C in the cryostat chamber. Sections were cut 10 μm thick, collected on 
Superfrost glass slides and allowed to dry for 30 minutes at room temperature to avoid 
freezing artefacts.   
3.8.2 H&E staining of human tissue Sections 
Slides were washed for 2 minutes in dH2O and were placed in Haemalum solution for 
1 minute. Slides were washed again for 2 minutes in dH2O and placed in Eosin solution 
for 1 minute. Slides were washed for 2 minutes in dH2O before being dehydrated in 
graded alcohol: 70% EtOH 30 seconds, 95% EtOH for 30 seconds, 100% EtOH for 
2 minutes. Sections were covered in DPX solution and a glass coverslip was placed on 
top.  
3.8.3 Immunostaining human tissue sections 
Tissue sections on slides were fixed using 4% paraformaldehyde (PFA, Sigma Aldrich, 
Dorset, UK Aldrich) for 10 minutes. Slides were washed 3 times with PBS to completely 
remove the PFA. Sections were permeabilised by adding 0.5% Triton X-100/PBS for 
10 minutes. After washing 3 times with PBS the Sections were blocked in buffer (5% 
FBS/0.1% Tween20/PBS) for 1 hour at room temperature. Primary antibodies were 
diluted in 2% FBS/PBS and were added to the Sections and left to incubate at 4 °C 
overnight.  
Sections were washed twice for 5 minutes with cold PBS before the addition of the 
secondary fluorochrome-conjugated antibody diluted in 2% FBS/0.1% Tween20/PBS. 
Slides were incubated for 1 hour at room temperature in the dark. Slides were washed 
3 x 5 minutes in PBS. Each Section was covered with VECTASHIELD Anti-fade Mounting 
Medium with DAPI (Vectorlabs). 
3.8.4 Immunostaining cultured cells  
Cells were grown on glass coverslips pre-coated with poly-L-lysine (Sigma Aldrich, 
Dorset, UK). Briefly, coverslips were washed in 70% EtOH before being placed into the 
well of a 6 well tissue culture plate and subjected to UV light for 20 minutes. 1 mL 
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poly-L-lysine was added to each well to completely cover the surface area. The plate was 
incubated at room temperature for 30 minutes. The poly-L-lysine solution was removed 
and the wells were washed twice with sterile PBS. Plates were covered with parafilm 
and stored at 4 °C until required or were used immediately by washing once with DMEM 
before cells were plated. 
When the cells were ready to image, growth media was removed and cells were fixed in 
4% PFA at room temperature for 10 minutes. Cells were then washed twice with PBS for 
2 minutes each time. Blocking buffer (PBS/5% normal goat serum/0.3% Triton X-100) 
was added to the cells for 1 hour at room temperature before the addition of primary 
antibody in dilution buffer (PBS/1% BSA/0.3% Triton X-100) overnight at 4 °C. Cells 
were washed three times with PBS before addition of the secondary fluorochrome-
conjugated antibody for 1 hour in the dark. Cells were washed three times with PBS 
before the addition of VECTASHIELD Anti-fade Mounting Medium with DAPI 
(Vectorlabs). All antibodies used are detailed in Table 3.5. 
  
Antibody Manufacturer Catalog # Dilution  
Anti-PRDM9 Abcam, Cambridge, UK  ab85654 1:500 
Anti-FLAG M2 Sigma Aldrich F1804 1:500 
Anti-OPA1 Abcam, Cambridge, UK  ab42364 1:250 
Anti-TFAM Source Bioscience, Manchester, UK LS-C143233 1:250 
Anti-HSP60 Abcam, Cambridge, UK  ab46798 1:400 
Anti-TOMM20 Santa Cruz, Dallas, Texas, USA sc-17764 1:1000 
Goat anti-mouse  
Alexa Fluor® 488 
Fisher Scientific, Loughborough, UK A-11001 1:1000 
Goat anti-rabbit 
Alexa Fluor® 488 
Fisher Scientific, Loughborough, UK A-11034 1:1000 
Goat anti-mouse 
Alexa Fluor® 594 
Fisher Scientific, Loughborough, UK A-11032 1:1000 
Table 3.5 List of antibodies used for immunostaining in this study. 
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3.8.5 Microscopy 
Cells were imaged using the Nikon Confocal Microscope and or the AxioImager (Zeiss).  
 
3.9 Cloning 
Cloning was performed using the pGEM-T easy vector system (Promega, Southampton 
UK). Incubations carried out at 37 °C were performed in a temperature controlled 
microbiology incubator (Thermo Fisher Scientific, Loughborough, UK). 
3.9.1 Product preparation 
cDNA sequences of interest were provided already integrated into a vector DNA 
backbone. In order to subclone insert sequences into another vector system, restriction 
enzymes (Table 3.6) were utilised to digest the insert from the pcDNA3.1(+) vector 
sequence. Reaction mixture was as follows: 50 ng plasmid DNA, 10 U each restriction 
enzyme, 2 μL CutSmart buffer (New England Biolabs inc.), 3 μL10X BSA made up to a 
final volume of 50 μL with dH2O. Reactions were incubated at 37 °C for 1 hour. The total 
volume of digested sample was run on a size selection gel as previously described. The 
product of interest was gel extracted using the QIAquick gel extraction kit following 
manufacturers instructions (Qiagen, Manchester, UK, Manchester UK). 
  
Restriction enzyme Manufacturer 5’-3’ Cut site 
ApaI New England Biolabs Inc. GGGCCC 
BamHI New England Biolabs Inc. GGATCC 
EcoRV New England Biolabs Inc. GATATC 
HindIII New England Biolabs Inc. AAGCTT 
PmeI New England Biolabs Inc. GTTTAAAC 
XhoI New England Biolabs Inc. CTCGAG 
Table 3.6 List of restriction enzymes used in this study. 
 
3.9.2 Ligation 
Next, a ligation reaction was set up using the ligase provided in the pGEM-T easy kit 
(Promega, Southampton UK). Reaction mixture was as follows: 2X Rapid ligation buffer, 
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50 ng pcDNA5 vector, 3U T4 DNA ligase, dH2O and the volume of insert DNA from the 
restriction enzyme digest as calculated by the following equation: 
 
𝑖𝑛𝑠𝑒𝑟𝑡: 𝑣𝑒𝑐𝑡𝑜𝑟 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 =  
𝑛𝑔 𝑣𝑒𝑐𝑡𝑜𝑟 𝑥 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 (𝐾𝑏)
𝑠𝑖𝑧𝑒 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 (𝐾𝑏)
 
 
To maximise the number of positive transformants from the reaction, ligation was 
performed at 16 °C for 12 hours. 
3.9.3 Transformation 
Ligation transformation was performed using JM109 high efficiency competent cells 
(Promega, Southampton UK), 2X Yeast Tryptone broth (2YT) and 2YT agar plates were 
used as growth medium. 2YT agar was autoclaved and allowed to cool to approximately 
55 °C before being supplemented with 100 mg/mL ampicillin, 75 μg/mL X-Gal and 
0.5 mM IPTG. Agar was poured into 90 mm plates under aseptic conditions and left to 
cool and solidify at room temperature. Plates were either dried at 37 °C or stored at 4 °C 
for up to 1 month. 5 μL of ligation product was added to pre-aliquoted (25 μL) 
competent cells on ice, gently agitating the tube to ensure the ligation product and cells 
were mixed. Competent cells used in this study are detailed in Table 3.7. The mixture 
was incubated on ice for 20 minutes before being subjected to heat shock for 45 seconds 
at 42 °C using a dry heat bath with 200 μL water added to the well. The tube was then 
returned to ice for 2 minutes before 470 μL autoclaved 2YT broth was added to the 
transformants and incubated at 37 °C for 1 hour at 150 rpm. To plate the cells, 200 μL of 
the cell suspension was spread onto an agar plate under aseptic conditions using a glass 
spreader dipped in ethanol and flamed. Plates were incubated for 16 hours at 37 °C. 
White colonies were picked for colony PCR and sequencing. Growth of white colonies 
indicates a successful ligation and transformation. Blue colonies indicate a successful 
transformation but inefficient ligation due to the activation of β-galactosidase. To 
perform the PCR 10 μL dH2O was added to each tube in a sterile 8 strip PCR tube. 
Autoclaved pipette tips were used to pick single colonies from the growth plate and 
were dipped in the PCR tube before being streaked onto a new growth plate and placed 
in 5 mL fresh 2YT broth, supplemented with 100 mg/mL ampicillin. The plate was 
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incubated at 37 °C to expand the colonies and the 5 mL inoculated 2YT broth was 
incubated at 37 °C at 150 rpm for 16 hours. Due to the size of the insert DNA sequences 
used in this study, long range PCR was performed as follows; to the 10 μL dH2O colony 
pick, 10% betaine, 10 %10X LA PCR Buffer II (Mg2+), 200 μM dNTP, 0.2 μM forward 
primer, 0.2 μM reverse primer and 1.25 U TaKaRa LA Taq was added to a final reaction 
volume of 25 μL. Thermocycling conditions were performed in 30 cycles of; 94 °C for 
1 minute, denaturing at 98 °C for 10 seconds, primer annealing at 62 °C for 15 minutes 
followed by final extension at 72 °C for 10 minutes. Sequencing was performed as 
previously described. Once the desired product was confirmed by running PCR products 
on size separation gels and sequencing, 1 mL of the 5 mL inoculated broth was used to 
inoculate 100 mL 2YT broth. This broth was incubated at 37 °C for 16 hours at 150 rpm. 
The remaining 4 mL of original inoculated broth was used to create glycerol stocks of 
the colony, 150 μL glycerol was added to 850 μL broth in a 2 mL cryovial and stored 
at -80 °C. 
  
Competent Cell Type Manufacturer Application 
JM109 Promega Plasmids <10Kb 
One Shot® Stbl3™ Invitrogen Large unstable plasmids 
One Shot® MAX Efficiency® DH5α™ Invitrogen Large plasmids 
Table 3.7 Details of all competent cell types used throughout the study. 
 
3.9.4 Plasmid purification  
Growth medium inoculated with colonies carrying the correct plasmid and insert was 
centrifuged for 15 minutes at 6000 x rcf at 4 °C. Pellets were then processed using the 
Qiagen, Plasmid Maxi Kit (Qiagen, Manchester, UK) according to the manufacturers 
instructions. The final pellet was air dried for 10 minutes to allow any remaining ethanol 
to evaporate and the DNA was resuspended in 500 μL dH2O.  DNA concentration was 
measured using the Nanodrop2000 UV-vis Spectrophotometer (Thermo Fisher 
Scientific, Loughborough, UK). 
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3.10 Transfection of cultured cells 
3.10.1 Transient overexpression system 
Transfection of HEK293 cells was carried out in 6 well tissue culture plates. Briefly, 
HEK293 cells were harvested as previously described (Section 3.4.1), cell pellets were 
resuspended in 10 mL DMEM and counted using a haemocytometer. Cells were seeded 
at 30, 000 cells/well in 4 mL fresh DMEM and were left to adhere for 24 hours. The 
transfection mixture was prepared by adding 97 μL Optimem (Invitrogen, Thermo 
Fisher Scientific, Loughborough, UK) serum free media and 3 μL Genejuice (Novagen) to 
a 1.5 mL tube, mixed by vortexing and left to incubate at room temperature for 5 
minutes. To this 1 μg plasmid DNA (cloned and purified as previously described in 
Section 3.10) was added and the mixture was incubated at room temperature for 20 
minutes. The transfection mixture was added dropwise to the cell culture well 
containing the cells seeded previously. The cells were incubated at 37 °C for 3 days 
before harvesting and being processed for further analysis. For imaging protocols, 22 
mm glass cover slips were placed in the wells of the tissue culture plates and were 
coated with 1 mL poly-L-lysine for 30 minutes at room temperature, washed twice with 
PBS, washed once with DMEM and then seeded with cells as described above. After 
transfection for 3 days, the cover slips were removed from the plates and processed for 
immunostaining as described in Section 3.8.4.  
3.10.2 Stable overexpression cell line  
The Flp-In T-Rex system (Invitrogen, Thermo Fisher Scientific, Loughborough, UK) was 
used to selectively induce overexpression of genes of interest in HEK293 cells previously 
modified to contain a stable FRT site and the tetracycline repressor in the genome (a 
kind gift from Professor Robert Lightowlers, Institute of Cell and Molecular Biology 
Newcastle University). Cells were transfected with a reaction mixture comprising; 91 μL 
OptiMem (GIBCO, Thermo Fisher Scientific, Loughborough, UK), 9 μL Genejuice 
(Novagen, EMD Biosciences, USA), a range of 2 μg, 4 μg and 6 μg pcDNA5/FRT/TO 
plasmid and 1.8 μg pOG44 plasmid expressing Flp recombinase. Expression of Flp 
recombinase enzyme is required to catalyse the transfer of the insert DNA sequence 
from the pcDNA5 plasmid into the genome of the cell through homologous 
recombination. This occurs at specific recognition sites present in the pcDNA5 construct 
sequence and the genome. Stable integration of the gene of interest confers hygromycin 
resistance to the cell.  
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After 24 hours the cells were split to 50% confluency and stably integrated colonies 
were selected for by adding 50 mg/mL hygromycin to growth medium. To ensure the 
stability of the tetracycline promoter in the HEK293 genome, 100 mg/mL blasticidin 
was added to appropriate growth medium and added to the cells every third media feed. 
After several weeks of colony selection, pure cultures of transfected cells were obtained. 
Tetracycline (1 µg/mL) was added to the growth media to induce gene expression 
before cells were harvested for further investigation. 
 
3.11 Quantitative polymerase chain reaction 
3.11.1 Reverse transcription of RNA to cDNA 
Total RNA was extracted from HEK293 cells as described in Section 3.6. RNA was 
converted to cDNA using the High Capacity Reverse Transcription Kit (Thermo Fisher 
Scientific, Loughborough, UK). RNA was diluted to a final concentration of 2 μg in a 10 
μL volume using nuclease free water before the reaction mixture was added. The 
reaction mixture was as follows: 2 μL 10X RT buffer, 4 mM dNTPs, 2 μL 10X random 
primers, 1 μL MultiScribe reverse transcriptase made to a final volume of 10 μL with 
nuclease free water. The 20 μL reactions were incubated at 25 °C for 10 minutes, 37 °C 
for 120 minutes and finally 85 °C 5 minutes. Samples were stored at -20 °C until 
required. 
3.11.2 PRDM9 gene expression 
Quantification of the relative transcription of specific genes was carried out by real time 
quantitative PCR (RT-qPCR) using either a double stranded DNA intercalating dye 
(SYBR) or the TaqMan® gene Expression Assay (Applied Biosystems, Thermo Fisher 
Scientific, Loughborough, UK). The SYBR® reactions were comprised as follows; 1X iQ™ 
SYBR® green, 0.5 µM forward and reverse primer, 1-5 µg sample cDNA, made up to 25 
µL with dH2O. All reactions were carried out on the MyIQ™ thermocycler (BioRad 
Laboratories, Hemel Hempsted, UK) with the following program: initial denaturation at 
95 °C for 3 minutes followed by 40 cycles of; 95 °C for 10 seconds and 62.5 °C for 1 
minute with a final 95 °C for 1 minute and a melt curve. A melt curve was performed by 
measuring loss of fluorescence after each 10 second incubation step, rising from 62 – 
95 °C, in 0.5 °C increments. 
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For the TaqMan® gene Expression Assay, target specific probes are designed, nested in 
between target specific primers, and covalently attached to a fluorescent reporter dye 
on the 5’ end and a non-fluorescent quencher dye on the 3’ end. When the reporter and 
quencher are in close proximity the excitation energy of the fluorescent reporter is 
transferred to the quencher through FRET chemistry (fluorescent resonance energy 
transfer). During the PCR reaction when the amplicon extends, the fluorescent reporter 
dye is cleaved from the probe by Taq polymerase exonuclease activity and the emission 
spectra of the reporter can be measured. 
RT-qPCR was carried out on a 7500 Fast Real Time PCR System. Reaction mix was as 
follows, 1X TaqMan® Gene Expression Master Mix, 250 nM TaqMan® probe, 4 μg cDNA 
made up to a final volume of 20 μL nuclease free water. The reaction was as follows, 
initial incubation at 50 °C for 2 minutes, denaturing at 95 °C for 20 seconds and 40 
cycles of primer annealing at 60 °C for 30 seconds and 95 °C for 3 seconds when 
fluorescence was detected. Serial 1:10 dilutions of cDNA in nuclease free water were 
used to ensure linearity and efficiency of the reaction and for standard curve 
quantification.  Each sample was measured in triplicate and contamination of reagents 
excluded by the use of cDNA negative controls. Targets and their probes are listed in 
Table 3.8.  
  
Target Probe Location Length (bp) Supplier 
PRDM9 Hs01633270_s1 3569 179 Applied Biosystems 
PRDM9 Hs00360639_m1 360 143 Applied Biosystems 
β-actin Hs01060665 208 63 Applied Biosystems 
Table 3.8 Probes used in this study. 
 
3.11.3 Mitochondrial DNA copy number 
Quantification of mtDNA copy number and mtDNA deletion level was carried out using 
an RT-qPCR assay.  This method allows detection of multiple target specific fluorescent 
probes in the same reaction using Taqman® qPCR amplification as described in Section 
3.11.2. Each probe was designed so that the emission spectra of the fluorophore did not 
overlap with the other probes therefore allowing accurate detection of each amplicon. 
Quencher dyes were also designed to have an absorbance spectrum which overlapped 
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the emission spectra of the fluorophore, limiting background signal from the probe 
itself. Serial 1:10 dilutions of DNA from non-transfected HEK293 cells were used to 
ensure linearity of the reaction and for standard curve quantification. The reaction 
mixture was as follows: 0.6 μL of each primer, 0.4 μL of each probe, 10 μL iTaq SuperMix 
reaction buffer (BioRad Laboratories, Hemel Hempsted, UK) and 1 μL of sample DNA 
made up to 20 μL with nuclease free water. Probes used in this study are outlined in 
Table 3.9. 
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Target Forward Primer 5’-3’ Reverse Primer 5’-3’ Dye Quencher Probe 5’-3’ 
RNase P AGATTTGGACCTGCGAGCG GAGCGGCTGTCTCCACAAGT HEX BHQ-2 TTCTGACCTGAAGGCTCTGCGCG 
B2M CACTGAAAAAGATGAGTATGCC AACATTCCCTGACAATCCC FAM BHQ_1 CCGTGTGAACCATGTGACTTTGTC 
MT-CYB ATGACCCCAATACGCAAAA CGAAGTTTCATCATGCGGAG CY5 BHQ-2 CATTCATCGACCTCCCCACCC 
MT-CO3 ATGACCCACCAATCACATGC ATCACATGGCTAGGCCGGAG FAM BHQ-1 ACCCAGCCCATGACCCCTAAC 
MT-ND1 ACGCCATAAAACTCTTCACCAAAG GGGTTCATAGTAGAAGAGCGATGG HEX BHQ_1 ACCCGCCACATCTACCATCACCCTC 
MT-ND4 ACCTTGGCTATCATCACCCGAT AGTGCGATGAGTAGGGGAAGG Cy5 BHQ_2 CAACCAGCCAGAACGCCTGAACGCA 
Table 3.9 Primer and probe details used for mtDNA copy number quantification. 
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Chapter 4 Analysis of PRDM9 binding motifs in mtDNA sequences. 
 
4.1 Overview 
The role of PRDM9 in creating recombination hotspots within the human genome is 
predicted to occur when the protein binds to the DNA recognition motif through its zinc 
finger domain (Myers et al., 2008; Baudat et al., 2010; Billings et al., 2013). Due to the 
polymorphic nature of the PRDM9 zinc finger repeat region, each PRDM9 allele in the 
population is predicted to have a subtly different genomic binding motif. A previous 
study showed that the predicted PRDM9 binding motif is also present in mtDNA at the 
site flanking the 4977bp ‘common’ deletion (Myers et al., 2008). To determine whether 
this predicted recognition motif is present in human mtDNA we used an in silico 
screening approach.  A large cohort (n=31,516) of mtDNA sequences downloaded from 
the Genbank sequence depository were computationally screened for the presence of 
each of the eleven predicted PRDM9 binding motifs. This is of interest as protein-DNA 
binding motifs within the mtDNA could explain why certain regions of the molecule are 
prone to deletion formation (Figure 4.1). 
 
 
Figure 4.1 Location of mtDNA deletions in respect to the region of the molecule based on the reported 
cases. Adapted from the Mitobreak mitochondrial deletion database (Damas et al., 2014). 
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In addition, the matrilineal nature of mtDNA can be utilised to define sequences based 
on their phylogenetic ancestry allowing population differences to be explored (Emery et 
al., 2015). Associations between haplogroup status and disease risk have been described 
previously, however no study has interrogated the potential difference in mtDNA 
deletion susceptibility between population haplogroups. Deletion frequency and 
haplogroup-associated disease prevalence have been extensively reported in European 
populations (Taylor and Turnbull, 2005; Bua et al., 2006; Campbell et al., 2014; 
Komulainen et al., 2015; Mancuso et al., 2015) however there is a lack of data for 
populations from other geographical regions. The mtDNA sequences screened for the 
presence of PRDM9 binding sites were also segregated by haplogroup to assess whether 
there is any correlation between PRDM9 motif presence and haplogroup status.   
 
4.2 Hypothesis 
Background mtDNA sequence variation will alter the frequency of the PRDM9 
recognition motif potentially giving an insight into the differential frequency of mtDNA 
deletions between human populations.  
 
4.3 Aims 
This study aims to determine whether the PRDM9 recognition motif is present in human 
mtDNA sequences and identify whether different mtDNA haplogroups have unique 
PRDM9 motifs. 
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4.4 Results 
4.3.1 Pilot screen of PRDM9 binding motifs in 9, 769 sequences 
European mtDNA sequence files were downloaded from the NCBI Nucleotide Database 
(http://www.ncbi.nlm.nih.gov/nuccore/) in FASTA format. In order to quickly screen 
for the presence of the PRDM9 recognition motif, Perl was used to search sequence files 
for the most common motif (motif A) ‘CCNCCNTNNCCNC’. The script used is shown in 
Figure 4.2. 
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Figure 4.2 Custom Perl script to screen sequence files for the PRDM9 recognition motif ‘A’ Output file will 
contain; the filename for each sequence file containing a matching sequence, the sequence matched and 
the start position in the sequence file (when the first base of the sequence file is counted as 1). 
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Using a simple find loop, regions of the sequences matching the motif were counted and 
given as total matches per sequence along with the base position where the match 
occurred (Table 4.1). In contrast to the site described by Myers et al, motif A was found 
at position m.5327 in 99.9% of sequences screened (Table 4.1). Several sequences 
contained the motif in more than one position. Interestingly, nine (0.00092%) of the 
sequences did not contain this recognition site due to the polymorphism m.5333T>C in 
the gene coding for the OXPHOS subunit mitochondrial NADH dehydrogenase 2 
(MT-ND2). This SNP is not a population haplogroup marker and is a synonymous 
mutation not previously reported in the NCBI dbSNP database 
(http://www.ncbi.nlm.nih.gov/variation/view/), suggesting that the population 
frequency is very low.  
Sixteen (0.0016%) of the sequences screened had a motif starting at position m.14481 
caused by the transition m.14484T>C, one of three pathogenic mutations found in 
Leber’s hereditary optic neuropathy (LHON) (Johns et al, 1992; Mackey and 
Howell, 1992; Man et al, 2003). This mutation causes a non-synonymous change in the 
gene encoding mitochondrial NADH dehydrogenase 6 (MT-ND6, rs199476104).  
Position m.304 contains a variable poly-C tract with a tyrosine nucleotide in the middle 
that differs in length from 12-18 bp within the population (Marchington et al., 1997). An 
insertion of an extra cytosine nucleotide leads to the creation of a PRDM9 recognition 
motif in twelve (0.0012%) of the sequences screened (Table 4.1). In twenty-eight 
(0.0029%) of the sequences screened there was an insertion of a tyrosine nucleotide at 
position m.311 leading to the creation of a PRDM9 motif shifted by one base pair to 
begin at m.304. 
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Table 4.1 PRDM9 motif search in 9769 mtDNA sequences. The frequency of each motif match is shown in column 1, this corresponds to the number of mtDNA 
sequences that have the motif. The matched sequence start and end positions are shown in columns 2 & 3 and correspond to the mtDNA position 5’-3’. The DNA 
sequence matched is shown in column 4. The revised Cambridge Reference Sequence (rCRS) is used as the ‘wild type’ reference sequence. SNP changes from rCRS 
causing a motif site to be created are shown in column 6.   
Frequency Motif Start Motif End Motif Match Array ID SNP
CCNCCNTNNCCNC
9760 5327 5340 CCTCCTTAACCTC rCRS rCRS
9 5327 5340 CCTCCTCAACCTC 5333 m.5332T>C
1 303 316 CCCCC-TCCCCCC cTRAC -
8 303 316 CCCCCCTCCCCCC cTRAC 316insC
3 304 317 CCCCCCT-CCCCC cTRAC -
28 304 317 CCCCCCTTCCCCC cTRAC 311insT
3 8131 8144 CCACCTTCACCGC 8134 m.8133T>C
3 8273 8286 CCCCCCTACCCCC 8277 m.8276T>C
6 14054 14067 CCTCCATCACCAC 14063 m.14062T>C
1 14058 14071 CCACCATCACCTC 14060 m.14059T>C
16 14481 14494 CCACCATTCCCCC 14485 m.14484T>C
1 14481 14494 CCACCATCCCCCC 14485 14488 m.14484T>C//m.14487T>C
GGNGGNAGGGG
9655 9529 9540 CCCCTACCCCC rCRS rCRS
11 9529 9540 CCCCTGCCCCC 9531 m.9530A>G
28 308 319 CCCCTTCCCCC cTRAC 311insT
9 308 319 CCCCTCCCCCC cTRAC 316insC
3 308 319 CCCCT-CCCCC cTRAC -
7 459 470 CCCCTCCCACC 467 m.466T>C
1 5441 5452 CCCCTTCCTCC 5441 m.5440A>C
2 6224 6235 CCCCTCCCTCC 6221 6227 m.6220T>C m.6226T>C
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The sequence files were screened for an alternative A motif (GGnGGnAGGGG) suggested 
in the literature to be a PRDM9 binding motif (Berg et al, 2011). When the mtDNA was 
screened for the antisense strand sequence of this motif there was a positive hit in 
almost every sequence (98.8%) at position m.9529 (Table 4.1). A SNP at m.9531 (A>G) 
changes the binding motif in eleven of the sequences screened (0.0011%). This SNP 
gives place to a non-synonymous change m.9531A>G/p.MT-CO3:T109A (rs386829082).  
Having determined that the PRDM9 ‘A’ motif binding site was present in human mtDNA, 
the search was scaled up to include a larger number of sequences. 
 
 88 
 
4.3.2 Expanded search for PRDM9 binding motifs n=31, 516 sequences 
Sequence files were downloaded as above and were converted from FASTA to BAM 
format. BAM files were aligned using the Integrated Genome Viewer (IGV) and 
Haplogrep was used to determine mtDNA haplogroup. Haplogrep searches a defined set 
of mitochondrial haplogroup specific SNPs continuously updated and documented in 
PhyloTree (van Oven and Kayser, 2009; Kloss-Brandstatter et al., 2011). The files were 
then screened using a custom Perl script written by Dr H. Griffin (Institute of Genetic 
Medicine, Newcastle University) for all eleven possible PRDM9 motif matches listed in 
Table 4.2 (Berg et al., 2012). Each sequence was searched for every motif several times 
to ensure that all possible matches were counted as hits at specific nucleotide positions. 
  
PRDM9 Allele Match Motif Sequence Motif Search No. 
A/B CCNCCNTNNCCNC 1 
A/B 2 CCNCCNTNNCCNCC 2 
C CCNCNNTNNNCNTNNC 3 
D CCNCNNNCNTNNCCNC 4 
E CNNNNCNNNTNNCCNCC 5 
L1 CNNNCCNTNNCCNC 6 
L4/L8/L14/L16/L17/L18 CCNCNNTNNNCNTNNC 7 
L5 CNNCNNNNNNNNNCCNC 8 
L6 CCNCNNTNNNCNTNNC 9 
L7/L11/L12 CCNCCNTNNC 10 
L19 NCNNTNNNCNTNNCCNC 11 
Table 4.2 Sequences of the eleven PRDM9 recognition motifs used to search the mtDNA sequence files. 
The corresponding PRDM9 alleles are shown in the left hand column, the protein products of which are 
predicted to bind the motif sequence shown in the middle column. Each motif was assigned a motif search 
number shown in the right hand column. Adapted from Berg et al., 2012. 
 
Sequences were categorised into three main groups based on macro-haplogroup status: 
European, African and Asian. Out of the total 31, 516 sequences screened; 16, 490 were 
European (52.32%), 4020 were African (12.75%) and 11, 006 were Asian (34.92%) 
(Figure 4.3). The nature of maternal inheritance has allowed these sequences to be 
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further sub-grouped based on a well-established set of mtDNA population SNPs 
(Torroni et al., 1994; Brown et al., 1998; Finnila et al., 2001).  
European haplogroups comprised over half of the sequences in this data set (Figure 4.3 
A). Within the European group itself, sub-haplogroups appeared to be present in 
frequencies representative of the European population observed in other studies for 
example haplogroup H was present in 39.9% of our samples, mirroring the observed 
population frequency of 40% (Figure 4.3 B). Asian sub-haplogroups also showed 
population distribution as the most frequent haplogroup represented was M at 24.5% of 
the Asian population (Figure 4.3 C). All African haplogroups were denoted as L due to 
the most ancestral mtDNA’s being extremely similar in sequence and belonging almost 
exclusively to haplogroups L0, L1, L2 or L3 (Emery et al., 2015). 
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Figure 4.3 Distribution of mitochondrial haplogroup frequencies in the 31,516 sequences analysed. A) Haplogroup frequency as a percentage of the total number of 
sequences used in the analysis. B) European haplogroup frequency as a proportion of the total number of European sequences used in the analysis. C) Asian 
haplogroup frequency as a proportion of the total number of Asian sequences used in the analysis.  
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Firstly, the frequency of binding sites was assessed in each population group. All eleven 
binding motifs were analysed, however the most informative are the motifs bound by 
the most common PRDM9 alleles A, B and C. Slight differences were seen in motif A 
binding sites between the three population groups (Figure 4.4 A). Most mtDNA 
sequences contained two motif A binding sites. Asian sequences appeared to have a 
higher frequency of genomes containing one motif site. European sequences had a 
higher frequency of mtDNAs with three binding sites. Although it was rare to have 
mtDNA sequences with no motif A recognition sites, there was a higher number of 
African sequences lacking any binding motif (Figure 4.4 A).  
 
 
Figure 4.4 PRDM9 ‘Motif A’ binding sites. A)  Number of times motif A was found in mtDNA sequences 
from African, Asian and European mtDNA sequence groups. Proportion of population refers to the 
percentage of mtDNA sequences from each of the three population groups as a fraction of 1. B) Number of 
times Motif A was found in mtDNA sequences from each European haplogroup present in the mtDNA 
sequencing files. Proportion of population refers to the percentage of mtDNA sequences from the 
European population group as a fraction of 1. 
 
European sequences were then subdivided by haplogroup (Figure 4.4 B). This analysis 
showed that most of the mtDNAs containing three motif A sites were haplogroup J. 
There were subtle differences between sub-haplogroups containing one or two motif A 
sites however the general trend followed that of the population with more European 
sequences containing two motif A sites (Figure 4.4 A & B). 
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The second most common PRDM9 allele in Europeans is B. The motif for allele B was 
analysed by broad population grouping (Figure 4.5 A). Most sequences analysed did not 
contain any motif B sites. A small proportion of sequences in each population had one 
motif B site.  
 
 
Figure 4.5 PRDM9 ‘Motif B’ binding sites. A)  Number of times Motif B was found in mtDNA sequences 
from African, Asian and European mtDNA sequence groups. Proportion of population refers to the 
percentage of mtDNA sequences from each of the three population groups as a fraction of 1. B) Number of 
times Motif B was found in mtDNA sequences from each European haplogroup present in the mtDNA 
sequencing files. Proportion of population refers to the percentage of mtDNA sequences from the 
European population group as a fraction of 1. 
 
When the European sequences were analysed by sub-haplogroup, haplogroup J was 
over represented in the sequences containing one motif B site (Figure 4.5 B). 
Interestingly, haplogroup J was the only mtDNA sequence to have two motif B sites. 
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The second most prevalent PRDM9 allele in African populations is the C allele. Several 
motif C sites were found within mtDNA in all populations analysed with the majority of 
sequences containing ten sites (Figure 4.6 A). The proportion of African alleles 
containing eleven motif C sites was higher than that of the European and Asian groups. 
Conversely, a larger proportion of European and Asian sequences tended to have less 
motif C sites. A slightly higher proportion of Asian sequences contained nine motif C 
sites compared to European and African groups. European sequences were further 
sub-haplogrouped and analysed (Figure 4.6 B). Interestingly, the proportion of 
sequences containing nine motif C sites were haplogroups I, R, W & X (denoted as ‘other’ 
in Figure 4.6 B).  
 
 
Figure 4.6 PRDM9 ‘Motif C’ binding sites. A) Number of times Motif C was found in mtDNA sequences from 
African, Asian and European mtDNA sequence groups. Proportion of population refers to the percentage 
of mtDNA sequences from each of the three population groups as a fraction of 1. B) Number of times Motif 
C was found in mtDNA sequences from each European haplogroup present in the mtDNA sequencing files. 
Proportion of population refers to the percentage of mtDNA sequences from the European population 
group as a fraction of 1. 
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Next, the positions of the binding motifs along the mtDNA molecule were investigated 
(Figure 4.7). The analysis was performed by Dr H. Griffin (Institute of Genetic Medicine, 
Newcastle University). There appear to be clusters of PRDM9 recognition motif sites on 
the mtDNA molecule as depicted by peaks of dots extending to the outer edge of the 
circle. The outer circle shows the frequency of the three most common allele binding 
motifs A, B and C in red, blue and green respectively. Of note are positions m.5327 and 
m.14484 which appear to be sites of multiple PRDM9 motifs, not just motif A as 
previously described in the pilot screen in Section 4.3.1. There is also a motif cluster at 
position m.12400 which appears to be a site containing multiple PRDM9 motifs. This is 
expected as the eleven motifs searched for are very similar in sequence (Table 4.2) due 
to the degeneracy required for compatibility of a variety of PRDM9 allele combinations 
within individuals. 
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Figure 4.7 Circos plot of all eleven PRDM9 binding motifs searched in this study. Outer circle represents 
the mtDNA sequence in clockwise orientation with base positions denoted. From outer circle to the centre 
the order of the motif searches plotted is; 1, 2 & 3 (red, blue, green respectively); 4; 5; 6; 7; 8; 9; 10; 11.   
 
Two of the motifs searched showed sequence matches over almost the entire mtDNA 
molecule (Figure 4.7). Motif 8, shown in orange on the circos plot, displays coverage of 
the whole mtDNA sequence. Additionally, motif 10 which is shown in dark green 
towards the centre of Figure 4.7 also shows sequence matches across a large proportion 
of the mtDNA molecule. It is likely that this representation is due to the degeneracy of 
these two motifs. Highly degenerate sequence motifs will by nature match more regions 
than those with a more specific sequence.  
 96 
 
4.3.3 Alignment of known mtDNA deletion breakpoints with PRDM9 motifs 
All 807 reported mtDNA deletions are recorded within the MitoBreak database (Damas 
et al., 2014). Breakpoint data for each deletion is available and the frequencies of each, 
displayed as number of cases, are shown in Figure 4.8. Both 5’ and 3’ breakpoints are 
observed as occurring more frequently within the major arc of the molecule, between 
positions m.5721 and m.15887. Breakpoints have also been observed within the minor 
arc but are less frequent (Figure 4.8). 
 
 
Figure 4.8 mtDNA deletion breakpoint frequencies. The x-axis represents the position along the mtDNA, 
with values shown every 100 nucleotides. The y-axis represents the number of reported cases in which 
each deletion breakpoint has been observed. Blue bins represent 5’ breakpoint positions, red bins 
represent 3’ breakpoint positions. This image was adapted from www.mitobreak.portugene.com (Damas 
et al., 2014). 
 
Available breakpoint data were downloaded for all 807 published deletions and 
subsequently aligned with the PRDM9 motif data presented in Section 4.3.2, to ascertain 
whether any breakpoints occur at or within the proposed PRDM9 motif sites. Briefly, a 
simple count command was used to determine whether any of the deletion breakpoint 
positions were also PRDM9 motif positions. Results were transformed back to the 
mtDNA base positions and plotted as a histogram. This analysis was performed for all 9 
genetically distinct motif positions identified (Table 4.2). The frequencies of breakpoints 
which coincided with PRDM9 motif sites are shown in Figure 4.9.
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Figure 4.9 Frequency histogram of mtDNA deletion breakpoints aligned with PRDM9 motif sites identified within the mtDNA. All 9 genetically distinct PRDM9 
motifs are displayed in different colours (listed at the top of the graph). The x-axis represents the mtDNA position and the y-axis represents the number of 
breakpoints that were found to align with a particular motif site.
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Motifs 8 and 10 were not included in this analysis because they were genetically 
identical to partial segments of the 9 other PRDM9 motifs. Several mtDNA breakpoints 
were found either within or immediately adjacent to a PRDM9 motif site. Interestingly, 
some PRDM9 motif sites were found to coincide with more than one breakpoint 
position. For example, there were 24 breakpoints at position m.7400, which is inside a 
PRDM9 motif 4 site (largest peak, Figure 4.9). Frequencies of breakpoint and PRDM9 
motif alignment varied across the molecule however, generally, higher frequencies were 
observed in the major arc of the molecule than in the minor arc. In addition, breakpoints 
aligning with PRDM9 motif sites were observed more often within the major arc of the 
molecule, as would be expected given that most breakpoints occur within this region.  
Next, the data was analysed visually for each individual PRDM9 motif using the UCSC 
Genome Browser (www.genome.ucsc.edu). Briefly, the 5’ and 3’ breakpoints of each 
mtDNA deletion were saved in BED file format. This file format was also created for the 
start and end positions of all identified PRDM9 motifs within the mtDNA (described in 
Section 4.3.2). The reference chromosome used was the mitochondrial genome (ChrM). 
The data files were uploaded into the Genome Browser as a custom track and aligned 
with the Human Genome Assembly GRCh38/hg38. This analysis was performed for all 9 
genetically distinct PRDM9 motifs. Each PRDM9 motif data file was uploaded to the 
browser alongside the mtDNA breakpoint data file for direct comparison. A visual 
representation of the data for PRDM9 motif 1 (CCnCCnTnnCCnC) is shown in Figure 4.10. 
The images in this figure show the entire mtDNA molecule along the top with PRDM9 
motif 1 sites shown underneath as vertical dots (more clearly shown in Figure 4.10 C). 
The number of PRDM9 motif A ‘dots’ signifies the frequency of that particular motif site 
in the sequences used to identify the presence of the motifs, as described in Section 4.3.2 
and represented in Figure 4.7. Underneath this are the mtDNA deletions, shown as black 
horizontal lines spanning from their reported 5’ to their 3’ breakpoint (Figure 4.10). 
 99 
 
 
Figure 4.10 Visual representation of the alignment between deletion breakpoints and PRDM9 motif 1 sites 
within the mtDNA.  Images were generated using the UCSC genome browser. A) The whole image 
generated using this online tool. B) Magnified version of image A. C) Magnified version of image C. Blue 
arrows represent regions where there is visual alignment of the breakpoints and PRDM9 motif 1 sites. 
 
Images B and C are simply cropped versions of image A to more clearly display the 
alignment and to view the PRDM9 motif 1 sites. The blue arrows in Figure 4.10 C show 
regions of the molecule where PRDM9 motif 1 sites align with mtDNA breakpoints. This 
proof of concept experiment shows that there is a potential relationship between the 
regions within the mtDNA where PRDM9 motifs have been identified and know mtDNA 
breakpoint positions. Similar patterns were observed for the other PRDM9 motif 
sequences searched (Appendix A). 
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4.5 Discussion 
An in silico approach was used to investigate whether the PRDM9 binding motif was 
present in mtDNA sequences from a large dataset. The 13bp degenerate PRDM9 binding 
motif A (CCNCCNTNNCCNC) was identified in almost all mitochondrial genomes 
searched. In contrast to a previous publication, motif A was not found to exclusively 
flank the mitochondrial 4977bp ‘common’ deletion but was present at several positions 
across the molecule flanking other reported deletion sites (Myers et al., 2008). There 
were subtle population differences in the motif positions found although the functional 
significance of these differences remains to be experimentally determined.  
A motif site at m.304 is questionable due to the known variability of the poly-C tract 
present at this position. This poly-C tract is normally 12-18 bp in length with a T 
nucleotide in the middle at position m.310, known as the D310 variant position. Length 
variants at D310 have been associated with disease, particularly in a number of cancers 
(Coto et al., 2011; Alhomidi et al., 2013). Heteroplasmy of D310 length variation has also 
been described in oocytes from the same mother suggesting that this region is prone to 
variation probably due to the repetitive nature of the sequence (Marchington et al., 
1997).  
Interestingly, the motif position at m.5327 was present in 99.9% of sequences searched 
and flanks a deletion described in the literature (Samuels et al., 2004). Deletions in 
mtDNA have been reported at positions m.5328, m.5329, m.5330 and m.5331, only a 
few base pairs downstream of the PRDM9 binding site found in this study. These 
deletions have all been reported in healthy tissues and remove part of the minor and 
major arcs with 3’ break sites around position m.16076 (Kajander et al., 2000; Samuels 
et al., 2004). Although these deletions have only been reported for a small number of 
samples there may be many healthy individuals in the population harbouring these 
deletions as they do not seem to be associated with any particular disease.  
It is unclear as to the role of PRDM9 binding sites in the mtDNA. To ascertain whether 
there is any correlation between mtDNA deletion breakpoint positions and the PRDM9 
motif sites found, analysis was carried out to align these two data sets. Several 
breakpoints were found to align within or adjacent to the PRDM9 motif sites. When this 
data was visually displayed using a genome browser tool, there was a pattern of PRDM9 
motif sites aligning with the 5’ deletion breakpoints. 
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There are several ways to test the significance of the presence of PRDM9 binding motifs 
within mtDNA. For example, an algorithm could be constructed and used to test the 
probability that other randomly generated motif sequences with the same degeneracy 
as the motif considered here will be found in the mtDNA sequence (Basu et al., 2005; 
Basha Gutierrez and Nakai, 2016). Another way would be to use a replication cohort. 
This would require more mitochondrial sequencing data from individuals from several 
populations, however due to a lack of African mtDNA sequences it would also be 
beneficial to have more of these sequences in particular. There is an absence of data 
regarding mtDNA deletion accumulation in African populations due to limited resources 
as well as difficulties surrounding mitochondrial patient diagnosis. Studies using African 
mtDNAs have comprised small sample numbers or have been comprised of populations 
such as South African or African-American which will typically have some 
representation of European haplogroups and are not representative of the variety of 
African populations (van der Walt et al., 2012; Silva et al., 2015; Farha et al., 2016; 
Scheible et al., 2016). The frequency of pathogenic mtDNA mutations, deletions and 
insertions in African and Asian populations are not as well reported or understood as in 
European populations (Schaefer et al., 2004).  
The discovery of multiple PRDM9 binding motifs within the human mtDNA sequence, as 
well as the potential pattern of these sites aligning with mtDNA breakpoints, raises the 
possibility that PRDM9 protein has a functional role within this organelle.  
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Chapter 5 Genotyping PRDM9 in patients harbouring mtDNA deletions 
 
5.1 Overview 
The mechanisms leading to mtDNA deletion formation remain elusive and are thought 
to primarily be related to replication or transcription events.  Individuals harbouring 
mtDNA deletions often have mutations in nuclear genes involved in mtDNA 
maintenance such as PolG and twinkle helicase (PEO1) (Spelbrink et al., 2001; Van 
Goethem et al., 2001; Tyynismaa et al., 2004). Due to the frequency of mtDNA deletions 
and the frequency of variants in these genes within the human population it is 
reasonable to assume that other genes could be associated with an increased incidence 
of mtDNA deletions.  
The C2H2 zinc finger (ZnF) repeat region of PRDM9 is responsible for binding to DNA 
motifs through hydrogen bonding between the amino acids of the protein and the 
nucleic acids present in the major groove of the DNA molecule (Wu et al., 2013).  This 
ZnF region is highly polymorphic in the human population, driven by selection 
pressures acting to create different recombination sites within individual genomes 
(Berg et al., 2010).  
There are twenty-one PRDM9 alleles found in the human population (Figure 5.1 B). 
Allelic differences can be caused by single nucleotide polymorphisms (SNPs) within the 
ZnF repeat region (Figure 5.1 A) or by the number of repeat regions present (Jeffreys et 
al., 2013). PRDM9 recognises regions of DNA containing the binding motif which is of 
interest in a mitochondrial setting due to PRDM9 binding motifs being present in the 
mtDNA.  
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Figure 5.1 List of all PRDM9 zinc finger repeats and alleles known in H.Sapiens. A) Sequences of each zinc finger, SNPs are highlighted in colour. B) The structure and 
number of ZnF repeats comprising the ZnF domain for each PRDM9 allele. Adapted from (Berg et al., 2011).
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5.2 Hypothesis 
PRDM9 binding sites within the mtDNA are potentially mediating mtDNA deletion 
formation, therefore, PRDM9 alleles will be associated with the risk of deletion 
formation within the population. 
 
5.3 Aims  
The principle aim of this study is to amplify, sequence and haplotype the ZnF repeat 
region of PRDM9 in patient and control DNA samples and determine if there is an 
association between any of the PRDM9 haplotypes and the formation of mtDNA 
deletions.  
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5.4 Sample Cohort  
Obtaining the case and control DNA cohorts is described in Section 3.1. Further 
information about the single deletion patient DNA samples is provided in Table 5.1.  
ID DNA number Tissue Type DNA conc. (ng) Genotyped 
M0044-13 2013/0049 SKM 66.9   
M005-04 2004/0010 SKM   Yes 
M0078-11 2011/0449 SKM 83.6 Yes 
M0101-09  2009/0103 SKM 81.8 Yes 
M0112-10 2010/0143  SKM 81.8 Yes 
M0116-10 2010/0145 SKM 75.6   
M0183-11 2011/0210 SKM   Yes 
M0202-09 2009/0175 SKM 47   
M0205-08 2008/0347 NF   Yes 
M0216-13 2013/0206 SKM 5.9 Yes 
M0221-11 2011/0241 SKM 37.9 Yes 
M0223-11 2011/0243 SKM 34 Yes 
M0226-12 2012/0289 SKM 192 Yes 
M0229-11 2011/0899 SKM 94.2 Yes 
M0271-12 2012/0379 CD   Yes 
M0271-12 2012/0380 CD 60 Yes 
M0271-12 2012/0381 CD 43.1 Yes 
M0271-12 2012/0382 CD 58.5 Yes 
M0283-03 2003/0319 SKM   Yes 
M0283-04 2004/0377 UR   Yes 
M0284-09 2009/0234 SKM 31.5   
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M0284-12 2012/0329 SKM 136.1   
M0292-11 2011/0924 SKM 72.5   
M0293-11 2011/0923 SKM 142.9 Yes 
M0298-10 2010/0317 SKM 144.8   
M0451-09 2009/0412 SKM 95.5 Yes 
M0478-11 2011/0527 SKM 49.2   
M0483-11 2011/0499 SKM 44.8 Yes 
M0511-10 2010/0496 SKM 65.4 Yes 
M0516-11 2011/0502 SKM 14.7   
M0517-11 2011/0503 SKM 23.9   
M0531-09 2009/0498 SKM 46.6 Yes 
M0532-08 2008/0461 SKM   Yes 
M0560-07 2007/0616 SKM   Yes 
M0585-11 2011/0564 SKM 45.5 Yes 
M0625-11 2011/0629 SKM 242   
M0626-12 2012/0675 SKM 3.5   
M0653-08 2008/0590 SKM   Yes 
M0680-11 2011/0702 SKM 74.9 Yes 
M0688-09 2009/0612 SKM 500 Yes 
M0734-08 2008/0705 SKM   Yes 
M0766-12 2012/0803 SKM 51.6 Yes 
M0812-11 2011/0794 SKM     
M0858-11 2011/0827 SKM     
M0936-09 2009/0919 SKM 28.2 Yes 
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M0941-10 2010/0859 SKM 122   
M0959-12 2012/1020 SKM 53.4 Yes 
M0966-10 2010/0940 SKM 53.4 Yes 
M0987-12 2012/1022 SKM 59.2 Yes 
M1074-10 2010/1051 SKM 14.6 Yes 
M1089-09 2010/0023 SKM 153.6 Yes 
M1207-11 2011/1381 SKM 137.9   
M1352-12 2012/1360 SKM 7.4 Yes 
M1480-12 2012/1465 SKM 6.6   
M1648-12 2012/1627 SKM 14.3 Yes 
M0413-04 2010/1253 SKM   Yes 
M0124-05 2005/0192 SKM   Yes 
M0158-06 2006/0132 SKM   Yes 
M0180-03 2003/0244 NF   Yes 
M0258-08 2008/0255 SKM   Yes 
M0274-05 2005/0352 SKM   Yes 
M0288-04 2004/0632 UR   Yes 
M0629-07 2007/0686 SKM   Yes 
M0919-08 2008/0792 SKM     
 M0265-05 2005/0869 SKM   Yes 
 M0433-10 2010/0172 SKM   Yes 
 M0999-06 2006/0387 SKM   Yes 
M0478-11 2011/0527 SKM 49.2 Yes 
Table 5.1 Details of patient DNA samples used in this study. Newcastle Mitochondrial NSCT Diagnostic 
Service codes are given along with the unique DNA number, tissue type the DNA was extracted from and 
concentration (if known). CD = cardiac muscle, SKM = skeletal muscle, UR = urine. Successfully sequenced 
and genotyped samples denoted with 'yes' were included in the analysis. 
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5.5 Experimental Method  
Highly repetitive regions of DNA are known to be difficult to amplify and sequence due 
to mispriming events leading to PCR artefacts or collapsing of partially amplified 
oligonucleotides (Stirling, 2003). The ZnF repeat region of the PRDM9 gene proved to be 
one such region therefore requiring substantial method optimisation. 
 
5.5.1 Polymerase chain reaction amplification of the zinc finger repeat region of 
PRDM9 
Primers specific to the PRDM9 zinc finger region (NCBI Reference Sequence: 
NC_000005.10) were selected based on a previous publication (Berg et al., 2011) which 
extensively genotyped the PRDM9 ZnF repeat region in human blood and sperm DNA 
samples.  
 
 
Figure 5.2 Schematic of the functional domains of PRDM9. The C2H2 ZnF domain is at the C-terminus. 
Primer annealing sites are depicted by blue arrows and nested sequencing primers are in orange. 
 
Primer set 1 (PN0.6F and PN2.5R) was used for initial PCR amplification. Nested primers 
(PN1.2F and PN2.4R) were then used to sequence the amplicon. Primer annealing sites 
are shown in the schematic Figure 5.2. Primer sequences are detailed in Table 5.2. 
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Gene Primer Sequence Application Product 
length (bp) 
Origin Annealing 
temp. 
PRDM9  PN0.6F   TGAGGTTACCTAGTCTGGCA PCR 1864 Berg 
et al. 
62°C 
PRDM9  PN2.5R   ATAAGGGGTCAGCAGACTTC PCR 1864 Berg 
et al. 
62°C 
PRDM9  PN1.2F   TGAATCCAGGGAACACAGGC Sequencing 1257 Berg 
et al. 
50°C 
PRDM9  PN2.4R   GCAAGTGTGTGGKGACCACA Sequencing 1257 Berg 
et al. 
50°C 
Table 5.2 Details of primers used to amplify and sequence PRDM9 amplicons. 
 
The PRDM9 PCR amplicon is 1864 bp in length and is highly repetitive. Initial PCR was 
attempted using Immolase Taq polymerase protocols (Bioline, London, UK). However, 
due to the repetitive nature of this DNA fragment, long-range high fidelity PCR 
techniques were required for sufficient amplification. TaKaRa protocols were optimised 
using healthy control DNA as template. 
Temperature gradients were used to determine the optimum annealing temperature of 
the PRDM9 primers (Figure 5.3). PCR reaction mixture was as follows; 0.5 mM betaine, 
200 μM dNTPs, 1.25 U TaKaRa LA Taq polymerase, 0.2 μM primers (forward and 
reverse), dH2O and 100 ng DNA made to final volume of 25 μL with nanopure water. 
Thermocycling conditions were: denaturation at 94 °C for 1 min, 98 °C for 10 secs, 
annealing at 62 °C for 15 min, for 30 cycles followed by a final extension for 10 min at 
72 °C. PCR conditions were optimised using a control DNA sample (Figure 5.3). PRDM9 
amplicons were visualised via electrophoresis and UV exposure, showing highly specific 
amplification of one clear band at 1900 bp representing the full length ZnF region of 
PRDM9 (Figure 5.3). 
 
 111 
 
 
Figure 5.3 Gradient PCR of the PRDM9 ZnF region. Control DNA was used as a template. Annealing 
temperatures were as follows; lane 1 55°C, lane 2 57°C, lane 3 59°C, lane 4 60°C, lane 5 62 °C, lane 6 64 °C, 
lane 7 negative control. PRDM9 PCR products were electrophoresed on a 1% agarose gel. 
 
Single deletion patient DNA samples were then amplified using this reaction (Figure 
5.4). Lanes 1 to 13 of Figure 5.4 show specific PCR amplification of PRDM9. Individuals 
with ZnF length differences could be distinguished by the presence of additional bands 
on the electrophoresis, for example lane 9 (Figure 5.4) which appears is heterozygous 
for the haplotypes A and a shorter allele. 
 
 
Figure 5.4 PCR of the PRDM9 ZnF region in single deletion patient samples. PRDM9 PCR product was 
visualised after electrophoresis on 1% agarose gels. A molecular weight marker was used to size the 
products (far left lane). Sizes are denoted in base pairs. 
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The size of the fragments was used to identify individual samples that could be 
heterozygous for the ZnF repeat region of PRDM9. For example, PCR products in lanes 5 
and 19 (Figure 5.5) clearly have additional bands to the 1900 bp expected product. 
These individuals are potentially heterozygous for haplotypes A and a longer allele. 
 
 
Figure 5.5 PCR of the PRDM9 ZnF region in single deletion patient samples. PRDM9 PCR product was 
visualised after electrophoresis on 1% agarose gels. A molecular weight marker was used to size the 
products (far left lane). Sizes are denoted in base pairs. 
 
Samples typically had faint bands at lower molecular weight such as the samples in 
Figure 5.5. These bands are probably fragments which have collapsed during the 
amplification due to the complexity of this repeat region. Mispriming events may also 
produce a small amount of shorter product detectable by gel electrophoresis. 
 
5.5.2 Sequencing and molecular cloning of single deletion patients 
Nested primers specific to the PRDM9 amplicon were used to sequence the ZnF repeat 
region, 1257 bp in size (Table 5.2). Initial Sanger sequencing reads were only 600 bp in 
length due to the capacity of the capillary used on the ABI3130xl Genetic analyser. Using 
a forward primer in one sequencing reaction and a reverse primer in a separate, but 
identical, reaction, 1200 bp reads could be analysed for each individual DNA sample. 
Sequencing data was analysed using Seqscape sequencing software aligning to the 
reference PRDM9 sequence (NCBI Reference Sequence: NC_000005.10). 
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Figure 5.6 Electropherograms of the PRDM9 ZnF repeat in a representative DNA sample. Top image; 
alignment of forward and reverse amplicons to the reference sequence entered into the Seqscape 
software. Middle image; sequencing trace for the reverse primed amplicon. Bottom image; sequencing 
trace for the forward primed amplicon. 
 
Depending on the quality of the sequencing there was a gap spanning 6 to 56 
nucleotides as highlighted by the red box in Figure 5.6. This gap was in the middle of the 
region of interest where the most allele defining repeats lie. In addition, sequencing 
traces usually became less efficient towards the end of the amplicon due to technical 
limitations of the machine in detecting nucleotides effectively. Electropherograms lose 
quality towards the end of forward and reverse strand reads and therefore much of the 
middle section of the PRDM9 amplicon was impossible to genotype. In this instance 
genotyping was not possible. 
To modify this protocol the capillary array length in the sequencing machine was 
changed to a longer array allowing longer high quality and highly accurate nucleotide 
calls along the read length. This allowed sequencing of almost the entire amplicon for 
each primer used and allowed comparisons to be made between the sequence obtained 
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with the forward and reverse primers individually. This array allowed for overlap in the 
sequencing traces obtained from each individual primer so that variants could be 
confirmed using both forward and reverse reads (Figure 5.7). 
 
 
Figure 5.7 Electropherograms of the PRDM9 ZnF repeat in a representative DNA sample using a longer 
sequencing capillary. Top image; alignment of the forward and reverse amplicons to the reference 
sequence entered into the Seqscape software. Bottom image; sequencing traces of forward and reverse 
amplicons over the middle region of the ZnF repeat domain.  
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Although electropherograms were of high quality using the longer array, there were still 
artefacts observed in samples sequenced using this method. Figure 5.8 shows a typical 
sequencing trace for one of the ZnF repeats used to genotype the individual. Multiple 
peaks are present at each position making it difficult to define a real heterozygous signal 
from noise. 
 
 
Figure 5.8 Electropherogram of the PRDM9 ZnF region. Top image; sequencing trace of the PRDM9 ZnF 
repeat in a representative DNA sample. The 150 base pair window is shown at the top of the image. Below 
are magnified images of the sequencing traces depicted in the red boxes. 
 
The green arrow in Figure 5.8 shows a base which would be considered as heterozygous 
T/C due to the peaks being of equal height. The red arrows depict bases where there are 
two peaks present but the expected bases GG are not reduced in height, or where the 
expected C nucleotide is under the signal for an A nucleotide. 
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Aligning DNA sequences from individuals that were heterozygous for repeat length 
variation in the PRDM9 allele proved difficult to genotype as the Seqscape software was 
unaware of the length differences. To overcome this I created reference sequences using 
only the ‘A’ or ‘J’ repeats listed in Figure 5.1. Figure 5.9 shows the misalignment of one 
such DNA sample that was heterozygous for a 13 repeat length allele and a longer allele. 
Variant calling in blue shows the number of base pair calls that did not match the 
reference sequence due to the ‘insertion’ of an extra ZnF repeat sequence. 
 
 
Figure 5.9 Electropherogram of the PRDM9 ZnF region in a patient with a heterozygous extended repeat 
allele. The red arrow shows variant calls highlighted in blue along the length of the amplicon analysed. 
The red box shows mismatching of the sequencing calls (green base pairs) to the reference sequence 
(black base pairs) in the sample. 
 
The ‘A’ repeat is present in every PRDM9 allele as the first repeat in the sequence and 
the ‘J’ allele is always the last repeat of the allele with the exception of allele L15 (Figure 
5.1). Forward sequencing files were aligned to a continuous ‘A’ repeat reference and 
reverse sequencing files to the continuous ‘J’ reference. For most individuals harbouring 
length variants this strategy allowed accurate genotyping.   
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To validate the allele status assigned to each DNA sample, molecular cloning of each 
allele was performed. PRDM9 was amplified in the patient DNA samples. PCR products 
were electrophoresed, gel extracted and ligated into the pGEM-T Easy Vector. Colonies 
containing a single allele were picked and PRDM9 was amplified using primers 
annealing to the pGEM-T vector sequence (Table 5.3).  
  
Target Primer Sequence Annealing Temp Source 
p-GEM vector 
Reverse 
5´-d(TCACACAGGAAACAGCTATGAC)-3´   62 °C Promega Cat. No. 
Q5421 
p-GEM vector 
Forward 
5´-d(CGCCAGGGTTTTCCCAGTCACGAC)-3´ 62 °C Promega Cat. No. 
Q5601 
Table 5.3 Details of primers used to amplify the PRDM9 insert sequence in the p-GEM vector sequence 
used to clone the amplicon. 
 
Colony PCR reaction mixture was as follows; 0.5 mM betaine, 200 μM dNTPs, 1.25 U 
TaKaRa LA Taq polymerase, 0.2 μM primers (forward and reverse), 10 μL dH2O 
containing a colony stab. Thermocycling conditions were: denature at 94 °C for 1 min, 
98 °C for 10 secs, annealing at 62 °C for 15 min, for 30 cycles followed by a final 
extension for 10 min at 72 °C. 
PRDM9 amplicons were successfully cloned as confirmed by colony PCR (Figure 5.10). 
Length variants can be seen in lanes 5 and 8 (Figure 5.10). 
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Figure 5.10 Colony PCR followed by gel electrophoresis of PRDM9 amplicons from single deletion patients. 
PCR products were electrophoresed on a 1% agarose gel. M corresponds to the molecular weight marker. 
Lanes 1-15 contain patient PRDM9 PCR product, lane 16 is a negative control PCR product. 
 
The PCR products were then sequenced as described above. Sequencing traces appeared 
to be of good quality (Figure 5.11) and length variants were genotyped using a different 
reference sequence as described above. 
 
 
Figure 5.11 Sequencing traces of the ZnF repeat region from colony PCR DNA samples. Representative 
150bp section is shown. 
 
Sequencing analysis was performed as before and the results were documented in a 
separate file to the original results. In addition, a second experimentally blind invigilator 
carried out the genotyping of the sequencing traces obtained and the allele status results 
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were compared. Both assessors agreed on the vast majority of the genotypes showing 
that there was no analysis bias. 
 
5.6 Results 
5.6.1 Statistical analysis of genotyping results  
Overall, 8 PRDM9 alleles were detected in the case group and 6 in the control group. 
Chi-squared comparisons were performed on the allele counts to determine if there was 
any statistically significant difference between the groups.    
   
  Cases   Controls   
 
Allele   100   96 P value 
A 15 85 13 83 0.8397 
B 97 4 94 2 0.6833 
C 98 2 95 1 1 
D 99 1 96 0 1 
E 99 1 96 0 1 
L9 98 2 94 2 1 
L20 99 1 95 1 1 
L24 96 4 93 3 1 
 
  100   92 
 
  
Students t-test 0.9462064 
 
Table 5.4 Distribution of alleles in case and control groups. Total allele counts are shown for each group. 
The number of each allele type is shown in the right hand columns versus all other alleles (left hand 
columns). P values were calculated using Chi squared and two-tailed Fishers exact test or a two-tailed 
Students t-test. 
 
Total allele counts were 100 and 96 for the case and control groups respectively (50 
cases versus 48 controls). Firstly, alleles were counted for each group and a Students 
t-test performed on the allele distribution (Table 5.4). Of the total alleles 85% of case 
and 87% of control cohort alleles were ‘A’. This was representative of the population 
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frequency of the ‘A’ allele published by Berg et al., 2012 as 85.7% in Europeans. The 
distribution of the other alleles found in the cohorts was also similar to those previously 
published for the population. Cases and controls had a similar distribution of alleles 
(Two-tailed Students t-test, p = 0.9462).   
Alleles were grouped into allele ‘A’, allele ‘B’ and ‘Rare’ (all other alleles). There was no 
statistically significant difference between the number of A, B or Rare alleles in cases 
versus the control group (Table 5.5). 
 
  
Cases 
100   
Controls  
96   P value 
A 15 85 13 83  0.8397 
B 96 4 94 2 1.00 
Rare 89 11 89 7 0.4609  
Table 5.5 Allele counts for case and control groups. Alleles were grouped as ‘A’, ‘B’ or ‘Rare’ referring to 
any allele that was not A or B genotype. P values were calculated using Chi-squared and two-tailed 
Fisher’s exact test. 
 
Allele length variation was tested by grouping alleles into ‘Short’ <13 repeats, ‘Normal’ 
13 repeats or ‘Long’ >13 repeats. There was no statistically significant difference 
between the number of Short, Normal or Long alleles in cases versus controls (Table 
5.6). 
  
    
Cases 
100   
Controls 
96   P value 
E <13 Short 99 1 96 0  1.00 
A Normal 4 96 1 95  0.3691 
C,D >13 Long 97 3 95 1  0.6214 
Table 5.6 Allele counts for case and control groups. Alleles were grouped by ZnF repeat length. P values 
were calculated using Chi-square and two-tailed Fisher’s exact test. 
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Finally, the distribution of individuals who were homozygous ‘A’, heterozygous ‘A/N’ or 
homozygous ‘N/N’ (where N is any other allele) was tested. All samples apart from one 
control individual were homozygous or heterozygous for the ‘A’ allele, consistent with 
both patient and control DNA samples being collected in the UK and assumed to be of 
European descent. Differences in genotype were statistically significant in the cases 
versus controls (Table 5.7). There were significantly more (p=0.0047) heterozygous 
individuals in the case group. 
  
  
AA AN NN P value 
Cases 100 85 15 0 0.0047  
Controls 96 88 7 1   
Cases 100 85 15    0.0097 
Controls 96 88 8     
Table 5.7 Allele counts for case and control groups. Alleles were grouped by genotype ‘AA’, ‘AN’ or ‘NN’. P 
values were calculated using Chi squared test. 
 
5.6 Discussion 
PRDM9 binding motifs are present at multiple sites along the mtDNA sequence, leading 
us to hypothesise that there may be a functional role for PRDM9 in the mitochondria. 
The ZnF region of PRDM9 is responsible for binding to DNA and is a highly polymorphic 
region. This ability to rapidly alter the nucleotide sequence of the ZnF domain allows 
PRDM9 protein to adapt to shifts in the recombination hotspots of the nuclear genome 
between generations. Loss of this ability leads to a lack of viable offspring and ultimately 
speciation events (Myers et al., 2010; Flachs et al., 2014). The possible role of PRDM9 in 
mitochondria lead us to hypothesise that PRDM9 alleles may increase susceptibility to 
mtDNA deletion formation in individuals. Access to mitochondrial patients harbouring 
single deletions provided us with a means to perform a gene screen to address whether 
any PRDM9 allele is over-represented in this cohort. 
 The ZnF region of the human PRDM9 gene was successfully genotyped in 50 mtDNA 
single deletion patient and 48 healthy control DNA samples. The distribution of PRDM9 
alleles found in both case and control groups was indicative of the population 
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frequencies previously published, validating the European nature of our DNA samples. 
There was no statistically significant association between PRDM9 allele status and the 
presence of mtDNA single deletions. There were significantly more heterozygous 
individuals in the case group versus controls (p=0.0047). However based on the results 
in Table 5.4, there does not seem to be any particular PRDM9 allele associated with this 
observation. The alleles most common after ‘A’ are ‘B’ and ‘L24’ but the frequency of 
these alleles was not statistically different between case and control groups (Table 5.4). 
There are several reasons for this observation. Firstly, the number of individual samples 
in both the case and control groups was small (50 and 48 respectively). An association 
between a particular SNP or genotype and the disease being studied would have to be 
strong to be significant with such a small sample size. Using the parameters; a 
significance level (p value) of 0.05 and an effect size of 0.5 (Cohen’s d = medium), 
statistical power calculations show that 130 individual samples would be required for 
an 80% chance of statistical significance. A smaller effect size would require even more 
samples suggesting that this study was underpowered.  
Secondly, this genomic region is highly polymorphic and appears to be under selective 
pressures acting to recombine the genome and allow for higher genetic diversity 
between individuals within the population. This means that the individual zinc finger 
repeat units that comprise the PRDM9 ZnF domain are not highly conserved and are 
therefore not predicted to have a detrimental effect when mutated. This is also possible 
because of the ability of PRDM9 to adapt its amino acid sequence to bind slightly 
different DNA motif regions. Heterozygous individuals will more than likely have subtle 
shifts in recombination events at the genome level compared to homozygous individuals 
but this does not necessarily have a negative impact on the health of the individual. In 
addition, if PRDM9 protein binds to mtDNA then it must be able to recognise a wide 
range of mtDNA haplogroups. It is exclusively the maternal mtDNA haplogroup which is 
inherited by the offspring however, there are four possible PRDM9 alleles (two maternal 
and two paternal) leading to potentially dramatic genomic recombination shifts. If 
PRDM9 could only interact with some subsets of mtDNA sequences then there would be 
very little chance of viable offspring from individuals with different PRDM9 allele status 
and mtDNA haplogroups. Since both PRDM9 haplotype and mtDNA haplogroup are 
associated with global population location then this would lead to possible speciation 
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events within the human population. This is unlikely as genetic theories determine that 
it is advantageous to outbreed and increase individual and population fitness. 
Several patient samples shown in Table 5.1 failed to amplify and therefore could not 
have a PRDM9 genotype assigned. This is likely due to the quality of the DNA samples. 
The PRDM9 ZnF domain is a highly repetitive PCR product and therefore proved difficult 
to amplify. Successful amplification relies on good quality starting template DNA in 
terms of purity as well as concentration. In addition to ensure that the PCR reaction 
itself is successful, most of the amplicon produced in each amplification cycle must be 
the full-length product so that miss-priming doesn’t occur. The longer and more 
repetitive a DNA fragment, the more likely it is that the copy of the template DNA will 
collapse during the extension phase to produce smaller fragments than the intended 
amplicon. 
Analysis of the PRDM9 ZnF repeat region also proved difficult due to the repetitive 
nature of this amplicon. Genotype specific SNPs were highlighted in Berg et al., 2011. 
Due to the polymorphic nature and complexity of this genomic region it was often 
difficult to assign a genotype to each repeat and sometimes appeared to be somewhat 
subjective. Mostly this was due to the quality of the DNA sequence obtained for each 
individual DNA sample. Any heterozygous signals were scrutinized and assessed for 
likelihood of the assigned nucleotide, that is to say, if there was no reported alternative 
in the literature or in a database then the wild type nucleotide was assumed to be 
homozygous. To ensure that the genotyping was not wholly subjective an independent 
marker was used to verify the sequencing and assign a genotype to the samples. The 
complexities of the PRDM9 ZnF repeat region proved technically challenging for 
genotyping and allele association. Although there was a significant difference between 
the numbers of heterozygous individuals in the case cohort it is unlikely that this result 
is truly informative.  
Larger cohorts of mtDNA deletion patients are required to confirm this finding in 
combination with relevant functional studies. It would be particularly interesting to 
haplotype trios including the parents of the affected individual to identify if there is a 
trend in the likelihood that one parent might pass on a particular haplotype to their 
affected offspring. This was the case in a study where mothers were statistically more 
likely to carry the associated PRDM9 allele present in her affected child (Woodward et 
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al., 2014). With the increasing availability and affordability of next generation 
sequencing (NGS) technologies it would perhaps also be more efficient to haplotype 
PRDM9 amplicons using a long range sequencing protocol. This would allow for single 
molecule sequencing reads that have more accurate base calling and can be haplotyped 
with higher throughput than the method presented in this chapter. 
In conclusion, PRDM9 alleles were genotyped in a single deletion patient cohort and 
compared to healthy controls. There was a significant increase in the number of 
individuals carrying heterozygous PRDM9 alleles in the patient cohort. However, no 
single allele was over-represented indicating that PRDM9 genotype is unlikely to affect 
mtDNA deletion risk. Functional studies are required to experimentally determine 
whether PRDM9 interacts with mtDNA in vivo. 
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Chapter 6 PRDM9 expression in human tissue and cell lines. 
 
6.1 Overview 
In order to understand the relevance of PRDM9 binding motifs found in mtDNA 
sequences, PRDM9 protein expression was investigated in human cell lines and tissue 
samples. PRDM9 remains an elusive protein with previous studies focussing on Mus 
musculus or partial recombinant human proteins (Hayashi et al., 2005; Mihola et al., 
2009; Eram et al., 2014; Davies et al., 2016; Patel et al., 2016). Although these studies 
have confirmed the methyltransferase activity of the protein as well as its ability to 
direct DNA cross-over events, the true functional role of full length human PRDM9, as 
well as interacting partner proteins, timing of expression and cellular localisation 
remains unknown. Although murine models are of importance to our understanding of 
molecular pathways and interactions, the PRDM9 proteins differ between mouse and 
human at the amino acid sequence level and thus might function differently in vitro. In 
addition, PRDM9 has been described as the primary genetic candidate for speciation 
events. This is suspected to be due to its polymorphic nature and motif binding ability, 
which leads to a genetic complementation barrier resulting in non-viable zygotes (Berg 
et al., 2010; Jeffreys et al., 2013; Flachs et al., 2014). For this reason, cross species 
comparisons of PRDM9 protein functions are helpful and necessary but investigations 
using human PRDM9 are warranted to ascertain its function.  
The human PRDM9 protein is not predicted to have a mitochondrial targeting sequence 
according to an in silico prediction tool (MitoP2 Elstner et al. (2009)) and does not 
appear on the extensive mitochondrial proteome database (MitoCarta2.0 Pagliarini et al. 
(2008); Calvo et al. (2016)). Due to the discovery of PRDM9 binding sites within the 
mitochondrial genome, it would be important to explore PRDM9 protein localisation in 
the context of the mitochondria. To investigate the expression of PRDM9, we had unique 
access to a range of difficult to obtain human tissue samples as well as both primary and 
immortalised cell lines.  
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6.2 Aim 
The aim of this study was to identify PRDM9 protein in human tissue and cell lines using 
a variety of detection methods. This would provide an appropriate model to study the 
localisation of this protein, in particular, to elucidate any mitochondrial function. 
 
6.3 Tissue samples and cell lines 
Details of the tissue samples used in this study are provided in Table 6.1.  
Tissue Log no. Stage Storage Source Disease 
Human Foetal Gonad HDBR#11942 11pcw -80 °C HDBR N/A 
Human Placenta HDBR#12168 5pcw -80 °C HDBR N/A 
Human Placenta HDBR#12169 6pcw -80 °C HDBR N/A 
Human Placenta HDBR#12170 10pcw -80 °C HDBR N/A 
Human Skeletal 
Muscle 
PFC_H_351_126 23yrs -80 °C MRG Tissue 
Resource 
N/A 
Human Ovary (Left) PFC_H_02_07 50yrs -80 °C MRG Tissue 
Resource 
MELAS 
Human Ovary (Right) PFC_H_01_07 50yrs -80 °C MRG Tissue 
Resource 
MELAS 
Table 6.1 Details of tissue samples used in the study. Tissue type, identification number, age, storage 
conditions, source and disease state are provided. 
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Details of the cell lines used in this study are provided in Table 6.2. 
Cell Line Type State Source 
HEK293 Human Embryonic Kidney Immortalised Prof. R.N. Lightowlers 
143B Osteosarcoma Immortalised Dr A. Gómez-Durán 
NT2 Neuron-committed Teratocarcinoma Immortalised Dr A. Gómez-Durán 
H9 Human Embryonic Stem Cell Stem cell Prof. M. Lako 
AM Fibroblast Primary Newcastle Biobank 
F011 Fibroblast Primary Newcastle Biobank 
M014 Myoblast Primary Newcastle Biobank 
M062 Myoblast Primary Newcastle Biobank 
M235 Myoblast Primary Newcastle Biobank 
M259 Myoblast Primary Newcastle Biobank 
Table 6.2 Cell lines used in this study. Cell line, cell type, state and source are provided. Professor R.N. 
Lightowlers, Institute of Neuroscience: Dr A. Gómez-Durán and Professor M. Lako, Institute of Genetic 
Medicine, all Newcastle University. 
 
Detailed methods and a full list of antibodies used in this study are provided in Methods 
Sections 3.6, 3.8 and Table 3.2. 
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6.4 Results 
6.4.1 Detecting PRDM9 in cell lines 
Available cell lines were investigated for the presence of PRDM9 protein by gel 
electrophoresis followed by Western blotting with a commercially available PRDM9 
antibody (Abcam, Cambridge, UK). To assess which cell model would be most 
appropriate; primary myoblast, primary fibroblasts and immortalised HEK293 cell 
lysates were run alongside a human testes (HuT) protein lysate sample (Figure 6.1). 
Testes tissue lysate was a kind gift from Professor David Elliot (Institute of Genetic 
Medicine, Newcastle University). After 60 minutes of exposure there was a faint signal 
detected in all sample lanes however there were three bands visible at ~90, ~65 and 
~40 kDa. There was no protein detection in the human testes lysate using 4 µL of lysate 
of unknown concentration, however GAPDH signal was also low suggesting that there 
might not have been a high enough quantity of protein used to detect PRDM9. 
 
Figure 6.1 Western blot detection of PRDM9 in different cell lines. Protein size marker was included (M), 
sizes are provided in kDa. 20 µg of myoblast, fibroblast and HEK293 cell lysate was loaded on a 4-20% 
bis-tris gel alongside 4 µL human testes lysate of unknown protein concentration (HuT). Membrane was 
incubated with anti-PRDM9 (1:500 dilution) or GAPDH (1:1000 dilution) overnight at 4°C. 
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In order to determine whether the faint bands observed in Figure 6.1 were PRDM9, 
larger amounts of protein were required. HEK293 cells were chosen as the most 
appropriate model because immortalised cells typically divide at a much faster rate 
without replicative senescence and provide more cellular material than primary cell 
lines (Hayflick, 1965). Optimal protein concentration for detection was performed by 
running concentration gradients (Figure 6.2). Double the volume (8 µL) of human testis 
tissue lysate was used compared to the previous blot (Figure 6.2 A). There was a single 
band corresponding to a peptide slightly larger than the predicted molecular weight of 
103 kDa in both the HEK293 and human testes sample lanes. There was also a band at 
~60 kDa in the highest concentration HEK293 sample lanes. Detection of these bands 
was very weak and required long exposure times. Next, a higher protein concentration 
gradient of HEK293 cell lysate was tested (Figure 6.2 B). Bands were observed at ~100 
and ~60 kDa but additional bands were also seen at ~120 and ~30 kDa. Thus, loading 
higher amounts of protein onto the gel gave more non-specific banding when using the 
anti-PRDM9 antibody to detect protein levels. 
 
Figure 6.2 Western blot detection of PRDM9 in HEK293 cell and human testes lysate. Protein size marker 
was included on each blot (M), sizes are denoted in kDa. A) HEK293 cell lysate gradient from 40-5 µg 
protein was loaded on a 4-20% bis-tris gel alongside 8 µL human testes lysate of unknown protein 
concentration (HuT). B) HEK293 cell lysate gradient from 120-50 µg was loaded on a 4-20% bis-tris gel. 
Membrane was incubated with anti-PRDM9 (1:500 dilution) or GAPDH (1:1000 dilution) overnight at 4°C. 
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Due to the embryonic nature of PRDM9 expression, the human embryonic stem cell line 
H9 (H9 hESC) was investigated for PRDM9 protein expression (Figure 6.3).  The HEK293 
cell lysate was immunoblotted alongside H9 as a comparison. As expected from previous 
results, HEK293 lysate gave bands at ~120 and ~60 kDa in size as well as faint bands at 
several other molecular weights. Bands were observed at ~60, ~50 and ~20 kDa in the 
H9 sample lanes. The band at ~120 kDa and a weaker band at ~80 kDa observed in the 
HEK293 samples were not present in the H9 samples. Overall, this suggests that the 
HEK293 and H9 cell lines have completely different protein expression profiles using the 
commercially available PRDM9 antibody in this study. Importantly, the band detectable 
at a molecular weight close to that of PRDM9 (103 kDa) was observed in the HEK293 
sample lysate only.  
 
 
Figure 6.3 Western blot detection of PRDM9 in HEK293 and H9_hESC cell lysates. Protein size marker was 
included (M), sizes are denoted in kDa. Protein concentration gradient for each sample lysate was loaded 
on a 4-20% bis-tris gel (100 – 25 µg). Membrane was incubated with anti-PRDM9 (1:500 dilution) 
overnight at 4°C. 
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The well-established immortalised cell line Neuron-committed Teratocarcinoma (NT2) 
is derived from a human embryonic teratoma. As it is of embryonic origin, it was tested 
for PRDM9 protein expression by immunoblotting alongside three primary myoblast cell 
lines available in our laboratory (Figure 6.4). Detection of PRDM9 was unsuccessful in 
all cell lines tested, even after 1 hour of membrane exposure. Incubation of the samples 
with anti-βactin showed that protein was detectable in all sample wells further 
confirming that PRDM9 was not present in these cell lines (Figure 6.4). 
 
 
Figure 6.4 Western blot detection of PRDM9 in primary myoblast and NT2 cell lysates. Protein size marker 
was included (M), sizes are denoted in kDa. 75 µg sample lysate was loaded on a 4-20% bis-tris gel. 
Membrane was incubated with anti-PRDM9 (1:500 dilution) overnight at 4°C. 
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To check antibody specificity, two antibodies against PRDM9 were kindly provided by 
the HPA (AlbaNova, Stockholm, Sweden). These antibodies were used for Western blot 
detection of PRDM9 in HEK293 cell lysate (Figure 6.5). Bands were detected at ~55, ~45 
and ~25 kDa using the Abcam and HPA antibodies respectively (Figure 6.5Figure 6.5). 
When compared to levels of β-actin detectable in the lysate (Figure 6.5) the bands 
detected using the Abcam and HPA059555 antibodies appeared to be very faint 
compared to HPA063372 (Figure 6.5). No band was observed at the predicted PRDM9 
weight, 103 kDa, using any of the antibodies.  
 
 
Figure 6.5 Western blot detection of PRDM9 in HEK293 cell lysate. 100 µg total protein was loaded in each 
sample well and electrophoresed on 4-20% bis-tris gels. Protein size marker was included on each blot 
(M), sizes are provided in kDa. A) PRDM9 protein was immunoblotted using either Abcam, HPA059555 or 
HPA063372 antibody against PRDM9. B) β-actin protein was immunoblotted for each sample lane as a 
loading control. Membrane was incubated with anti-PRDM9 (1:500 dilution) or anti-βactin (1:1000) 
overnight at 4°C. 
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The peptide sequence used to generate the antibody against PRDM9 was commercially 
available (Abcam, Cambridge, UK). This peptide comprises amino acids 432-481 of the 
human PRDM9 protein sequence and could therefore be used for antigen binding assays 
to elucidate which of the protein bands detected by blotting could potentially be PRDM9. 
Briefly, HEK293 cell lysate was incubated with purified PRDM9 antigen peptide, 
Western blotted and compared to untreated HEK293 total lysate. The strongest band at 
~55 kDa in the total cell lysate sample lane was blocked in the sample incubated with 
the antigen (Figure 6.6, red arrow).  
 
Figure 6.6 Western blot detection of PRDM9 in HEK293 cell lysate blocked with 1 µg/mL antigen peptide. 
Protein size marker was included on each blot (M), sizes are provided in kDa. Total lysate: 100 µg total 
HEK293 cell lysate was loaded and electrophoresed on a 4-20% bis-tris gel (left).  Blocked lysate: after 
incubation with PRDM9 peptide antigen, 100 µg HEK293 cell lysate was loaded and electrophoresed on a 
4-20% bis-tris gel (right).    
 
Together, these data suggest that the protein observed at ~55 kDa is the specific target 
of this antibody. Although this does not confirm that full length human PRDM9 is being 
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detected, the protein target at ~55 kDa is detectable in HEK293 cell lysate using this 
antibody. 
 
6.4.2 Detecting PRDM9 in subcellular fractions 
In order to localise PRDM9 to the mitochondria, subcellular fractions were carried out 
using HEK293 cells. Nucleus, cytoplasm and mitochondria were isolated by differential 
centrifugation and each fraction lysed for protein content. Detection of PRDM9 by 
Western blotting showed differential protein binding in the mitochondria compared to 
nucleus or cytoplasm which showed similar banding profiles (Figure 6.7).  
 
 
Figure 6.7 Immunoblotting of HEK293 subcellular fractions. 50 µg total protein was loaded in each sample 
well and electrophoresed through 4-20% bis-tris gels. Protein size marker was included (M), sizes are 
denoted in kDa. Membrane was incubated with anti-PRDM9 (1:500 dilution), anti-MTCO2 (1:1000) or 
anti-βactin (1:1000) overnight at 4°C. 
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Mitochondrial fractions showed enrichment of a band at ~60 kDa which was also 
present in the nuclear and cytoplasmic fractions (Figure 6.7). Bands at ~100 kDa and 
~30 kDa were observed exclusively in the mitochondrial fractions.  Although there was 
slight contamination of the nuclear fraction, the cytoplasmic and mitochondrial fractions 
were pure as shown by mitochondrial encoded cytochrome C oxidase II (MT-CO2) 
protein detection.  
In order to purify the mitochondrial fractions further, a percoll gradient method was 
used to separate the mitochondria and the mitochondrial associated membrane (MAM) 
so that the ‘pure’ mitochondria could be compared to the ‘crude’ mitochondrial fractions 
(Section 3.6.3). When this subcellular fraction was immunoblotted with anti-PRDM9 
there was a faint band detected in the crude mitochondrial sample lanes (Figure 6.8 A). 
This band was not present in the pure mitochondrial fraction or the cytosol or nuclear 
fractions. Purity of the fractions was tested by blotting with different antibodies specific 
to different cellular compartments (Figure 6.8 B). Heat shock protein family A member 5 
(HSPA5/Bip1) is an endoplasmic reticulum (ER) chaperone protein of 72 kDa in size and 
was mostly present in the cytoplasmic fraction as shown in the left hand panel in Figure 
6.8 B. The protein was also detected in the nuclear and mitochondrial fractions 
suggesting some contamination most likely due to the chaperone/stress response 
nature of Bip1 when it will shuttle from the ER to the cytosol. The structural protein α-
tubulin was detected in the nuclear and cytosolic fractions at 50 kDa but was not 
detected in the mitochondrial fractions suggesting that these samples were not 
contaminated by components of the cytoskeleton. An integral component of the 
mitochondrial outer membrane is the voltage-dependant anion-selective channel 
protein 1 (VDAC1/Porin) protein which creates a channel for the diffusion of small 
hydrophilic molecules. Immunodetection of VDAC1 (31 kDa) showed that it was present 
in the mitochondrial fractions but absent in the cytoplasm (Figure 6.8 B, right hand 
panel). There was faint VDAC1 detection in the nuclear fraction suggesting that some 
mitochondrial membrane may have contaminated this. VDAC1 is also present in the 
plasma membrane of the cell which may suggest why a relatively small amount was 
present in the nuclear/membrane fraction. Finally, histone H3 protein was used to show 
purity of the nuclear fraction. This protein is an important structural protein involved in 
chromosomal packaging, transcriptional silencing and epigenetic modification within 
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the nucleus. Detection of this 13 kDa protein was observed in nuclear, cytosolic and 
crude mitochondrial fractions suggesting that the nuclear membrane may have been 
disrupted during initial cell fractionation or that some cell nuclei were present in the 
subsequent fraction steps (Figure 6.8 B, left hand panel). 
 
 
Figure 6.8 Immunoblotting of HEK293 subcellular fractions. 40 µg total protein was loaded in each sample 
well and electrophoresed through 4-20% bis-tris gels. Protein size marker was included (M), sizes are 
denoted in kDa. Membrane was incubated with anti-PRDM9 (1:500), anti-HSPA5 (Bip1, 1:1000) 
anti-VDAC1 (1:250) anti-α tubulin (1:1000) or anti-histone H3 (1:1000) overnight at 4°C. 
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The detection of PRDM9 by Western blotting of whole cell protein lysates and 
subcellular fractions proved difficult. Cell lines either showed very low protein levels or 
no protein at all when commercially available PRDM9 antibodies were used. Each 
detection method and cell line appeared to give different peptide banding profiles 
suggesting that the protein was not produced in any of the cell lines tested or that the 
available antibodies are not reliable.  
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6.4.3 Detecting PRDM9 expression in tissue 
Several tissue types were investigated for PRDM9 expression by immunofluorescent 
staining. Tissues were chosen based on the likelihood that they would contain cells 
possibly undergoing meiosis and therefore express PRDM9: foetal gonad tissue isolated 
from an 11 post-conception week foetus, human placenta samples from 5, 6 and 10 post 
conception weeks and ovary tissue from an adult with a known mitochondrial disease 
(MELAS syndrome). Human skeletal muscle was used as an internal control because it is 
post mitotic and should not express PRDM9. 
In order to increase antibody specificity a fragment antigen binding (F(ab)) antibody 
against human PRDM9 was kindly provided by Dr M. Vedadi (Toronto Children’s 
Hospital, Toronto, Canada).  This F(ab) fragment is an antibody which still binds to the 
antigen but is monovalent, lacking the Fc portion of the antibody structure. This allows 
for more targeted binding to the antigen without potential cell surface receptor binding 
by the Fc fragment. It also allows better tissue penetration since the F(ab) fragment is 
much smaller in size than a traditional divalent antibody structure. This antibody was 
raised in phage λ and requires anti-human IgG as a secondary antibody for detection. 
Two commercially available PRDM9 antibodies were also tested as a comparison. 
Firstly, human muscle tissue was analysed for the presence of PRDM9 using the 
anti-PRDM9 F(ab) antibody and anti-human IgG secondary antibody (Figure 6.9).  
Secondary antibody specificity was tested on muscle sections at different concentrations 
(Figure 6.9 A, B & C). Positive staining was observed at all concentrations indicating that 
the secondary antibody produced a high level of non-specific binding. Tissue sections 
stained with both primary and secondary antibodies gave positive signal around the 
periphery of the individual muscle fibres (Figure 6.9 D, E & F). PRDM9 signal did not 
co-localise with the nuclei as shown by nuclear staining with 4’6-diamidino-2-
phenylindole dihydrochloride (DAPI) which binds to AT rich regions of DNA and emits 
blue fluorescence. Different concentrations of secondary antibody were tested to 
estimate levels of background staining. All three secondary antibody concentrations 
showed similar staining patterns (Figure 6.9 D, E & F).  
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Figure 6.9 Immunofluorescent staining of human skeletal muscle tissue. A, B & C) human muscle section stained with secondary anti-human IgG antibody. (A) 
1:1000 antibody dilution. (B) 1:2000 dilution. (C) 1:5000 dilution. D, E &F) human muscle section stained with anti-PRDM9 F(ab) primary and anti-human IgG 
secondary antibodies. (D) 1:1000 dilution. (E) 1:2000 dilution. (F) 1:5000 dilution. Nuclei are stained with DAPI in all samples. 
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Ovary tissue sections were assessed for PRDM9 expression by immunofluorescence 
(Figure 6.10). Positive staining was observed using the PRDM9 F(ab) antibody (Figure 
6.10 A). However, anti-human IgG control sections showed high levels of non-specific 
staining using only this antibody on the tissue (Figure 6.10 B). This suggested that the 
anti-human IgG was not a suitable antibody for use on human tissue sections as shown 
by previous staining in muscle tissue (Figure 6.9).  
 
 
Figure 6.10 Immunofluorescent staining of human ovary tissue. All samples were imaged using the 
AxioImager (Leica). A & B) Serial sections were incubated with anti-PRDM9 F(ab) primary and anti-
human IgG-594 secondary (A) or secondary only (B). C & D) Serial sections were incubated with anti-
PRDM9 (Novex) primary and anti-mouse-594 secondary (C) or secondary only (D). E & F) Serial sections 
were incubated with anti-TOMM20 primary and anti-mouse-488 secondary (E) or secondary only (F).  
Nuclei are stained with DAPI in all samples. 
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Secondly, the anti-PRDM9 commercially available antibody (Novex, ThermoFisher 
Scientific, Loughborough, UK) was used to stain ovary tissue sections.  This antibody is 
recommended for immunoprecipitation only but was tested as a comparison to the 
F(ab) antibody. Positive staining was observed (Figure 6.10 C) however, there was also a 
high level of background staining when using only anti-mouse IgG antibody on the tissue 
(Figure 6.10 D). This suggests that the ovary tissue is sequestering the secondary 
antibody due to some sort of physical property of the tissue rather than a true antigen 
binding reaction with the antibody. 
Finally, an antibody targeted to translocase of outer mitochondrial membrane 20 
(TOMM20) was used to stain the tissue as a positive control. Positive staining was 
observed (Figure 6.10 E) and appeared to be specific to the mitochondria as there was 
no co-immunofluorescence with the nuclear DAPI staining. Interestingly, the 
mitochondria appeared to be clumped within the cell and not the dynamic network that 
is often observed in other cell and tissue types. Moreover, secondary anti-mouse IgG2 
control sections showed that the staining was not due to non-specific antigen binding 
(Figure 6.10 F). 
Immunofluorescent staining of human ovary sections showed that the PRDM9 
antibodies gave positive staining however, secondary antibody controls suggest that this 
positive signal is not specific. This is perhaps due to the nature of the tissue itself or the 
non-specificity of the antibodies. Staining of this tissue with a mitochondrial specific 
antibody (TOMM20) showed specific staining patterns but the mitochondrial network 
appeared clumpy and distorted. This could be due to the nature of the mitochondrial 
disease state of the female the tissue was taken from (MELAS syndrome) or due to the 
storage and treatment of the tissue once removed. Haematoxylin and eosin staining of 
the tissue showed freezing artefacts as well as degradation of the tissue structures when 
compared to other ovary sections in the literature (see Appendix B). 
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Isolated foetal gonad tissue sections were a kind gift from Dr V. Floros (MRC 
Mitochondrial Biology Unit, Cambridge University, UK). Sections were stained using 
both the PRDM9 F(ab) and anti-PRDM9 Novex antibodies (Figure 6.11). Sections stained 
with secondary anti-human IgG and anti-mouse IgG showed positive staining (Figure 
6.11 B & E). Sections that had not come into contact with any antibody and had only 
been treated with DAPI also showed positive staining suggesting that this tissue has high 
levels of auto-fluorescence (Figure 6.11 C & F).  In contrast, staining of this tissue with 
an antibody targeted to mitochondrial translocase of outer membrane (TOMM20) was 
specific to the mitochondrial network in this tissue (Figure 6.11 G, H & I). No 
background staining was observed in secondary antibody only or DAPI only controls 
(Figure 6.11 H & I).
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Figure 6.11 Immunofluorescent staining of foetal gonad sample. All samples were imaged using the AxioImager (Leica). A-C) Serial sections were incubated with 
anti-PRDM9 F(ab) primary and anti-human IgG-594 secondary (A), secondary only (B) or no antibody (C). D-E) Serial sections were incubated with anti-PRDM9 
(Novex) primary and anti-mouse-594 secondary (D), secondary only (E) or no antibody (F). G-I) Serial sections were incubated with anti-TOMM20 primary and 
anti-mouse-488 IgG2a secondary (G), secondary only (H) or no antibody (I). Nuclei are stained with DAPI in all samples. 
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Immunofluorescence was also performed using placenta tissue (Figure 6.12). Staining 
tissue sections with PRDM9 F(ab) antibody produced a positive fluorescent stain 
however as shown in previous tissue sections, the anti-human IgG antibody alone also 
gave a similar fluorescent stain suggesting that this signal is non-specific (Figure 6.12 
A & B). Staining placenta tissue with the anti-PRDM9 Novex antibody did not show any 
positive fluorescent stain (Figure 6.12 C). Secondary only control staining with anti-
mouse antibody also showed no fluorescent signal (Figure 6.12 D).  Therefore we 
conclude that PRDM9 is not detectable in placenta tissue using the antibodies tested in 
this study.  
 
 
Figure 6.12 Immunofluorescence of human placenta tissue. All samples were imaged using the AxioImager 
(Leica). A & B) Serial sections were incubated with anti-PRDM9 F(ab) primary and anti-human IgG-594 
secondary (A) or secondary only (B). C & D) Serial sections were incubated with anti-PRDM9 (Novex) 
primary and anti-mouse-594 secondary (C) or secondary only (D). Nuclei are stained with DAPI in all 
samples. 
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PRDM9 protein was not detected by immunofluorescent staining in the tissues used in 
this study. The F(ab) fragment antibody used is not appropriate for human tissue 
staining as it was not raised in an animal and therefore requires anti-human IgG as a 
secondary antibody for detection. This antibody can react with most IgG antigens 
present in the tissue samples therefore producing off target staining. The Novex 
anti-PRDM9 antibody required anti-mouse IgG secondary antibody for detection. This 
antibody produced a non-specific fluorescent signal when used to stain both ovary and 
foetal gonad tissue sections but not in the placenta sample.   
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Tissue samples were also analysed for protein expression by gel electrophoresis and 
Western blotting. Ovary tissue lysate was blotted with anti-PRDM9 giving a strong single 
band at a large molecular weight >200 kDa (Figure 6.13 A). Before the gel was 
transferred to a PVDF membrane, it was reversibly stained with InstantBlue™ 
Coomassie brilliant blue stain (Figure 6.13 B). Staining total protein showed a strong 
signal at ~180 kDa most likely due to multiple high molecular weight proteins. 
 
 
Figure 6.13 Western blot detection of PRDM9 in ovary lysate. Protein size marker was included on each 
blot (M), sizes are denoted in kDa. A) Ovary lysate gradient from 20-60 µg protein was loaded on a 4-20% 
bis-tris gel. B) Ovary lysate gradient from 20-60 µg protein was loaded on a 4-20% bis-tris gel. Gel was 
stained with Coomassie brilliant blue and imaged. Membrane was incubated with anti-PRDM9 (1:500 
dilution) or GAPDH (1:1000 dilution) overnight at 4°C.  
 
Foetal gonad tissue (F3) was kind gift from Dr V. Floros (MRC Mitochondrial Biology 
Unit, Cambridge University, UK). F3 tissue lysate was immunoblotted with anti-PRDM9 
(Figure 6.14 A). No protein was detected in this sample lysate using the PRDM9 
antibody, when the GAPDH antibody was used a band was detected confirming that 
there was protein present in the sample lanes. Staining the gel before transfer to PVDF 
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membrane with InstantBlue™ Coomassie brilliant blue confirmed total protein content 
of the F3 lysate correlates with the concentration of protein loaded (Figure 6.14 B).  
 
 
Figure 6.14 Western blot detection of PRDM9 in foetal gonad (F3) tissue lysate. Protein size marker was 
included on each blot (M), sizes are denoted in kDa. A) F3 lysate gradient from 20-60 µg protein was 
loaded on a 4-20% bis-tris gel. B) F3 lysate gradient from 20-60 µg protein was loaded on a 4-20% bis-tris 
gel. Gel was stained with Coomassie brilliant blue and imaged. Membrane was incubated with anti-PRDM9 
(1:500 dilution) or GAPDH (1:1000 dilution) overnight at 4°C.  
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6.4.4 Immunoprecipitation of PRDM9  
Due to the non-specific protein banding observed by Western blotting, 
immunoprecipitation (IP) of PRDM9 was carried out using a range of different PRDM9 
antibodies. Four different anti-PRDM9 antibodies were used for IP throughout this study 
as detailed in Section 3.7.4 (Table 3.3). 
Initial IP was carried out using the Novex anti-PRDM9 antibody. This antibody was 
specified as only appropriate for IP and not for other immunodetection methods, 
therefore it was potentially more suitable than the antibody used in previous detection 
methods. After incubation of total HEK293 cell lysate with anti-PRDM9 antibody the 
unbound, wash and final elution lysates were electrophoresed. Staining the gel with 
Coomassie brilliant blue showed strong protein detection in the unbound lysate lanes as 
expected (Figure 6.15 A & B). Weak protein staining was seen in the wash lysate lanes, 
which was also expected as any further unbound protein would be captured in this 
washing step. No protein bands were detectable in the final elution lysates suggesting 
that no protein had bound to the anti-PRDM9-A/G bead complexes during the assay.  
As a test for sensitivity of the Coomassie stain, gels were next treated with metallic silver 
(Ag). Using this staining method, protein bands were visualised in the final elution 
sample lanes (Figure 6.15 C & D). This was also the case in the ‘blank’ sample lane where 
no antibody was present in the reaction suggesting that some protein was either 
contaminating this sample or that the A/G beads themselves were contributing protein 
during the final elution step (Figure 6.15 D). Interestingly, a band at ~100 kDa was 
present in the elution sample lanes where the initial protein input was 5000 and 
3000 µg (Figure 6.15 C & D). As expected, a band was present at ~50 kDa in the samples 
where antibody was added to the reaction mix. This band corresponds to the IgG heavy 
chain of the antibody complex which is pulled-down in the final elution step and is 
present in high amounts.     
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Figure 6.15 Immunoprecipitation of PRDM9 from HEK293 cell lysate. Protein lysate was incubated in the 
presence or absence (denoted Blank) of the Novex anti-PRDM9 antibody. Unbound protein (U), bead wash 
(W) and final protein elute (E) were loaded on 4-20% bis-tris gels and electrophoresed until samples had 
migrated through the entire gel. A & B) Gels were stained with Coomassie® blue. C & D) Gels were stained 
with metallic silver (Ag). Protein size markers were run on each gel in the left hand lane, sizes in kDa are 
denoted.  
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In order to determine whether the ~100 kDa band detected by silver staining in Figure 
6.15 was PRDM9, Western blotting was carried out using gels run in parallel with the 
same IP sample lysates. After probing with anti-PRDM9 (Abcam) three distinct bands 
could be detected in final elution sample lanes but were absent in the blank sample lane 
(Figure 6.16). The band at ~50 kDa most likely corresponds to the IgG heavy chain 
which is detectable by secondary antibody binding. Other bands were observed at ~140 
and ~45 kDa, the identity of these protein species is unknown. A faint band was 
detectable in the unbound protein lysate lanes at ~25 kDa, most likely corresponding to 
the IgG light chain. 
 
Figure 6.16 Western blot detection of immunoprecipitated PRDM9 from HEK293 cell lysate. Protein lysate 
was incubated in the presence or absence (denoted Blank) of the Novex anti-PRDM9 antibody. Unbound 
protein (U), bead wash (W) and final protein elute (E) were loaded on 4-20% bis-tris gels and transferred 
onto PVDF membranes. 
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Next, the four anti-PRDM9 antibodies (Novex, Abcam, HPA063372 and HPA059555) 
were compared to determine whether any were appropriate for IP of PRDM9 protein 
(Figure 6.17). The Novex antibody produced a single band at ~100 kDa in the final 
elution lysate (Figure 6.17 A). The other three antibodies gave multiple bands in the 
final elution lysates. The Abcam antibody gave three bands at ~50 kDa which could be 
the IgG heavy chain or unknown proteins of this size. As previous Western blot 
detections had shown this antibody to bind a species of ~55 kDa, this result was 
expected when using it for IP. The HPA antibodies were used at different concentrations 
as there was a limited amount of these samples. The results seen in Figure 6.17 B are 
most likely due to an excess of antibody in the HPA063372 reaction and too little 
antibody in the HPA059555 sample.  
 
 
Figure 6.17 Immunoprecipitation of PRDM9 in HEK293 cell lysate. Protein lysate was incubated in the 
presence or absence (denoted Blank) of the Novex, Abcam, HAP063372 or HPA059555 anti-PRDM9 
antibodies. Unbound protein (U), bead wash (W) and final protein elute (E) were loaded on 4-20% bis-tris 
gels and electrophoresed until samples had migrated through the entire gel. A & B) Gels were stained with 
Coomassie® blue. Protein size markers were run on each gel in the left hand lane, sizes in kDa are denoted. 
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Immunoprecipitation of PRDM9 was attempted using ovary lysate, which had previously 
shown PRDM9 detection by Western blot (Figure 6.13). Gel staining using Coomassie 
brilliant blue showed three protein bands at ~48, ~45 and ~12 kDa (Figure 6.18 A). 
Silver staining the gel also showed these three bands and additionally bands at ~100 
and ~140 kDa (Figure 6.18 B). Interestingly there were some high molecular weight 
proteins detected in the ‘blank’ elution sample lanes where antibody was not added to 
the reaction mix (Figure 6.18 A & B).    
 
Figure 6.18 Immunoprecipitation of PRDM9 from ovary tissue lysate. Ovary lysate was incubated in the 
presence or absence (denoted Blank) of anti-PRDM9 F(ab). Unbound protein (U), bead wash (W) and final 
protein elute (E) were loaded on 4-20% bis-tris gels and electrophoresed until samples had migrated 
through the entire gel. A) Gel was stained with Coomassie® blue. B) Gel was stained with metallic silver 
(Ag). C) Gel was transferred onto PVDF membrane and Western blot detection performed using anti-
PRDM9 antibody (Abcam). Protein size markers were run on each gel in the left hand lane, sizes in kDa are 
denoted. 
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Western blot detection of PRDM9 was tested for in the IP sample lysates. When 
incubated with anti-PRDM9 (Abcam) a single band was detected in the elution sample 
lanes at ~50 kDa but was absent in the blank sample lanes (Figure 6.18 C). This band 
corresponds to the IgG heavy chain of the antibody used in the IP reaction. A high 
molecular weight band was detected in the unbound lysate sample lanes of the 2400 µg 
and blank IP reactions. This protein species might be a non-specific binding target of the 
antibody or could be a peptide present in the ovary lysate containing a PRDM9 molecule 
in complex with other peptides making it much larger than the predicted molecular 
weight of 103 kDa. 
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In order to determine whether there were different proteins binding the anti-PRDM9 
antibody in the ovary tissue and HEK293 cell lysates we directly compared ovary, 
HEK293 and 143B lysates (Figure 6.19).  When gels were stained with Coomassie 
brilliant blue there were two protein bands present in the final elution lanes at ~45 and 
~12 kDa (Figure 6.19 A & B). There was also a faint band at ~100 kDa in the HEK293 
elution sample lane (Figure 6.19 A). The control ‘blank’ sample, where no antibody was 
added to the IP reaction mix, showed a single band at ~12 kDa which could correspond 
to a contaminating peptide or perhaps a peptide fragment present on the A/G beads 
used in the assay (Figure 6.19 B).  
 
 
Figure 6.19 Immunoprecipitation of PRDM9 in ovary, HEK293 and 143B lysates. Lysates were incubated 
in the presence or absence (denoted Blank) of anti-PRDM9 F(ab). Unbound protein (U), bead wash (W) 
and final protein elute (E) were loaded on 4-20% bis-tris gels and electrophoresed until samples had 
migrated through the entire gel. A & B) Gels were stained with Coomassie® blue. C & D) Gels were 
transferred onto PVDF membranes and Western blot detection performed using anti-PRDM9 antibody 
(Abcam). Protein size markers were run on each gel in the left hand lane, sizes in kDa are denoted. 
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To test for PRDM9 presence in the IP samples, Western blot detection was performed on 
gels run in parallel using the IP sample lysates. Incubation of the membranes with anti-
PRDM9 (Abcam) detected a band at ~50 kDa in the unbound and final elution sample 
lanes corresponding to the IgG heavy chain (Figure 6.19 C & D). A band at ~25 kDa was 
also observed in the final elution sample lanes which corresponds to the IgG light chain. 
These bands were absent in the control ‘blank’ sample further confirming that they are 
most likely IgG peptides from the antibody used in the IP reactions (Figure 6.19 D).  
Ovary tissue, HEK293 and 143B cell lysates showed the same protein profile when IP 
was attempted using the Novex PRDM9 antibody. There was a faint band in the HEK293 
elution sample at ~100 kDa which was not detected by Western blot detection 
suggesting that this might be contamination by another peptide of this molecular weight 
and most likely not PRDM9. 
In almost all IP reactions there was detection of protein in the ‘blank’ sample where 
beads were incubated with protein lysate only. To determine whether this detection was 
due to contaminating protein from the sample lysate or from the A/G beads themselves, 
two different beads (Thermo Fisher Scientific, Loughborough, UK) were incubated in 
wash buffer in the presence or absence of PRDM9 F(ab) antibody (Figure 6.20). When 
incubated in the presence of PRDM9 F(ab), a protein band was detected at ~40 kDa in 
the elution sample from both beads (M280 and T1). There was a band detected at 
~10 kDa that was also present when there was no antibody added to the reaction 
suggesting that the beads themselves contaminate the elution samples with a peptide 
species. 
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Figure 6.20 Test of A/G bead contamination in immunoprecipitation reactions. M280 or T1 beads were 
incubated in the presence or absence of F(ab) PRDM9. Wash (lanes W) sample and elution (lanes E) 
sample were electrophoresed on 4-20% bis-tris gels and stained with Coomassie brilliant blue. Protein 
size marker (lane M) was included on the gel, sizes are denoted in kDa. 
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6.4.5 Mass spectrometry analysis of PRDM9 immunoprecipitation samples 
Mass spectrometry (MS) analysis was performed on bands cut out from gels containing 
the IP samples. Peptide fragments were analysed in a shotgun approach where amino 
acid sequences were re-aligned using online protein databases to identify the peptides 
present in the sample. Methods relating to the MS analysis are detailed in Section 3.8.5. 
HEK293 cell lysate was incubated with the Novex anti-PRDM9 antibody and the gel 
containing the samples sent for mass spectrometry analysis (Figure 6.21). Final elution 
lysate showed three bands at ~100, ~45 and ~15 kDa. To identify the peptides being 
pulled down by this antibody, we analysed all three bands from this elute (Figure 6.21).  
 
 
Figure 6.21 Immunoprecipitation of PRDM9 in HEK293 cell lysate. Lysate was incubated with Novex 
anti-PRDM9 antibody. Unbound (U), bead wash (W) and final protein elute (E) were loaded on 4-20% 
bis-tris gels and electrophoresed until samples had migrated through the entire gel. 
 
The top 16 peptides, based on confidence score (log(e)), identified by MS are shown in 
Table 6.3. Unfortunately, PRDM9 peptide sequence was not detected in the sample. The 
most abundant peptides were members of the keratin protein family, from 
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contamination of the gel by hair or skin cells present during the sample or gel 
preparation. Trypsin was also found in the MS analysis, this is most likely excess enzyme 
remaining after digestion of the gel slices during preparation of the sample. 
Immunoglobulin heavy variable 3-7 protein was identified and is a fragment from the 
antibody used in the IP reaction. In addition, filaggrin family member 2 (FLG2) peptide 
was detected in the sample. This protein is primarily involved in epithelial homeostasis 
and is important for cornification of skin suggesting that it was likely another 
contaminant of the IP gel during processing (Dang et al., 2016). 
Other identified peptides were found in very low abundance but are also predicted to be 
contaminants of the pull down (Table 6.3). For example, eukaryotic translation 
elongation factor 1 alpha (EEF1A1), actin alpha 1 (ACTA1) and phenylalanyl-tRNA 
synthetase (FARSB) were all identified in the sample however this is probably due to the 
relative abundance of these proteins within the cell and therefore the lysate. Actin 
filaments and members of the transcription/translation processes are some of the most 
abundant cellular proteins and are in this case presumed to be carry over contamination 
in the IP elution. 
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Table 6.3 Mass spectrometry protein read-out for HEK293 lysate IP. Identifier protein code, log (I), refractive index (rI), expectation value (log(e)), isoelectric point 
(pI) and molecular weight is provided along with a description of the protein.
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Mass spectrometry was also performed on an IP sample using ovary tissue lysate and 
the PRDM9 F(ab) fragment antibody (Figure 6.22).  
 
 
Figure 6.22 Immunoprecipitation of PRDM9 in ovary tissue lysate. Lysate was incubated with Novex 
anti-PRDM9 antibody. Unbound (U), bead wash (W) and final protein elute (E) were loaded on 4-20% bis-
tris gels and electrophoresed until samples had migrated through the entire gel. 
 
The most abundant peptides identified in the MS analysis were subunits of the 
immunoglobulin protein family (Table 6.4). The abundance of these peptides indicates 
that the band identified on the IP gel was most likely a large multiprotein complex 
mostly comprised of antibody fragments. This was caused by insufficient amounts of 
sample reducing agent used to linearise the peptide molecules and limit protein 
aggregation or insufficient denaturation of the sample by heating at 95 °C. These two 
steps usually effectively separate the IgG peptides from any other protein in the sample, 
which was clearly not the case in this reaction given the MS result (Table 6.4). 
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Table 6.4 Mass spectrometry protein read-out for ovary lysate IP. Identifier protein code, log (I), refractive index (rI), expectation value (log(e)), isoelectric point 
(pI) and molecular weight is provided along with a description of the protein.  
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6.4.6 PRDM9 mRNA expression analysis by RT q-PCR 
Expression of PRDM9 mRNA was analysed in HEK293 cells by RT q-PCR. Primers were 
designed to align to the full length human PRDM9 mRNA transcript (NM_020227). 
Primer details are listed in Table 6.5. Reactions were set up as follows; 10 µL 2X iTaq™ 
Universal SYBR® Green supermix, 1 - 4 µM forward and reverse primer, 2 - 5 µg cDNA, 
made up to a final volume of 25 µL with dH2O. All reaction plates were run on the Bio-
Rad® iQ™5 thermocycler using the following program; denaturation at 95 °C for 30 
seconds followed by 40 cycles of 95 °C for 15 seconds and 62.5 °C for 30 seconds. 
Immediately after product amplification melt curve analysis was performed using a 
0.5 °C/2 seconds increment from 65 - 95 °C.   
 
Primer Forward Sequence 5’-3’ Reverse Sequence 5’-3’ Product length 
PRDM9 1 AGGCTGTGAACTGCTGGTCTGG GGCCCTTGAAATCTCCCTCTG 364 bp 
PRDM9 2 GAAACCCTTGAGCCTTTGGC AGAAGGCCCTGCTCCAATTC 77 bp 
PRDM9 3 TTTGTCGTGCAGCGTGAAAC GAAGGCCCTGCTCCAATTCT 91 bp 
GAPDH CTGACTTCAACAGCGACACC ATGAGGTCCACCACCCTGT 94 bp 
Table 6.5 Details of primers used for gene expression analysis by RT q-PCR amplification. Transcript 
target, forward and reverse primer sequence and amplicon product length are shown. 
 
Amplification of a product using these primers was technically challenging. Firstly, 
PRDM9 primer set 1 was described in a publication assessing mRNA expression in 
human samples (Liu et al., 2007). These primers were then tested with HEK293 whole 
cell RNA which was reverse transcribed to cDNA before RT q-PCR was performed. 
Reactions were attempted with increasing primer concentrations of 1, 2 and 4 µM using 
a 1 in 10 dilution series of cDNA, from a starting concentration of 2 µg. Product 
amplification was only achieved when 4 µM of each primer was used (Figure 6.23). Melt 
curve analysis confirmed that primers were specific for the PRDM9 transcript as they 
did not denature until temperatures of >85 °C (Figure 6.23 A & B). However, 
amplification was not achieved until after cycle 34 suggesting that the amount of 
transcript was very low in abundance (Figure 6.23 C). The PRDM9 threshold cycle (Ct) 
values from standard curve analysis showed that PRDM9 was being amplified and that 
there was no contamination in the negative control wells (Figure 6.23 D). However, the 
variation was large between triplicate samples and only the two highest concentration 
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standards showed any amplification suggesting again that the transcript level was low in 
the HEK293 cell sample. 
 
 
Figure 6.23 PRDM9 expression measured by RT q-PCR. Primer set 1 was used to amplify a 364bp PRDM9 
product. A) Melt curve chart of primer set 1 in each sample well is shown by plotting relative fluorescence 
units (RFU) against temperature (°C). B) Melt peak chart of primer set 1 C) Amplification chart of primer 
set 1 product shown by plotting RFU against reaction cycle. D) Plot of threshold cycle values (Ct) against 
starting quantity of cDNA. 
 
Next, primers for the house keeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) were tested using HEK293 cDNA. Efficient amplification of the product was 
achieved when using 1 µM of each primer and 2 µg of cDNA (Figure 6.24). Melt curve 
analysis showed specificity of the primers by denaturing at ~84 °C and in relation to the 
amount of template cDNA added to each reaction (Figure 6.24 A & B). Amplification of 
GAPDH product was achieved at 18 cycles and dilutions of standards showed a linear 
decrease in Ct values as cDNA concentration increased ten-fold (Figure 6.24 C & D). 
 164 
 
 
Figure 6.24 GAPDH expression measured by RT q-PCR. Primers specific for GAPDH transcript were used 
to amplify a product. A) Melt curve chart in each sample well is shown by plotting relative fluorescence 
units (RFU) against temperature (°C). B) Melt peak chart of C) Amplification chart of GAPDH product 
shown by plotting RFU against reaction cycle. D) Plot of threshold cycle values (Ct) against starting 
quantity of cDNA. 
 
In order to increase PRDM9 product amplification, another set of primers specific for 
PRDM9 were designed. PRDM9 primer set 2 showed amplification when using 4 µM of 
each primer and 4 µg HEK293 cDNA (Figure 6.25). Amplification was achieved after 30 
cycles of PCR amplification (Figure 6.25 A). This primer set was slightly less specific than 
primer set 1 as shown by melt curve analysis (Figure 6.25 B). This primer set did 
however give product amplification in four of the standard cDNA dilutions tested 
(Figure 6.25 C). Compared to GAPDH product amplification the PRDM9 Ct values were 
high suggesting that transcript abundance was low in the HEK293 cell sample (Figure 
6.25 D).  
 165 
 
 
Figure 6.25 PRDM9 and GAPDH expression measured by RT q-PCR. A, B & C) PRDM9 product 
amplification using primer set 2. A) Amplification shown by plotting relative fluorescence units (RFU) 
against PCR amplification cycle number.  B) Melt peak chart of PRDM9 primer set 2 shown by plotting RFU 
against temperature (°C). C) Plot of threshold cycle values (Ct) against starting quantity of cDNA. D) 
GAPDH product amplification. Plot of threshold cycle values (Ct) against starting quantity of cDNA. 
 
A final primer set, PRDM9 primer set 3, was used and showed amplification using 4 µM 
of each primer with 5 µg of HEK293 cDNA (Figure 6.26). Again, amplification was not 
achieved until ~30 cycles of PCR amplification (Figure 6.26 A). This primer set appeared 
to be less specific than primer sets 1 and 2, as shown by melt curve analysis (Figure 
6.26 B). Threshold values were variable between the sample triplicates (Figure 6.26 C). 
PRDM9 amplification was again very low when compared to the efficiency of GAPDH 
product amplification (Figure 6.26 D). 
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Figure 6.26 PRDM9 and GAPDH expression measured by RT q-PCR. A, B & C) PRDM9 product 
amplification using primer set 3. A) Amplification shown by plotting relative fluorescence units (RFU) 
against PCR amplification cycle number.  B) Melt peak chart of PRDM9 primer set 2 shown by plotting RFU 
against temperature (°C). C) Plot of threshold cycle values (Ct) against starting quantity of cDNA. D) 
GAPDH product amplification. Plot of threshold cycle values (Ct) against starting quantity of cDNA. 
 
Expression analysis of PRDM9 was attempted using three different primer sets designed 
to anneal to the mRNA transcript sequence. Primer set 2 appeared to amplify the 
product most efficiently however, this was only achieved when using high amounts of 
starting cDNA. Even when 5 µg of cDNA was used in the reaction the threshold cycle 
values were high suggesting that transcript levels were very low in the sample. 
Unfortunately due to a lack of appropriate tissue, a positive control of PRDM9 
expression was not available to test the efficiency of the primer sets. Isolation of RNA 
from human testes tissue would be the most appropriate tissue in which to test the 
expression levels and compare the HEK293 cell sample. 
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6.5 Discussion 
In order to detect human PRDM9 protein in cell lines and tissue samples a variety of 
assays were used including immunodetection, IP, IF, MS and q-PCR. Given the embryonic 
nature of the PRDM9 protein, tissues and cell lines were selected based on their 
embryonic origin.  Tissue samples were selected based on the likelihood that they would 
contain cell types undergoing meiosis and therefore express PRDM9. Ovary, foetal gonad 
and placenta were tested for PRDM9 expression alongside skeletal muscle, presumed to 
not express PRDM9 as it is a post-mitotic tissue type. 
Several cell lines available in the laboratory were tested for PRDM9 protein expression. 
Primary myoblast and fibroblast cell lines showed very low levels of protein expression 
when a PRDM9 antibody was used for detection. The nature of these cells in culture 
makes them slow to divide and they reach replicative senescence by 15-18 cell divisions. 
For this reason it was not feasible to grow sufficient amounts of cells for investigations 
which require high quantities of protein such as immunoprecipitation or subcellular 
localisation.  
Protein was not detected using the PRDM9 antibody with lysate from the immortalised 
cell lines derived 143B and NT2. Therefore, cell investigations in this study primarily 
used HEK293 cells. This was due to the embryonic nature of this cell line as well as its 
ability to proliferate quickly and indefinitely, providing a large amount of cellular 
material for these investigations. When high quantities of protein were used, a protein 
band at ~100 kDa could be detected in HEK293 and human testis lysate leading us to 
believe that this cell line was appropriate for further investigation of PRDM9. 
Subcellular fractions of HEK293 cells were also blotted for using PRDM9 and a range of 
antibodies against organelle specific proteins. Protein detected with the PRDM9 
antibody showed the presence of two peptides which were exclusively localised to the 
mitochondrial fraction. However, multiple bands were detected using these samples and 
methods to separate the fractions further by dissociation of the MAM showed a 
completely different peptide profile to previous membranes. 
Unfortunately, commercially available antibodies against PRDM9 appear to be 
non-specific and unreliable, giving multiple band detection on immunoblots as well as 
different protein banding profiles. This intra-assay variability means that any positive 
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PRDM9 detection is not reproducible. For this reason, PRDM9 localisation studies 
cannot confirm the presence of this protein in the mitochondrial fraction of HEK293 
cells although enrichment of a ~60 kDa band was observed via subcellular fraction 
immunoblotting. Peptide blocking experiments were carried out to identify which 
protein band detected by the PRDM9 antibody was likely to be the desired protein. 
These experiments show that a ~55 kDa peptide was the target of this antibody 
however, this does not confirm that this commercially available antibody recognises full 
length human PRDM9 protein. Currently, three PRDM9 transcripts have been identified 
although only one is predicted to be protein encoding. The existence of two alternative 
transcripts could partially explain the different peptides identified by immunodetection 
however, further peptide characterisation would be needed to confirm this. 
Immunofluorescent assays were attempted using two PRDM9 antibodies available. 
Staining of tissues appeared to be dependent on the condition and age of the tissue 
samples used. For example, ovary tissue had been stored for a long period of time whilst 
muscle, foetal gonad and placenta samples were frozen more recently. The F(ab) 
antibody was not appropriate for human tissues as the secondary (anti-human IgG) 
antibody reacted with multiple peptide antigens, not exclusively the anti-PRDM9 F(ab). 
In addition, the Novex antibody gave high levels of background staining on all samples 
tested apart from placenta. The IF images showed that high fluorescence was normally 
detected in fibrous regions of the tissues where there were connective structures but no 
DAPI positive cell types. This suggested that the nature of these regions prevented the 
antibodies (primary or secondary) from penetrating the tissue or prevented the wash 
out of excess antibody during the preparation of these samples.   
Immunoprecipitation of PRDM9 was attempted in HEK293 and ovary tissue lysates. 
These IP experiments were largely unsuccessful again due to the unreliability of PRDM9 
antibodies. Samples from IP were also sent for mass spectrometry analysis to confirm 
the presence or absence of PRDM9 protein. Unfortunately, both samples only contained 
contaminating peptides and antibody fragments from the reaction itself. PRDM9 was not 
detected in the MS analysis. 
Furthermore, gene expression of PRDM9 was investigated by RT-qPCR amplification in 
HEK293 cells. Although the primer sets used appeared to be specific to the PRDM9 
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mRNA transcript there was a very low level of the product detected in the samples. Even 
when high quantities of cDNA were used as template the threshold cycle values 
appeared high suggesting that any PRDM9 transcript produced by the cell was in low 
abundance and could therefore not be reliably quantified. The amount of cDNA required 
for low level detection is achievable using immortalised cell RNA but would prove more 
difficult for tissue analysis.  
Human PRDM9 is expressed during meiosis in gametocytes and therefore has so far only 
been detected in testis tissue, which continually produces new gametes in 
post-pubescent males as well as in foetal ovarian tissue at 23 weeks post conception 
(Liu et al., 2007). PGCs are difficult to obtain and require specialist dissection and 
sorting techniques to ensure a pure cell population (Tang et al., 2015). Collecting cells in 
this way from foetal tissue would result in very small amounts of cellular material and 
would therefore require high sensitivity single cell based assays to perform analysis for 
the presence of PRDM9. Primordial germ cell differentiation is possible using mouse 
ESCs and would provide a unique insight into characterising the expression profile of 
this protein either by transcript analysis or protein levels (Nakatsuji and Chuma, 2001). 
The main limiting factor of this experimental approach is the lack of a PRDM9 antibody 
against the murine protein.  
Human testis would appear to be the most appropriate tissue in which to study PRDM9 
expression given the availability of cells undergoing meiosis within this tissue. 
Availability of this tissue type is limited due to a lack of samples available for research. 
Most testicular biopsies from adult males are carried out to investigate infertility issues 
or suspected tumours (Ni et al., 2016; Song et al., 2016a; Zhang et al., 2016). The amount 
of tissue taken at biopsy tends to be small and would therefore provide a limited amount 
of RNA, DNA or protein for analysis, especially after clinical investigations for which the 
tissue was taken have been performed.  
Human PRDM9 expression analysis should either focus on utilising testicular tissue 
samples available for research or using primordial germ cell differentiation techniques. 
As shown in this study, PRDM9 protein did appear to be detectable in testis lysate and 
using freshly extracted protein and RNA would hopefully further confirm this finding. 
The low levels of PRDM9 expression coupled with rapid turnover of the protein will 
 170 
 
make detection of PRDM9 extremely difficult. In this case, producing a cell culture based 
model or purifying recombinant protein would provide the largest amount of material 
for functional assays.  
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Chapter 7 Modifying PRDM9 expression levels in a cell culture model. 
 
7.1 Overview 
Previous studies attempting to elucidate the functional role and structure of the PRDM9 
protein have focussed on Mus musculus  protein as a model or partial PRDM9 constructs 
utilising recombinant protein technologies (Mihola et al., 2009; Billings et al., 2013; 
Eram et al., 2014). These studies have interrogated the histone methyltransferase 
activity of the PR domain, which has homology to the well characterised SET domain; 
known to be essential for methyltransferase function in other protein families posessing 
this characteristic (Eram et al., 2014; Powers et al., 2016). Purified PRDM9 zinc finger 
array constructs have been used to assess DNA binding affinity and motif specificity 
(Davies et al., 2016). Crystal structures of human PRDM9 have also been described, 
giving an insight into the potential functions of each region of the protein (Patel et al., 
2016). Other regions of the PRDM9 protein are predicted to have important functional 
roles including protein-protein interactions through the Krüpple-associated box (KRAB) 
domain and transcriptional regulation through the SSX repression domain (SSXRD), 
however these have not yet been experimentally determined. A schematic of PRDM9 
protein structure is shown in Figure 7.1. 
 
 
Figure 7.1 Structure of the human PRDM9 protein. KRAB, SSXRD, zinc knuckle, PR/SET, zinc finger and 
C2H2 zinc finger array are denoted. 
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7.2 Aims 
The aims of this Chapter are; 
1. To identify PRDM9 protein expression by immunodetection using transient 
knockdown.  
2. To perform PRDM9 protein overexpression.  
This will provide two different cell culture models for investigating some of the 
functions of this protein in mammalian cells. 
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7.3 Experimental Methods 
Overlapping Methods are described in Chapter 3, Sections 3.8.6, 3.10.3 and 3.11.1. 
 
7.3.1 PRDM9 siRNA transfection optimisation 
The PRDM9 antibodies commercially available showed nonspecific binding by 
immunodetection methods outlined in Chapter 6. In order to further investigate 
whether any of the detected peptides were indeed PRDM9, knockdown of PRDM9 was 
attempted using short interfering RNA oligonucleotides (siRNA). This transient system 
allows targeted knockdown of mRNA species produced by the cell (Rao and Huang, 
1979; Hillman et al., 1987). Degradation of RNA by siRNA occurs through the RNA 
interference (RNAi) pathway involving many members of the Argonaute protein family, 
namely an RNAseIII-like protein (DICER) and RNA induced silencing complex (RISC) 
(Hammond et al., 2001; Hutvagner and Zamore, 2002; Doi et al., 2003). An siRNA oligo, 
specific to the PRDM9 transcript, was transfected into HEK293 cells in a dose dependent 
manner. After 72 hours of transfection, cells treated with siRNA targeted to PRDM9 
displayed cytotoxicity with concentrations higher than 5 nM (Figure 7.2). Control cells 
treated with lipofectamine transfection agent or 20 nM non-targeting scramble siRNA 
did not display cytotoxic effects compared to untreated controls. Cells treated with 5 nM 
PRDM9 siRNA showed normal cell growth suggesting that this was the optimum 
concentration of this oligo in HEK293 cells (Figure 7.2). 
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Figure 7.2 Cell counts of HEK293 cells after 72 hours of treatment with siRNA. Cells were seeded in 9.5cm2 
tissue culture plates at a density of 1.2x106 cells/well at the start of the experiment. Cells were either; 
untreated, PRDM9 siRNA treated (5, 10 or 20 nM) or non-targeting scramble siRNA (20 nM) treated for 72 
hours before harvested and counted using trypan blue to assess cell death. 
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7.3.2 Overexpression plasmid validation 
The transient overexpression system used in this study was the pcDNA3.1(+) plasmid 
containing full length PRDM9 cDNA (Figure 7.3).  
 
 
Figure 7.3 Plasmid map of pcDNA3.1(+) containing full length human PRDM9 cDNA. Cytomegalovirus 
(CMV) enhancer and TATA box (green), MCS denotes the multiple cloning site, BGH polyadenylation signal 
(pink), SV40 early polyadenylation signal (blue), ampicillin/hygromycin/kanamycin resistance elements 
(yellow), pUC ori sites on complementary strands (light blue). 
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Three different pcDNA3.1(+) plasmids were used in this study. Firstly, a 
pcDNA3.1(+)PRDM9 plasmid was a kind gift from Dr M.Vedadi (Toronto Childrens 
Hospital, Toronto, Ca).  This plasmid contained full length human PRDM9 cDNA 
validated in the laboratory of Dr Vedadi. Secondly, an independent full length huPRDM9 
pcDNA3.1(+)PRDM9 was designed (synthesised by Genscript, Ontario, CA). Thirdly, a 
partial huPRDM9 plasmid containing amino acids 195-385 was designed (synthesised 
by Genscript, Ontario, CA). These plasmids will herein be referred to as plasmid 1, 
plasmid 2 and plasmid 3 respectively. 
All three plasmids were validated by PCR and Sanger sequencing of the PRDM9 insert 
sequence (Figure 7.4). Colony PCR amplification of purified plasmids 1 and 2 showed a 
single band at ~2700 bp corresponding to the full length PRDM9 cDNA insert sequence 
(Figure 7.4 A & B). The PCR products were Sanger sequenced and compared to all 
available sequences using NCBI Basic Local Alignment Search Tool (BLAST). The 
constructs from both labs had 98% amino acid similarity to human PRDM9 protein. 
Plasmid 3 was also PCR amplified and as predicted, a clear band corresponding to partial 
PRDM9 at ~740 bp in size was observed (Figure 7.4 B). This construct had 97% amino 
acid sequence similarity to human PRDM9. Colony number 1 was chosen to be purified 
for each plasmid (Figure 7.4; lane 1 A, lanes 1 and 5 B). 
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Figure 7.4 Validation of PRDM9 plasmids by PCR amplification. A) Colony PCR of pcDNA3_PRDM9_Flag 
plasmid 1 (provided by the Vedadi lab). Lanes 1-5: PCR product of insert DNA from colonies transformed 
with the pcDNA3_PRDM9_Flag construct. Lanes 6-10: PCR product of insert DNA from colonies 
transformed with pcDNA3 plasmid DNA as a control. B) Colony PCR of pcDNA3_PRDM9_Flag plasmid 2 
and partial pcDNA3_PRDM9_Flag plasmid 3. Lanes 1-5: PCR product of insert DNA from colonies 
transformed with plasmid 2. Lanes 6-10: PCR product of insert DNA from colonies transformed with 
plasmid 3. 
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7.3.3 Transfection efficiency optimisation 
In order to easily monitor the transfection efficiency of HEK293 cells using the 
pcDNA3.1 system, a plasmid expressing green fluorescent protein (GFP) was kindly 
provided by Professor Hanns Lochmüller (Institute of Genetic Medicine, Newcastle 
University, UK). The expression of this protein can be visualised whilst the cells are in 
culture using a GFP filter on a benchtop microscope (Zeiss Axiovert). Images were 
collected at 24 and 48 hours post transfection and compared (Figure 7.5). Using 6 µg of 
plasmid DNA for 24 hours appeared to be sufficient for a satisfactory level of 
transfection. 
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Figure 7.5 Transfection of HEK293 cells with a green fluorescent protein (GFP) expressing pcDNA3.1 plasmid. Cells were transfected with 6, 9 or 12 µg plasmid DNA 
for 24 hours (top panel) and 48 hours (bottom panel). Cells were imaged under normal culture conditions using the GFP filter on a bright-field microscope (Zeiss 
Axiovert). 
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As there was no difference in transfection efficiency between 6 and 12 µg plasmid DNA, 
the plasmid was tested at a lower amount of 3 µg (Figure 7.6). When compared to the 6 
µg plasmid transfection image (Figure 7.6 B), there was less GFP signal but still a high 
level of transfection when using 3 µg plasmid DNA (Figure 7.6 A). 
 
 
Figure 7.6 Transfection of HEK293 cells with a green fluorescent protein (GFP) expressing pcDNA3.1 
plasmid. Cells were transfected with 3 (A) or 6 (B) µg plasmid DNA for 72 hours Cells were imaged under 
normal culture conditions using the GFP filter on a bright-field microscope (Zeiss Axiovert). 
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7.4 Results 
7.4.1 PRDM9 knockdown by siRNA 
Expression of PRDM9 protein was previously tested in HEK293 cells by various protein 
detection methods (Chapter 6). By using this model it was observed that multiple 
peptides were detected using available antibodies against PRDM9. Blocking anti-PRDM9 
with immunising peptide showed that a peptide of 55 kDa was the target of this 
antibody (Figure 6.6). To elucidate whether any of these detected peptides were 
specifically PRDM9, knockdown was attempted using siRNA. Cells were transfected for 
48 and 96 hours before pellets were collected and protein expression investigated by 
immunoblotting. Using the anti-PRDM9 antibody, three peptide bands could be detected 
in all PRDM9 siRNA samples as well as control treatments (Figure 7.7 A & B). These 
peptides were ~75, ~55 and ~30 kDa in size which correlated with previous 
immunoblots using this antibody (Chapter 6). After 48 hours of treatment, there was a 
slight reduction in the expression level of the 55 kDa band in the 20 nM siRNA treated 
cells compared to 5 and 10 nM treatments (Figure 7.7 A). However, none of these 
peptides were detected in the scramble siRNA control and only two bands were detected 
in cells treated with transfection agent lipofectamine only, suggesting that this was not a 
PRDM9 specific observation and was most likely due to variability of the antibody. 
The 55 kDa band detected in the immunoblots in Figure 7.7 were quantified by 
measurement and normalisation of densitometric band intensity relative to β-actin 
(Figure 7.7 C). Detection of this band was previously shown to be blocked by addition of 
the PRDM9 immunising peptide indicating that it is the primary peptide bound by the 
commercially available anti-PRDM9 antibody. Quantification of samples after 48 hours 
siRNA treatment showed that this peptide was present at higher levels in the 10 nM 
siRNA treated cells compared to untreated or control samples (Figure 7.7 C). 
Quantification of samples after 96 hours siRNA treatment showed no difference in band 
intensity between treated or control samples (Figure 7.7 C). This observation confirms 
that this siRNA knockdown was either not PRDM9 specific or that PRDM9 was not 
present within the cell line and could therefore not be targeted for degradation. 
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Figure 7.7 Immunoblot detection of PRDM9 in HEK293 cells treated with PRDM9 siRNA. 60 µg of protein was loaded onto 4-20% bis-tris gels. A) Cells were treated 
for 48 hours with siRNA targeting PRDM9 mRNA. B) Cells were treated for 96 hours with siRNA targeting PRDM9 mRNA. Membranes were incubated with anti-
PRDM9 (1:500) or anti-βactin (1:1000) overnight at 4°C. C) Quantification of PRDM9 after 48 and 96 hours of treatment with siRNA. Immunoblot detection of a 55 
kDa peptide band was quantified by optical density relative to β-actin. 
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7.4.2 Transient overexpression of PRDM9 in HEK293 cells 
To determine whether PRDM9 protein could be detected in a cell culture model, 
transient overexpression was attempted using plasmid 1. Cells were transfected with 
1 µg of Flag-PRDM9 or empty pcDNA3.1 plasmid DNA for 24, 48 or 72 hours and 
compared to non-transfected control HEK293 cells. Cells were then harvested and lysed 
for total cellular protein. Immunodetection using an antibody against Flag tag protein 
did not detect Flag peptide in any of the samples (Figure 7.8).  
 
 
Figure 7.8 Immunodetection of Flag-PRDM9 in cells transfected with overexpression plasmid DNA. 1 µg 
plasmid DNA was transfected for 24, 48 or 72 hours. 75 µg protein was loaded on 4-12% bis-tris gels in 
duplicate. Blank lysates were untreated HEK293 cells grown in parallel with transfected cells. Vector 
lysates were HEK293 cells treated with pcDNA3.1 plasmid not containing any insert cDNA. Protein size 
marker was included on the gel (M), sizes are denoted in kDa. Membranes were incubated with anti-Flag 
(1:1000) or anti-βactin (1:1000) overnight at 4 °C. 
 
 184 
 
Next, expression was attempted with 3 and 6 µg of plasmid 1 DNA for 72 hours in 
parallel, with plasmids expressing GFP and doking protein 7 (DOK7) as transfection and 
antibody detection controls respectively (Figure 7.9). The pcDNA3.1 plasmid containing 
Flag tagged DOK7 cDNA was a kind gift from Dr Juliane Muller (Institute of Genetic 
Medicine, Newcastle University, UK). DOK7 protein was detected at the predicted weight 
of ~55 kDa using 3 µg plasmid DNA with a marked increase in protein band intensity 
using 6 µg suggesting that the transfection efficiency using this method is satisfactory 
for protein overexpression. Peptide bands were detected in all samples at ~80 and 
~100 kDa in size using the Flag antibody, implying that these bands were non-specific 
antibody binding events. This PVDF membrane was overexposed to ensure that no 
PRDM9 protein was present and this most likely lead to the detection of non-specific 
peptides (Figure 7.9). 
 
 
Figure 7.9 Immunoblot detection of PRDM9-Flag overexpression. 75 µg of protein was loaded onto 4-20% 
bis-tris gels. Cells were transfected for 72 hours with 3 or 6 µg plasmid DNA. Untreated controls are 
denoted as ‘Blank’.  Protein size marker was included on the gel (M), sizes are denoted in kDa. Membranes 
were incubated with anti-Flag (1:1000) or anti-βactin (1:1000) overnight at 4 °C. 
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Higher quantities of plasmid were used for cell transfection. Plasmid DNA at 6, 9, 12, 15 
and 18 µg was transfected to enable detection of PRDM9 protein (Figure 7.10). When 
the Flag antibody was used for immunodetection, a single band was present at 
~100 kDa in the PRDM9 transfected samples only (Figure 7.10). Again, DOK7 protein 
was also detected at a molecular weight of ~55 kDa, detectable at shorter exposure 
times than the 100 kDa PRDM9 band suggesting that the DOK7 expression plasmid was 
producing much higher amounts of detectable protein than the PRDM9 expression 
plasmid. 
 
 
Figure 7.10 Immunodetection of PRDM9 in an overexpression cell model. Cells were transfected with 6, 9, 
12 or 18 µg plasmid DNA for 72 hours. 75 µg of protein was loaded onto 4-20% bis-tris gels. Protein size 
marker was included on the gel (M), sizes are denoted in kDa. Membranes were incubated with anti-Flag 
(1:1000) or anti-βactin (1:1000) overnight at 4 °C. 
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In order to determine whether the inefficiency of Flag-PRDM9 overexpression level was 
due to the protein itself or the plasmid used, two new pcDNA3.1(+)-PRDM9 contructs 
were designed (synthesised by Genescript). Cells were transfected with plasmid 
containing full length PRDM9 cDNA (plasmid 2) or partial PRDM9 cDNA (amino acids 
195-385, plasmid 3) for 72 hours before being analysed for expression by 
immunoblotting. Plasmids 2 and 3 were transfected in 1, 3 or 5 µg quantities to 
determine the optimum amount of plasmid required to induce protein expression 
(Figure 7.11). Immunoblot detection using the Flag antibody showed that full length 
PRDM9 was produced after transfection (Figure 7.11 A). A clear band was detected at 
~100 kDa in all samples transfected with plasmid 2, with the strongest detection 
observed using 1 µg of plasmid. Weak bands were also detected at ~140, ~80 and ~70 
kDa. The plasmid expressing DOK7 was used as a positive control and as expected 
produced a single band at ~55 kDa. Flag protein was not detected in non-transfected 
HEK293 cells further supporting that the peptide detected in the transfected samples is 
Flag-PRDM9. 
As expected, a low molecular weight protein was detected after plasmid transfections 
with plasmid 3 (Figure 7.11 B). A single band, at ~28 kDa, was strongly detected at all 
plasmid 3 amounts transfected. This band was detected using a shorter exposure time 
and expressed at higher levels than that of the full length PRDM9 protein product 
suggesting that the partial protein is more easily expressed using this system. In 
addition, when compared to the DOK7 control plasmid, the partial PRDM9 protein 
overexpression appeared to be more efficient than the full length construct.  
 
 187 
 
 
Figure 7.11 Immunodetection of PRDM9 in an overexpression cell model. A) Full length huPRDM9 protein was transiently expressed in HEK293 cells for 72 hours. 
DOK7 construct was also transiently expressed as a control. Cell lysate was electrophoresed in 4-20% bis-tris gels and Western blotted. B) Partial huPRDM9 protein 
was transiently expressed in HEK293 cells for 3 days. DOK7 construct was also transiently expressed as a control. Cell lysate was electrophoresed in 4-20% bis-tris 
gels and Western blotted. Protein size markers were included on each gel, sizes are denoted in kDa. Membranes were incubated with anti-Flag (1:1000) or 
anti-βactin (1:1000) overnight at 4 °C. 
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Detection of full length PRDM9 by immunoblotting was achieved twice using this 
transient transfection system. To assess whether low levels of transfection efficiency 
could be detected in single cells, immunofluorescent staining was attempted. Due to the 
nature of HEK293 cells, imaging protocols were developed using poly-L-lysine coated 
glass cover slips to enhance cell attachment and limit the loss of cells during the staining 
protocol. This cell line tends to clump, with poor adhesion to glass or plastics, rather 
than a monolayer, making it difficult to image single cells in isolation. Protocols were 
therefore developed to image the cells after 24 hours of transfection with plasmid DNA 
whilst the cells were at a low density (~60% confluent), hence forming a monolayer. 
Antibodies against mitochondrial proteins; heat shock protein 60 kDa (HSP60), optic 
atrophy 1 (OPA1), PEO1 and TFAM or Flag protein were optimised on non-transfected 
HEK293 control cells (Figure 7.12). Positive staining was achieved using anti-HSP60, 
which has mitochondrial localisation but functions as a chaperone from the cytoplasm to 
the inner mitochondrial matrix, therefore also appears to have cytosolic localisation 
(Figure 7.12 A). Staining with anti-OPA1 showed clear mitochondrial localisation and 
staining of the entire mitochondrial network (Figure 7.12 B). Similarly, staining with 
anti-PEO1 (Twinkle helicase) showed mitochondrial network staining due to its location 
within the mitochondrial matrix within proximity of mtDNA (Figure 7.12 C). 
Unfortunately, anti-TFAM stained cells did not show positive mitochondrial staining 
possibly due to non-specificity of this particular antibody or due to its suitability for 
immunofluorescent staining procedures (Figure 7.12 D). As OPA1 staining gave the 
clearest mitochondrial staining signal it was used in subsequent staining experiments. 
Staining for Flag protein did not show any positive staining as expected in this cell line 
(Figure 7.12 E). HEK293 cells stained with secondary antibodies only showed that there 
was no auto-fluorescence at antibody dilutions of 1:1000 (Figure 7.12 F).  
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Figure 7.12 Immunofluorescent staining of HEK293 cells with antibodies against mitochondrial proteins. Cells were seeded at 2 x 105 cells/well and grown on poly-
L-lysine coated glass coverslips for 24 hours. A) Staining with anti-PEO1 (1:100) overnight at 4 °C and anti-rabbit alexafluor®-488 secondary (green). B) Staining 
with anti-HSP60 (1:200) overnight at 4 °C and anti-rabbit alexafluor®-488 secondary (green). C) Staining with anti-OPA1 (1:250) overnight at 4 °C and anti-rabbit 
alexafluor®-488 secondary (green). D) Staining with anti-TFAM (1:100) overnight at 4 °C and anti-rabbit alexafluor®-488 secondary (green). E) Staining with anti-
Flag (1:1000) overnight at 4 °C and anti-mouse alexafluor®-594 secondary (red). F) Staining with alexafluor®-488 (green) and alexafluor®-594 (red). All slides were 
stained with DAPI nuclear stain (blue) and imaged on the AxioImager (Zeiss).  
 190 
 
Cells were transfected with each of the three overexpression plasmids: full length 
Flag-PRDM9, partial Flag-PRDM9 or control Flag-DOK7. Transfection was carried out 
using 1 µg plasmid DNA for 24 hours before the cells were stained with both anti-OPA1 
and anti-Flag (Figure 7.13). Anti-OPA1 (green) showed mitochondrial network staining 
in all transfected samples although some single cells appeared to have very little visible 
mitochondria or clustering of mitochondria around the nucleus (shown in blue). This is 
most likely due to the rounded cell shape and clumped nature of HEK293 cells. Staining 
of Flag protein (red) showed primarily nuclear localisation of both full length and partial 
PRDM9 proteins (Figure 7.13 A, B, D and E). There also appeared to be Flag signal in the 
cytoplasm of the cells. Interestingly, Flag signal in the DOK7 expressing cells also 
showed nuclear localisation (Figure 7.13 C and F). This protein is known to play a key 
role in the function of the neuromuscular junctions of skeletal muscle cells and therefore 
usually localises to the plasma membrane (Okada et al., 2006). As HEK293 cells are 
distinct in their properties from muscular and neuronal cell types it would be 
reasonable to assume that localisation of this protein would be different in this cell type. 
However, nuclear localisation of DOK7 might indicate that there is aberrant expression 
within the HEK293 cells. Perhaps this protein is aggregated within compartments 
surrounding or close to the nucleus or perhaps there is delivery of the protein into the 
nucleus. The images taken are from one plane and do not represent any 3D image stacks 
(such as Z stacks), therefore localisation cannot be reliably determined as it could be 
that the 3D orientation of the cell shows that any ‘nuclear’ localisation is in fact just 
cytoplasmic signal close to or surrounding the cell nuclei.          
 191 
 
 
Figure 7.13 Immunofluorescent staining of transfected cells using OPA1 and Flag antibodies. Cells were seeded at 2 x 105 cells/well and grown on Poly-L-lysine 
coated glass coverslips for 6 hours before transfection with 1 µg plasmid DNA for 24 hours. Coverslips were incubated with anti-OPA1 (1:250) and anti-Flag 
(1:1000) overnight at 4 °C followed by secondary antibodies (Alexafluor®-488 or Alexafluor®-594) at 1:1000 dilution. A&D) Cells were transfected with full length 
Flag-PRDM9 pcDNA3.1 plasmid DNA. B&E) Cells were transfected with partial Flag-PRDM9 pcDNA3.1 plasmid DNA. C&F) Cells were transfected with Flag-DOK7 
pcDNA3.1 plasmid DNA. DAPI was used as a nuclear stain on all coverslips (blue). All images were taken using the Axioimager (Zeiss) at x40 magnification. 
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7.5 Discussion 
PRDM9 protein expression level was modified in a cell culture model; firstly using 
targeted siRNA knockdown and secondly using plasmid overexpression. Experimentally 
altering the PRDM9 transcript and protein levels was attempted because previous 
analysis showed PRDM9 was not reliably detected in several cell lines and tissue 
samples (Chapter 6). Creating an appropriate experimental model is essential to further 
understand the functional role of this protein.  
To determine which peptide band was actually the target of the PRDM9 commercial 
antibodies described in Chapter 6, knockdown of PRDM9 was attempted in HEK293 cells 
using a pre-designed siRNA transfection system. Due to the inaccuracy of the PRDM9 
antibodies available as well as a lack of positive control for PRDM9 expression, it was 
not possible to effectively assess whether the siRNA oligo had silenced the PRDM9 
transcripts using this system. A band at 55 kDa was successfully blocked when 
incubated with the immunizing PRDM9 peptide (Chapter 6), however this band was not 
a specific target of the siRNA oligo used in this study. This suggests that the 55 kDa 
peptide detected is either not PRDM9, is a PRDM9 peptide from an alternative transcript 
or does not contain the region of the sequence targeted by this particular siRNA oligo.  
As PRDM9 is a meiotic specific protein, it is unlikely that the full length functional 
transcript is expressed in HEK293 cells. In this case, there would be no target for the 
PRDM9 specific siRNA oligo to bind to and degrade via the DICER and RISC RNA 
interference pathway. To test this hypothesis, a cell line or tissue type expressing 
PRDM9 would need to be used in the knockdown experiment to confirm that this system 
is specific to PRDM9 and that it is measurable either by protein expression analysis or 
q-PCR of mRNA levels. The tissue expressing the highest levels of detectable PRDM9 
protein is human testis and this tissue type, or cells derived from such tissue would be 
the most appropriate positive control for this siRNA experiment. 
Overexpression of PRDM9 was attempted using three different plasmids. Firstly, 
transfection with plasmid 1 produced modest PRDM9 expression. Western blot 
detection showed a protein band at the expected size of ~100 kDa but only in cells 
transfected with very high quantities of plasmid. Unfortunately, this overexpression was 
only achieved once using this system and was therefore not reliable for use in further 
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experiments. It is not clear why plasmid 1 transfection was not efficient, it could be due 
to protein folding based on the amino acid sequence used to generate the peptide. 
Transfection with plasmid 2 showed expression of a band at the expected size of 
~100 kDa when cells were transfected with only 1 µg of plasmid DNA. The 
overexpression product was produced at very low levels when compared to a control 
transfection using a DOK7 construct as well as a loading control. To test whether this 
was caused specifically by the construct cDNA sequence used, a partial PRDM9 construct 
was also synthesised and transfected. This smaller protein product was highly 
expressed in our system when compared to the DOK7 and loading control protein levels. 
In conclusion, partial PRDM9 constructs express detectable peptides much more 
efficiently than full length PRDM9 constructs. This is likely due to the smaller overall 
size of the plasmid being transfected as well as the faster transcription and translation 
rates associated with smaller DNA sequences. Following this observation, localisation 
experiments could be performed using partial PRDM9 peptides to elucidate whether any 
portion of the protein has mitochondrial localisation.   
Differences in overexpression efficiency could be due to the number of cells successfully 
transfected with the plasmid or the stability of the full length protein product. 
Transfection efficiency estimated using a pcDNA3 plasmid expressing GFP, showed that 
only ~30% of the cells are transfected with and express the desired protein using this 
transfection protocol. Several key steps are involved in expression of transfected DNA 
constructs; accessibility of plasmid DNA (pDNA) to transcription machinery within the 
cytosol, which is dependent on endosomal escape and dissociation of mRNA complexes; 
the stability of the nucleic acids; the extent of compaction of pDNA within the lipo- or 
lipopoly-plex used for delivery and finally the ability to unpackage nucleic acids once 
inside the cytoplasm (Goncalves et al., 2016). The pDNA must be delivered into the cell 
by either electroporation, heat shock or lipid coating, however, recent assay 
developments for mammalian cell culture recommend cationic lipid based delivery as 
the most efficient and least cytotoxic method (Jafari et al., 2012; Cai et al., 2016). Of 
course, this delivery method presents possible problems in terms of pDNA unpackaging 
followed by accessibility to the transcription and translation machinery required for 
expression. Lipid coated DNA is much less likely to be accessed by cellular components 
than naked DNA due to the longer time required for the pDNA to escape its protective 
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coating (Prasad et al., 2003). Another consideration when altering expression by 
plasmid transfection is the role of cellular responses to the transfected pDNA. For 
example, clatherin-dependent or calveolae-mediated endocytosis are the mechanisms 
by which the pDNA is taken up by the cell and transported internally (Das et al., 2016). 
The pDNA must be taken up efficiently by these endosomes and then released so as to be 
available for transcription/translation machinery. Activation of immune-response or 
cellular stress pathways to clear away any foreign DNA molecule might also be 
upregulated leading to a dampening down of the effectiveness of the transfected plasmid 
either by exocytosis or degradation of the molecule (Poecheim et al., 2016). 
Overexpression of full length PRDM9 protein using the transient pcDNA3.1 plasmid 
system allowed low levels of protein to be detected via immunoblotting and 
immunofluorescence. However, results were variable and unreliable using these two 
detection techniques as only three PVDF membranes and only one immunofluorescent 
assay successfully showed detection of PRDM9. Immunoprecipitation followed by mass 
spectrometry would be the best method to determine whether the positive detection 
observed was in fact PRDM9 protein. In addition, all transfections were performed on 
cells grown in 9.5 cm2 tissue culture wells, yielding a relatively low quantity of protein, 
not sufficient for mitochondrial extractions, localisation or DNA binding studies.  
Achieving PRDM9 expression to perform localisation studies and DNA binding assays 
using the system described would require large amounts of transfection agent and 
plasmid DNA. To overcome the technical challenges surrounding the investigation of this 
protein, cell lines containing stable overexpression constructs were created as described 
in Chapter 8.   
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Chapter 8 Characterisation of a PRDM9 stable overexpression cell 
culture model. 
 
8.1 Overview 
PRDM9 protein levels were undetectable in tissue samples or cell lines investigated 
previously (Chapter 6) most likely due to the fact that the expression of this protein may 
be highly regulated during meiosis. In addition, transient overexpression systems 
outlined in Chapter 7 were inconclusive and did not provide enough material for 
mitochondrial investigations which typically require substantial amounts of cellular 
material. To address this, two stable cell lines were created with full length PRDM9 
cDNA constructs under the tetracycline inducible promoter (Hillen and Berens, 1994; 
Hinrichs et al., 1994; Yao et al., 1998).  One cell line was created using human PRDM9 
cDNA, whilst the other contained an identical PRDM9 cDNA with an N-terminal Flag-tag 
(Figure 8.1).  
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Figure 8.1 Overview of the system used in this study to stably overexpress PRDM9 cDNA in mammalian 
cells. Two PRDM9 cDNA constructs are depicted 1. no tag, 2. Flag tag. After integration of the constructs 
into the genome, tetracycline is added to the cells in culture. Expression of PRDM9 is induced.  PRDM9 
protein can be detected using anti-PRDM9 or anti-Flag antibodies. 
 
8.2 Aim 
The aim of this study was to create a stable cell culture model expressing PRDM9 
protein using an inducible promoter to control the induction and level of expression. 
This is advantageous as it would allow large quantities of cells overexpressing PRDM9 to 
be used for experiments such as mitochondrial fractionation. Using a Flag-tagged cDNA 
construct allows protein detection independent of PRDM9 antibodies. 
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8.3 Experimental Method 
Brief methods are detailed in Section 3.11.2. 
8.3.1 Overexpression plasmid validation 
Plasmid map of the pcDNA5/FRT/TO vector containing PRDM9 cDNA is shown below 
with multiple cloning sites depicted (Figure 8.1). The location of the PRDM9 cDNA insert 
sequence can be seen in orange; in this vector the insert is under the control of the CMV 
promoter but with tetracycline operator elements in between (Figure 8.1). Tetracycline 
must bind to these elements before expression of the insert gene can occur.  
 
 
Figure 8.2 pcDNA5/FRT/TO containing the PRDM9 cDNA insert sequence. Plasmid elements are: 
cytomegalovirus (CMV) enhancer and TATA box (green), multiple cloning site (MCS), BGH 
polyadenylation signal (pink), SV40 early polyadenylation signal (blue), 
ampicillin/hygromycin/kanamycin resistance elements (yellow), pUC ori sites on complementary strands 
(light blue), tetracycline operator elements and Flp recombination target (FRT) site are shown in black. 
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The PRDM9 cDNA sequence described previously (Chapter 6) was sub-cloned from the 
pcDNA3.1 plasmid into pcDNA5/FRT/TO plasmid by restriction enzyme digestion 
(Figure 8.3). To create a PRDM9 insert construct without a tag, ApaI and BamHI 
enzymes were used for DNA digestion (Figure 8.3 A). The PRDM9 cDNA insert sequence 
with an N-terminal Flag-tag was digested using XhoI and HindIII enzymes (Figure 8.3 B). 
Products from both digests were electrophoresed on 1% agarose gels and visualised by 
UV exposure to show a clear band at ~2.7 Kb corresponding to the PRDM9 insert 
sequence (Figure 8.3).  
 
Figure 8.3 Sub-cloning of full length PRDM9 cDNA from pcDNA3 into pcDNA5/FRT/TO. A & B) Restriction 
enzyme digestion products were resolved on 1% agarose gels by electrophoresis. DNA size marker was 
included on the gel (M), sizes are given in base pairs. A) Digestion of full length PRDM9 cDNA using ApaI 
and BamHI enzymes. B) Digestion of Flag tagged PRDM9 cDNA using XhoI and HindIII enzymes. 
pcDNA3.1: ~8111 bp, pcDNA5/FRT/TO: ~7837 bp, PRDM9: ~2700 bp. 
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The PRDM9 product was gel extracted and used in subsequent ligation reactions with 
digested and gel extracted pcDNA5/FRT/TO plasmids (Figure 8.3). Successfully ligated 
plasmids were determined by colony PCR of competent E.coli transformed with the 
ligation product. Two sets of primers were used, one pair aligned to the CMV promoter 
sequence and pcDNA5 plasmid sequence, the other pair aligned to the CMV promoter 
and the BGH polyadenylation sequence (Figure 8.4). 
 
 
Figure 8.4 Schematic showing alignment of the primer sets used to amplify the pcDNA5 insert sequence.  
  
Primer details are listed in Table 8.1. Temperature gradients were used to determine the 
optimum annealing temperature of the primer sets. PCR reaction mix was as follows; 
0.5 mM betaine, 200 μM dNTPs, 1.25 U TaKaRa LA Taq polymerase, 0.2 μM primers 
(forward and reverse), dH2O and 50 ng DNA made to final volume of 25 μL with 
nanopure water. Thermocycling conditions were: denaturation at 94 °C for 1 min, 98 °C 
for 10 secs, annealing at 62 °C for 15 min, for 30 cycles followed by a final extension for 
10 min at 72 °C.  
 
Target Sequence 5’-3’ Annealing Temperature 
CMV Forward CGCAAATGGGCGGTAGGCGTG 62 °C 
pcDNA5 Reverse GAGGAAATTGCATCGCATTGT 62 °C 
BGH Reverse CCTCGACTGTGCCTTCTA 62 °C 
Table 8.1 Primer details for amplification of insert sequences from pcDNA3.1 and pcDNA5 plasmids. 
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PRDM9 amplicons were visualised via electrophoresis and UV exposure, showing 
amplification of a band at 2.7 kb corresponding to the PRDM9 cDNA construct (Figure 
8.5).  
 
 
Figure 8.5 Colony PCR using plasmid specific primers. PCR products were electrophoresed on 1% agarose 
gels and visualised with UV exposure. DNA size marker was included on the gel (M), sizes are given in base 
pairs. A) Colony PCR of PRDM9 insert ligated into pcDNA5/FRT/TO, 16 colonies were screened. B) Colony 
PCR of Flag-PRDM9 insert ligated into pcDNA5/FRT/TO, 16 colonies were screened.  
 
In order to successfully integrate the PRDM9 insert sequences from the pcDNA5 vector 
into the genome of the HEK293 cells, a second plasmid expressing Flp recombinase 
enzyme must be co-transfected (Figure 8.6). The enzyme catalyses recombination 
between FRT sites present on the pcDNA5/FRT/TO plasmid and within the TRex293™ 
genome. As the genomic DNA recombines and is repaired by double strand break repair 
complexes, the hygromycin, tetracycline operator and PRDM9 elements are 
incorporated between FRT sites. The cell now harbouring this gene cassette confers 
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hygromycin resistance and will express PRDM9 in the presence of tetracycline (Figure 
8.6). 
 
Figure 8.6 Schematic of the Flp mediated recombination event. PRDM9 cDNA on pcDNA5 plasmid is 
recombined into the transfected cell genome using the integrated FRT sites and Flp recombinase enzyme 
expressed on the pOG44 plasmid. 
  
The plasmid containing Flp recombinase, pOG44, was a kind gift from Prof R.N. 
Lightowlers (Institute of Neuroscience, Newcastle University) and was expanded in our 
lab via transformation of competent E.coli. Purified plasmid DNA was digested with XbaI 
enzyme which cuts the plasmid at one site and KpnI which cuts the plasmid at two sites 
producing two different sized DNA fragments. After digestion with XbaI, a clear band 
could be seen at 5785 bp (Figure 8.7). After digestion with KpnI there were two clear 
bands at 347 bp and 5438 bp confirming that pOG44 had been successfully purified 
(Figure 8.7). Colony number 1 (Figure 8.7 lane 1 & 9) was taken forward for use in all 
related experiments. 
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Figure 8.7 Restriction digest of pOG44 plasmid DNA purified from competent E.coli. 50 ng DNA was 
electrophoresed on a 1% agarose gel and visualised by UV exposure. DNA size marker was included on the 
gel (M), sizes are given in base pairs. Lanes 1-8 show DNA digested with XbaI enzyme. Lanes 9-16 show 
DNA digested with KpnI enzyme. 
 
8.3.2 Creation of stable overexpression cell lines 
The HEK293 cell line was previously modified to contain an FRT recombinase site 
within the genome (TRex™293 cells, Invitrogen, Thermo Fisher Scientific, 
Loughborough, UK), herein referred to as HEK293 cells. Both PRDM9 cDNA constructs 
were integrated into a ‘transcriptionally silent’ region of the genome through cell 
transfection as described in Section 3.11.2. Non-transfected cells were used as a control 
in all experiments. After 14 days of culture in antibiotic selection media, colonies of 
successfully transfected cells could be seen (Figure 8.8). Colonies were left to grow and 
colonise the well completely before being transferred into larger culture plates and 
flasks. 
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Figure 8.8 Cell colony formation following transfection of TRex™293 cells with pcDNA5_PRDM9 
constructs and selection with 200 µg/mL hygromycin and blasticidin. A) Colony formed after integration 
of the PRDM9 pcDNA5 construct. B) Colony formed after integration of the Flag-PRDM9 pcDNA5 
construct. 
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After 8-10 weeks of antibiotic resistance and establishment of a homogenous 
population, cell lines were screened for PRDM9 cDNA integration into the genome by 
PCR amplification as described above. PCR products were electrophoresed using 1% 
agarose gels and visualised via UV exposure. Amplification of a band at ~2700 bp was 
achieved when the CMV and pcDNA5 primers were used. This band corresponds to the 
PRDM9 cDNA construct and is observed in both of the overexpression cell lines but not 
in control HEK293 cells (Figure 8.9). The origin of the other PCR products was most 
likely due to non-specificity of the primers used. These primers would ordinarily be 
used with isolated plasmid DNA and would therefore not have off target binding. Indeed, 
when these primer sequences were entered into NCBI BLAST they did align to other 
regions of the human genome. The product at 2.7 kb was then gel extracted and Sanger 
sequenced and aligned to the PRDM9 mRNA sequence (NM_001310214.1) to confirm 
that this was indeed the PRDM9 cDNA sequence. 
 
 
Figure 8.9 PCR amplification of PRDM9 constructs in stably transfected cell lines. PCR products were 
electrophoresed on a 1% agarose gel. DNA size marker was included on the gel (M), sizes are given in base 
pairs. Lanes 2-4 show the PCR product from each of the cell lines using primer set 1. Lanes 6-8 show the 
PCR product from each of the cell lines using primer set 2. Lanes 5 & 9 are negative controls where PCR 
mix did not contain DNA. Arrow indicates the PRDM9 insert sequence at the predicted size of ~2700 bp. 
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8.4 Results 
8.4.1 Analysis of PRDM9 overexpression by immunoblotting 
To determine whether the pcDNA5/FRT/TO stable overexpression model was 
successful, PRDM9 protein expression was investigated. Cells were seeded at 3 x 105 
cells per well and when 60% confluency was reached, tetracycline was added to the 
growth media for 24 hours. Protein from both the PRDM9 construct and the 
Flag-PRDM9 construct were blotted for using either PRDM9 or Flag antibodies. After 24 
hours of tetracycline treatment there was a band observed in the PRDM9 cell line at 
~80 kDa in size (Figure 8.10 A). The band was present in cells treated with the highest 
doses of tetracycline but was not detected at lower treatment concentrations or in the 
untreated control (Figure 8.10 A). In the cell lines transfected with Flag-PRDM9 there 
was an observed band at ~100 kDa in size (Figure 8.10 B). Similarly, this band was 
detected in cells treated with the highest concentration of tetracycline but was not 
present at lower treatment concentrations or in the untreated control (Figure 8.10 B). 
 
 
Figure 8.10 Immunodetection of PRDM9 protein in overexpression cell lines. Stably transfected cells were 
treated with tetracycline for 24 hours at decreasing concentrations. Blank refers to untreated cells. 
A) Protein extracted from PRDM9 stably transfected cells. PVDF membrane was incubated with 
anti-PRDM9 (1:500) overnight at 4°C. B) Protein extracted from Flag-tagged PRDM9 transfected cells. 
PVDF membrane was incubated with anti-Flag (1:1000) overnight at 4°C. Membranes were incubated 
with anti-βactin (1:1000) overnight at 4°C. 
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The protein bands detected in the two cell lines differed in molecular weight by ~20 kDa 
(Figure 8.10). Only the Flag-PRDM9 cell line showed a band at the expected size of 
~100 kDa whereas the PRDM9 cell line showed a band at ~80 kDa. In Figure 8.10 B the 
band at ~100 kDa was faint even after the membrane was overexposed suggesting that 
there was a low level of detectable protein in the cells. The presence of multiple bands 
also points to the abundance of PRDM9 protein being low as Flag should only be 
detectable in cells transfected with the construct and treated with tetracycline. The 
presence of these bands in the untreated sample indicates that these bands are 
non-specific. 
PRDM9 detection was achieved once although multiple passages of these cell lines were 
investigated by immunoblotting. This suggested that the earliest passages of the cells, 
after the selection process, were more likely to have PRDM9 expression induced by 
tetracycline treatment. To determine whether this detection issue was due to a 
heterogeneous cell population, transfected cells were re-selected using single cell 
dilution followed by hygromycin resistant clone selection. Colonies derived from a single 
cell containing the stably integrated constructs were assessed for PRDM9 expression by 
immunoblot analysis of protein lysate (Figure 8.11). Five single cell colonies were 
expanded from the PRDM9 containing cell line and six from the Flag-PRDM9 line. Each 
colony was split into two wells; one treated with 1 µg/mL tetracycline whilst the other 
was grown in standard culture medium as an internal control. When the samples were 
immunoblotted with anti-Flag there was a band detected at ~100 kDa in five of the 
colonies from the Flag-PRDM9 cell line but no detection in the untreated controls, the 
PRDM9 cell line or parental HEK293 cells (Figure 8.11). There was also a band detected 
at ~60 kDa which appeared in all sample lanes suggesting it is a non-specific peptide 
bound by anti-Flag. The detected peptide at ~100 kDa in size was very weak compared 
to the detected band at ~60 kDa and the loading control β-actin suggesting that if this 
peptide is PRDM9, the expression level is very low in this cell line. This immunoblot was 
also incubated with commercially available anti-PRDM9 but no peptide was detected 
suggesting that the antibody was not appropriate for detection in these transgenic cell 
lines.
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Figure 8.11 Immunodetection of PRDM9 in cells derived from hygromycin resistant single colonies.   Five colonies were selected for PRDM9 construct integration, 
six colonies were selected for Flag-PRDM9 construct integration and compared to HEK293 parental cell line. Colonies were treated with 1 µg/mL tetracycline (+) for 
24 hours or untreated (-). Protein size ladder was included on the gel (M), sizes are denoted in kDa.  
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Clone number 3 from each of the overexpression cell lines was then treated with 
1 µg/mL tetracycline and the mitochondria extracted using a digitonin-based protocol 
described in Section 3.6.4. This mitochondrial extract (Mt) was then compared to whole 
cell protein extract (WhC) and immunodetection was carried out using anti-Flag (Figure 
8.12). There was not a clear single peptide detected using anti-Flag and any faint bands 
detected were also present in the HEK293 control cell line.  
 
 
Figure 8.12 Immunodetection of Flag-PRDM9 in mitochondrial extracts from overexpression cell lines. 
75 µg protein from mitochondrial (Mt) or whole cell (WhC) extracts was loaded on 4-20% bis-tris gels. 
Protein size marker was included on the gel (M), sizes are given in kDa. Membrane was incubated with 
anti-Flag (1:1000), anti-SDHA (1:2000), anti-VDAC (1:500), anti-TFAM (1:500), anti-mtCO2 (1:1000) or 
anti-βactin (1:1000) overnight at 4 °C. 
 
To assess the purity of this mitochondrial fraction several antibodies against 
mitochondrial proteins were used (Figure 8.12). Detection of VDAC1, transcription 
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factor A mitochondrial (TFAM) and succinate dehydrogenase complex flavoprotein 
subunit A (SDHA) proteins showed that the mitochondrial extracts did contain 
mitochondria but at much lower levels than the whole cell protein extracts. There was 
also a high amount of β-actin in the mitochondrial extracts suggesting that the extraction 
was not pure and also contained contaminating cytosolic proteins. 
 
8.4.2 Analysis of PRDM9 expression by RT q-PCR 
Protein detection was inconclusive in the overexpression cell lines as only three blots 
showed possible Flag-PRDM9 peptide detection at 100 kDa. To assess whether PRDM9 
transcript was being produced in the overexpression cell lines created, PRDM9 mRNA 
levels were measured by RT q-PCR amplification using PRDM9 specific probes. PRDM9 
transcript detection was normalised to the house-keeping gene β-actin as described in 
Section 3.12.2. Two PRDM9 assays were tried however, one probe/primer set 
(Hs00360639_m1) did not detect PRDM9 amplification on several real time assay runs 
and was therefore not used again. The PRDM9 probe/primer set Hs01633270_s1 gave 
PRDM9 amplification and was used on all samples measured in triplicate on each plate, 
and each plate was run in triplicate to control inter-plate and intra-run assay variability.  
Cycle threshold (Ct) values were very high for the PRDM9 amplicon measured in all cell 
lines tested, indicating low level expression. When normalised to β-actin transcript 
levels, the amount of PRDM9 transcript measured in the HEK293 control cell line was 
higher than in either of the PRDM9 overexpression cell lines (Figure 8.13). Differences in 
transcript expression could be seen between cell lines but also between tetracycline 
treated or untreated cells over the time course of 24-72 hours. Unexpectedly, in several 
of the sample groups tested there appeared to be higher PRDM9 transcript expression in 
the untreated cell lines compared to tetracycline treated, contrary to the expected result 
(Figure 8.13). 
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Figure 8.13 Quantification of PRDM9 transcript levels in overexpression cell lines and HEK293 controls. A, B & C) Cells were untreated (yellow) or treated (lilac) 
with 1 µg/mL tetracycline for 24, 48 or 72 hours. 2-ΔCt values were normalised to β-actin transcript levels and plotted using Graphpad Prism analysis software. D & 
E) PRDM9 transcript levels (2-ΔCts) in overexpression cell lines were normalised to control HEK293 transcript values, shown by the dotted line at y = 1. Students 
t-test was used to assess significance of each treatment group vs the un-treated partnered group. ≥0.05 = *: ≥0.005 = **: ≥0.0005 = ***. n=27     
 
 211 
 
Although there were statistically significant differences between treated and untreated 
samples in all three cell lines (Figure 8.13 A, B and C) there was no correlation or trend 
in the transcript levels with respect to increased or decreased transcript levels before or 
after treatment. In addition, normalising 2-ΔCt values of the transgenic lines to the 
HEK293 control cell line showed that the PRDM9 transcript level was less than or 
equivalent to the control at majority of time points tested (Figure 8.13 D and E). 
If the transgenic cell lines created in this study were actively transcribing PRDM9 after 
addition of tetracycline then it would be expected that the PRDM9 mRNA transcript 
levels would be higher in these cell lines compared to control HEK293 cells. This was not 
the case, as measured in three independent experiments, suggesting that PRDM9 
transcript is not overexpressed in these transgenic cell lines.   
 
8.4.3 Immunofluorescent staining of PRDM9 in overexpression cell lines 
Detection of PRDM9 by protein and mRNA detection experiments was inconclusive, 
therefore, immunofluorescent staining using the Flag antibody was attempted in fixed 
cells as described in Section 3.9.4. If PRDM9 is being expressed at low levels in a 
proportion of the cultured cells then single cell imaging analysis may show detectable 
protein expression. As a positive control, cells were stained using the mitochondrial 
protein OPA1 as optimised previously on HEK293 cells (Chapter 7). 
Cells overexpressing Flag-PRDM9 were treated with 1 µg/mL tetracycline for 72 hours 
before staining with anti-Flag (red) and anti-OPA1 (green) and compared with 
untreated controls (Figure 8.14). All slides imaged showed positive OPA1 staining of the 
mitochondria in the Flag-PRDM9 cells (Figure 8.14, green signal). Positive staining was 
also seen with the Flag antibody (Figure 8.14, red signal) however, this signal was also 
seen in untreated control samples. The single cells shown (Figure 8.14) are 
representative of the variable pattern of anti-Flag staining observed, suggesting that this 
is not a specific signal. Furthermore, the presence of this staining in the untreated cells 
suggests that this is not Flag-PRDM9 protein, as it would not be expressed in the absence 
of tetracycline (Figure 8.14 B and D).  
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Figure 8.14 Immunofluorescent staining of Flag-PRDM9 cells. Cells were treated with 1 µg/mL tetracycline for 72 hours (A, C&E) or were untreated (B, D&F). 
Staining with anti-Flag (1:1000) and anti-OPA1 (1:250) overnight at 4 °C, anti-mouse alexafluor®-594 secondary (red), anti-rabbit alexafluor®-488 (green) and 
DAPI nuclear stain (blue). All slides were imaged on the AxioImager (Zeiss) using GFP and DAPI filter sets. 
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Next, the PRDM9 commercially available antibody (Abcam, Cambridge, UK) was used for 
staining in PRDM9 overexpressing cells. This staining procedure was carried out on 
untreated cells or cells treated with 1 µg/mL tetracycline for 72 hours as an internal 
control. In addition, the PRDM9 antibody was raised in rabbit and could not be used 
alongside the OPA1 antibody described previously. In this case, an antibody against 
TFAM, raised in mouse, was used as a positive staining control. Positive staining of 
TFAM was seen in both treated and untreated cell samples (Figure 8.15, red signal). 
Positive staining of PRDM9 (green) was observed in some of the single cells imaged 
(Figure 8.15 A). However, there was also green fluorescent signal observed in some of 
the cells not treated with tetracycline (Figure 8.15 B) suggesting that this staining was 
not specific. 
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Figure 8.15 Immunofluorescent staining of PRDM9 cells. Cells were treated with 1 µg/mL tetracycline for 72 hours (A&C) or were untreated (B&D). A & B) Staining 
with anti-PRDM9 (1:500) and anti-TFAM (1:250) overnight at 4 °C, anti-mouse alexafluor®-594 secondary (red), anti-rabbit alexafluor®-488 (green) and DAPI 
nuclear stain (blue). C & D) Staining with anti-TFAM (1:250) overnight at 4 °C, anti-mouse alexafluor®-594 secondary (red) and DAPI nuclear stain (blue). All slides 
were imaged on the AxioImager (Zeiss) using GFP and DAPI filter sets.
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8.4.4 Indirect measurement of PRDM9 activity by assessing histone methylation 
levels 
Detection of PRDM9 mRNA and protein levels was variable in the cell lines created in 
this study. PRDM9 has been shown previously to mono-, di- and tri-methylate H3K4 in 
the nucleus (Hayashi et al., 2005; Grey et al., 2011; Eram et al., 2014). To determine 
whether the transient PRDM9 protein was having any effect in the stable cell lines, H3K4 
methylation status was investigated by immunoblotting (Figure 8.16). Mono-, di- and tri-
methylation status was visibly increased in the PRDM9 overexpression cell lines 
compared to the HEK293 non-transfected control cell line. 
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Figure 8.16 Immunodetection of histone methylation status in cell lines. PRDM9 and Flag-PRDM9 overexpression cell lines were compared to the HEK293 parental 
cell line. Cells were treated with 1 µg/mL tetracycline (+) or untreated (-) for 24, 48 or 72 hours. Membranes were incubated with anti-H3K4me3 (1:1000), 
anti-H3K4me2 (1:1000), anti-H3K4me1 (1:1000) or anti-βactin (1:1000) overnight at 4 °C. 
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Quantification of protein levels showed that tri-methylation of H3K4 (H3K4me3) was 
significantly increased in the PRDM9 transgenic cell lines at all treatment time points 
compared to the control cell line (Figure 8.17).  
 
 
Figure 8.17 Quantification of Western blot analysis for H3K4 methylation status. Untreated samples are 
shown in grey, tetracycline treated samples in purple. Densitometric analysis was performed using ImageJ 
software. Values were normalised to β-actin levels and analysed using Graphpad analysis software. Error 
bars show SD. Students t-test was used to assess significance of each treatment group vs the un-treated 
partnered group. ≥0.05 = *: ≥0.005 = **: ≥0.0005 = ***. n=27     
 
Di-methylation of H3K4 (H3K4me2) was also significantly increased at all treatment 
time points in the Flag-PRDM9 but not the PRDM9 overexpression line (Figure 8.18). 
Although not statistically significant, there was a trend towards increase of H3K4me2 in 
the PRDM9 transgenic line after tetracycline treatment (Figure 8.18 C). 
 
 
Figure 8.18 Quantification of Western blot analysis for H3K4 methylation status. Untreated samples are 
shown in pink, tetracycline treated samples are shown in red. Densitometric analysis was performed 
using ImageJ software. Values were normalised to β-actin levels and analysed using Graphpad analysis 
software. Error bars show SD. Students t-test was used to assess significance of each treatment group vs 
the un-treated partnered group. ≥0.05 = *: ≥0.005 = **: ≥0.0005 = ***. n=27     
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Finally, mono-methylation of H3K4 (H3K4me1) was significantly increased at 72 hours 
of tetracycline treatment in the Flag-PRDM9 but not the PRDM9 overexpression line. 
Although not significant, it does appear that levels of H3K4me1 are trending towards an 
increase in the PRDM9 overexpression cell line after 24 hours of tetracycline treatment 
(Figure 8.19 C). 
 
 
Figure 8.19 Quantification of Western blot analysis for H3K4 methylation status. Untreated samples are 
shown in pale blue, tetracycline treated samples are shown in dark blue. Densitometric analysis was 
performed using ImageJ software. Values were normalised to β-actin levels and analysed using Graphpad 
analysis software. Error bars show SD. Students t-test was used to assess significance of each treatment 
group vs the un-treated partnered group. ≥0.05 = *: ≥0.005 = **: ≥0.0005 = ***. n=27     
 
The control cell line (HEK293) also had significantly increased levels of tri- and di-
methylation of H3K4 at 24 hours of tetracycline treatment (Figure 8.17 and Figure 8.18). 
This could be due to the tetracycline treatment itself which might be having off target 
effects on the cell leading to activation of other factors controlling histone methylation. 
If this is the case, then PRDM9 overexpression might only be influencing the methylation 
status of H3K4 after 48 hours of treatment.  
 
8.4.5 Measuring mitochondrial protein expression in overexpression cell lines 
Indirect measurement of PRDM9 function was achieved by the observed increase in 
histone methylation status in the overexpression cell lines (Section 8.4.4). Next, 
mitochondrial protein levels were investigated to assess whether PRDM9 expression 
was affecting either nuclear encoded or mtDNA encoded mitochondrial protein levels.  
TFAM plays an essential role in mtDNA transcription as well as replication and repair 
and is also thought to be the main protein moiety required for efficient packaging of the 
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plasmid mtDNA into nucleoid structures (Kukat et al., 2015). In this case, TFAM protein 
levels cannot be used to directly quantify mtDNA copy number inside the cell but can be 
used to estimate whether cells are depleted of mtDNA or have increased mtDNA (Collu-
Marchese et al., 2015; Ikeda et al., 2015; West et al., 2015; Stiles et al., 2016). Protein 
levels of TFAM were measured in the PRDM9 overexpression cell lines and the HEK293 
parental cell line as a control (Figure 8.20).  
 
 
Figure 8.20 Immunodetection of TFAM protein levels in cell lines. A) PRDM9 and Flag-PRDM9 
overexpression cell lines were compared to the HEK293 parental cell line. Cells were treated with 
1 µg/mL tetracycline (+) or untreated (-) for 24, 48 or 72 hours. Membranes were incubated with 
anti-TFAM (1:500) or anti-βactin (1:1000) overnight at 4 °C. B-D) Quantification of immunodetection. 
Untreated samples are shown in white, tetracycline treated samples are shown in dark grey. 
Densitometric analysis was performed using ImageJ software. Values were normalised to β-actin levels 
and analysed using Graphpad analysis software. Error bars show SD. Students t-test was used to assess 
significance of each treatment group vs the un-treated partnered group. ≥0.05 = *: ≥0.005 = **: ≥0.0005 = 
***. n=27.     
 
Quantification of TFAM immunoblotting showed no statistically significant difference in 
TFAM protein expression when tetracycline treated cells were compared to untreated 
cells (Figure 8.20 B-D). 
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Next, nuclear encoded OXPHOS subunit proteins were investigated by immunodetection 
(Figure 8.21). There was no statistically significant differences in protein levels between 
tetracycline treated or untreated cells with respect to mitochondrial ATP synthase 
subunit alpha (CV-α), complex III subunit core 2 (CIII-core2) or complex II subunit 
30 kDa (CII-30) when normalised to β-actin. There was also no difference in protein 
levels over the treatment time period tested (24-72 h). 
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Figure 8.21 Immunodetection of mitochondrial oxidative phosphorylation subunit levels in cell lines. PRDM9 and Flag-PRDM9 overexpression cell lines were 
compared to the HEK293 parental cell line. Cells were treated with 1 µg/mL tetracycline (+) or untreated (-) for 24, 48 or 72 hours. Membranes were incubated 
with anti-OXPHOS (1:250) or anti-βactin (1:1000) overnight at 4 °C. 
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8.4.6 Assessing mtDNA in overexpression cell lines 
As PRDM9 motif binding sites were found in mtDNA (Chapter 4), we hypothesised that 
overexpression of the protein might have an impact on mtDNA copy number levels. 
Quantification of mtDNA levels was measured by multiplex probe based assay 
amplification of MT-ND1, MT-ND4 and the nuclear encoded house-keeping gene RNASEP. 
An mtDNA deletion control DNA sample was included on each run as a comparison. This 
control was previously extracted from a cell line known to harbour a large scale deletion 
between positions m.7982- m.15504 at a heteroplasmy level of 70% (Diaz et al., 2002). 
mtDNA copy number was significantly increased in the treated Flag-PRDM9 cells 
compared to untreated controls at all time points measured (Figure 8.22 B). This was 
also the case for the PRDM9 cell line but only at 48 hours of treatment. Copy number in 
the HEK293 control cell line was varied, with a significant increase at 24 hours 
tetracycline treatment followed by a decrease at 48 hours and then stabilisation by 72 
hours (Figure 8.22 A). 
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Figure 8.22 Quantification of mtDNA copy number in overexpression cell lines. A, B & C) Cells were untreated (pink) or treated (grey) with 1 µg/mL tetracycline for 
24, 48 or 72 hours. 2-ΔCt values were normalised to RNase P and plotted using Graphpad Prism analysis software. D & E) 2-ΔCts in overexpression cell lines were 
normalised to control HEK293 values, shown by the dotted line at y = 1. Students t-test was used to assess significance of each treatment group vs the un-treated 
partnered group. ≥0.05 = *: ≥0.005 = **: ≥0.0005 = ***. n=27    
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As described previously (Chapters 4 & 5) we hypothesised that a functional role for 
PRDM9 in the mitochondria could be to mediate deletion formation, a common 
occurrence during the normal ageing process and in several mitochondrial disorders. 
Whole mitochondrial DNA was amplified using a long range PCR protocol in the cell lines 
overexpressing PRDM9 to test for any possible mtDNA deletion formation. Reaction 
mixture was as follows; 2 mM Mg2+ buffer, 200 µM dNTPs, 0.25 µM primer (forward and 
reverse) and 1.25 U GXL PrimeSTAR DNA polymerase made to a final volume of 25 µL 
with dH2O. The reactions were carried out in a thermocycler using the following 
program; denaturation for 1 minute at 94 °C, followed by 30 cycles of denaturation at 98 
°C for 10 minutes, annealing and extension at 68 °C for 15 minutes and final extension at 
72 °C for 10 minutes. Details of mtDNA specific primers used in this PCR are detailed in 
Table 8.2. 
  
Target Primer 5’-3’ Annealing Temp 
mtDNA 16F CTCAAAGGACCTGGCGGTGCTTC 68 °C 
mtDNA 16R GTAGTGTTCTGGCGAGCAGTTTTG 68 °C 
Table 8.2 Details of mtDNA long range PCR primers used in this study. 
 
No mtDNA deletion was observed in any of the samples tested in three independent 
experiments (Figure 8.23). The deletion control DNA described above (~70% deletion 
heteroplasmy) was included in each experiment. This control shows two bands when 
electrophoresed, one at ~16.5 Kb and another at ~10 Kb confirming the presence of a 
large scale mtDNA deletion using this assay (Figure 8.23).   
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Figure 8.23 Assessment of deletions in mitochondrial DNA. Long range PCR products were 
electrophoresed on 1% agarose gels. HEK293 cells, PRDM9 overexpression and Flag-PRDM9 
overexpression cell lines were compared against a cell line known to harbour a large mtDNA deletion at 
~60% heteroplasmy. A DNA size marker was included on the gel (M), sizes are denoted in base pairs. 
 
Measurement of mtDNA deletion by PCR can be subject to amplification bias of the 
larger more dominant DNA molecule, in this case the full-length mtDNA. To assess 
whether there were low level mtDNA deletions in the transgenic cell lines, RT-qPCR data 
(described in Figure 8.22) was analysed for differences in mtDNA encoded genes 
MT-ND1 and MT-ND4. No difference was seen in the copy number ratio of the two genes 
suggesting no deletion of the MT-ND4 region of the molecule.  
To test whether there were deletions occurring elsewhere on the molecule, copies of 
MT-ND1 and MT-COIII were directly compared. There was no statistically significant 
difference (Figure 8.24). A value of 1 corresponds to there being no difference in the 
number of copies of the two genes, as seen in all cell lines (Figure 8.24). The mtDNA 
deletion control described in Section 8.4.5 showed an increased copy number of MT-ND1 
compared to MT-COIII, as expected since the region of mtDNA containing MT-COIII is 
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deleted (Figure 8.24, DEL control bin). The deletion heteroplasmy level within this cell 
line is ~70%, as shown by the 3:1 ratio of MT-ND1 to MT-COIII (Figure 8.24). 
This result confirmed that there were no mtDNA deletions in the control HEK293, 
Flag-PRDM9 or PRDM9 transgenic cell lines. 
 
 
Figure 8.24 Quantification of mtDNA deletion level from qPCR data in overexpression cell lines. Cells were 
untreated (blue) or treated with 1 µg/mL tetracycline (green). Ratios of MT-ND1 and MT-COIII amplicons 
were compared and plotted using Graphpad analysis software.  A deletion control DNA sample was run in 
triplicate on each qPCR plate (DEL control). Students t-test was used to assess significance of each 
treatment group vs the un-treated partnered group. ≥0.05 = *: ≥0.005 = **: ≥0.0005 = ***. n=27     
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8.4.7 DNA damage repair pathway analysis 
The function of PRDM9 protein is to mark sites of the genome for DNA double strand 
breakage and repair through the breast cancer type 2 susceptibility protein (BRCA2) 
mediated homologous recombination pathway. The BRCA2 protein interacts with Rad51 
recombinase to mediate DNA repair mechanisms during DNA crossover events which 
are an integral part of the meiotic cell cycle (Thorslund et al., 2007; Chatterjee et al., 
2016). The Mre11 double strand break repair nuclease protein complex is important for 
homologous recombination via BRCA1 mediated DNA repair mechanisms during the 
mitotic cell cycle (Jensen and Russell, 2016). Importantly, these two repair mechanisms 
act at different times due to cell type and whether the cell is undergoing meiotic or 
mitotic cell divisions (Roy et al., 2012). In order to assess whether the PRDM9 expressed 
in our cell lines was influencing either pathway, protein levels of Rad51 and Mre11 were 
assessed through immunodetection (Figure 8.25). 
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Figure 8.25 Immunodetection of Rad51 and Mre11 protein levels in cell lines. PRDM9 and Flag-PRDM9 overexpression cell lines were compared to the HEK293 
parental cell line. Cells were treated with 1 µg/mL tetracycline or untreated for 72 hours. Membranes were incubated with anti-Rad51 (1:1000), anti-Mre11 
(1:1000) or anti-βactin (1:1000) overnight at 4 °C. 
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Rad51 protein levels measured in three independent experiments were quantified 
(Figure 8.26). In all three cell lines protein levels were variable however there was a 
general trend towards a decrease in Rad51 protein levels in the treated groups after 48 
and 72 hours of tetracycline treatment. However, this was only significantly different in 
the treated Flag-PRDM9 cell line at 48 and 72 hour time points (Figure 8.26 B).    
 
Figure 8.26 Quantification of Western blot analysis for Rad51 protein expression. Untreated samples are 
shown in yellow, tetracycline treated samples are shown in lilac. Densitometric analysis was performed 
using ImageJ software. Values were normalised to β-actin levels and analysed using Graphpad analysis 
software. Error bars show SD. Students t-test was used to assess significance of each treatment group vs 
the un-treated partnered group. ≥0.05 = *: ≥0.005 = **: ≥0.0005 = ***. n=9     
 
Quantification of Mre11 protein levels showed that there was no significant difference in 
the transgenic cell lines when treated with tetracycline compared to untreated controls 
(Figure 8.27). There was a significant decrease in Mre11 protein level in the HEK293 
control cell line at 24 hours tetracycline treatment.  
 
Figure 8.27 Quantification of Western blot analysis for Mre11 protein expression. Untreated samples are 
shown in blue, tetracycline treated samples are shown in orange. Densitometric analysis was performed 
using ImageJ software. Values were normalised to β-actin levels and analysed using Graphpad analysis 
software. Error bars show SD. Students t-test was used to assess significance of each treatment group vs 
the un-treated partnered group. ≥0.05 = *: ≥0.005 = **: ≥0.0005 = ***. n=9     
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8.5 Discussion 
In order to investigate the cellular functions of human PRDM9 protein, full length cDNA 
constructs were stably integrated into the HEK293 cell genome under the control of a 
tetracycline inducible promoter. In this model, it is possible to switch on the 
overexpression of the cDNA construct by addition of tetracycline to the cell growth 
medium. This system allows for proteins which are potentially cytotoxic to be expressed 
in low quantities for a controlled period of time. This was a potentially advantageous 
system for PRDM9 protein overexpression as previous experiments indicated that this 
construct was difficult to express and isolate using transient expression plasmids 
(Chapter 7). Although it was not possible to reliably reproduce detectable full length 
PRDM9 protein expression using this experimental system, it was possible to indirectly 
measure PRDM9 function by assessing histone protein methylation status.  
 
8.5.1 PRDM9 expression in stably transfected cell lines 
When the cell lines were treated with tetracycline it appeared that PRDM9 protein 
expression was induced compared to untreated controls, as shown by Flag antibody 
immunodetection. However, this detection showed that protein expression was low and 
was not reliable as most lysates tested did not have detectable levels of PRDM9 protein. 
In addition, PRDM9 overexpression was more reliably detected in the cell line 
harbouring the Flag tagged construct than the untagged PRDM9 cell line. This is most 
likely due to the unreliable nature of the anti-PRDM9 antibody when compared to the 
well-established and experimentally verified anti-Flag antibody.  
Quantifying PRDM9 mRNA transcript levels in the cell lines was also variable. A lack of 
positive PRDM9 control meant that optimisation of Taqman™ assays was difficult. 
 
8.5.2 Indirect measurements of PRDM9 function 
In order to establish whether PRDM9 was being transiently expressed at all in these two 
cell lines, we next asked whether it was possible to assess any functional consequences 
of this protein. Both murine and human PRDM9 have known methyltransferase activity 
and specifically target histone 3 lysine 4 (Hayashi et al., 2005; Grey et al., 2011; Eram et 
al., 2014). It was possible to quantify tri-, di- and mono- methylation of H3K4 protein by 
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immunodetection using well established commercially available antibodies. The 
overexpression cell lines showed increased levels of both H3K4me3 and H3K4me2 after 
gene expression induction by tetracycline treatment. This effect was increased over time 
with cells treated for 72 hours showing the largest increase in methylation status when 
compared to 24 and 48 hours treatment as well as the HEK293 control samples. 
Previous methyltransferase activity studies have shown that recombinant PRDM9 
peptide has a higher affinity for H3K4 protein when it is mono- or di- methylated 
suggesting that the primary function is to increase both di- and tri- methylation levels, 
consistent with our data. Levels of mono-methylation were increased in the Flag-PRDM9 
cells treated with tetracycline suggesting that there is also the potential for the protein 
to act on un-methylated H3K4, consistent with previous reported data. The PRDM9 
cDNA construct might be more stable when expressed with the Flag tag present than 
without it.  
Overall, the assessment of Rad51 and Mre11 protein levels showed variation in the 
expression of both when cells were treated with tetracycline compared to untreated 
controls. Although there was an overall trend towards decreased expression of Rad51 in 
the Flag-PRDM9 transgenic cell line there was a similar trend in the HEK293 control cell 
line, although not statistically significant. This data suggests that attempting to dissect 
the protein family members involved in DSB repair mechanisms is complex and variable 
depending on treatment with tetracycline and timing of cell divisions. In this case, the 
effect of PRDM9 overexpression on Rad51 and Mre11 protein levels cannot be 
elucidated using this method. 
 
8.5.3 Perspectives and future recommendations 
A major problem with the use of this stable overexpression experimental system is that 
tetracycline is used as the inducer of expression by the CMV promoter element. 
Tetracyclines are a widely used group of antibiotics in agriculture and healthcare 
applications however they are also potent inhibitors of mitochondrial biogenesis, 
through the binding of rRNA elements of the 16S ribosome (Chatzispyrou et al., 2015). 
However, investigations into the exact binding sites and the mechanisms by which 
tetracyclines protect against bacterial, viral, protozoan and non-infectious health 
conditions remain conflicted in the literature. The broad range of targets inhibited by 
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tetracycline and its derivatives suggests that RNA species present in the cell may be the 
elements which are bound and inhibited, in particular double stranded RNA molecules 
(Chukwudi, 2016). In any case, the use of tetracycline or its derivatives in laboratory 
research, and in particular mitochondrial based investigations, has limitations with 
respect to data analysis and interpretation (Chatzispyrou et al., 2015; Moullan et al., 
2015). Any observation deemed statistically significant is likely to be confounded by the 
impact of the treatment itself rather than exclusively the effect of the protein/gene of 
interest, in this case PRDM9 overexpression. To overcome this, cell lines could be 
created to constitutively overexpress PRDM9 without the need for a tetracycline 
controlled promoter sequence. This was not attempted since experiments using 
transient constitutive expression did not show any detectable PRDM9 expression 
(Chapter 7) however this result might differ when using a stably transfected model. 
In this experimental system, PRDM9 is being expressed in a mammalian cell line which 
is not undergoing meiosis and therefore the protein is not required by the cell. The 
functional role of PRDM9 as a methyltransferase is primarily to allow DSB events to 
occur followed by homologous chromosome crossovers. This process itself would be 
potentially detrimental to a post mitotic cell which has no requirement for DSB events 
within the nucleus. In this case, the cell would presumably try to silence any transcript 
or peptide which might be contributing to DSB events through several possible cellular 
degradation pathways. 
Proteasomal degradation is a complex and highly regulated cellular pathway which 
targets proteins or peptide fragments for breakdown and recycling in response to 
several cellular signals. For example, proteins could be misfolded, aggregated, retarded 
or pathogenic therefore compromising cellular function in some way. In such cases, the 
proteins are targeted for ubiquitination followed by proteasomal degradation either 
through autophagosome formation or delivery by chaperone protein complexes (Hjerpe 
et al., 2016). It is possible to experimentally block such protein degradation through 
several small chemical inhibitors or antibiotics. For example, chloroquine and leupeptin 
are well-established inhibitors of lysosomal degradation and has previously been used 
to show lysosome specific mRNA-protein complex degradation and endocytosis (Seguin 
et al., 2014; Hashimoto et al., 2015). The compound MG132 is a potent proteasome 
inhibitor which specifically targets the 26S pathway (Han et al., 2009) and can be used 
to elucidate the proteasomal pathway responsible for degradation of proteins of interest 
 233 
 
(Pedersen et al., 2016). Brefeldin A blocks protein transport from the ER to the Golgi 
apparatus and can be used to elucidate the levels of protein recycling (Fernandez-
Messina et al., 2016). Cyclohexamide binds to the ribosome preventing the translocation 
step of peptide elongation in eukaryotic cells (Schneider-Poetsch et al., 2010). Using 
cyclohexamide in pulse-chase experiments could be informative for assessing the rate of 
protein degradation, although it would only be specific to the protein of interest through 
immunoprecipitation pull down assays. 
The functional role of PRDM9 in nuclear recombination is also unknown. Recent data 
shows that PRDM9 most likely interacts with SPO11 which is required for DNA double 
strand break formation (Lange et al., 2016) and it is reasonable to assume that other 
proteins within this pathway are interacting or are affected by PRDM9 during meiosis. 
The cell lines created could be used to further uncover the mechanisms underlying 
meiotic recombination. Chromosome crossover events and global histone methylation 
changes could be studied in this model however investigations would still require 
stabilisation of overexpressed PRDM9 protein. 
Although it was possible to create cell lines harbouring full length human PRDM9 cDNA 
under the control of a tetracycline inducible promoter, the detection of PRDM9 by 
immunoblotting, immunofluorescence or RT-qPCR was not reproducible. Indirectly 
measuring PRDM9 function through H3K4 methylation status shows that our model is 
consistent with previously published data with respect to its nuclear methyltransferase 
activity. Due to a lack of expression, it was not possible to determine PRDM9 cellular 
localisation with respect to the mitochondria in the cell lines created. However, through 
further efforts to block degradation of this protein by the proteasome, lysosome or 
mRNA processing pathways, it would be possible to use this model to answer further 
questions surrounding the localisation and function of PRDM9. 
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Chapter 9 General Discussion  
 
9.1 Overview  
In addition to the detailed discussion sections in each results chapter, the main findings 
of this thesis will be described in the context of the results as a whole. The limitations of 
each study will be described along with suggestions for future investigations which will 
be necessary to fully determine the observations outlined in this thesis. 
The main aim of this thesis was to determine the presence of PRDM9 binding sites 
within the human mtDNA sequence and to elucidate the mechanism by which PRDM9 
protein potentially binds to the molecule, or functions within the mitochondria. In order 
to investigate the possible link between PRDM9 and mtDNA deletion mediation, three 
broad approaches were undertaken; an in silico assessment of PRDM9 motifs within 
mtDNA sequences, a PRDM9 genotyping association study in a single deletion patient 
cohort and investigations into PRDM9 protein function using several approaches.  
 
9.2 Main findings and experimental limitations 
9.2.1 PRDM9 binding motifs are present in human mtDNA 
A DNA motif was found to be enriched within recombination hotspots throughout the 
human genome and was later identified as the target of PRDM9 protein binding (Myers 
et al., 2008). The function of human PRDM9 protein is of interest in a mitochondrial 
context due to the previous identification of a protein binding motif within the mtDNA 
sequence (Myers et al., 2008). The presence of PRDM9 motifs within the mtDNA was 
further explored in this thesis.  
Chapter 4 outlines the in silico method used to detect the presence of 11 independent 
PRDM9 motifs previously identified within the nuclear genome (Jeffreys et al., 2013). 
Motifs were identified in a large cohort (n=31,554) of mtDNA sequences screened using 
this pipeline. Overall, the 11 motif sites showed clustering within the molecule at sites 
within both the major and minor arcs. Population stratification was then performed, 
revealing differences in motif presence between populations shown by broad 
haplogrouping of European, Asian and African sequences. The motifs found within the 
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mtDNA sequences trended towards the expected population specific PRDM9 allele. For 
example, European sequences were expected to contain more motif sites recognized by 
allele ‘A’ than African sequences, which in contrast show more motif sites recognized by 
allele ‘C’. This was expected based on previous PRDM9 allele data from both European 
and African genome analysis (Berg et al., 2010; Berg et al., 2011; Jeffreys et al., 2013). 
Some motif positions identified in this analysis were described previously as flanking 
mtDNA deletion sites (Samuels et al., 2004) suggesting that there might be a functional 
role for PRDM9 protein within the organelle. The data suggest that PRDM9 motif sites 
are prevalent within the molecule and that the position and number of these sites is 
somewhat determined by population mtDNA haplogroup.  
This analysis alone does not prove that there is any functional role for PRDM9 within the 
mitochondria. Available mtDNA deletion breakpoint data was therefore downloaded and 
aligned with the known PRDM9 motif sites to ascertain whether or not the two data sets 
show a pattern of overlap. It was observed that several breakpoints occur at or within 
PRDM9 motif sites on the mtDNA molecule suggesting that there was adequate data to 
prompt functional investigations into the potential role of this protein within the 
mitochondria in vivo. 
9.2.2 PRDM9 alleles are not associated with increased risk of mtDNA single deletion 
The PRDM9 ZnF region is highly polymorphic due to rapidly changing hotspot usage 
throughout human evolution (Myers et al., 2010; Lesecque et al., 2014). Interestingly, 
SNPs within the ZnF region of this gene have been associated with several genomic 
rearrangement disorders, cancer and infertility (Irie et al., 2009; Borel et al., 2012; 
Hussin et al., 2013), though the true pathogenic nature of these variants remains to be 
determined in larger cohorts. In order to determine whether PRDM9 alleles are 
associated with a greater risk of mtDNA deletion formation, the ZnF region was 
genotyped in a cohort of 48 single deletion patients versus 50 healthy controls. Although 
multiple PRDM9 alleles were identified in both case and control cohorts, there was no 
association between any of the alleles and deletion risk. However, there was a 
statistically significant difference in the number of heterozygous individuals in the case 
group compared to the controls. This result could be due to sample bias as only 98 
individuals were genotyped and only 48 of those were patients, or it could be that 
increased heterozygosity at the PRDM9 allele locus is influencing mtDNA deletion 
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formation in this patient group. This genotyping analysis would need to be performed 
using a larger cohort to determine whether this heterozygosity observation is truly 
statistically significant. Additionally, further information concerning characterisation of 
patient mtDNA could be used to better understand whether there is any difference in 
PRDM9 allele distribution due to haplogroup status or deletion breakpoint sites. 
9.2.3 Identifying a model system in which to study PRDM9 protein function 
Expression of PRDM9 is predicted to occur during meiosis of male and female gametes 
(Hayashi et al., 2005; Sun et al., 2015). For this reason, PRDM9 protein studies in mice 
have focused on using testes tissue, where spermatocytes undergo maturation 
(Parvanov et al., 2010). Little is known about the expression pattern of the human 
PRDM9 protein however it is assumed to be similar, if not identical, to that of the mouse. 
Studies into the functional role of human PRDM9 have used partial protein constructs, 
either using the C-terminal ZnF array or a section of the protein spanning the PR/SET 
domain (Wu et al., 2013; Eram et al., 2014; Patel et al., 2016).  
In this study, detection of PRDM9 protein was tested in several cell lines and human 
tissue samples. In order to use tissues as close as possible to embryonic origin, we 
established a collection of female gonadal samples including ovary, placenta and foetal 
gonad. The cell type explored most in this thesis was HEK293, which is embryonic in 
origin. Using protein lysates from tissue and cells, PRDM9 protein detection was not 
possible, as confirmed by mass spectrometry of immunoprecipitated protein. Several 
different PRDM9 antibodies were used throughout this study however, no positive 
PRDM9 signal could be detected. This is most likely due to two factors; the sensitivity of 
protein detection relative to abundance within the cell/tissue and the unreliability of 
appropriate antibodies used to detect this protein. Detection of PRDM9 mRNA 
expression was also performed using RT-qPCR. Although standard curve analysis 
showed that there was amplification of the target transcript, it was present at in very 
low quantity making detection difficult. Together these data suggest that PRDM9 
transcript levels are in low abundance within the cell lines and tissue types tested and 
that the mRNA species are likely rapidly degraded when the cell is not undergoing active 
meiosis. This presents as a major limitation in studying the functional role of this protein 
in human cells and tissues. 
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9.2.4 Characterisation of a PRDM9 overexpression system 
Overexpression of full length PRDM9 was attempted using a transient plasmid 
transfection system. This system showed partial success, as PRDM9 was detected on 
three occasions by immunoblotting. However, the variability of this technique in 
addition to the relatively low number of cells used in this experimental system lead us to 
create a stable overexpression model. These cell lines showed modest PRDM9 
expression under the control of a tetracycline inducible promoter. One cell line, 
harboring PRDM9 fused to a Flag tag, showed expression of a protein at the expected 
size of 103 kDa, specifically detected with anti-Flag. The second cell line, expressing 
untagged PRDM9, did not always show expression of a protein at the expected size, 
possibly due to the nonspecific nature of the PRDM9 antibody.  
In order to assess whether PRDM9 was not being adequately expressed or being rapidly 
degraded by the cell, histone H3 methylation status was assessed. Interestingly, the cell 
lines overexpressing PRDM9 showed an increased amount of H3K4 methylation. Eram et 
al. (2014) showed previously that overexpression of a partial human PRDM9 construct 
was able to carry out methyltransferase activity in HEK293 cells. This is confirmed in 
our model using the full length PRDM9 protein.  
 
9.3 Future investigations 
9.3.2 PRDM9 localisation 
Whilst the PRDM9 overexpression cell lines showed increased H3K4 methylation, there 
was variable detection of the protein itself. When PRDM9 protein was detectable by 
immunoblot, it was expressed in low quantities compared to other proteins suggesting 
that PRDM9 is being actively degraded by the cell, possibly through ubiquitin pathways 
and the proteasome. A lack of detection of mRNA also suggests that the mRNA product 
could be targeted for degradation by deadenylation or endonuclease mediated 
pathways. These hypotheses could be experimentally tested by adding small chemical 
inhibitors to the cell lines in culture.  
It is important to establish whether PRDM9 has any mitochondrial localization before 
further investigations are carried out. Overexpression of a partial PRDM9 peptide 
sequence was successful (as shown in Chapter 7). This experiment could be extended to 
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other regions of the protein to establish whether any are targeted to the mitochondria. 
Based on the observations from such experiments, further organelle investigations could 
be warranted. 
9.3.4 Studies using animal models 
Using animal models such as mouse or zebrafish would be beneficial to further explore 
the potential role of PRDM9 in the mitochondria. Zebrafish can be used as an excellent 
model for oogenesis and reproduction, as gametocytes can be easily harvested (Elkouby 
and Mullins, 2016). These qualities could be employed to further understand the timing 
of expression of PRDM9 and localization of PRDM9 protein. Transgenic zebrafish lines 
are widely available and could be used to model whether a loss of the PRDM9 gene has 
any effect on cellular function (Howe et al., 2017). Localisation of PRDM9 to the nucleus 
was observed in mouse testes tissue (Flachs et al., 2014). However, the authors 
concluded that PRDM9 shuttles to the cytoplasm, although its function in this 
compartment was not clear and has not been studied. Immunofluorescent imaging 
analysis of this tissue could be explored using different antibody markers to understand 
where PRDM9 localises to within the cytosol. Lysosomal, endoplasmic reticulum and 
mitochondrial specific markers would help to further understand what happens to 
PRDM9 when it does not translocate to the nuclear compartment. 
Additionally, a putative binding site for PRDM9 protein has been identified in the mouse 
genome and this could be explored in the mtDNA sequence of several mouse strains 
using publically available sequencing data (Davies et al., 2016). The in silico approach 
outlined in this study could be extended to various taxa, specifically to species closely 
related to Homo sapiens to determine whether a conserved mechanism for PRDM9 
binding in mammalian mtDNA exists. This has not been explored, most likely due to a 
lack of identification of the PRDM9 motif in each individual species. Due to the 
polymorphic nature of the gene, it is probable that the binding motif varies between 
species.  
9.3.3 Elucidating the role of PRDM9 in the nucleus 
Partial recombinant PRDM9 protein has been used previously to assess 
methyltransferase activity and binding affinity of PRDM9 protein to oligonucleotides 
containing the genomic recognition motif (Wu et al., 2013; Eram et al., 2014). In 
addition, a recent study showed that PRDM9 interacts with SPO11 further supporting 
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the role of PRDM9 in the nDNA double strand break pathway (Lange et al., 2016). The 
cell lines created in this project could be utilized to further investigate the mechanisms 
of action of the protein within the nucleus and perhaps help uncover other potential 
protein-protein interactions. Directed mutagenesis of PRDM9 in this cell model could be 
used to understand how different regions of the protein affect nuclear genomic 
recombination patterns.  
 
9.4 Final conclusions 
Throughout this thesis the experimental steps taken to determine whether the 
recombination regulator PRDM9 has involvement in the mediation of mtDNA deletions 
have been described.  
 PRDM9 recognition motifs were identified within 99.9% of human mtDNA 
sequences, however the true functional role of this protein within the 
mitochondria remains unknown.  
 Finding a model in which to study PRDM9 protein function proved difficult due to 
its meiotic specific expression profile.  
 Two stable overexpression cell lines were created and showed promising results 
based on Flag-tag immunodetection and upregulated histone H3 lysine 
methylation. This cell culture model may provide some insights into the function 
of PRDM9 but must be interpreted with caution due to the biologically 
engineered nature of this system.  
 Using animal models would allow further charactrisation of PRDM9 in the tissues 
and cell types in which it is normally expressed, i.e. testes and gametocytes. 
Mitochondrial localization and mtDNA binding have not been determined during this 
study, however to the best of my knowledge this is the first time a cell culture model has 
been created to express full length human PRDM9 and might be of use in future 
experiments.  
 
 241 
 
References 
Al Rawi, S., Louvet-Vallee, S., Djeddi, A., Sachse, M., Culetto, E., Hajjar, C., Boyd, L., Legouis, 
R. and Galy, V. (2011) 'Postfertilization autophagy of sperm organelles prevents paternal 
mitochondrial DNA transmission', Science, 334(6059), pp. 1144-7. 
Alhomidi, M.A., Vedicherla, B., Movva, S., Rao, P.K., Ahuja, Y.R. and Hasan, Q. (2013) 
'Mitochondrial D310 instability in Asian Indian breast cancer patients', Tumour Biol, 
34(4), pp. 2427-32. 
Ancelin, K., Lange, U.C., Hajkova, P., Schneider, R., Bannister, A.J., Kouzarides, T. and 
Surani, M.A. (2006) 'Blimp1 associates with Prmt5 and directs histone arginine 
methylation in mouse germ cells', Nat Cell Biol, 8(6), pp. 623-30. 
Andrews, R.M., Kubacka, I., Chinnery, P.F., Lightowlers, R.N., Turnbull, D.M. and Howell, 
N. (1999) 'Reanalysis and revision of the Cambridge reference sequence for human 
mitochondrial DNA', Nat Genet, 23(2), p. 147. 
Ardissone, A., Lamantea, E., Invernizzi, F., Zeviani, M., Genitrini, S., Moroni, I. and Uziel, G. 
(2014) 'Mitochondrial Diseases in Childhood', Curr Mol Med. 
Auton, A., Fledel-Alon, A., Pfeifer, S., Venn, O., Segurel, L., Street, T., Leffler, E.M., Bowden, 
R., Aneas, I., Broxholme, J., Humburg, P., Iqbal, Z., Lunter, G., Maller, J., Hernandez, R.D., 
Melton, C., Venkat, A., Nobrega, M.A., Bontrop, R., Myers, S., Donnelly, P., Przeworski, M. 
and McVean, G. (2012) 'A fine-scale chimpanzee genetic map from population 
sequencing', Science, 336(6078), pp. 193-8. 
Axelsson, E., Webster, M.T., Ratnakumar, A., Consortium, L., Ponting, C.P. and Lindblad-
Toh, K. (2012) 'Death of PRDM9 coincides with stabilization of the recombination 
landscape in the dog genome', Genome Res, 22(1), pp. 51-63. 
Baker, C.L., Kajita, S., Walker, M., Saxl, R.L., Raghupathy, N., Choi, K., Petkov, P.M. and 
Paigen, K. (2015) 'PRDM9 drives evolutionary erosion of hotspots in Mus musculus 
through haplotype-specific initiation of meiotic recombination', PLoS Genet, 11(1), p. 
e1004916. 
Balcova, M., Faltusova, B., Gergelits, V., Bhattacharyya, T., Mihola, O., Trachtulec, Z., 
Knopf, C., Fotopulosova, V., Chvatalova, I., Gregorova, S. and Forejt, J. (2016) 'Hybrid 
Sterility Locus on Chromosome X Controls Meiotic Recombination Rate in Mouse', PLoS 
Genet, 12(4), p. e1005906. 
Basha Gutierrez, J. and Nakai, K. (2016) 'A study on the application of topic models to 
motif finding algorithms', BMC Bioinformatics, 17(Suppl 19), p. 502. 
Basu, A., Chaudhuri, P. and Majumder, P.P. (2005) 'Identification of polymorphic motifs 
using probabilistic search algorithms', Genome Res, 15(1), pp. 67-77. 
Baudat, F., Buard, J., Grey, C., Fledel-Alon, A., Ober, C., Przeworski, M., Coop, G. and de 
Massy, B. (2010) 'PRDM9 is a major determinant of meiotic recombination hotspots in 
humans and mice', Science, 327(5967), pp. 836-40. 
 242 
 
Baum, H. and Rieske, J.S. (1966) 'Involvement of water in electron transport in 
complexes III and IV of the mitochondrial electron transport chain', Biochem Biophys Res 
Commun, 24(1), pp. 1-9. 
Bellizzi, D., D'Aquila, P., Scafone, T., Giordano, M., Riso, V., Riccio, A. and Passarino, G. 
(2013) 'The control region of mitochondrial DNA shows an unusual CpG and non-CpG 
methylation pattern', DNA Res, 20(6), pp. 537-47. 
Berg, I.L., Neumann, R., Lam, K.W., Sarbajna, S., Odenthal-Hesse, L., May, C.A. and Jeffreys, 
A.J. (2010) 'PRDM9 variation strongly influences recombination hot-spot activity and 
meiotic instability in humans', Nat Genet, 42(10), pp. 859-63. 
Berg, I.L., Neumann, R., Sarbajna, S., Odenthal-Hesse, L., Butler, N.J. and Jeffreys, A.J. 
(2011) 'Variants of the protein PRDM9 differentially regulate a set of human meiotic 
recombination hotspots highly active in African populations', Proc Natl Acad Sci U S A, 
108(30), pp. 12378-83. 
Berger, S.L., Kouzarides, T., Shiekhattar, R. and Shilatifard, A. (2009) 'An operational 
definition of epigenetics', Genes Dev, 23(7), pp. 781-3. 
Beri, S., Bonaglia, M.C. and Giorda, R. (2013) 'Low-copy repeats at the human VIPR2 gene 
predispose to recurrent and nonrecurrent rearrangements', Eur J Hum Genet, 21(7), pp. 
757-61. 
Billings, T., Parvanov, E.D., Baker, C.L., Walker, M., Paigen, K. and Petkov, P.M. (2013) 
'DNA binding specificities of the long zinc-finger recombination protein PRDM9', 
Genome Biol, 14(4), p. R35. 
Blazer, L.L., Lima-Fernandes, E., Gibson, E., Eram, M.S., Loppnau, P., Arrowsmith, C.H., 
Schapira, M. and Vedadi, M. (2016) 'PR Domain-containing Protein 7 (PRDM7) Is a 
Histone 3 Lysine 4 Trimethyltransferase', J Biol Chem, 291(26), pp. 13509-19. 
Bogenhagen, D., Gillum, A.M., Martens, P.A. and Clayton, D.A. (1979) 'Replication of 
mouse L-cell mitochondrial DNA', Cold Spring Harb Symp Quant Biol, 43 Pt 1, pp. 253-62. 
Bogenhagen, D.F. (2012) 'Mitochondrial DNA nucleoid structure', Biochim Biophys Acta, 
1819(9-10), pp. 914-20. 
Borel, C., Cheung, F., Stewart, H., Koolen, D.A., Phillips, C., Thomas, N.S., Jacobs, P.A., Eliez, 
S. and Sharp, A.J. (2012) 'Evaluation of PRDM9 variation as a risk factor for recurrent 
genomic disorders and chromosomal non-disjunction', Hum Genet, 131(9), pp. 1519-24. 
Boulton, A., Myers, R.S. and Redfield, R.J. (1997) 'The hotspot conversion paradox and 
the evolution of meiotic recombination', Proc Natl Acad Sci U S A, 94(15), pp. 8058-63. 
Bradford, M.M. (1976) 'A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding', Anal Biochem, 72, pp. 
248-54. 
 243 
 
Brick, K., Smagulova, F., Khil, P., Camerini-Otero, R.D. and Petukhova, G.V. (2012) 
'Genetic recombination is directed away from functional genomic elements in mice', 
Nature, 485(7400), pp. 642-5. 
Brierley, E.J., Johnson, M.A., Lightowlers, R.N., James, O.F. and Turnbull, D.M. (1998) 'Role 
of mitochondrial DNA mutations in human aging: implications for the central nervous 
system and muscle', Ann Neurol, 43(2), pp. 217-23. 
Brown, M.D., Hosseini, S.H., Torroni, A., Bandelt, H.J., Allen, J.C., Schurr, T.G., Scozzari, R., 
Cruciani, F. and Wallace, D.C. (1998) 'mtDNA haplogroup X: An ancient link between 
Europe/Western Asia and North America?', Am J Hum Genet, 63(6), pp. 1852-61. 
Brown, M.D., Sun, F. and Wallace, D.C. (1997) 'Clustering of Caucasian Leber hereditary 
optic neuropathy patients containing the 11778 or 14484 mutations on an mtDNA 
lineage', Am J Hum Genet, 60(2), pp. 381-7. 
Brown, T.A., Cecconi, C., Tkachuk, A.N., Bustamante, C. and Clayton, D.A. (2005) 
'Replication of mitochondrial DNA occurs by strand displacement with alternative light-
strand origins, not via a strand-coupled mechanism', Genes Dev, 19(20), pp. 2466-76. 
Bua, E., Johnson, J., Herbst, A., Delong, B., McKenzie, D., Salamat, S. and Aiken, J.M. (2006) 
'Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels 
in aged human skeletal muscle fibers', Am J Hum Genet, 79(3), pp. 469-80. 
Buard, J., Rivals, E., Dunoyer de Segonzac, D., Garres, C., Caminade, P., de Massy, B. and 
Boursot, P. (2014) 'Diversity of Prdm9 zinc finger array in wild mice unravels new facets 
of the evolutionary turnover of this coding minisatellite', PLoS One, 9(1), p. e85021. 
Cai, J., Yue, Y., Wang, Y., Jin, Z., Jin, F. and Wu, C. (2016) 'Quantitative study of effects of 
free cationic chains on gene transfection in different intracellular stages', J Control 
Release, 238, pp. 71-79. 
Calvo, S.E., Clauser, K.R. and Mootha, V.K. (2016) 'MitoCarta2.0: an updated inventory of 
mammalian mitochondrial proteins', Nucleic Acids Res, 44(D1), pp. D1251-7. 
Campbell, C.L., Bherer, C., Morrow, B.E., Boyko, A.R. and Auton, A. (2016) 'A Pedigree-
Based Map of Recombination in the Domestic Dog Genome', G3 (Bethesda). 
Campbell, G., Krishnan, K.J., Deschauer, M., Taylor, R.W. and Turnbull, D.M. (2014) 
'Dissecting the mechanisms underlying the accumulation of mitochondrial DNA 
deletions in human skeletal muscle', Hum Mol Genet. 
Cann, R.L., Stoneking, M. and Wilson, A.C. (1987) 'Mitochondrial DNA and human 
evolution', Nature, 325(6099), pp. 31-6. 
Cao, L., Shitara, H., Horii, T., Nagao, Y., Imai, H., Abe, K., Hara, T., Hayashi, J. and 
Yonekawa, H. (2007) 'The mitochondrial bottleneck occurs without reduction of mtDNA 
content in female mouse germ cells', Nat Genet, 39(3), pp. 386-90. 
Cardon, L.R., Burge, C., Clayton, D.A. and Karlin, S. (1994) 'Pervasive CpG suppression in 
animal mitochondrial genomes', Proc Natl Acad Sci U S A, 91(9), pp. 3799-803. 
 244 
 
Carelli, V., Achilli, A., Valentino, M.L., Rengo, C., Semino, O., Pala, M., Olivieri, A., Mattiazzi, 
M., Pallotti, F., Carrara, F., Zeviani, M., Leuzzi, V., Carducci, C., Valle, G., Simionati, B., 
Mendieta, L., Salomao, S., Belfort, R., Jr., Sadun, A.A. and Torroni, A. (2006) 'Haplogroup 
effects and recombination of mitochondrial DNA: novel clues from the analysis of Leber 
hereditary optic neuropathy pedigrees', Am J Hum Genet, 78(4), pp. 564-74. 
Chaban, Y., Boekema, E.J. and Dudkina, N.V. (2014) 'Structures of mitochondrial 
oxidative phosphorylation supercomplexes and mechanisms for their stabilisation', 
Biochim Biophys Acta, 1837(4), pp. 418-26. 
Chang, D.D., Hauswirth, W.W. and Clayton, D.A. (1985) 'Replication priming and 
transcription initiate from precisely the same site in mouse mitochondrial DNA', EMBO J, 
4(6), pp. 1559-67. 
Chatterjee, G., Jimenez-Sainz, J., Presti, T., Nguyen, T. and Jensen, R.B. (2016) 'Distinct 
binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity', 
Nucleic Acids Res, 44(11), pp. 5256-70. 
Chatzispyrou, I.A., Held, N.M., Mouchiroud, L., Auwerx, J. and Houtkooper, R.H. (2015) 
'Tetracycline antibiotics impair mitochondrial function and its experimental use 
confounds research', Cancer Res, 75(21), pp. 4446-9. 
Chen, H., Vermulst, M., Wang, Y.E., Chomyn, A., Prolla, T.A., McCaffery, J.M. and Chan, D.C. 
(2010) 'Mitochondrial fusion is required for mtDNA stability in skeletal muscle and 
tolerance of mtDNA mutations', Cell, 141(2), pp. 280-9. 
Chen, Y.S., Torroni, A., Excoffier, L., Santachiara-Benerecetti, A.S. and Wallace, D.C. 
(1995) 'Analysis of mtDNA variation in African populations reveals the most ancient of 
all human continent-specific haplogroups', Am J Hum Genet, 57(1), pp. 133-49. 
Chinnery, P.F., DiMauro, S., Shanske, S., Schon, E.A., Zeviani, M., Mariotti, C., Carrara, F., 
Lombes, A., Laforet, P., Ogier, H., Jaksch, M., Lochmuller, H., Horvath, R., Deschauer, M., 
Thorburn, D.R., Bindoff, L.A., Poulton, J., Taylor, R.W., Matthews, J.N. and Turnbull, D.M. 
(2004) 'Risk of developing a mitochondrial DNA deletion disorder', Lancet, 364(9434), 
pp. 592-6. 
Chukwudi, C.U. (2016) 'rRNA Binding Sites and the Molecular Mechanism of Action of 
the Tetracyclines', Antimicrob Agents Chemother, 60(8), pp. 4433-41. 
Collu-Marchese, M., Shuen, M., Pauly, M., Saleem, A. and Hood, D.A. (2015) 'The 
regulation of mitochondrial transcription factor A (Tfam) expression during skeletal 
muscle cell differentiation', Biosci Rep, 35(3). 
Cooper, C. and Lehninger, A.L. (1957) 'Oxidative phosphorylation by an enzyme complex 
from extracts of mitochondria. V. The adenosine triphosphate-phosphate exchange 
reaction', J Biol Chem, 224(1), pp. 561-78. 
Copeland, W.C. and Longley, M.J. (2014) 'Mitochondrial genome maintenance in health 
and disease', DNA Repair (Amst). 
 245 
 
Corneo, G., Moore, C., Sanadi, D.R., Grossman, L.I. and Marmur, J. (1966) 'Mitochondrial 
DNA in yeast and some mammalian species', Science, 151(3711), pp. 687-9. 
Coto, E., Gomez, J., Alonso, B., Corao, A.I., Diaz, M., Menendez, M., Martinez, C., Calatayud, 
M.T., Moris, G. and Alvarez, V. (2011) 'Late-onset Alzheimer's disease is associated with 
mitochondrial DNA 7028C/haplogroup H and D310 poly-C tract heteroplasmy', 
Neurogenetics, 12(4), pp. 345-6. 
Crane, F.L., Lester, R.L., Widmer, C. and Hatefi, Y. (1959) 'Studies on the electron 
transport system. XVIII. Isolation of coenzyme Q (Q275) from beef heart and beef heart 
mitochondria', Biochim Biophys Acta, 32(1), pp. 73-9. 
Cree, L.M., Samuels, D.C., de Sousa Lopes, S.C., Rajasimha, H.K., Wonnapinij, P., Mann, J.R., 
Dahl, H.H. and Chinnery, P.F. (2008) 'A reduction of mitochondrial DNA molecules 
during embryogenesis explains the rapid segregation of genotypes', Nat Genet, 40(2), pp. 
249-54. 
Damas, J., Carneiro, J., Amorim, A. and Pereira, F. (2014) 'MitoBreak: the mitochondrial 
DNA breakpoints database', Nucleic Acids Res, 42(Database issue), pp. D1261-8. 
Dang, N., Ma, X., Meng, X., An, L. and Pang, S. (2016) 'Dysregulated function of normal 
human epidermal keratinocytes in the absence of filaggrin', Mol Med Rep, 14(3), pp. 
2566-72. 
Das, J., Han, J.W., Choi, Y.J., Song, H., Cho, S.G., Park, C., Seo, H.G. and Kim, J.H. (2016) 
'Cationic lipid-nanoceria hybrids, a novel nonviral vector-mediated gene delivery into 
mammalian cells: investigation of the cellular uptake mechanism', Sci Rep, 6, p. 29197. 
das Neves, R.P., Jones, N.S., Andreu, L., Gupta, R., Enver, T. and Iborra, F.J. (2010) 
'Connecting variability in global transcription rate to mitochondrial variability', PLoS 
Biol, 8(12), p. e1000560. 
Davies, B., Hatton, E., Altemose, N., Hussin, J.G., Pratto, F., Zhang, G., Hinch, A.G., Moralli, 
D., Biggs, D., Diaz, R., Preece, C., Li, R., Bitoun, E., Brick, K., Green, C.M., Camerini-Otero, 
R.D., Myers, S.R. and Donnelly, P. (2016) 'Re-engineering the zinc fingers of PRDM9 
reverses hybrid sterility in mice', Nature, 530(7589), pp. 171-6. 
Dawid, I.B. (1974) '5-methylcytidylic acid: absence from mitochondrial DNA of frogs and 
HeLa cells', Science, 184(4132), pp. 80-1. 
Dayama, G., Emery, S.B., Kidd, J.M. and Mills, R.E. (2014) 'The genomic landscape of 
polymorphic human nuclear mitochondrial insertions', Nucleic Acids Res, 42(20), pp. 
12640-9. 
de Vries, S., Albracht, S.P., Berden, J.A. and Slater, E.C. (1981) 'A new species of bound 
ubisemiquinone anion in QH2: cytochrome c oxidoreductase', J Biol Chem, 256(23), pp. 
11996-8. 
Derenko, M.V., Malyarchuk, B.A., Dambueva, I.K., Shaikhaev, G.O., Dorzhu, C.M., Nimaev, 
D.D. and Zakharov, I.A. (2000) 'Mitochondrial DNA variation in two South Siberian 
 246 
 
Aboriginal populations: implications for the genetic history of North Asia', Hum Biol, 
72(6), pp. 945-73. 
Diaz, F., Bayona-Bafaluy, M.P., Rana, M., Mora, M., Hao, H. and Moraes, C.T. (2002) 
'Human mitochondrial DNA with large deletions repopulates organelles faster than full-
length genomes under relaxed copy number control', Nucleic Acids Res, 30(21), pp. 
4626-33. 
Dittwald, P., Gambin, T., Gonzaga-Jauregui, C., Carvalho, C.M., Lupski, J.R., Stankiewicz, P. 
and Gambin, A. (2013) 'Inverted low-copy repeats and genome instability--a genome-
wide analysis', Hum Mutat, 34(1), pp. 210-20. 
Dobzhansky, T. (1936) 'Studies on Hybrid Sterility. II. Localization of Sterility Factors in 
Drosophila Pseudoobscura Hybrids', Genetics, 21(2), pp. 113-35. 
Doi, N., Zenno, S., Ueda, R., Ohki-Hamazaki, H., Ui-Tei, K. and Saigo, K. (2003) 'Short-
interfering-RNA-mediated gene silencing in mammalian cells requires Dicer and eIF2C 
translation initiation factors', Curr Biol, 13(1), pp. 41-6. 
Doynova, M.D., Berretta, A., Jones, M.B., Jasoni, C.L., Vickers, M.H. and O'Sullivan, J.M. 
(2016) 'Interactions between mitochondrial and nuclear DNA in mammalian cells are 
non-random', Mitochondrion. 
Ebner, S., Mangge, H., Langhof, H., Halle, M., Siegrist, M., Aigner, E., Paulmichl, K., 
Paulweber, B., Datz, C., Sperl, W., Kofler, B. and Weghuber, D. (2015) 'Mitochondrial 
Haplogroup T Is Associated with Obesity in Austrian Juveniles and Adults', PLoS One, 
10(8), p. e0135622. 
Elkouby, Y.M. and Mullins, M.C. (2016) 'Methods for the analysis of early oogenesis in 
Zebrafish', Dev Biol. 
Elstner, M., Andreoli, C., Klopstock, T., Meitinger, T. and Prokisch, H. (2009) 'The 
mitochondrial proteome database: MitoP2', Methods Enzymol, 457, pp. 3-20. 
Emery, L.S., Magnaye, K.M., Bigham, A.W., Akey, J.M. and Bamshad, M.J. (2015) 'Estimates 
of continental ancestry vary widely among individuals with the same mtDNA 
haplogroup', Am J Hum Genet, 96(2), pp. 183-93. 
Eom, G.H., Kim, K., Kim, S.M., Kee, H.J., Kim, J.Y., Jin, H.M., Kim, J.R., Kim, J.H., Choe, N., Kim, 
K.B., Lee, J., Kook, H., Kim, N. and Seo, S.B. (2009) 'Histone methyltransferase PRDM8 
regulates mouse testis steroidogenesis', Biochem Biophys Res Commun, 388(1), pp. 131-
6. 
Eram, M.S., Bustos, S.P., Lima-Fernandes, E., Siarheyeva, A., Senisterra, G., Hajian, T., 
Chau, I., Duan, S., Wu, H., Dombrovski, L., Schapira, M., Arrowsmith, C.H. and Vedadi, M. 
(2014) 'Trimethylation of Histone H3 Lysine 36 by Human Methyltransferase PRDM9', J 
Biol Chem. 
 247 
 
Farha, S., Hu, B., Comhair, S., Zein, J., Dweik, R., Erzurum, S.C. and Aldred, M.A. (2016) 
'Mitochondrial Haplogroups and Risk of Pulmonary Arterial Hypertension', PLoS One, 
11(5), p. e0156042. 
Feichtinger, J., Aldeailej, I., Anderson, R., Almutairi, M., Almatrafi, A., Alsiwiehri, N., 
Griffiths, K., Stuart, N., Wakeman, J.A., Larcombe, L. and McFarlane, R.J. (2012) 'Meta-
analysis of clinical data using human meiotic genes identifies a novel cohort of highly 
restricted cancer-specific marker genes', Oncotarget, 3(8), pp. 843-53. 
Felsenstein, J. (1974) 'The evolutionary advantage of recombination', Genetics, 78(2), pp. 
737-56. 
Fernandez-Messina, L., Reyburn, H.T. and Vales-Gomez, M. (2016) 'A short half-life of 
ULBP1 at the cell surface due to internalization and proteosomal degradation', Immunol 
Cell Biol, 94(5), pp. 479-85. 
Fernandez-Vizarra, E., Ferrin, G., Perez-Martos, A., Fernandez-Silva, P., Zeviani, M. and 
Enriquez, J.A. (2010) 'Isolation of mitochondria for biogenetical studies: An update', 
Mitochondrion, 10(3), pp. 253-62. 
Finnila, S., Lehtonen, M.S. and Majamaa, K. (2001) 'Phylogenetic network for European 
mtDNA', Am J Hum Genet, 68(6), pp. 1475-84. 
Flachs, P., Bhattacharyya, T., Mihola, O., Pialek, J., Forejt, J. and Trachtulec, Z. (2014) 
'Prdm9 incompatibility controls oligospermia and delayed fertility but no selfish 
transmission in mouse intersubspecific hybrids', PLoS One, 9(4), p. e95806. 
Flachs, P., Mihola, O., Simecek, P., Gregorova, S., Schimenti, J.C., Matsui, Y., Baudat, F., de 
Massy, B., Pialek, J., Forejt, J. and Trachtulec, Z. (2012) 'Interallelic and intergenic 
incompatibilities of the Prdm9 (Hst1) gene in mouse hybrid sterility', PLoS Genet, 8(11), 
p. e1003044. 
Fog, C.K., Galli, G.G. and Lund, A.H. (2012) 'PRDM proteins: important players in 
differentiation and disease', Bioessays, 34(1), pp. 50-60. 
Forejt, J., Vincek, V., Klein, J., Lehrach, H. and Loudova-Mickova, M. (1991) 'Genetic 
mapping of the t-complex region on mouse chromosome 17 including the Hybrid 
sterility-1 gene', Mamm Genome, 1(2), pp. 84-91. 
French, S.L., Santangelo, T.J., Beyer, A.L. and Reeve, J.N. (2007) 'Transcription and 
translation are coupled in Archaea', Mol Biol Evol, 24(4), pp. 893-5. 
Freyer, C., Cree, L.M., Mourier, A., Stewart, J.B., Koolmeister, C., Milenkovic, D., Wai, T., 
Floros, V.I., Hagstrom, E., Chatzidaki, E.E., Wiesner, R.J., Samuels, D.C., Larsson, N.G. and 
Chinnery, P.F. (2012) 'Variation in germline mtDNA heteroplasmy is determined 
prenatally but modified during subsequent transmission', Nat Genet, 44(11), pp. 1282-5. 
Fuhrmann, G., Chung, A.C., Jackson, K.J., Hummelke, G., Baniahmad, A., Sutter, J., 
Sylvester, I., Scholer, H.R. and Cooney, A.J. (2001) 'Mouse germline restriction of Oct4 
expression by germ cell nuclear factor', Dev Cell, 1(3), pp. 377-87. 
 248 
 
Fuste, J.M., Wanrooij, S., Jemt, E., Granycome, C.E., Cluett, T.J., Shi, Y., Atanassova, N., Holt, 
I.J., Gustafsson, C.M. and Falkenberg, M. (2010) 'Mitochondrial RNA polymerase is 
needed for activation of the origin of light-strand DNA replication', Mol Cell, 37(1), pp. 
67-78. 
Ghosh, S., Sengupta, S. and Scaria, V. (2014) 'Comparative analysis of human 
mitochondrial methylomes shows distinct patterns of epigenetic regulation in 
mitochondria', Mitochondrion, 18, pp. 58-62. 
Giordano, C., Iommarini, L., Giordano, L., Maresca, A., Pisano, A., Valentino, M.L., Caporali, 
L., Liguori, R., Deceglie, S., Roberti, M., Fanelli, F., Fracasso, F., Ross-Cisneros, F.N., 
D'Adamo, P., Hudson, G., Pyle, A., Yu-Wai-Man, P., Chinnery, P.F., Zeviani, M., Salomao, 
S.R., Berezovsky, A., Belfort, R., Jr., Ventura, D.F., Moraes, M., Moraes Filho, M., Barboni, P., 
Sadun, F., De Negri, A., Sadun, A.A., Tancredi, A., Mancini, M., d'Amati, G., Loguercio 
Polosa, P., Cantatore, P. and Carelli, V. (2014) 'Efficient mitochondrial biogenesis drives 
incomplete penetrance in Leber's hereditary optic neuropathy', Brain, 137(Pt 2), pp. 
335-53. 
Gitschlag, B.L., Kirby, C.S., Samuels, D.C., Gangula, R.D., Mallal, S.A. and Patel, M.R. (2016) 
'Homeostatic Responses Regulate Selfish Mitochondrial Genome Dynamics in C. elegans', 
Cell Metab, 24(1), pp. 91-103. 
Gomez-Duran, A., Pacheu-Grau, D., Lopez-Gallardo, E., Diez-Sanchez, C., Montoya, J., 
Lopez-Perez, M.J. and Ruiz-Pesini, E. (2010) 'Unmasking the causes of multifactorial 
disorders: OXPHOS differences between mitochondrial haplogroups', Hum Mol Genet, 
19(17), pp. 3343-53. 
Gomez-Duran, A., Pacheu-Grau, D., Martinez-Romero, I., Lopez-Gallardo, E., Lopez-Perez, 
M.J., Montoya, J. and Ruiz-Pesini, E. (2012) 'Oxidative phosphorylation differences 
between mitochondrial DNA haplogroups modify the risk of Leber's hereditary optic 
neuropathy', Biochim Biophys Acta, 1822(8), pp. 1216-22. 
Goncalves, C., Akhter, S., Pichon, C. and Midoux, P. (2016) 'Intra-cellular availability of 
pDNA and mRNA after transfection: A comparative study in between polyplexes, 
lipoplexes and lipopolyplexes', Mol Pharm. 
Goto, Y., Nonaka, I. and Horai, S. (1990) 'A mutation in the tRNA(Leu)(UUR) gene 
associated with the MELAS subgroup of mitochondrial encephalomyopathies', Nature, 
348(6302), pp. 651-3. 
Gould, M.P., Bosworth, C.M., McMahon, S., Grandhi, S., Grimerg, B.T. and LaFramboise, T. 
(2015) 'PCR-Free Enrichment of Mitochondrial DNA from Human Blood and Cell Lines 
for High Quality Next-Generation DNA Sequencing', PLoS One, 10(10), p. e0139253. 
Grady, J.P., Campbell, G., Ratnaike, T., Blakely, E.L., Falkous, G., Nesbitt, V., Schaefer, A.M., 
McNally, R.J., Gorman, G.S., Taylor, R.W., Turnbull, D.M. and McFarland, R. (2014) 
'Disease progression in patients with single, large-scale mitochondrial DNA deletions', 
Brain, 137(Pt 2), pp. 323-34. 
 249 
 
Grey, C., Barthes, P., Chauveau-Le Friec, G., Langa, F., Baudat, F. and de Massy, B. (2011) 
'Mouse PRDM9 DNA-binding specificity determines sites of histone H3 lysine 4 
trimethylation for initiation of meiotic recombination', PLoS Biol, 9(10), p. e1001176. 
Groeneveld, L.F., Atencia, R., Garriga, R.M. and Vigilant, L. (2012) 'High diversity at 
PRDM9 in chimpanzees and bonobos', PLoS One, 7(7), p. e39064. 
Guantes, R., Rastrojo, A., Neves, R., Lima, A., Aguado, B. and Iborra, F.J. (2015) 'Global 
variability in gene expression and alternative splicing is modulated by mitochondrial 
content', Genome Res, 25(5), pp. 633-44. 
Hammond, S.M., Boettcher, S., Caudy, A.A., Kobayashi, R. and Hannon, G.J. (2001) 
'Argonaute2, a link between genetic and biochemical analyses of RNAi', Science, 
293(5532), pp. 1146-50. 
Han, Y.H., Moon, H.J., You, B.R. and Park, W.H. (2009) 'The effect of MG132, a proteasome 
inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH', Oncol 
Rep, 22(1), pp. 215-21. 
Hashimoto, Y., Kondo, C. and Katunuma, N. (2015) 'An Active 32-kDa Cathepsin L Is 
Secreted Directly from HT 1080 Fibrosarcoma Cells and Not via Lysosomal Exocytosis', 
PLoS One, 10(12), p. e0145067. 
Hayashi, K., Yoshida, K. and Matsui, Y. (2005) 'A histone H3 methyltransferase controls 
epigenetic events required for meiotic prophase', Nature, 438(7066), pp. 374-8. 
Hayflick, L. (1965) 'The Limited in Vitro Lifetime of Human Diploid Cell Strains', Exp Cell 
Res, 37, pp. 614-36. 
Hazkani-Covo, E. and Covo, S. (2008) 'Numt-mediated double-strand break repair 
mitigates deletions during primate genome evolution', PLoS Genet, 4(10), p. e1000237. 
He, X.J., Ruan, J., Du, W.D., Cao, Y.X., Chen, G., Zuo, X.B., Peng, Y.W., Wu, H., Song, B. and 
Zhang, X.J. (2013) 'PRDM9 gene polymorphism may not be associated with defective 
spermatogenesis in the Chinese Han population', Syst Biol Reprod Med, 59(1), pp. 38-41. 
Hillen, W. and Berens, C. (1994) 'Mechanisms underlying expression of Tn10 encoded 
tetracycline resistance', Annu Rev Microbiol, 48, pp. 345-69. 
Hillman, B.I., Carrington, J.C. and Morris, T.J. (1987) 'A defective interfering RNA that 
contains a mosaic of a plant virus genome', Cell, 51(3), pp. 427-33. 
Hinch, A.G., Tandon, A., Patterson, N., Song, Y., Rohland, N., Palmer, C.D., Chen, G.K., Wang, 
K., Buxbaum, S.G., Akylbekova, E.L., Aldrich, M.C., Ambrosone, C.B., Amos, C., Bandera, 
E.V., Berndt, S.I., Bernstein, L., Blot, W.J., Bock, C.H., Boerwinkle, E., Cai, Q., Caporaso, N., 
Casey, G., Cupples, L.A., Deming, S.L., Diver, W.R., Divers, J., Fornage, M., Gillanders, E.M., 
Glessner, J., Harris, C.C., Hu, J.J., Ingles, S.A., Isaacs, W., John, E.M., Kao, W.H., Keating, B., 
Kittles, R.A., Kolonel, L.N., Larkin, E., Le Marchand, L., McNeill, L.H., Millikan, R.C., 
Murphy, A., Musani, S., Neslund-Dudas, C., Nyante, S., Papanicolaou, G.J., Press, M.F., 
Psaty, B.M., Reiner, A.P., Rich, S.S., Rodriguez-Gil, J.L., Rotter, J.I., Rybicki, B.A., Schwartz, 
 250 
 
A.G., Signorello, L.B., Spitz, M., Strom, S.S., Thun, M.J., Tucker, M.A., Wang, Z., Wiencke, J.K., 
Witte, J.S., Wrensch, M., Wu, X., Yamamura, Y., Zanetti, K.A., Zheng, W., Ziegler, R.G., Zhu, 
X., Redline, S., Hirschhorn, J.N., Henderson, B.E., Taylor, H.A., Jr., Price, A.L., Hakonarson, 
H., Chanock, S.J., Haiman, C.A., Wilson, J.G., Reich, D. and Myers, S.R. (2011) 'The 
landscape of recombination in African Americans', Nature, 476(7359), pp. 170-5. 
Hinrichs, W., Kisker, C., Duvel, M., Muller, A., Tovar, K., Hillen, W. and Saenger, W. (1994) 
'Structure of the Tet repressor-tetracycline complex and regulation of antibiotic 
resistance', Science, 264(5157), pp. 418-20. 
Hjerpe, R., Bett, J.S., Keuss, M.J., Solovyova, A., McWilliams, T.G., Johnson, C., Sahu, I., 
Varghese, J., Wood, N., Wightman, M., Osborne, G., Bates, G.P., Glickman, M.H., Trost, M., 
Knebel, A., Marchesi, F. and Kurz, T. (2016) 'UBQLN2 Mediates Autophagy-Independent 
Protein Aggregate Clearance by the Proteasome', Cell. 
Howe, D.G., Bradford, Y.M., Eagle, A., Fashena, D., Frazer, K., Kalita, P., Mani, P., Martin, R., 
Moxon, S.T., Paddock, H., Pich, C., Ramachandran, S., Ruzicka, L., Schaper, K., Shao, X., 
Singer, A., Toro, S., Van Slyke, C. and Westerfield, M. (2017) 'The Zebrafish Model 
Organism Database: new support for human disease models, mutation details, gene 
expression phenotypes and searching', Nucleic Acids Res, 45(D1), pp. D758-D768. 
Howell, N., Herrnstadt, C., Shults, C. and Mackey, D.A. (2003) 'Low penetrance of the 
14484 LHON mutation when it arises in a non-haplogroup J mtDNA background', Am J 
Med Genet A, 119A(2), pp. 147-51. 
Huang, C.Y., Grunheit, N., Ahmadinejad, N., Timmis, J.N. and Martin, W. (2005) 
'Mutational decay and age of chloroplast and mitochondrial genomes transferred 
recently to angiosperm nuclear chromosomes', Plant Physiol, 138(3), pp. 1723-33. 
Huang, S., Shao, G. and Liu, L. (1998) 'The PR domain of the Rb-binding zinc finger 
protein RIZ1 is a protein binding interface and is related to the SET domain functioning 
in chromatin-mediated gene expression', J Biol Chem, 273(26), pp. 15933-9. 
Hudson, G., Carelli, V., Spruijt, L., Gerards, M., Mowbray, C., Achilli, A., Pyle, A., Elson, J., 
Howell, N., La Morgia, C., Valentino, M.L., Huoponen, K., Savontaus, M.L., Nikoskelainen, 
E., Sadun, A.A., Salomao, S.R., Belfort, R., Jr., Griffiths, P., Yu-Wai-Man, P., de Coo, R.F., 
Horvath, R., Zeviani, M., Smeets, H.J., Torroni, A. and Chinnery, P.F. (2007) 'Clinical 
expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-
haplogroup background', Am J Hum Genet, 81(2), pp. 228-33. 
Hudson, G., Gomez-Duran, A., Wilson, I.J. and Chinnery, P.F. (2014) 'Recent 
mitochondrial DNA mutations increase the risk of developing common late-onset human 
diseases', PLoS Genet, 10(5), p. e1004369. 
Hunter, S.E., Gustafson, M.A., Margillo, K.M., Lee, S.A., Ryde, I.T. and Meyer, J.N. (2012) 'In 
vivo repair of alkylating and oxidative DNA damage in the mitochondrial and nuclear 
genomes of wild-type and glycosylase-deficient Caenorhabditis elegans', DNA Repair 
(Amst), 11(11), pp. 857-63. 
 251 
 
Hussin, J., Sinnett, D., Casals, F., Idaghdour, Y., Bruat, V., Saillour, V., Healy, J., Grenier, J.C., 
de Malliard, T., Busche, S., Spinella, J.F., Lariviere, M., Gibson, G., Andersson, A., Holmfeldt, 
L., Ma, J., Wei, L., Zhang, J., Andelfinger, G., Downing, J.R., Mullighan, C.G. and Awadalla, P. 
(2013) 'Rare allelic forms of PRDM9 associated with childhood leukemogenesis', 
Genome Res, 23(3), pp. 419-30. 
Hutvagner, G. and Zamore, P.D. (2002) 'A microRNA in a multiple-turnover RNAi enzyme 
complex', Science, 297(5589), pp. 2056-60. 
Ikeda, M., Ide, T., Fujino, T., Arai, S., Saku, K., Kakino, T., Tyynismaa, H., Yamasaki, T., 
Yamada, K., Kang, D., Suomalainen, A. and Sunagawa, K. (2015) 'Overexpression of TFAM 
or twinkle increases mtDNA copy number and facilitates cardioprotection associated 
with limited mitochondrial oxidative stress', PLoS One, 10(3), p. e0119687. 
Irie, S., Tsujimura, A., Miyagawa, Y., Ueda, T., Matsuoka, Y., Matsui, Y., Okuyama, A., 
Nishimune, Y. and Tanaka, H. (2009) 'Single-nucleotide polymorphisms of the PRDM9 
(MEISETZ) gene in patients with nonobstructive azoospermia', J Androl, 30(4), pp. 426-
31. 
Ishmukhametova, A., Chen, J.M., Bernard, R., de Massy, B., Baudat, F., Boyer, A., Mechin, 
D., Thorel, D., Chabrol, B., Vincent, M.C., Khau Van Kien, P., Claustres, M. and Tuffery-
Giraud, S. (2013) 'Dissecting the structure and mechanism of a complex duplication-
triplication rearrangement in the DMD gene', Hum Mutat, 34(8), pp. 1080-4. 
Jafari, M., Soltani, M., Naahidi, S., Karunaratne, D.N. and Chen, P. (2012) 'Nonviral 
approach for targeted nucleic acid delivery', Curr Med Chem, 19(2), pp. 197-208. 
Jeffreys, A.J., Cotton, V.E., Neumann, R. and Lam, K.W. (2013) 'Recombination regulator 
PRDM9 influences the instability of its own coding sequence in humans', Proc Natl Acad 
Sci U S A, 110(2), pp. 600-5. 
Jensen, K.L. and Russell, P. (2016) 'Ctp1-dependent clipping and resection of DNA 
double-strand breaks by Mre11 endonuclease complex are not genetically separable', 
Nucleic Acids Res. 
Jia, L., Li, J., He, B., Jia, Y., Niu, Y., Wang, C. and Zhao, R. (2016) 'Abnormally activated one-
carbon metabolic pathway is associated with mtDNA hypermethylation and 
mitochondrial malfunction in the oocytes of polycystic gilt ovaries', Sci Rep, 6, p. 19436. 
Johns, D.R., Neufeld, M.J. and Park, R.D. (1992) 'An ND-6 mitochondrial DNA mutation 
associated with Leber hereditary optic neuropathy', Biochem Biophys Res Commun, 
187(3), pp. 1551-7. 
Ju, Y.S., Alexandrov, L.B., Gerstung, M., Martincorena, I., Nik-Zainal, S., Ramakrishna, M., 
Davies, H.R., Papaemmanuil, E., Gundem, G., Shlien, A., Bolli, N., Behjati, S., Tarpey, P.S., 
Nangalia, J., Massie, C.E., Butler, A.P., Teague, J.W., Vassiliou, G.S., Green, A.R., Du, M.Q., 
Unnikrishnan, A., Pimanda, J.E., Teh, B.T., Munshi, N., Greaves, M., Vyas, P., El-Naggar, 
A.K., Santarius, T., Collins, V.P., Grundy, R., Taylor, J.A., Hayes, D.N., Malkin, D., Group, 
I.B.C., Group, I.C.M.D., Group, I.P.C., Foster, C.S., Warren, A.Y., Whitaker, H.C., Brewer, D., 
Eeles, R., Cooper, C., Neal, D., Visakorpi, T., Isaacs, W.B., Bova, G.S., Flanagan, A.M., 
 252 
 
Futreal, P.A., Lynch, A.G., Chinnery, P.F., McDermott, U., Stratton, M.R. and Campbell, P.J. 
(2014) 'Origins and functional consequences of somatic mitochondrial DNA mutations 
in human cancer', Elife, 3. 
Ju, Y.S., Tubio, J.M., Mifsud, W., Fu, B., Davies, H.R., Ramakrishna, M., Li, Y., Yates, L., 
Gundem, G., Tarpey, P.S., Behjati, S., Papaemmanuil, E., Martin, S., Fullam, A., Gerstung, 
M., Group, I.P.C.W., Group, I.B.C.W., Group, I.B.C.W., Nangalia, J., Green, A.R., Caldas, C., 
Borg, A., Tutt, A., Lee, M.T., van't Veer, L.J., Tan, B.K., Aparicio, S., Span, P.N., Martens, J.W., 
Knappskog, S., Vincent-Salomon, A., Borresen-Dale, A.L., Eyfjord, J.E., Flanagan, A.M., 
Foster, C., Neal, D.E., Cooper, C., Eeles, R., Lakhani, S.R., Desmedt, C., Thomas, G., 
Richardson, A.L., Purdie, C.A., Thompson, A.M., McDermott, U., Yang, F., Nik-Zainal, S., 
Campbell, P.J. and Stratton, M.R. (2015) 'Frequent somatic transfer of mitochondrial 
DNA into the nuclear genome of human cancer cells', Genome Res, 25(6), pp. 814-24. 
Kajander, O.A., Rovio, A.T., Majamaa, K., Poulton, J., Spelbrink, J.N., Holt, I.J., Karhunen, P.J. 
and Jacobs, H.T. (2000) 'Human mtDNA sublimons resemble rearranged mitochondrial 
genoms found in pathological states', Hum Mol Genet, 9(19), pp. 2821-35. 
Kang, D., Miyako, K., Kai, Y., Irie, T. and Takeshige, K. (1997) 'In vivo determination of 
replication origins of human mitochondrial DNA by ligation-mediated polymerase chain 
reaction', J Biol Chem, 272(24), pp. 15275-9. 
Kenney, M.C., Chwa, M., Atilano, S.R., Falatoonzadeh, P., Ramirez, C., Malik, D., Tarek, M., 
Del Carpio, J.C., Nesburn, A.B., Boyer, D.S., Kuppermann, B.D., Vawter, M.P., Jazwinski, 
S.M., Miceli, M.V., Wallace, D.C. and Udar, N. (2014) 'Molecular and bioenergetic 
differences between cells with African versus European inherited mitochondrial DNA 
haplogroups: implications for population susceptibility to diseases', Biochim Biophys 
Acta, 1842(2), pp. 208-19. 
Kim, K.C., Geng, L. and Huang, S. (2003) 'Inactivation of a histone methyltransferase by 
mutations in human cancers', Cancer Res, 63(22), pp. 7619-23. 
Kirby, D.M., Thorburn, D.R., Turnbull, D.M. and Taylor, R.W. (2007) 'Biochemical assays 
of respiratory chain complex activity', Methods Cell Biol, 80, pp. 93-119. 
Kishita, Y., Pajak, A., Bolar, N.A., Marobbio, C.M., Maffezzini, C., Miniero, D.V., Monne, M., 
Kohda, M., Stranneheim, H., Murayama, K., Naess, K., Lesko, N., Bruhn, H., Mourier, A., 
Wibom, R., Nennesmo, I., Jespers, A., Govaert, P., Ohtake, A., Van Laer, L., Loeys, B.L., 
Freyer, C., Palmieri, F., Wredenberg, A., Okazaki, Y. and Wedell, A. (2015) 'Intra-
mitochondrial Methylation Deficiency Due to Mutations in SLC25A26', Am J Hum Genet, 
97(5), pp. 761-8. 
Kloss-Brandstatter, A., Pacher, D., Schonherr, S., Weissensteiner, H., Binna, R., Specht, G. 
and Kronenberg, F. (2011) 'HaploGrep: a fast and reliable algorithm for automatic 
classification of mitochondrial DNA haplogroups', Hum Mutat, 32(1), pp. 25-32. 
Komulainen, T., Hautakangas, M.R., Hinttala, R., Pakanen, S., Vahasarja, V., Lehenkari, P., 
Olsen, P., Vieira, P., Saarenpaa-Heikkila, O., Palmio, J., Tuominen, H., Kinnunen, P., 
Majamaa, K., Rantala, H. and Uusimaa, J. (2015) 'Mitochondrial DNA Depletion and 
 253 
 
Deletions in Paediatric Patients with Neuromuscular Diseases: Novel Phenotypes', JIMD 
Rep, 23, pp. 91-100. 
Kong, Q.P., Yao, Y.G., Sun, C., Bandelt, H.J., Zhu, C.L. and Zhang, Y.P. (2003) 'Phylogeny of 
east Asian mitochondrial DNA lineages inferred from complete sequences', Am J Hum 
Genet, 73(3), pp. 671-6. 
Koopman, W.J., Distelmaier, F., Smeitink, J.A. and Willems, P.H. (2013) 'OXPHOS 
mutations and neurodegeneration', EMBO J, 32(1), pp. 9-29. 
Krishnan, K.J. and Birch-Machin, M.A. (2006) 'The incidence of both tandem duplications 
and the common deletion in mtDNA from three distinct categories of sun-exposed 
human skin and in prolonged culture of fibroblasts', J Invest Dermatol, 126(2), pp. 408-
15. 
Krishnan, K.J., Reeve, A.K., Samuels, D.C., Chinnery, P.F., Blackwood, J.K., Taylor, R.W., 
Wanrooij, S., Spelbrink, J.N., Lightowlers, R.N. and Turnbull, D.M. (2008) 'What causes 
mitochondrial DNA deletions in human cells?', Nat Genet, 40(3), pp. 275-9. 
Ku, C., Nelson-Sathi, S., Roettger, M., Sousa, F.L., Lockhart, P.J., Bryant, D., Hazkani-Covo, 
E., McInerney, J.O., Landan, G. and Martin, W.F. (2015) 'Endosymbiotic origin and 
differential loss of eukaryotic genes', Nature, 524(7566), pp. 427-32. 
Kuhl, I., Miranda, M., Posse, V., Milenkovic, D., Mourier, A., Siira, S.J., Bonekamp, N.A., 
Neumann, U., Filipovska, A., Polosa, P.L., Gustafsson, C.M. and Larsson, N.G. (2016) 
'POLRMT regulates the switch between replication primer formation and gene 
expression of mammalian mtDNA', Sci Adv, 2(8), p. e1600963. 
Kukat, C., Davies, K.M., Wurm, C.A., Spahr, H., Bonekamp, N.A., Kuhl, I., Joos, F., Polosa, 
P.L., Park, C.B., Posse, V., Falkenberg, M., Jakobs, S., Kuhlbrandt, W. and Larsson, N.G. 
(2015) 'Cross-strand binding of TFAM to a single mtDNA molecule forms the 
mitochondrial nucleoid', Proc Natl Acad Sci U S A, 112(36), pp. 11288-93. 
Laemmli, U.K. (1970) 'Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4', Nature, 227(5259), pp. 680-5. 
Lange, J., Yamada, S., Tischfield, S.E., Pan, J., Kim, S., Zhu, X., Socci, N.D., Jasin, M. and 
Keeney, S. (2016) 'The Landscape of Mouse Meiotic Double-Strand Break Formation, 
Processing, and Repair', Cell, 167(3), pp. 695-708 e16. 
Lapuente-Brun, E., Moreno-Loshuertos, R., Acin-Perez, R., Latorre-Pellicer, A., Colas, C., 
Balsa, E., Perales-Clemente, E., Quiros, P.M., Calvo, E., Rodriguez-Hernandez, M.A., Navas, 
P., Cruz, R., Carracedo, A., Lopez-Otin, C., Perez-Martos, A., Fernandez-Silva, P., 
Fernandez-Vizarra, E. and Enriquez, J.A. (2013) 'Supercomplex assembly determines 
electron flux in the mitochondrial electron transport chain', Science, 340(6140), pp. 
1567-70. 
Larsson, N.G. and Holme, E. (1992) 'Multiple short direct repeats associated with single 
mtDNA deletions', Biochim Biophys Acta, 1139(4), pp. 311-4. 
 254 
 
Lesecque, Y., Glemin, S., Lartillot, N., Mouchiroud, D. and Duret, L. (2014) 'The red queen 
model of recombination hotspots evolution in the light of archaic and modern human 
genomes', PLoS Genet, 10(11), p. e1004790. 
Lester, R.L., Hatefi, Y., Widmer, C. and Crane, F.L. (1959) 'Studies on the electron 
transport system. XX. Chemical and physical properties of the coenzyme Q family of 
compounds', Biochim Biophys Acta, 33(1), pp. 169-85. 
Li, M., Schroeder, R., Ko, A. and Stoneking, M. (2012) 'Fidelity of capture-enrichment for 
mtDNA genome sequencing: influence of NUMTs', Nucleic Acids Res, 40(18), p. e137. 
Lightowlers, R.N., Taylor, R.W. and Turnbull, D.M. (2015) 'Mutations causing 
mitochondrial disease: What is new and what challenges remain?', Science, 349(6255), 
pp. 1494-9. 
Lin, I.Y., Chiu, F.L., Yeang, C.H., Chen, H.F., Chuang, C.Y., Yang, S.Y., Hou, P.S., Sintupisut, N., 
Ho, H.N., Kuo, H.C. and Lin, K.I. (2014) 'Suppression of the SOX2 Neural Effector Gene by 
PRDM1 Promotes Human Germ Cell Fate in Embryonic Stem Cells', Stem Cell Reports, 
2(2), pp. 189-204. 
Lin, Y.F., Schulz, A.M., Pellegrino, M.W., Lu, Y., Shaham, S. and Haynes, C.M. (2016) 
'Maintenance and propagation of a deleterious mitochondrial genome by the 
mitochondrial unfolded protein response', Nature, 533(7603), pp. 416-9. 
Liu, B., Du, Q., Chen, L., Fu, G., Li, S., Fu, L., Zhang, X., Ma, C. and Bin, C. (2016) 'CpG 
methylation patterns of human mitochondrial DNA', Sci Rep, 6, p. 23421. 
Liu, Y., Wu, C., Lyu, Q., Yang, D., Albertini, D.F., Keefe, D.L. and Liu, L. (2007) 'Germline 
stem cells and neo-oogenesis in the adult human ovary', Dev Biol, 306(1), pp. 112-20. 
Logan, A., Shabalina, I.G., Prime, T.A., Rogatti, S., Kalinovich, A.V., Hartley, R.C., Budd, R.C., 
Cannon, B. and Murphy, M.P. (2014) 'In vivo levels of mitochondrial hydrogen peroxide 
increase with age in mtDNA mutator mice', Aging Cell. 
Longley, M.J., Ropp, P.A., Lim, S.E. and Copeland, W.C. (1998) 'Characterization of the 
native and recombinant catalytic subunit of human DNA polymerase gamma: 
identification of residues critical for exonuclease activity and dideoxynucleotide 
sensitivity', Biochemistry, 37(29), pp. 10529-39. 
Lopez-Gallardo, E., Lopez-Perez, M.J., Montoya, J. and Ruiz-Pesini, E. (2009) 'CPEO and 
KSS differ in the percentage and location of the mtDNA deletion', Mitochondrion, 9(5), 
pp. 314-7. 
Luo, S.M., Ge, Z.J., Wang, Z.W., Jiang, Z.Z., Wang, Z.B., Ouyang, Y.C., Hou, Y., Schatten, H. 
and Sun, Q.Y. (2013) 'Unique insights into maternal mitochondrial inheritance in mice', 
Proc Natl Acad Sci U S A, 110(32), pp. 13038-43. 
Ma, H., Marti Gutierrez, N., Morey, R., Van Dyken, C., Kang, E., Hayama, T., Lee, Y., Li, Y., 
Tippner-Hedges, R., Wolf, D.P., Laurent, L.C. and Mitalipov, S. (2016) 'Incompatibility 
 255 
 
between Nuclear and Mitochondrial Genomes Contributes to an Interspecies 
Reproductive Barrier', Cell Metab, 24(2), pp. 283-94. 
Mackey, D. and Howell, N. (1992) 'A variant of Leber hereditary optic neuropathy 
characterized by recovery of vision and by an unusual mitochondrial genetic etiology', 
Am J Hum Genet, 51(6), pp. 1218-28. 
Magner, M., Kolarova, H., Honzik, T., Svandova, I. and Zeman, J. (2015) 'Clinical 
manifestation of mitochondrial diseases', Dev Period Med, 19(4), pp. 441-9. 
Magnusdottir, E., Dietmann, S., Murakami, K., Gunesdogan, U., Tang, F., Bao, S., Diamanti, 
E., Lao, K., Gottgens, B. and Azim Surani, M. (2013) 'A tripartite transcription factor 
network regulates primordial germ cell specification in mice', Nat Cell Biol, 15(8), pp. 
905-15. 
Malik, A.N., Czajka, A. and Cunningham, P. (2016) 'Accurate quantification of mouse 
mitochondrial DNA without co-amplification of nuclear mitochondrial insertion 
sequences', Mitochondrion, 29, pp. 59-64. 
Mancuso, M., Orsucci, D., Angelini, C., Bertini, E., Carelli, V., Comi, G.P., Donati, M.A., 
Federico, A., Minetti, C., Moggio, M., Mongini, T., Santorelli, F.M., Servidei, S., Tonin, P., 
Toscano, A., Bruno, C., Bello, L., Caldarazzo Ienco, E., Cardaioli, E., Catteruccia, M., Da 
Pozzo, P., Filosto, M., Lamperti, C., Moroni, I., Musumeci, O., Pegoraro, E., Ronchi, D., 
Sauchelli, D., Scarpelli, M., Sciacco, M., Valentino, M.L., Vercelli, L., Zeviani, M. and 
Siciliano, G. (2015) 'Redefining phenotypes associated with mitochondrial DNA single 
deletion', J Neurol, 262(5), pp. 1301-9. 
Marchington, D.R., Hartshorne, G.M., Barlow, D. and Poulton, J. (1997) 'Homopolymeric 
tract heteroplasmy in mtDNA from tissues and single oocytes: support for a genetic 
bottleneck', Am J Hum Genet, 60(2), pp. 408-16. 
McClintock, B. (1939) 'The Behavior in Successive Nuclear Divisions of a Chromosome 
Broken at Meiosis', Proc Natl Acad Sci U S A, 25(8), pp. 405-16. 
Mihola, O., Trachtulec, Z., Vlcek, C., Schimenti, J.C. and Forejt, J. (2009) 'A mouse 
speciation gene encodes a meiotic histone H3 methyltransferase', Science, 323(5912), 
pp. 373-5. 
Mita, S., Rizzuto, R., Moraes, C.T., Shanske, S., Arnaudo, E., Fabrizi, G.M., Koga, Y., 
DiMauro, S. and Schon, E.A. (1990) 'Recombination via flanking direct repeats is a major 
cause of large-scale deletions of human mitochondrial DNA', Nucleic Acids Res, 18(3), pp. 
561-7. 
Miyamoto, T., Koh, E., Sakugawa, N., Sato, H., Hayashi, H., Namiki, M. and Sengoku, K. 
(2008) 'Two single nucleotide polymorphisms in PRDM9 (MEISETZ) gene may be a 
genetic risk factor for Japanese patients with azoospermia by meiotic arrest', J Assist 
Reprod Genet, 25(11-12), pp. 553-7. 
Moullan, N., Mouchiroud, L., Wang, X., Ryu, D., Williams, E.G., Mottis, A., Jovaisaite, V., 
Frochaux, M.V., Quiros, P.M., Deplancke, B., Houtkooper, R.H. and Auwerx, J. (2015) 
 256 
 
'Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for 
Caution in Biomedical Research', Cell Rep. 
Muller, H.J. (1964) 'The Relation of Recombination to Mutational Advance', Mutat Res, 
106, pp. 2-9. 
Munoz-Fuentes, V., Di Rienzo, A. and Vila, C. (2011) 'Prdm9, a major determinant of 
meiotic recombination hotspots, is not functional in dogs and their wild relatives, wolves 
and coyotes', PLoS One, 6(11), p. e25498. 
Murakami, K., Gunesdogan, U., Zylicz, J.J., Tang, W.W., Sengupta, R., Kobayashi, T., Kim, S., 
Butler, R., Dietmann, S. and Surani, M.A. (2016) 'NANOG alone induces germ cells in 
primed epiblast in vitro by activation of enhancers', Nature, 529(7586), pp. 403-7. 
Myers, S., Bottolo, L., Freeman, C., McVean, G. and Donnelly, P. (2005) 'A fine-scale map 
of recombination rates and hotspots across the human genome', Science, 310(5746), pp. 
321-4. 
Myers, S., Bowden, R., Tumian, A., Bontrop, R.E., Freeman, C., MacFie, T.S., McVean, G. and 
Donnelly, P. (2010) 'Drive against hotspot motifs in primates implicates the PRDM9 
gene in meiotic recombination', Science, 327(5967), pp. 876-9. 
Myers, S., Freeman, C., Auton, A., Donnelly, P. and McVean, G. (2008) 'A common 
sequence motif associated with recombination hot spots and genome instability in 
humans', Nat Genet, 40(9), pp. 1124-9. 
Nakatsuji, N. and Chuma, S. (2001) 'Differentiation of mouse primordial germ cells into 
female or male germ cells', Int J Dev Biol, 45(3), pp. 541-8. 
Narasimhan, V.M., Hunt, K.A., Mason, D., Baker, C.L., Karczewski, K.J., Barnes, M.R., 
Barnett, A.H., Bates, C., Bellary, S., Bockett, N.A., Giorda, K., Griffiths, C.J., Hemingway, H., 
Jia, Z., Kelly, M.A., Khawaja, H.A., Lek, M., McCarthy, S., McEachan, R., O'Donnell-Luria, A., 
Paigen, K., Parisinos, C.A., Sheridan, E., Southgate, L., Tee, L., Thomas, M., Xue, Y., Schnall-
Levin, M., Petkov, P.M., Tyler-Smith, C., Maher, E.R., Trembath, R.C., MacArthur, D.G., 
Wright, J., Durbin, R. and van Heel, D.A. (2016) 'Health and population effects of rare 
gene knockouts in adult humans with related parents', Science, 352(6284), pp. 474-7. 
Nass, M.M. (1973) 'Differential methylation of mitochondrial and nuclear DNA in 
cultured mouse, hamster and virus-transformed hamster cells. In vivo and in vitro 
methylation', J Mol Biol, 80(1), pp. 155-75. 
Ni, K., Dansranjavin, T., Rogenhofer, N., Oeztuerk, N., Deuker, J., Bergmann, M., Schuppe, 
H.C., Wagenlehner, F., Weidner, W., Steger, K. and Schagdarsurengin, U. (2016) 'TET 
enzymes are successively expressed during human spermatogenesis and their 
expression level is pivotal for male fertility', Hum Reprod, 31(7), pp. 1411-24. 
Nikkanen, J., Forsstrom, S., Euro, L., Paetau, I., Kohnz, R.A., Wang, L., Chilov, D., Viinamaki, 
J., Roivainen, A., Marjamaki, P., Liljenback, H., Ahola, S., Buzkova, J., Terzioglu, M., Khan, 
N.A., Pirnes-Karhu, S., Paetau, A., Lonnqvist, T., Sajantila, A., Isohanni, P., Tyynismaa, H., 
Nomura, D.K., Battersby, B.J., Velagapudi, V., Carroll, C.J. and Suomalainen, A. (2016) 
 257 
 
'Mitochondrial DNA Replication Defects Disturb Cellular dNTP Pools and Remodel One-
Carbon Metabolism', Cell Metab, 23(4), pp. 635-48. 
Nunes, M.D., Dolezal, M. and Schlotterer, C. (2013) 'Extensive paternal mtDNA leakage in 
natural populations of Drosophila melanogaster', Mol Ecol, 22(8), pp. 2106-17. 
Nunnari, J. and Suomalainen, A. (2012) 'Mitochondria: in sickness and in health', Cell, 
148(6), pp. 1145-59. 
Ohinata, Y., Payer, B., O'Carroll, D., Ancelin, K., Ono, Y., Sano, M., Barton, S.C., Obukhanych, 
T., Nussenzweig, M., Tarakhovsky, A., Saitou, M. and Surani, M.A. (2005) 'Blimp1 is a 
critical determinant of the germ cell lineage in mice', Nature, 436(7048), pp. 207-13. 
Ojala, D., Montoya, J. and Attardi, G. (1981) 'tRNA punctuation model of RNA processing 
in human mitochondria', Nature, 290(5806), pp. 470-4. 
Okada, K., Inoue, A., Okada, M., Murata, Y., Kakuta, S., Jigami, T., Kubo, S., Shiraishi, H., 
Eguchi, K., Motomura, M., Akiyama, T., Iwakura, Y., Higuchi, O. and Yamanashi, Y. (2006) 
'The muscle protein Dok-7 is essential for neuromuscular synaptogenesis', Science, 
312(5781), pp. 1802-5. 
Otten, A.B., Theunissen, T.E., Derhaag, J.G., Lambrichs, E.H., Boesten, I.B., Winandy, M., 
van Montfoort, A.P., Tarbashevich, K., Raz, E., Gerards, M., Vanoevelen, J.M., van den 
Bosch, B.J., Muller, M. and Smeets, H.J. (2016) 'Differences in Strength and Timing of the 
mtDNA Bottleneck between Zebrafish Germline and Non-germline Cells', Cell Rep, 16(3), 
pp. 622-30. 
P, Y.W.-M., Griffiths, P.G., Brown, D.T., Howell, N., Turnbull, D.M. and Chinnery, P.F. 
(2003) 'The epidemiology of Leber hereditary optic neuropathy in the North East of 
England', Am J Hum Genet, 72(2), pp. 333-9. 
Pagliarini, D.J., Calvo, S.E., Chang, B., Sheth, S.A., Vafai, S.B., Ong, S.E., Walford, G.A., 
Sugiana, C., Boneh, A., Chen, W.K., Hill, D.E., Vidal, M., Evans, J.G., Thorburn, D.R., Carr, S.A. 
and Mootha, V.K. (2008) 'A mitochondrial protein compendium elucidates complex I 
disease biology', Cell, 134(1), pp. 112-23. 
Papa, S., Martino, P.L., Capitanio, G., Gaballo, A., De Rasmo, D., Signorile, A. and 
Petruzzella, V. (2012) 'The oxidative phosphorylation system in mammalian 
mitochondria', Adv Exp Med Biol, 942, pp. 3-37. 
Parfrey, L.W., Lahr, D.J., Knoll, A.H. and Katz, L.A. (2011) 'Estimating the timing of early 
eukaryotic diversification with multigene molecular clocks', Proc Natl Acad Sci U S A, 
108(33), pp. 13624-9. 
Park, J., Lai, L., Samuel, M.S., Wax, D., Prather, R.S. and Tian, X. (2015) 'Disruption of 
Mitochondrion-To-Nucleus Interaction in Deceased Cloned Piglets', PLoS One, 10(6), p. 
e0129378. 
Parvanov, E.D., Petkov, P.M. and Paigen, K. (2010) 'Prdm9 controls activation of 
mammalian recombination hotspots', Science, 327(5967), p. 835. 
 258 
 
Patel, A., Horton, J.R., Wilson, G.G., Zhang, X. and Cheng, X. (2016) 'Structural basis for 
human PRDM9 action at recombination hot spots', Genes Dev, 30(3), pp. 257-65. 
Paulsson, K., An, Q., Moorman, A.V., Parker, H., Molloy, G., Davies, T., Griffiths, M., Ross, 
F.M., Irving, J., Harrison, C.J., Young, B.D. and Strefford, J.C. (2009) 'Methylation of tumour 
suppressor gene promoters in the presence and absence of transcriptional silencing in 
high hyperdiploid acute lymphoblastic leukaemia', Br J Haematol, 144(6), pp. 838-47. 
Pavlakis, S.G., Phillips, P.C., DiMauro, S., De Vivo, D.C. and Rowland, L.P. (1984) 
'Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a 
distinctive clinical syndrome', Ann Neurol, 16(4), pp. 481-8. 
Payne, B.A., Wilson, I.J., Yu-Wai-Man, P., Coxhead, J., Deehan, D., Horvath, R., Taylor, R.W., 
Samuels, D.C., Santibanez-Koref, M. and Chinnery, P.F. (2013) 'Universal heteroplasmy of 
human mitochondrial DNA', Hum Mol Genet, 22(2), pp. 384-90. 
Pedersen, N.M., Thorvaldsen, T.E., Schultz, S.W., Wenzel, E.M. and Stenmark, H. (2016) 
'Formation of Tankyrase Inhibitor-Induced Degradasomes Requires Proteasome 
Activity', PLoS One, 11(8), p. e0160507. 
PhyloTree www.phylotree.org. 
Poecheim, J., Barnier-Quer, C., Collin, N. and Borchard, G. (2016) 'Ag85A DNA Vaccine 
Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune 
Responses', Vaccines (Basel), 4(3). 
Pohjoismaki, J.L., Holmes, J.B., Wood, S.R., Yang, M.Y., Yasukawa, T., Reyes, A., Bailey, L.J., 
Cluett, T.J., Goffart, S., Willcox, S., Rigby, R.E., Jackson, A.P., Spelbrink, J.N., Griffith, J.D., 
Crouch, R.J., Jacobs, H.T. and Holt, I.J. (2010) 'Mammalian mitochondrial DNA replication 
intermediates are essentially duplex but contain extensive tracts of RNA/DNA hybrid', J 
Mol Biol, 397(5), pp. 1144-55. 
Pollack, Y., Kasir, J., Shemer, R., Metzger, S. and Szyf, M. (1984) 'Methylation pattern of 
mouse mitochondrial DNA', Nucleic Acids Res, 12(12), pp. 4811-24. 
Poulton, J., Deadman, M.E., Bindoff, L., Morten, K., Land, J. and Brown, G. (1993) 'Families 
of mtDNA re-arrangements can be detected in patients with mtDNA deletions: 
duplications may be a transient intermediate form', Hum Mol Genet, 2(1), pp. 23-30. 
Poulton, J., Deadman, M.E., Ramacharan, S. and Gardiner, R.M. (1991) 'Germ-line 
deletions of mtDNA in mitochondrial myopathy', Am J Hum Genet, 48(4), pp. 649-53. 
Powers, N.R., Parvanov, E.D., Baker, C.L., Walker, M., Petkov, P.M. and Paigen, K. (2016) 
'The Meiotic Recombination Activator PRDM9 Trimethylates Both H3K36 and H3K4 at 
Recombination Hotspots In Vivo', PLoS Genet, 12(6), p. e1006146. 
Prasad, T.K., Gopal, V. and Madhusudhana Rao, N. (2003) 'Structural changes in DNA 
mediated by cationic lipids alter in vitro transcriptional activity at low charge ratios', 
Biochim Biophys Acta, 1619(1), pp. 59-69. 
 259 
 
Pyle, A., Hudson, G., Wilson, I.J., Coxhead, J., Smertenko, T., Herbert, M., Santibanez-Koref, 
M. and Chinnery, P.F. (2015) 'Extreme-Depth Re-sequencing of Mitochondrial DNA Finds 
No Evidence of Paternal Transmission in Humans', PLoS Genet, 11(5), p. e1005040. 
Rajala, N., Hensen, F., Wessels, H.J., Ives, D., Gloerich, J. and Spelbrink, J.N. (2015) 'Whole 
cell formaldehyde cross-linking simplifies purification of mitochondrial nucleoids and 
associated proteins involved in mitochondrial gene expression', PLoS One, 10(2), p. 
e0116726. 
Rao, D.D. and Huang, A.S. (1979) 'Synthesis of a small RNA in cells coinfected by 
standard and defective interfering particles of vesicular stomatitis virus', Proc Natl Acad 
Sci U S A, 76(8), pp. 3742-5. 
Raymann, K., Brochier-Armanet, C. and Gribaldo, S. (2015) 'The two-domain tree of life 
is linked to a new root for the Archaea', Proc Natl Acad Sci U S A, 112(21), pp. 6670-5. 
Reyes, A., Kazak, L., Wood, S.R., Yasukawa, T., Jacobs, H.T. and Holt, I.J. (2013) 
'Mitochondrial DNA replication proceeds via a 'bootlace' mechanism involving the 
incorporation of processed transcripts', Nucleic Acids Res, 41(11), pp. 5837-50. 
Ricchetti, M., Fairhead, C. and Dujon, B. (1999) 'Mitochondrial DNA repairs double-
strand breaks in yeast chromosomes', Nature, 402(6757), pp. 96-100. 
Richards, M., Macaulay, V., Hickey, E., Vega, E., Sykes, B., Guida, V., Rengo, C., Sellitto, D., 
Cruciani, F., Kivisild, T., Villems, R., Thomas, M., Rychkov, S., Rychkov, O., Rychkov, Y., 
Golge, M., Dimitrov, D., Hill, E., Bradley, D., Romano, V., Cali, F., Vona, G., Demaine, A., 
Papiha, S., Triantaphyllidis, C., Stefanescu, G., Hatina, J., Belledi, M., Di Rienzo, A., 
Novelletto, A., Oppenheim, A., Norby, S., Al-Zaheri, N., Santachiara-Benerecetti, S., 
Scozari, R., Torroni, A. and Bandelt, H.J. (2000) 'Tracing European founder lineages in 
the Near Eastern mtDNA pool', Am J Hum Genet, 67(5), pp. 1251-76. 
Roy, R., Chun, J. and Powell, S.N. (2012) 'BRCA1 and BRCA2: different roles in a common 
pathway of genome protection', Nat Rev Cancer, 12(1), pp. 68-78. 
Sadikovic, B., Wang, J., El-Hattab, A., Landsverk, M., Douglas, G., Brundage, E.K., Craigen, 
W.J., Schmitt, E.S. and Wong, L.J. (2010) 'Sequence homology at the breakpoint and 
clinical phenotype of mitochondrial DNA deletion syndromes', PLoS One, 5(12), p. 
e15687. 
Sallevelt, S.C., de Die-Smulders, C.E., Hendrickx, A.T., Hellebrekers, D.M., de Coo, I.F., 
Alston, C.L., Knowles, C., Taylor, R.W., McFarland, R. and Smeets, H.J. (2016) 'De novo 
mtDNA point mutations are common and have a low recurrence risk', J Med Genet. 
Samuels, D.C., Schon, E.A. and Chinnery, P.F. (2004) 'Two direct repeats cause most 
human mtDNA deletions', Trends Genet, 20(9), pp. 393-8. 
Sarbajna, S., Denniff, M., Jeffreys, A.J., Neumann, R., Soler Artigas, M., Veselis, A. and May, 
C.A. (2012) 'A major recombination hotspot in the XqYq pseudoautosomal region gives 
new insight into processing of human gene conversion events', Hum Mol Genet, 21(9), 
pp. 2029-38. 
 260 
 
Sasaki, K., Yokobayashi, S., Nakamura, T., Okamoto, I., Yabuta, Y., Kurimoto, K., Ohta, H., 
Moritoki, Y., Iwatani, C., Tsuchiya, H., Nakamura, S., Sekiguchi, K., Sakuma, T., Yamamoto, 
T., Mori, T., Woltjen, K., Nakagawa, M., Yamamoto, T., Takahashi, K., Yamanaka, S. and 
Saitou, M. (2015) 'Robust In Vitro Induction of Human Germ Cell Fate from Pluripotent 
Stem Cells', Cell Stem Cell, 17(2), pp. 178-94. 
Sato, M. and Sato, K. (2011) 'Degradation of paternal mitochondria by fertilization-
triggered autophagy in C. elegans embryos', Science, 334(6059), pp. 1141-4. 
Schaefer, A.M., Taylor, R.W., Turnbull, D.M. and Chinnery, P.F. (2004) 'The epidemiology 
of mitochondrial disorders--past, present and future', Biochim Biophys Acta, 1659(2-3), 
pp. 115-20. 
Scheible, M., Just, R., Sturk-Andreaggi, K., Saunier, J., Parson, W., Parsons, T., Coble, M. 
and Irwin, J. (2016) 'The mitochondrial landscape of African Americans: An examination 
of more than 2500 control region haplotypes from 22 U.S. locations', Forensic Sci Int 
Genet, 22, pp. 139-48. 
Schneider-Poetsch, T., Ju, J., Eyler, D.E., Dang, Y., Bhat, S., Merrick, W.C., Green, R., Shen, B. 
and Liu, J.O. (2010) 'Inhibition of eukaryotic translation elongation by cycloheximide 
and lactimidomycin', Nat Chem Biol, 6(3), pp. 209-217. 
Schon, E.A., DiMauro, S. and Hirano, M. (2012) 'Human mitochondrial DNA: roles of 
inherited and somatic mutations', Nat Rev Genet, 13(12), pp. 878-90. 
Schwartz, M. and Vissing, J. (2002) 'Paternal inheritance of mitochondrial DNA', N Engl J 
Med, 347(8), pp. 576-80. 
Seguin, S.J., Morelli, F.F., Vinet, J., Amore, D., De Biasi, S., Poletti, A., Rubinsztein, D.C. and 
Carra, S. (2014) 'Inhibition of autophagy, lysosome and VCP function impairs stress 
granule assembly', Cell Death Differ, 21(12), pp. 1838-51. 
Shimojima, K., Mano, T., Kashiwagi, M., Tanabe, T., Sugawara, M., Okamoto, N., Arai, H. 
and Yamamoto, T. (2012) 'Pelizaeus-Merzbacher disease caused by a duplication-
inverted triplication-duplication in chromosomal segments including the PLP1 region', 
Eur J Med Genet, 55(6-7), pp. 400-3. 
Shock, L.S., Thakkar, P.V., Peterson, E.J., Moran, R.G. and Taylor, S.M. (2011) 'DNA 
methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in 
mammalian mitochondria', Proc Natl Acad Sci U S A, 108(9), pp. 3630-5. 
Shoffner, J.M., Lott, M.T., Lezza, A.M., Seibel, P., Ballinger, S.W. and Wallace, D.C. (1990) 
'Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a 
mitochondrial DNA tRNA(Lys) mutation', Cell, 61(6), pp. 931-7. 
Shriver, M.D. and Kittles, R.A. (2004) 'Genetic ancestry and the search for personalized 
genetic histories', Nat Rev Genet, 5(8), pp. 611-8. 
Silva, M., Alshamali, F., Silva, P., Carrilho, C., Mandlate, F., Jesus Trovoada, M., Cerny, V., 
Pereira, L. and Soares, P. (2015) '60,000 years of interactions between Central and 
 261 
 
Eastern Africa documented by major African mitochondrial haplogroup L2', Sci Rep, 5, p. 
12526. 
Singhal, N.K., Li, S., Arning, E., Alkhayer, K., Clements, R., Sarcyk, Z., Dassanayake, R.S., 
Brasch, N.E., Freeman, E.J., Bottiglieri, T. and McDonough, J. (2015) 'Changes in 
Methionine Metabolism and Histone H3 Trimethylation Are Linked to Mitochondrial 
Defects in Multiple Sclerosis', J Neurosci, 35(45), pp. 15170-86. 
Smagulova, F., Brick, K., Pu, Y., Camerini-Otero, R.D. and Petukhova, G.V. (2016) 
'Erratum: The evolutionary turnover of recombination hot spots contributes to 
speciation in mice', Genes Dev, 30(7), p. 871. 
Smeets, H.J. (2013) 'Preventing the transmission of mitochondrial DNA disorders: 
selecting the good guys or kicking out the bad guys', Reprod Biomed Online, 27(6), pp. 
599-610. 
Song, W., Zhao, W., Yang, Q., Wang, X., Jin, H., Yao, G., Peng, Z., Shi, S., Yang, H. and Sun, Y. 
(2016a) 'Effect of rapid cryopreservation on meiotic recombination in human 
spermatocytes', Microsc Res Tech. 
Song, W.H., Yi, Y.J., Sutovsky, M., Meyers, S. and Sutovsky, P. (2016b) 'Autophagy and 
ubiquitin-proteasome system contribute to sperm mitophagy after mammalian 
fertilization', Proc Natl Acad Sci U S A. 
Soto-Calderon, I.D., Lee, E.J., Jensen-Seaman, M.I. and Anthony, N.M. (2012) 'Factors 
affecting the relative abundance of nuclear copies of mitochondrial DNA (numts) in 
hominoids', J Mol Evol, 75(3-4), pp. 102-11. 
Spang, A., Saw, J.H., Jorgensen, S.L., Zaremba-Niedzwiedzka, K., Martijn, J., Lind, A.E., van 
Eijk, R., Schleper, C., Guy, L. and Ettema, T.J. (2015) 'Complex archaea that bridge the gap 
between prokaryotes and eukaryotes', Nature, 521(7551), pp. 173-9. 
Speijer, D., Lukes, J. and Elias, M. (2015) 'Sex is a ubiquitous, ancient, and inherent 
attribute of eukaryotic life', Proc Natl Acad Sci U S A, 112(29), pp. 8827-34. 
Spelbrink, J.N., Li, F.Y., Tiranti, V., Nikali, K., Yuan, Q.P., Tariq, M., Wanrooij, S., Garrido, N., 
Comi, G., Morandi, L., Santoro, L., Toscano, A., Fabrizi, G.M., Somer, H., Croxen, R., Beeson, 
D., Poulton, J., Suomalainen, A., Jacobs, H.T., Zeviani, M. and Larsson, C. (2001) 'Human 
mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a 
phage T7 gene 4-like protein localized in mitochondria', Nat Genet, 28(3), pp. 223-31. 
Starikovskaya, Y.B., Sukernik, R.I., Schurr, T.G., Kogelnik, A.M. and Wallace, D.C. (1998) 
'mtDNA diversity in Chukchi and Siberian Eskimos: implications for the genetic history 
of Ancient Beringia and the peopling of the New World', Am J Hum Genet, 63(5), pp. 
1473-91. 
Steiner, C.C. and Ryder, O.A. (2013) 'Characterization of Prdm9 in equids and sterility in 
mules', PLoS One, 8(4), p. e61746. 
 262 
 
Stiles, A.R., Simon, M.T., Stover, A., Eftekharian, S., Khanlou, N., Wang, H.L., Magaki, S., 
Lee, H., Partynski, K., Dorrani, N., Chang, R., Martinez-Agosto, J.A. and Abdenur, J.E. 
(2016) 'Mutations in TFAM, encoding mitochondrial transcription factor A, cause 
neonatal liver failure associated with mtDNA depletion', Mol Genet Metab. 
Stirling, D. (2003) 'Technical notes for sequencing difficult templates', Methods Mol Biol, 
226, pp. 401-2. 
Stock, D., Leslie, A.G. and Walker, J.E. (1999) 'Molecular architecture of the rotary motor 
in ATP synthase', Science, 286(5445), pp. 1700-5. 
Sumegi, B. and Srere, P.A. (1984) 'Complex I binds several mitochondrial NAD-coupled 
dehydrogenases', J Biol Chem, 259(24), pp. 15040-5. 
Sun, F., Fujiwara, Y., Reinholdt, L.G., Hu, J., Saxl, R.L., Baker, C.L., Petkov, P.M., Paigen, K. 
and Handel, M.A. (2015) 'Nuclear localization of PRDM9 and its role in meiotic 
chromatin modifications and homologous synapsis', Chromosoma, 124(3), pp. 397-415. 
Suzuki, H., Owada, Y., Watanabe, Y., Inoue, T., Fukuharav, M., Yamaura, T., Mutoh, S., 
Okabe, N., Yaginuma, H., Hasegawa, T., Yonechi, A., Ohsugi, J., Hoshino, M., Higuchi, M., 
Shio, Y. and Gotoh, M. (2013) 'Recent advances in immunotherapy for non-small-cell 
lung cancer', Hum Vaccin Immunother, 10(2). 
Tang, S., Wang, J., Zhang, V.W., Li, F.Y., Landsverk, M., Cui, H., Truong, C.K., Wang, G., Chen, 
L.C., Graham, B., Scaglia, F., Schmitt, E.S., Craigen, W.J. and Wong, L.J. (2013) 'Transition 
to next generation analysis of the whole mitochondrial genome: a summary of molecular 
defects', Hum Mutat, 34(6), pp. 882-93. 
Tang, W.W., Dietmann, S., Irie, N., Leitch, H.G., Floros, V.I., Bradshaw, C.R., Hackett, J.A., 
Chinnery, P.F. and Surani, M.A. (2015) 'A Unique Gene Regulatory Network Resets the 
Human Germline Epigenome for Development', Cell, 161(6), pp. 1453-67. 
Taylor, R.W. and Turnbull, D.M. (2005) 'Mitochondrial DNA mutations in human 
disease', Nat Rev Genet, 6(5), pp. 389-402. 
Thomas, J.H., Emerson, R.O. and Shendure, J. (2009) 'Extraordinary molecular evolution 
in the PRDM9 fertility gene', PLoS One, 4(12), p. e8505. 
Thorslund, T., Esashi, F. and West, S.C. (2007) 'Interactions between human BRCA2 
protein and the meiosis-specific recombinase DMC1', EMBO J, 26(12), pp. 2915-22. 
Torroni, A., Huoponen, K., Francalacci, P., Petrozzi, M., Morelli, L., Scozzari, R., Obinu, D., 
Savontaus, M.L. and Wallace, D.C. (1996) 'Classification of European mtDNAs from an 
analysis of three European populations', Genetics, 144(4), pp. 1835-50. 
Torroni, A., Lott, M.T., Cabell, M.F., Chen, Y.S., Lavergne, L. and Wallace, D.C. (1994) 
'mtDNA and the origin of Caucasians: identification of ancient Caucasian-specific 
haplogroups, one of which is prone to a recurrent somatic duplication in the D-loop 
region', Am J Hum Genet, 55(4), pp. 760-76. 
 263 
 
Torroni, A., Richards, M., Macaulay, V., Forster, P., Villems, R., Norby, S., Savontaus, M.L., 
Huoponen, K., Scozzari, R. and Bandelt, H.J. (2000) 'mtDNA haplogroups and frequency 
patterns in Europe', Am J Hum Genet, 66(3), pp. 1173-7. 
Torroni, A., Schurr, T.G., Yang, C.C., Szathmary, E.J., Williams, R.C., Schanfield, M.S., Troup, 
G.A., Knowler, W.C., Lawrence, D.N., Weiss, K.M. and et al. (1992) 'Native American 
mitochondrial DNA analysis indicates that the Amerind and the Nadene populations 
were founded by two independent migrations', Genetics, 130(1), pp. 153-62. 
Torroni, A., Sukernik, R.I., Schurr, T.G., Starikorskaya, Y.B., Cabell, M.F., Crawford, M.H., 
Comuzzie, A.G. and Wallace, D.C. (1993) 'mtDNA variation of aboriginal Siberians reveals 
distinct genetic affinities with Native Americans', Am J Hum Genet, 53(3), pp. 591-608. 
Tranah, G.J., Santaniello, A., Caillier, S.J., D'Alfonso, S., Martinelli Boneschi, F., Hauser, S.L. 
and Oksenberg, J.R. (2015) 'Mitochondrial DNA sequence variation in multiple sclerosis', 
Neurology, 85(4), pp. 325-30. 
Tsuji, J., Frith, M.C., Tomii, K. and Horton, P. (2012) 'Mammalian NUMT insertion is non-
random', Nucleic Acids Res, 40(18), pp. 9073-88. 
Tyynismaa, H., Sembongi, H., Bokori-Brown, M., Granycome, C., Ashley, N., Poulton, J., 
Jalanko, A., Spelbrink, J.N., Holt, I.J. and Suomalainen, A. (2004) 'Twinkle helicase is 
essential for mtDNA maintenance and regulates mtDNA copy number', Hum Mol Genet, 
13(24), pp. 3219-27. 
van der Walt, E.M., Smuts, I., Taylor, R.W., Elson, J.L., Turnbull, D.M., Louw, R. and van der 
Westhuizen, F.H. (2012) 'Characterization of mtDNA variation in a cohort of South 
African paediatric patients with mitochondrial disease', Eur J Hum Genet, 20(6), pp. 650-
6. 
Van Goethem, G., Dermaut, B., Lofgren, A., Martin, J.J. and Van Broeckhoven, C. (2001) 
'Mutation of POLG is associated with progressive external ophthalmoplegia 
characterized by mtDNA deletions', Nat Genet, 28(3), pp. 211-2. 
van Oven, M. and Kayser, M. (2009) 'Updated comprehensive phylogenetic tree of global 
human mitochondrial DNA variation', Hum Mutat, 30(2), pp. E386-94. 
Vincent, S.D., Dunn, N.R., Sciammas, R., Shapiro-Shalef, M., Davis, M.M., Calame, K., Bikoff, 
E.K. and Robertson, E.J. (2005) 'The zinc finger transcriptional repressor Blimp1/Prdm1 
is dispensable for early axis formation but is required for specification of primordial 
germ cells in the mouse', Development, 132(6), pp. 1315-25. 
Wallace, D.C. (1992) 'Mitochondrial genetics: a paradigm for aging and degenerative 
diseases?', Science, 256(5057), pp. 628-32. 
Wallace, D.C., Garrison, K. and Knowler, W.C. (1985) 'Dramatic founder effects in 
Amerindian mitochondrial DNAs', Am J Phys Anthropol, 68(2), pp. 149-55. 
 264 
 
Weiss, J., Hurley, L.A., Harris, R.M., Finlayson, C., Tong, M., Fisher, L.A., Moran, J.L., Beier, 
D.R., Mason, C. and Jameson, J.L. (2012) 'ENU mutagenesis in mice identifies candidate 
genes for hypogonadism', Mamm Genome, 23(5-6), pp. 346-55. 
Wessels, H.J., Vogel, R.O., Lightowlers, R.N., Spelbrink, J.N., Rodenburg, R.J., van den 
Heuvel, L.P., van Gool, A.J., Gloerich, J., Smeitink, J.A. and Nijtmans, L.G. (2013) 'Analysis 
of 953 human proteins from a mitochondrial HEK293 fraction by complexome profiling', 
PLoS One, 8(7), p. e68340. 
West, A.P., Khoury-Hanold, W., Staron, M., Tal, M.C., Pineda, C.M., Lang, S.M., Bestwick, M., 
Duguay, B.A., Raimundo, N., MacDuff, D.A., Kaech, S.M., Smiley, J.R., Means, R.E., Iwasaki, 
A. and Shadel, G.S. (2015) 'Mitochondrial DNA stress primes the antiviral innate immune 
response', Nature, 520(7548), pp. 553-7. 
Wieckowski, M.R., Giorgi, C., Lebiedzinska, M., Duszynski, J. and Pinton, P. (2009) 
'Isolation of mitochondria-associated membranes and mitochondria from animal tissues 
and cells', Nat Protoc, 4(11), pp. 1582-90. 
Williams, T.A., Foster, P.G., Cox, C.J. and Embley, T.M. (2013) 'An archaeal origin of 
eukaryotes supports only two primary domains of life', Nature, 504(7479), pp. 231-6. 
Wilson, I.J., Carling, P.J., Alston, C.L., Floros, V.I., Pyle, A., Hudson, G., Sallevelt, S.C., 
Lamperti, C., Carelli, V., Bindoff, L.A., Samuels, D.C., Wonnapinij, P., Zeviani, M., Taylor, 
R.W., Smeets, H.J., Horvath, R. and Chinnery, P.F. (2016) 'Mitochondrial DNA sequence 
characteristics modulate the size of the genetic bottleneck', Hum Mol Genet, 25(5), pp. 
1031-41. 
Wockner, L.F., Morris, C.P., Noble, E.P., Lawford, B.R., Whitehall, V.L., Young, R.M. and 
Voisey, J. (2015) 'Brain-specific epigenetic markers of schizophrenia', Transl Psychiatry, 
5, p. e680. 
Woodward, E.L., Olsson, M.L., Johansson, B. and Paulsson, K. (2014) 'Allelic variants of 
PRDM9 associated with high hyperdiploid childhood acute lymphoblastic leukaemia', Br 
J Haematol. 
Wu, H., Mathioudakis, N., Diagouraga, B., Dong, A., Dombrovski, L., Baudat, F., Cusack, S., 
de Massy, B. and Kadlec, J. (2013) 'Molecular basis for the regulation of the H3K4 
methyltransferase activity of PRDM9', Cell Rep, 5(1), pp. 13-20. 
Yamaji, M., Seki, Y., Kurimoto, K., Yabuta, Y., Yuasa, M., Shigeta, M., Yamanaka, K., Ohinata, 
Y. and Saitou, M. (2008) 'Critical function of Prdm14 for the establishment of the germ 
cell lineage in mice', Nat Genet, 40(8), pp. 1016-22. 
Yamashita, S., Nishino, I., Nonaka, I. and Goto, Y. (2008) 'Genotype and phenotype 
analyses in 136 patients with single large-scale mitochondrial DNA deletions', J Hum 
Genet, 53(7), pp. 598-606. 
Yang, M.Y., Bowmaker, M., Reyes, A., Vergani, L., Angeli, P., Gringeri, E., Jacobs, H.T. and 
Holt, I.J. (2002) 'Biased incorporation of ribonucleotides on the mitochondrial L-strand 
accounts for apparent strand-asymmetric DNA replication', Cell, 111(4), pp. 495-505. 
 265 
 
Yao, F., Svensjo, T., Winkler, T., Lu, M., Eriksson, C. and Eriksson, E. (1998) 'Tetracycline 
repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion 
derivatives, regulates inducible gene expression in mammalian cells', Hum Gene Ther, 
9(13), pp. 1939-50. 
Yu-Wai-Man, P. and Chinnery, P.F. (2012) 'Dysfunctional mitochondrial maintenance: 
what breaks the circle of life?', Brain, 135(Pt 1), pp. 9-11. 
Zelazowski, M.J. and Cole, F. (2016) 'X marks the spot: PRDM9 rescues hybrid sterility by 
finding hidden treasure in the genome', Nat Struct Mol Biol, 23(4), pp. 267-9. 
Zhang, C., Xue, P., Gao, L., Chen, X., Lin, K., Yang, X., Dai, Y. and Xu, E.Y. (2016) 'Highly 
conserved epigenetic regulation of BOULE and DAZL is associated with human fertility', 
FASEB J. 
Zhang, D., Mott, J.L., Chang, S.W., Denniger, G., Feng, Z. and Zassenhaus, H.P. (2000) 
'Construction of transgenic mice with tissue-specific acceleration of mitochondrial DNA 
mutagenesis', Genomics, 69(2), pp. 151-61. 
Zheng, W., Khrapko, K., Coller, H.A., Thilly, W.G. and Copeland, W.C. (2006) 'Origins of 
human mitochondrial point mutations as DNA polymerase gamma-mediated errors', 
Mutat Res, 599(1-2), pp. 11-20. 
Zhou, Q., Li, H., Li, H., Nakagawa, A., Lin, J.L., Lee, E.S., Harry, B.L., Skeen-Gaar, R.R., 
Suehiro, Y., William, D., Mitani, S., Yuan, H.S., Kang, B.H. and Xue, D. (2016) 
'Mitochondrial endonuclease G mediates breakdown of paternal mitochondria upon 
fertilization', Science, 353(6297), pp. 394-9. 
Ziegler, D.M., Green, D.E. and Doeg, K.A. (1959) 'Studies on the electron transfer system. 
XXV. The isolation and properties of a lipoflavoprotein with diaphorase activity from 
beef heart mitochondria', J Biol Chem, 234(7), pp. 1916-21. 
Zoratti, M., Pietrobon, D. and Azzone, G.F. (1982) 'On the relationship between rate of 
ATP synthesis and H+ electrochemical gradient in rat-liver mitochondria', Eur J Biochem, 
126(3), pp. 443-51. 
 
 266 
 
Appendix A: Alignment of mtDNA deletion breakpoint data with 
PRDM9 motif sites 
 
Seven figures are presented below which show visual representations of alignment 
between the mtDNA deletion breakpoint data and PRDM9 motif sites as described in 
Section 4.3.3. 
 
 
Figure A.1 Visual representation of the alignment between deletion breakpoints and PRDM9 motif 2 sites 
within the mtDNA.  Images were generated using the UCSC genome browser. A) The whole image 
generated using this online tool. B) Magnified version of image A. C) Magnified version of image C. Blue 
arrows represent regions where there is visual alignment of the breakpoints and PRDM9 motif 2 sites. 
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Figure A.2 Visual representation of the alignment between deletion breakpoints and PRDM9 motif 4 sites 
within the mtDNA.  Images were generated using the UCSC genome browser. A) The whole image 
generated using this online tool. B) Magnified version of image A. C) Magnified version of image C. Blue 
arrows represent regions where there is visual alignment of the breakpoints and PRDM9 motif 4 sites. 
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Figure A.3 Visual representation of the alignment between deletion breakpoints and PRDM9 motif 5 sites 
within the mtDNA.  Images were generated using the UCSC genome browser. A) The whole image 
generated using this online tool. B) Magnified version of image A. C) Magnified version of image C. Blue 
arrows represent regions where there is visual alignment of the breakpoints and PRDM9 motif 5 sites. 
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Figure A.4 Visual representation of the alignment between deletion breakpoints and PRDM9 motif 6 sites 
within the mtDNA.  Images were generated using the UCSC genome browser. A) The whole image 
generated using this online tool. B) Magnified version of image A. C) Magnified version of image C. Blue 
arrows represent regions where there is visual alignment of the breakpoints and PRDM9 motif 6 sites. 
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Figure A.5 Visual representation of the alignment between deletion breakpoints and PRDM9 motif 7 sites 
within the mtDNA.  Images were generated using the UCSC genome browser. A) The whole image 
generated using this online tool. B) Magnified version of image A. C) Magnified version of image C. Blue 
arrows represent regions where there is visual alignment of the breakpoints and PRDM9 motif 7 sites. 
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Figure A.6 Visual representation of the alignment between deletion breakpoints and PRDM9 motif 9 sites 
within the mtDNA.  Images were generated using the UCSC genome browser. A) The whole image 
generated using this online tool. B) Magnified version of image A. C) Magnified version of image C. Blue 
arrows represent regions where there is visual alignment of the breakpoints and PRDM9 motif 9 sites. 
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Figure A.7 Visual representation of the alignment between deletion breakpoints and PRDM9 motif 11 sites 
within the mtDNA.  Images were generated using the UCSC genome browser. A) The whole image 
generated using this online tool. B) Magnified version of image A. C) Magnified version of image C. Blue 
arrows represent regions where there is visual alignment of the breakpoints and PRDM9 motif 11 sites. 
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Appendix B: PRDM9 ZnF genotyping data 
 
Two tables are presented below showing the genotyping data for the mtDNA single 
deletion patient cohort (Table B.1) and the control cohort (Table B.2) described in 
Chapter 5.  
     Repeat No.           
Patient ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Allele status 
10 A B C D D E C F G H F I J     A 
  A B C D D E C F T P F Q J     L24 
23 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
132 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
143 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
172 A B C D D E C F G H F I J     A 
  A B C D D C C F G H F I J     B 
192 A B C D D E C F G H F I J     A 
  A B C D D E C F G G F I J     A 
206 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
210 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
241 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
243 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
244 A B C D D E C F G H F I J   A 
  A B C D D C C F K H L H I J  C 
255 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     B 
289 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
319 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
347 A B C D D E C F G H F I J   A 
  A B C D D E C F G K F Q J   L20 
352 A B C D D E C F G H F I J     A 
  A B C D D E C F K G H F I J   D 
377 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
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379 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
380 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
381 A B C D D E C F G H F I J     A 
  A B C D D E C F T P F Q J     L24 
382 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
387 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
412 A B C D D E C F G H F I J     A 
  A B C D D E C F T P F Q J     L24 
449 A B C D D E C F G H F I J     A 
  A B C D D C C F G H F I J     B 
461 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
496 A B C D D E C F G H F I J     A 
  A B C D D E C F G P F Q J     L9 
498 A B C D D E C F G H F I J     A 
  A B C D D C F K H L H F I J   C 
499 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
527 A B C D D E C F G H F I J     A 
  A B C D H F I J         E 
564 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
590 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J    A 
612 A B C D D E C F G H F I J     A 
  A B C D D E C F G P F Q J     L9 
616 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
632 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J    A 
702 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
705 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
803 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
899 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
918 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
923 A B C D D E C F G H F I J     A 
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  A B C D D E C F T P F Q J     L24 
940 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
1020 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
1022 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
1051 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
1253 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
1360 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
1627 A B C D D D F C F G H F I J   C 
  A B C D D E C F G H F I J     A 
869 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F Q J     A 
103 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F F J     A 
 
Table B.1 Genotyping  analysis of single deletion patient cohort. PRDM9 ZnF repeat types are given in the 
order they appear on the amplicon and were designated a repeat type according to Berg et al 2012. 
 
 
     Repeat No.           
Control ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Allele status 
501                 
1 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
2 A B C D D E C F T P F Q J     L24 
  A B C D D C C F K H L H I J   C 
3 A B C D D E C F G P F Q J   L9 
  A B C D D E C F G H F I J     A 
4 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
5 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
6 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
7 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
8 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
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9 A B C D D E C F G H F I J     A 
  A B C D D E C F G K F Q J   L20 
10 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
11 A B C D D E C F G H F Q J     A 
  A B C D D C C F G H F I J   B 
12 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
13 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
14 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
15 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
16 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
17 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
18 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
19 A B C D D E C F G H F I J     A 
  A B C D D E C F T P F Q J   L24 
20 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
21 A B C D D E C F G H F I J   A 
  A B C D D E C F G H F I J     A 
22 A B C D D E C F G H F I J   A 
  A B C D D E C F G H F I J   A 
23 A B C D D E C F G H F I J     A 
  A B C D D E C F T P F Q J   L24 
24 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
601                 
1 A B C D D E C F G H F I J     A 
  A B C D D C C F G H F I J   B 
2 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
3 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
4 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
5 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
6 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
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7 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
8 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J   A 
9 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J    A 
10 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
11 A B C D D E C F G H F I J   A 
  A B C D D E C F G H F Q J   A 
12 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F Q J     A 
13 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F Q J     A 
14 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
15 A B C D D E C F G H F I J     A 
  A B C D D E C F G P F Q J   L9 
16 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J    A 
17 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J    A 
18 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J    A 
19 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J    A 
20 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J    A 
21 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F Q J     A 
22 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J    A 
23 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J    A 
24 A B C D D E C F G H F I J     A 
  A B C D D E C F G H F I J     A 
Table B.2 Genotyping  analysis of control cohort. PRDM9 ZnF repeat types are given in the order they 
appear on the amplicon and were designated a repeat type according to Berg et al 2012. 
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Appendix C: Histological staining 
 
To assess the quality of the ovary tissue samples compared to healthy control muscle 
tissue, hematoxylin and eosin (H & E) staining was performed (Figure C.1). Hematoxylin 
stains the cell nuclei whilst eosin counterstains, showing tissue morphology. Staining 
cryosections of the ovary samples described in Chapter 6 show that the gross 
morphology of the tissue was not as would be expected (Figure C.1 A, B, C & D). The 
state of the tissue suggests that perhaps multiple freeze/thaw cycles or poor tissue 
collection resulted in freezing artefacts. In contrast, healthy muscle tissue from a young 
individual showed expected muscle tissue morphology (Figure C.1 E & F). This tissue 
biopsy was taken recently and has only been through 2 freeze/thaw cycles when used 
for cryosectioning. Overall, the morphology observed from the H & E staining suggests 
that degraded ovary tissue might explain why immunofluorescent stainings described in 
Chapter 6 had a high level of background immunofluorescent signal. 
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Figure C.9.1 Hematoxylin and eosin staining of tissue cryosections. A & B: section from ovary sample PFC-
H-01-07 at 5X magnification (A) and 10X magnification (B). C & D: section from ovary sample PFC-H-02-
07 at 5X magnification (C) and 10X magnification (D). E & F: section from muscle sample PFC-H-351-126 
at 5X magnification (E) and 10X magnification (F). 
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Appendix D: Lentivirus overexpression system 
 
PRDM9 overexpression was also attempted by lentiviral plasmid overexpression, 
described in detail below. 
 
D.1 Lentivirus overexpression system 
In order to overexpress PRDM9 in cell lines other than the modified HEK293 line, for 
example 143B osteosarcoma or HeLa, lentiviral vector overexpression was attempted. 
Cloning of the full length PRDM9 cDNA construct into the pWPXLd plasmid was 
attempted using the pWPXLd vector (Figure D.1). Expression using this vector system 
relies on the retroviral elements derived from HIV-1 which allow stable integration of 
the gene of interest into the genome of both dividing and non-dividing cells. This system 
splits retroviral packaging elements over two plasmids, the transfer plasmid containing 
the gene of interest is shown in Figure D.1.  
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Figure D.9.1 Schematic of pW PXLd plasmid containing full length human PRDM9 cDNA insert sequence. 
Plasmid elements shown are: SV40 early polyadenylation signal (black), stem loop 2 HIV1 SD for HIV1 
splicing (dark blue), PsiΨ RNA binding site for packaging, Rev Response Elelment (dark blue), EF1α 
promoter element (green), Central Polypurine Tract for DNA transcription (black arrow), Woodchuck 
hepatitis virus post-transcriptional regulatory element WPRE (light blue), 5’ and 3’ Long Terminal 
Repeats (red), ampicillin/hygromycin/puromycin resistance elements (yellow) and gpt plasmid selective 
survival element (pink). 
 
The cloning strategy used for this expression system was to digest the Flag-PRDM9 
cDNA construct from the pcDNA3.1 plasmid used in previous experiments and sub-clone 
the product into pWPXLd using restriction enzyme digestion. The 
pcDNA3.1 Flag-PRDM9 plasmid sequence was checked for all possible restriction 
enzyme sites using the NEBcutter V2.0 (http://nc2.neb.com/NEBcutter2/). PmeI sites 
were found to flank either end of the PRDM9 insert sequence (Figure D.2 A) and could 
also be used to digest the pWPXLd vector. Digestion of pcDNA3 yielded a product at the 
predicted size of ~2700 bp as shown by agarose gel electrophoresis (Figure D.2 B).  
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Figure D.1.2 Sub-cloning of Flag-PRDM9 cDNA sequence into pWPXLd vectors. A) Restriction enzyme sites 
on the pcDNA3.1 Flag-PRDM9, PmeI sites are highlighted in boxes and flank the PRDM9 insert sequence 
(a). B) Agarose gel size separation of restriction enzyme digest products. pcDNA3.1, Flag-PRDM9 and 
pWPXLd digest products are indicated by arrows on the right hand side. 
 
Two pWPXLd plasmids were digested, one with hygromycin and the other with 
puromycin antibiotic resistance genes, both were successfully digested with PmeI in the 
presence of shrimp alkaline phosphatase (Figure D.2 B). The DNA products were 
purified from the gel shown in Figure D.2 B and used for ligation reactions. 
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A vector molar ratio of 1:3 was used for ligation of the Flag-PRDM9 cDNA insert into 
pWPXLd vectors. Briefly, ligation reactions were set up as follows; 5 µL T4 ligase, 2 µL 
2X ligase buffer, 50 ng vector DNA and 66.7 ng insert DNA were mixed by gentle 
pipetting and incubated at 16 °C for 16 hours. Due to the large plasmid size, several 
competent cells were used to produce expansion of the ligation product (detailed in 
Section 3.10) without successful colony growth. Next, a vector to insert ratio of 1:1 was 
used in ligation reactions, also without successful bacterial colony growth.  
Finally, to eliminate any possible negative effects of using only one restriction enzyme in 
the cloning procedure, such as self-religation, the PRDM9 cDNA sequence was PCR 
amplified using pcDNA3.1 Flag-PRDM9 as template.  Primers for PRDM9 cDNA were 
designed to introduce a BamHI restriction site in the reverse prime site (Table D.1). This 
would allow the use of BamHI and PmeI enzymes in the digest reactions and limit self-
ligation of the plasmids which is a risk when using only one enzyme.  
 
Primer Sequence 5’-3’ Annealing Temp. (°C) 
Forward PmeI GCTAGCGTTTAAACTTAAGCTT 72 
Reverse BamHI AGAATTCTGCAGGATCCCAGCACAGTGGCGG 72 
Table D.1 Details of primers used to amplify the Flag-PRDM9 insert sequence. 
 
PCR reaction mix was as follows; 1X reaction buffer, 250 µM dNTPs, 0.5 µM primer 
(forward and reverse), 1 U Phusion DNA polymerase, 10 ng DNA made up to a final 
volume of 20 µL with dH2O. Reactions were placed in a thermocycler using the following 
programme; denaturation at 98 °C for 30 seconds, followed by 30 cycles of denaturation 
at 98 °C for 10 seconds, annealing at 72 °C for 30 seconds, extension at 72 °C for 90 
seconds and final extension at 72 °C for 10 minutes. PCR products were visualised by 
1% agarose gel electrophoresis followed by UV exposure. Temperature gradients were 
performed using two different reaction buffers provided. No amplification was achieved 
using a gradient PCR from 50-60 °C using either buffer. Amplification did not occur 
using the High Fidelity PCR buffer at annealing temperatures ranging from 62-72 °C 
(Figure D.3). Amplification was achieved using the GC Rich Template PCR buffer at all 
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temperatures but was most specific at 70-72 °C (Figure D.3). A band at 2700 bp 
corresponds to the length of the PRDM9 insert sequence however bands were also 
detected at ~2800 and ~125 bp. These are most likely artefacts from the complex 
repetitive nature of the PRDM9 zinc finger array which could lead to collapsed 
fragments or mispriming events producing smaller or longer products than the expected 
2700 bp amplicon. 
 
 
Figure D.1.3 PCR amplification of Flag_PRDM9 cDNA using Phusion High Fidelity Taq polymerase. 
Temperature gradients were performed using High Fidelity (HF) buffer or GC rich template buffer.  Size 
marker in base pairs is shown in lane M. 
 
After gel extraction of the PCR product at 2700 bp, adenosine nucleotide overhangs 
were added using the Bioline polymerase kit as follows; 0.2 mM dATP, 1X PCR buffer, 1 
mM MgCl2, 1 U DNA Taq polymerase, 25 µL PCR product made up to final volume of 50 
µL with dH20. This reaction mix was incubated at 72 °C for 20 minutes. Next, to ensure 
that the size of the pWPXLd was the limiting step for successful bacterial 
transformation, the PCR product was ligated into the much smaller 4 Kb TOPO cloning 
vector (Thermo Fisher Scientific, Loughborough, UK). Briefly, 4 µL PCR product (with A 
overhangs), 1 mM NaCl and 50 ng TOPO vector DNA was incubated at room temperature 
for 5 minutes before transformation of competent cells, as described in Section 3.10.3. 
Unfortunately only three colonies had grown from the plated out transformed cells. One 
colony survived through antibiotic selection when grown in antibiotic selection medium 
and was used for maxi-prep DNA extraction. 
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Purified TOPO-PRDM9 plasmid was digested using BamHI and PmeI enzymes which had 
been incorporated into the 3’ and 5’ ends of the PRDM9 sequence by PCR. Digested DNA 
product was analysed by gel electrophoresis (Figure D.4). The pWPXLd plasmids were 
digested and gave a single band at ~11,000 bp as expected when digested with BamHI 
or PmeI alone and as a double digest. Digestion with PmeI or double enzyme digest 
showed a single band at ~6,000 bp as expected, however, the TOPO-PRDM9 plasmid 
gave two small bands when digested with BamHI alone suggesting that there was 
incorporation of more than one BamHI restriction site. 
  
 
Figure D.1.4 Restriction digest of plasmid DNA purified from competent E.coli. 25 ng DNA was 
electrophoresed on a 1% agarose gel and visualised by UV exposure. DNA size marker was included on the 
gel (M), sizes are given in base pairs. pWPXLd vectors containing either hygromycin or puromycin 
resistance genes were digested with BamHI, PmeI or both (Double digest). The TOPO-PRDM9 plasmid was 
also digested with BamHI, PmeI or both (Double digest).  
 
Sub-cloning the full length PRDM9 cDNA insert into the pWPXLd plasmid was not 
successful. Sub-cloning full length PRDM9 cDNA into pWPXLd was unsuccessful and 
some optimisation of the methodology was required. A number of different approaches 
were tested, such as; lowering incubation temperature (16, 25 and 37 °C), using low-salt 
growth media and agar plates (0.5%), transformation of several competent cell lines 
recommended for large plasmid transformations (TOP10, DH5α and Stbl3) as well as 
trying restriction digest and PCR amplification strategies. Due to the unreliability of this 
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insert incorporation and the difficulties in obtaining positively transformed E.coli 
colonies this lentivirus strategy was not continued.    
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Appendix E: Analysis of NuMt sites at recombination hotspots 
 
E.1 NuMt sites in relation to genomic recombination hotspot regions 
Genomic recombination ‘hotspots’ are defined as regions of the genome where 
chromosome crossovers have occurred, in accordance with genome reshuffling during 
meiosis. Hotspot location data was downloaded from the HapMap database for each 
chromosome. Nuclear mitochondrial (NuMt) sequence locations were downloaded from 
(Li et al., 2012). NuMt sequence locations were incorporated into the hotspot data sets 
for each chromosome and positions compared. Proximity of NuMts to hotspots was 
calculated by subtracting the start positions from each other and alignments were 
verified by eye. In total, 36 NuMts were identified within 20 hotspot regions (Table E.1). 
These regions were present on 13 chromosomes with chromosome 2 containing the 
highest number (4 different hotspot regions). Interestingly, single hotspots containing 
multiple NuMts were found on chromosomes 11 and 14 (Table E.1).   
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Chromosome Start End Type Length Distance from HS start
1 147327001 147350001 HS 23000
1 147332804 147332915 NUMT 111 5803
1 205442001 205445001 HS 3000
1 205444544 205444632 NUMT 88 2543
2 68485001 68491001 HS 6000
2 68487872 68488036 NUMT 164 2871
2 85294001 85301001 HS 7000
2 85295952 85296153 NUMT 201 1951
2 133179001 133183001 HS 4000
2 133182673 133182730 NUMT 57 3672
2 180604001 180608001 HS 4000
2 180604074 180604289 NUMT 215 73
2 180604379 180604467 NUMT 88 378
3 153370001 153378001 HS 8000
3 153376674 153376776 NUMT 102 6673
3 169653001 169656001 HS 3000
3 169654585 169654656 NUMT 71 1584
4* 14508001 14513001 HS 5000
4* 14507530 14507742 NUMT 212 -471
4* 14507834 14508073 NUMT 239 -167
4 182155001 182159001 HS 4000
4 182158556 182158693 NUMT 137 3555
5 93895001 93920001 HS 25000
5 93903161 93906623 NUMT 3462 8160
6 133470001 133474001 HS 4000
6 133471710 133471933 NUMT 223 1709
9 85041001 85047001 HS 6000
9 85042306 85042806 NUMT 500 4695
9 85042830 85042944 NUMT 114 4171
11 103271001 103279001 HS 8000
11 103272857 103273350 NUMT 493 6144
11 103274883 103275102 NUMT 219 4118
11 103275372 103276049 NUMT 677 3629
11 103276576 103276694 NUMT 118 2425
11 103276718 103276943 NUMT 225 2283
11 103277402 103277483 NUMT 81 1599
11 103277548 103277680 NUMT 132 1453
11 103277962 103278170 NUMT 208 1039
11 103278536 103278708 NUMT 172 465
11 103278904 103279035 NUMT 131 97
14 84634000 84640000 HS 6000
14 84637696 84638079 NUMT 383 2304
14 84638350 84638625 NUMT 275 1650
14 84638769 84639028 NUMT 259 1231
14 84639090 84639184 NUMT 94 910
14 84639187 84639382 NUMT 195 813
15 34685000 34689000 HS 4000
15 34686922 34687072 NUMT 150 1922
15 34833000 34837000 HS 4000
15 34833143 34833293 NUMT 150 143
18 59539001 59542001 HS 3000
18 59541804 59542118 NUMT 314 2803
21 46786000 46797000 HS 11000
21 46796121 46796299 NUMT 178 10121
22 46863000 46867000 HS 4000
22 46866181 46866230 NUMT 49 3181
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Table E.1 Alignment data of genomic hotspots and NuMt positions. HS denotes ‘hotspot’; NUMT denotes 
‘nuclear mitochondrial’. Chromosome location and start and end positions are provided. Length of HS or 
NuMt is shown along with the distance of the NuMt sequence from the start of the HS region. 
  
In contrast, a hotspot on chromosome 4 was identified as being downstream of two 
NuMt regions, one overlapping the beginning of the hotspot (Table E.1).  
 
The HapMap Phase III data consists of genome data from 1301 individuals from 11 
population groups. The Phase III build shows the most common ‘events’ based on the 
combined data to give an overall view of general human genome patterns. This makes 
the hotspot data unbiased as it is not population specific. The NuMt data used in this 
study was generated by Li et al using comparisons between the mitochondrial revised 
Cambridge Reference Sequence (rCRS) and the HG19 genome build. This genome is a 
composite of sequences from multiple individuals. The group also analysed data from 
artificial mixes of mtDNA sequences which differed at 34 positions along the molecule. 
These methods ensure that the NuMt data provided is reliable and not population 
biased. Although these data sets have been compiled with efforts to minimise 
confounding factors such as population genetics, there will undoubtedly be differences 
between individuals and this analysis is perhaps not applicable to all genomes. However, 
it provides an overview of the alignment between NuMt sequences and recombination 
hotspots in a model of a generic human genome which represents a large proportion of 
the population. 
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Appendix F: Attendance at scientific meetings 
 
The content of this thesis has been presented in the form of a poster presentation at 
three scientific meetings in 2016:  
1. Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease, May 
2016, Cambridge, UK. 
2. United Mitochondrial Disease Foundation: Mitochondrial Medicine 2016, June 2016, 
Seattle, USA. 
3. Newcastle University Institute of Ageing: Postgraduate Research Day 2016, June 2016, 
Newcastle, UK. 
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At present 805 mitochondrial DNA (mtDNA) deletions have been described. Short direct 
repeat regions of DNA flank many of these deletions, suggesting that specific regions of 
the mtDNA molecule have a susceptibility to deletion formation. PRDM9 is a meiotic-
specific protein responsible for determining where recombination hotspots will occur in 
the nuclear genome. It binds a specific DNA consensus sequence through its zinc finger 
repeat region. 
The aim of this project is to determine whether the PRDM9 binding motif is present in 
the mtDNA molecule and investigate whether PRDM9 plays a role in mtDNA deletion 
formation. 
A bioinformatic approach was used to screen mtDNA sequences from 31,000 individuals 
for the presence of the PRDM9 binding motif. The motif was found in 99.9% of the 
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sequences searched at a position known to flank a previously described deletion 
(m.5327). Several sequences contained the motif more than once with some sequences 
containing up to 3 motif sites in total. Classifying the sequences by broad haplogrouping 
(African, Asian and European) showed population differences with respect to the 
number of motifs present. Further analysis of the European sequences showed 
differences between sub-haplogroup status and the number of motifs present 
Genotyping via Sanger sequencing of the PRDM9 zinc finger repeat region in a cohort of 
48 single deletion patients and 50 healthy controls showed no correlation between 
PRDM9 allele status and the presence of the ‘common’ 4977bp mtDNA deletion.  
Subcellular fractions of HEK-293T cells followed by SDS-PAGE and immunoblotting with 
anti-PRDM9 antibody showed PRDM9 protein is enriched in mitochondria. However, the 
antibody gave unreliable multiple banding on Western blot membranes. To address this, 
stable cell lines overexpressing FLAG-tagged PRDM9 under control of the tetracycline 
inducible promoter were created. PRDM9 expression was detected by immunoblotting. 
PRDM9 was previously reported to directly methylate the lysine 4 residue on histone 3 
and measurement of H3K4me3 protein levels in these cell lines showed a significant 
increase.  
The PRDM9 recognition motif previously described is present in human mtDNA. PRDM9 
protein appears to be enriched in the mitochondrial fraction of HEK-293 cells suggesting 
that PRDM9 may play a role in mediating mtDNA maintenance during development.  
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